

## Reference List

- Aalto S, Hirvonen J, Kajander J, Scheinin H, Nagren K, Vilkmann H, Gustafsson L, Syvalahti E, Hietala J, 2002. Ketamine does not decrease striatal dopamine D(2) receptor binding in man. *Psychopharmacology (Berl)* 164,401-406
- Abadie P, Boulenger JP, Benali K, Barre L, Zarifian E, Baron JC, 1999. Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. *Eur.J.Neurosci.* 11,1470-1478
- Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M, 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. *Am J Psychiatry* 155,761-767
- Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M, 2000. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia [see comments]. *Proc.Natl.Acad.Sci.U.S.A* 97,8104-8109
- Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M, 2000. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [<sup>11</sup>C]NNC 112 in humans: validation and reproducibility. *J.Cereb.Blood Flow Metab.* 20,225-243
- Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M, 2002. Prefrontal dopamine D1 receptors and working memory in schizophrenia. *J Neurosci.* 22,3708-3719
- Abrahams S, Leigh PN, Kew JJ, Goldstein LH, Lloyd CM, Brooks DJ, 1995. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. *J Neurol.Sci.* 129 Suppl,44-46
- Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD, Leigh PN, 1996. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. *Brain* 119 ( Pt 6),2105-2120
- Ackerman RH, Correia JA, Alpert NM, Baron JC, Gouliamos A, Grotta JC, Brownell GL, Taveras JM, 1981. Positron imaging in ischemic stroke

- disease using compounds labeled with oxygen 15. Initial results of clinicophysiological correlations. Arch Neurol 38,537-543
- Adams HP, Jr., Powers WJ, Grubb RL, Jr., Clarke WR, Woolson RF, 2001. Preview of a new trial of extracranial-to-intracranial arterial anastomosis: the carotid occlusion surgery study. Neurosurg Clin.N Am 12,613-624
- Adams KM, Gilman S, Koeppe RA, Klun KJ, Brunberg JA, Dede D, Berent S, Kroll PD, 1993. Neuropsychological deficits are correlated with frontal hypometabolism in positron emission tomography studies of older alcoholic patients. Alcohol Clin.Exp.Res 17,205-210
- Adams KM, Gilman S, Johnson-Greene D, Koeppe RA, Junck L, Klun KJ, Martorello S, Johnson MJ, Heumann M, Hill E, 1998. The significance of family history status in relation to neuropsychological test performance and cerebral glucose metabolism studied with positron emission tomography in older alcoholic patients. Alcohol Clin.Exp.Res. 22,105-110
- Adler LJ, Gyulai FE, Diehl DJ, Mintun MA, Winter PM, Firestone LL, 1997. Regional brain activity changes associated with fentanyl analgesia elucidated by positron emission tomography. Anesth.Analg. 84,120-126
- Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, McCarthy T, McCarthy DW, Gambhir SS, 2002. Ex vivo cell labeling with <sup>64</sup>Cu-pyruvaldehyde-bis(N4- methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc.Natl.Acad.Sci.U.S.A 99,3030-3035
- Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR, 2001. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 21,RC189
- Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, Small GW, Cole GM, Barrio JR, 2003. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[<sup>18</sup>F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile. Neuroscience 117,723-730
- Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K, 2001. Schwannoma of the extremities: the role of PET in preoperative planning. Eur.J Nucl Med 28,1541-1551

- Akiyama H, Harrop R, McGeer PL, Peppard R, McGeer EG, 1989. Crossed cerebellar and uncrossed basal ganglia and thalamic diaschisis in Alzheimer's disease. *Neurology* 39,541-548
- Al Essa M, Bakheet S, Patay Z, Al Shamsan L, Al Sonbul A, Al Watban J, Powe J, Ozand PT, 1999. 18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in propionic acidemia: clinical and MRI correlations. *Brain Dev.* 21,312-317
- Al Essa M, Bakheet S, Al Shamsan L, Patay Z, Powe J, Ozand PT, 1999. 18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in type IV 3-methylglutaconic aciduria: clinical and MRI correlations. *Brain Dev.* 21,24-29
- al Mousawi AH, Evans N, Ebmeier KP, Roeda D, Chaloner F, Ashcroft GW, 1996. Limbic dysfunction in schizophrenia and mania. A study using 18F-labelled fluorodeoxyglucose and positron emission tomography. *British Journal of Psychiatry* 169,509-516
- Alauddin MM, Conti PS, 1998. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. *Nucl Med Biol.* 25,175-180
- Alauddin MM, Shahinian A, Gordon EM, Bading JR, Conti PS, 2001. Preclinical evaluation of the penciclovir analog 9-(4-[(18)F]fluoro-3-hydroxymethylbutyl)guanine for in vivo measurement of suicide gene expression with PET. *J Nucl Med* 42,1682-1690
- Alavi A, Newberg AB, Souder E, Berlin JA, 1993. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. *J.Nucl.Med.* 34,1681-1687
- Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M, 1988. Positron emission tomography in patients with glioma. A predictor of prognosis. *Cancer* 62,1074-1078
- Albani G, Kunig G, Soelch CM, Mauro A, Priano L, Martignoni E, Leenders KL, 2001. The role of language areas in motor control dysfunction in Parkinson's disease. *Neurol Sci.* 22,43-44
- Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM, 2002. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential

- Outcome Measure in Alzheimer's Disease Treatment Studies. *Am.J Psychiatry* 159,738-745
- Alexoff DL, Vaska P, Marsteller D, Gerasimov T, Li J, Logan J, Fowler JS, Taintor NB, Thanos PK, Volkow ND, 2003. Reproducibility of (11)C-Raclopride Binding in the Rat Brain Measured with the MicroPET R4: Effects of Scatter Correction and Tracer Specific Activity. *J Nucl Med* 44,815-822
- Alkire MT, Haier RJ, Barker SJ, Shah NK, Wu JC, Kao YJ, 1995. Cerebral metabolism during propofol anesthesia in humans studied with positron emission tomography. *Anesthesiology* 82,393-403
- Alkire MT, Haier RJ, Shah NK, Anderson CT, 1997. Positron emission tomography study of regional cerebral metabolism in humans during isoflurane anesthesia. *Anesthesiology* 86,549-557
- Alkire MT, Pomfrett CJ, Haier RJ, Gianzero MV, Chan CM, Jacobsen BP, Fallon JH, 1999. Functional brain imaging during anesthesia in humans: effects of halothane on global and regional cerebral glucose metabolism. *Anesthesiology* 90,701-709
- Alkire MT, Haier RJ, 2001. Correlating in vivo anaesthetic effects with ex vivo receptor density data supports a GABAergic mechanism of action for propofol, but not for isoflurane. *Br.J Anaesth.* 86,618-626
- Aloj L, Jogoda E, Lang L, Caraco C, Neumann RD, Sung C, Eckelman WC, 1999. Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. *J Nucl Med* 40,1547-1555
- Alpert NM, Eriksson L, Chang JY, Bergstrom M, Litton JE, Correia JA, Bohm C, Ackerman RH, Taveras JM, 1984. Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. *J.Cereb.Blood Flow Metab.* 4,28-34
- Alpert NM, Buxton RB, Correia JA, Katz PM, Ackerman RH, 1988. Measurement of end-capillary PO<sub>2</sub> with positron emission tomography. *J.Cereb.Blood Flow Metab.* 8,403-410
- Alpert NM, Berdichevsky D, Levin Z, Morris ED, Fischman AJ, 1996. IMPROVED METHODS FOR IMAGE REGISTRATION. *Neuroimage* 3,10-18

- Alpert NM, Badgaiyan RD, Livni E, Fischman AJ, 2003. A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems. *Neuroimage* 19,1049-1060
- Altman DI, Volpe JJ, 1987. Cerebral blood flow in the newborn infant: measurement and role in the pathogenesis of periventricular and intraventricular hemorrhage. [Review]. *Advances in Pediatrics* 34,111-138
- Altman DI, Powers WJ, Perlman JM, Herscovitch P, Volpe SL, Volpe JJ, 1988. Cerebral blood flow requirement for brain viability in newborn infants is lower than in adults. *Ann.Neurol* 24,218-226
- Altman DI, Perlman JM, Volpe JJ, Powers WJ, 1993. Cerebral oxygen metabolism in newborns. *Pediatrics* 92,99-104
- Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M, Buck A, Burger C, Samnick S, Quack G, Schubiger PA, 2002. PET studies of 18F-memantine in healthy volunteers. *Nucl Med Biol.* 29,227-231
- Anderson NE, Posner JB, Sidtis JJ, Moeller JR, Strother SC, Dhawan V, Rottenberg DA, 1988. The metabolic anatomy of paraneoplastic cerebellar degeneration. *Ann.Neurol* 23,533-540
- Andersson JL, Muhr C, Lilja A, Valind S, Lundberg PO, Langstrom B, 1997. Regional cerebral blood flow and oxygen metabolism during migraine with and without aura. *Cephalalgia* 17,570-579
- Andersson JL, Ashburner J, Friston K, 2001. A global estimator unbiased by local changes. *Neuroimage* 13,1193-1206
- Andersson JLR, Thurfjell L, 1997. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. *Journal of Computer Assisted Tomography* 21,136-144
- Andersson JLR, Onoe H, Hetta J, Lidstrom K, Valind S, Lilja A, Sundin A, Fasth KJ, Westerberg G, Broman JE, Watanabe Y, Langstrom B, 1998. Brain networks affected by synchronized sleep visualized by positron emission tomography. *J.Cereb.Blood Flow Metab.* 18,701-715
- Andersson JLR, Thurfjell L, 1999. A multivariate approach to registration of dissimilar tomographic images. *Eur.J.Nucl.Med.* 26,718-733

- Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Ponto LLB, Hichwa RD, 1997. HYPOFRONTALITY IN SCHIZOPHRENIA - DISTRIBUTED DYSFUNCTIONAL CIRCUITS IN NEUROLEPTIC-NAIVE PATIENTS. *Lancet* 349,1730-1734
- Andreason PJ, Zametkin AJ, Guo AC, Baldwin P, Cohen RM, 1994. Gender-related differences in regional cerebral glucose metabolism in normal volunteers. *Psychiatry Research* 51,175-183
- Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L, 1998. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. *J Clin.Psychopharmacol.* 18,317-323
- Andree B, Thorberg SO, Halldin C, Farde L, 1999. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. *Psychopharmacology (Berl)* 144,303-305
- Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ, 1999. Huntington's disease progression: PET and clinical observations. *Brain* 122,2353-2363
- Annane D, Fiorelli M, Mazoyer B, Pappata S, Eymard B, Radvanyi H, Junien C, Fardeau M, Merlet P, Gajdos P, Syrota A, Sansom Y, Duboc D, 1998. Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon. *Neuromuscul.Disord.* 8,39-45
- Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J, 2000. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. *Ann.Neurol* 48,105-108
- Antonini A, Leenders KL, Reist H, Thomann R, Beer HF, Locher J, 1993. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. *Arch.Neurol.* 50,474-480
- Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL, 1994. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. *Neurology* 44,1325-1329

- Antonini A, Vontobel P, Psylla M, Gunther I, Maguire PR, Missimer J, Leenders KL, 1995. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. *Arch.Neurol* 52,1183-1190
- Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL, 1997. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. *Mov Disord.* 12,33-38
- Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, Eidelberg D, 1998. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. *Mov Disord.* 13,268-274
- Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D, 1998. The metabolic anatomy of tremor in Parkinson's disease. *Neurology* 51,803-810
- Antonini A, Leenders KL, Eidelberg D, 1998. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. *Ann.Neurol* 43,253-255
- Antonini A, Moresco RM, Gobbo C, De Notaris R, Panzacchi A, Barone P, Calzetti S, Negrotti A, Pezzoli G, Fazio F, 2001. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. *Neurol Sci.* 22,47-48
- Aquilonius SM, Bergstrom K, Eckernas SA, Hartvig P, Leenders KL, Lundquist H, Antoni G, Gee A, Rimland A, Uhlin J, 1987. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. *Acta Neurol Scand.* 76,283-287
- Arahata Y, Hirayama M, Ieda T, Koike Y, Kato T, Tadokoro M, Ikeda M, Ito K, Sobue G, 1999. Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure. *J.Neurol.Sci.* 163,119-126
- Arigoni M, Kneifel S, Fandino J, Khan N, Burger C, Buck A, 2000. Simplified quantitative determination of cerebral perfusion reserve with H2(15)O PET and acetazolamide. *Eur.J Nucl Med* 27,1557-1563
- Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, Nordberg A, 2001. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. *Neuroreport* 12,851-855

- Arnold S, Berthele A, Drzezga A, Tolle TR, Weis S, Werhahn KJ, Henkel A, Yousry TA, Winkler PA, Bartenstein P, Noachtar S, 2000. Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia. *Epilepsia* 41,818-824
- Asahina M, Shinotoh H, Hirayama K, Suhara T, Shishido F, Inoue O, Tateno Y, 1995. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. *Acta Neurol Scand.* 91,437-443
- Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T, 1998. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. *J Neurol Neurosurg Psychiatry* 65,155-163
- Asano E, Chugani DC, Muzik O, Shen C, Juhasz C, Janisse J, Ager J, Canady A, Shah JR, Shah AK, Watson C, Chugani HT, 2000. Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex. *Neurology* 54,1976-1984
- Ashburner J, Neelin P, Collins DL, Evans A, Friston K, 1997. Incorporating prior knowledge into image registration. *Neuroimage* 6,344-352
- Ashburner J, Andersson JL, Friston KJ, 2000. Image registration using a symmetric prior--in three dimensions. *Hum.Brain Mapp.* 9,212-225
- Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM, 2003. Computer-assisted imaging to assess brain structure in healthy and diseased brains. *The Lancet Neurology* 2,79-88
- Aston JA, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN, 2002. Positron emission tomography partial volume correction: estimation and algorithms. *J Cereb.Blood Flow Metab* 22,1019-1034
- Aupee AM, Desgranges B, Eustache F, Lalevee C, de IS, V, Viader F, Baron JC, 2001. Voxel-based mapping of brain hypometabolism in permanent amnesia with PET. *Neuroimage* 13,1164-1173
- Avery RA, Spencer SS, Spanaki MV, Corsi M, Seibyl JP, Zubal IG, 1999. Effect of injection time on postictal SPET perfusion changes in medically refractory epilepsy. *Eur.J Nucl Med* 26,830-836
- Azari NP, Pietrini P, Horwitz B, Pettigrew KD, Leonard HL, Rapoport JL, Schapiro MB, Swedo SE, 1993. Individual differences in cerebral



- metabolic patterns during pharmacotherapy in obsessive-compulsive disorder: a multiple regression/discriminant analysis of positron emission tomographic data. *Biol.Psychiatry* 34,798-809
- Azari NP, Pettigrew KD, Schapiro MB, Haxby JV, Grady CL, Pietrini P, Salerno JA, Heston LL, Rapoport SI, Horwitz B, 1993. Early detection of Alzheimer's disease: a statistical approach using positron emission tomographic data. *J.Cereb.Blood Flow Metab.* 13,438-447
- Azari NP, Pettigrew KD, Pietrini P, Horwitz B, Schapiro MB, 1994. Detection of an Alzheimer disease pattern of cerebral metabolism in Down syndrome. *Dementia* 5,69-78
- Azari NP, Binkofski F, Pettigrew KD, Freund HJ, Seitz RJ, 1996. Enhanced regional cerebral metabolic interactions in thalamic circuitry predicts motor recovery in hemiparetic stroke. *Human Brain Mapping* 4,240-253
- Backman L, Andersson JL, Nyberg L, Winblad B, Nordberg A, Almkvist O, 1999. Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. *Neurology* 52,1861-1870
- Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boisse MF, Grandmougin T, Jeny R, Bartolomeo P, Dalla BG, Degos JD, Lisovsky F, Ergis AM, Pailhoux E, Cesaro P, Hantraye P, Peschanski M, 2000. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. *Lancet* 356,1975-1979
- Backman L, Almkvist O, Nyberg L, Anderson J, 2000. Functional changes in brain activity during priming in Alzheimer's disease. *J.Cogn Neurosci.* 12,134-141
- Bacskai BJ, Klunk WE, Mathis CA, Hyman BT, 2002. Imaging Amyloid-beta Deposits In Vivo. *J Cereb.Blood Flow Metab* 22,1035-1041
- Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang Gf, Mathis CA, Klunk WE, Hyman BT, 2003. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid- $\beta$  ligand in transgenic mice. *PNAS* epub,2034101100
- Bagary M, Fluck E, File SE, Joyce E, Lockwood G, Grasby P, 2000. Is benzodiazepine-induced amnesia due to deactivation of the left prefrontal cortex? *Psychopharmacology (Berl)* 150,292-299

- Bahn MM, Huang SC, Hawkins RA, Satyamurthy N, Hoffman JM, Barrio JR, Mazziotta JC, Phelps ME, 1989. Models for in vivo kinetic interactions of dopamine D2- neuroreceptors and 3-(2'-[18F]fluoroethyl)piperone examined with positron emission tomography. *J.Cereb.Blood Flow Metab.* 9,840-849
- Bahn MM, Lin W, Silbergeld DL, Miller JW, Kuppusamy K, Cook RJ, Hammer G, Wetzel R, Cross D, III, 1997. Localization of language cortices by functional MR imaging compared with intracarotid amobarbital hemispheric sedation. *AJR Am.J.Roentgenol.* 169,575-579
- Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ, 2001. Brainstem activation specific to migraine headache. *Lancet* 357,1016-1017
- Bahro M, Molchan SE, Sunderland T, Herscovitch P, Schreurs BG, 1999. The effects of scopolamine on changes in regional cerebral blood flow during classical conditioning of the human eyeblink response. *Neuropsychobiology* 39,187-195
- Bailey DL, Young H, Bloomfield PM, Meikle SR, Glass D, Myers MJ, Spinks TJ, Watson CC, Luk P, Peters AM, Jones T, 1997. ECAT ART - A continuously rotating PET camera: Performance characteristics, initial clinical studies, and installation considerations in a nuclear medicine department. *Eur.J.Nucl.Med.* 24,6-15
- Bailey DL, 1998. Quantitative procedures in 3D PET. In: Bendriem B, Townsend DW, eds. *The theory and practice of 3D PET*, Kluwer Academic Publishers, Dordrecht, pp 55-109
- Bairamian D, Di Chiro G, Theodore WH, Holmes MD, Dorwart RH, Larson SM, 1985. MR imaging and positron emission tomography of cortical heterotopia. *J Comput.Assist.Tomogr.* 9,1137-1139
- Bajcsy R, LIEBERSON R, Reivich M, 1983. A COMPUTERIZED SYSTEM FOR THE ELASTIC MATCHING OF DEFORMED RADIOGRAPHIC IMAGES TO IDEALIZED ATLAS IMAGES. *Journal of Computer Assisted Tomography* 7,618-625
- Bakar M, Kirshner HS, Wertz RT, 1996. Crossed aphasia. Functional brain imaging with PET or SPECT. *Arch.Neurol.* 53,1026-1032
- Baker SC, Frith CD, Dolan RJ, 1997. The interaction between mood and cognitive function studied with PET. *Psychological Medicine* 27,565-578

- Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, Brooks DJ, Jones T, Duncan JS, 1999. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. *Neurology* 53,2199-2203
- Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R, 2000. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. *Brain* 123 ( Pt 11),2321-2337
- Banati RB, 2002. Visualising microglial activation in vivo. *GLIA* 40,206-217
- Bancher C, Braak H, Fischer P, Jellinger KA, 1993. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. *Neuroscience Letters* 162,179-182
- Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivrotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J, 2000. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. *Exp.Neurol.* 164,2-14
- Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD, 1997. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. *Cancer* 79,115-126
- Baron JC, Bousser MG, Comar D, Duquesnoy N, Sastre J, Castaigne P, 1980. Crossed cerebellar diaschisis in human supratentorial brain infarction. *Transactions of the American Neurological Association* 105,459-461
- Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P, 1981. Reversal of focal "misery-perfusion syndrome" by extra- intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 15O positron emission tomography. *Stroke* 12,454-459
- Baron JC, Roeda D, Munari C, Crouzel C, Chodkiewicz JP, Comar D, 1983. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. *Neurology* 33,580-585
- Baron JC, Delattre JY, Bories J, Chiras J, Cabanis EA, Blas C, Bousser MG, Comar D, 1983. Comparison study of CT and positron emission

- tomographic data in recent cerebral infarction. *Ajnr: American Journal of Neuroradiology* 4,536-540
- Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, Comar D, 1984. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. *J.Cereb.Blood Flow Metab.* 4,140-149
- Baron JC, Maziere B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet AM, Agid Y, 1986. Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. *J.Cereb.Blood Flow Metab.* 6,131-136
- Baron JC, D'Antona R, Pantano P, Serdaru M, Samson Y, Bousser MG, 1986. Effects of thalamic stroke on energy metabolism of the cerebral cortex. A positron tomography study in man. *Brain* 109,1243-1259
- Baron JC, 1989. Depression of energy metabolism in distant brain structures: studies with positron emission tomography in stroke patients. *Semin.Neurol* 9,281-285
- Baron JC, Frackowiak RS, Herholz K, Jones T, Lammertsma AA, Mazoyer B, Wienhard K, 1989. Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. [Review]. *J.Cereb.Blood Flow Metab.* 9,723-742
- Baron JC, Levasseur M, Mazoyer B, Legault-Demare F, Mauguiere F, Pappata S, Jedynak P, Derome P, Cambier J, Tran-Dinh S, 1992. Thalamocortical diaschisis: positron emission tomography in humans. *J Neurol Neurosurg Psychiatry* 55,935-942
- Barrington SF, Koutroumanidis M, Agathonikou A, Marsden PK, Binnie CD, Polkey CE, Maisey MN, Panayiotopoulos CP, 1998. Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. *Epilepsia* 39,753-766
- Barrio JR, Satyamurthy N, Huang SC, Keen RE, Nissenson CH, Hoffman JM, Ackermann RF, Bahn MM, Mazziotta JC, Phelps ME, 1989. 3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. *J.Cereb.Blood Flow Metab.* 9,830-839

- Barrio JR, 1996. Radiofluorinated L-m-tyrosines: New in-vivo probes for central dopamine biochemistry. *J.Cereb.Blood Flow Metab.* 16,667-678
- Barrio JR, Huang SC, Phelps ME, 1997. Biological imaging and the molecular basis of dopaminergic diseases. *Biochem.Pharmacol.* 54,341-348
- Bartenstein PA, Duncan JS, Prevett MC, Cunningham VJ, Fish DR, Jones AK, Luthra SK, Sawle GV, Brooks DJ, 1993. Investigation of the opioid system in absence seizures with positron emission tomography. *J Neurol Neurosurg Psychiatry* 56,1295-1302
- Bartenstein PA, Prevett MC, Duncan JS, Hajek M, Wieser HG, 1994. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. *Epilepsy Res* 18,119-125
- Bartlett EJ, Brodie JD, Wolf AP, Christman DR, Laska E, Meissner M, 1988. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. *J Cereb.Blood Flow Metab* 8,502-512
- Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, Ling W, Bridge TP, 1999. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. *Neuropsychopharmacology* 20,582-590
- Basso U, Brandes AA, 2002. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. *Eur.J Cancer* 38,1298-1312
- Bauer A, Holschbach MH, Meyer PT, Boy C, Herzog H, Olsson RA, Coenen HH, Zilles K, 2003. In vivo imaging of adenosine A(1) receptors in the human brain with [F-18]CPFPX and positron emission tomography. *Neuroimage* 19,1760-1769
- Baumgartner C, Serles W, Leutmezer F, Patariaia E, Aull S, Czech T, Pietrzyk U, Relic A, Podreka I, 1998. Preictal SPECT in temporal lobe epilepsy: regional cerebral blood flow is increased prior to electroencephalography-seizure onset. *J.Nucl.Med.* 39,978-982
- Baxter LR, 1990. Brain imaging as a tool in establishing a theory of brain pathology in obsessive compulsive disorder. *J Clin.Psychiatry* 51 Suppl,22-25

- Baxter LR, Jr., Thompson JM, Schwartz JM, Guze BH, Phelps ME, Mazziotta JC, Selin CE, Moss L, 1987. Trazodone treatment response in obsessive-compulsive disorder--correlated with shifts in glucose metabolism in the caudate nuclei. *Psychopathology* 20 Suppl 1,114-122
- Baxter LR, Jr., Mazziotta JC, Phelps ME, Selin CE, Guze BH, Fairbanks L, 1987. Cerebral glucose metabolic rates in normal human females versus normal males. *Psychiatry Res.* 21,237-245
- Baxter LR, Jr., Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE, 1987. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. *Arch Gen Psychiatry* 44,211-218
- Baxter LR, Jr., Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, Fairbanks L, 1988. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. *Am J Psychiatry* 145,1560-1563
- Baxter LR, Jr., Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM, 1989. Reduction of prefrontal cortex glucose metabolism common to three types of depression. *Arch Gen Psychiatry* 46,243-250
- Baxter LR, Jr., Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, 1992. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. *Arch Gen Psychiatry* 49,681-689
- Belin P, Vaneeckhout P, Zilbovicius M, Remy P, Francois C, Guillaume S, Chain F, Rancurel G, Samson Y, 1996. Recovery from nonfluent aphasia after melodic intonation therapy - a PET study. *Neurology* 47,1504-1511
- Belohlavek O, Simonova G, Kantorova I, I, Novotny JJ, Liscak R, 2003. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? *Eur.J Nucl Med Mol.Imaging* 30,96-100
- Ben David I, Rozen Y, Ortu G, Mishani E, 2003. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride. *Appl.Radiat.Isot.* 58,209-217

- Bench CJ, Friston KJ, Brown RG, Scott LC, Frackowiak RS, Dolan RJ, 1992. The anatomy of melancholia--focal abnormalities of cerebral blood flow in major depression. *Psychological Medicine* 22,607-615
- Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ, 1993. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. *Psychological Medicine* 23,579-590
- Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, Cuddigan M, Turton DJ, Osman S, Frackowiak RS, 1993. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. *Psychopharmacology* 112,308-314
- Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ, 1993. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. *Psychol.Med* 23,579-590
- Bench CJ, Frackowiak RS, Dolan RJ, 1995. Changes in regional cerebral blood flow on recovery from depression. *Psychological Medicine* 25,247-261
- Bencherif B, Fuchs PN, Sheth R, Dannals RF, Campbell JN, Frost JJ, 2002. Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). *Pain* 99,589-598
- Bencherif B, Endres CJ, Musachio JL, Villalobos A, Hilton J, Scheffel U, Dannals RF, Williams S, Frost JJ, 2002. PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. *Synapse* 45,1-9
- Bendriem B, Townsend DW, 1998. *The theory and practice of 3D PET*, Kluwer Academic Publishers, Dordrecht
- Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM, 1990. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. *Arch Gen Psychiatry* 47,840-848
- Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A, Evans A, 1995. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. *Am J Psychiatry* 152,1180-1184

- Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY, 1983. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. *Arch.Neurol.* 40,711-714
- Bentourkia M, Michel C, Ferriere G, Bol A, Coppens A, Sibomana M, Bausart R, Labar D, De Volder AG, 1998. Evolution of brain glucose metabolism with age in epileptic infants, children and adolescents. *Brain Dev.* 20,524-529
- Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, Shing M, Kolbe H, Van Den Hoff J, Fricke H, Dengler R, Samii M, Knapp WH, 2001. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. *Mov Disord.* 16,1014-1022
- Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, Starosta-Rubinstein S, Hichwa R, Young AB, 1988. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. *Ann.Neurol* 23,541-546
- Berent S, Giordani B, Foster N, Minoshima S, Lajiness-O'Neill R, Koeppe R, Kuhl DE, 1999. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. *J.Psychiatr.Res.* 33,7-16
- Bergsneider M, Hovda DA, Shalmon E, Kelly DF, Vespa PM, Martin NA, Phelps ME, McArthur DL, Caron MJ, Kraus JF, Becker DP, 1997. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. *J Neurosurg* 86,241-251
- Bergsneider M, Hovda DA, Lee SM, Kelly DF, McArthur DL, Vespa PM, Lee JH, Huang SC, Martin NA, Phelps ME, Becker DP, 2000. Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury. *J.Neurotrauma* 17,389-401
- Bergsneider M, Hovda DA, McArthur DL, Etchepare M, Huang SC, Sehati N, Satz P, Phelps ME, Becker DP, 2001. Metabolic recovery following human traumatic brain injury based on FDG-PET: time course and relationship to neurological disability. *J Head Trauma Rehabil.* 16,135-148
- Bergstrom KA, Halldin C, Hall H, Lundkvist C, Ginovart N, Swahn CG, Farde L, 1997. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. *Eur.J Nucl Med* 24,596-601



- Bergstrom M, Muhr C, Lundberg PO, Bergstrom K, Gee AD, Fasth KJ, Langstrom B, 1987. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. *J Comput.Assist.Tomogr.* 11,815-819
- Bergstrom M, Ericson K, Hagenfeldt L, Mosskin M, von Holst H, Noren G, Eriksson L, Ehrin E, Johnstrom P, 1987. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. *Journal of Computer Assisted Tomography* 11,208-213
- Bergstrom M, Muhr C, Lundberg PO, Bergstrom K, Lundqvist H, Antoni G, Fasth KJ, Langstrom B, 1987. Amino acid distribution and metabolism in pituitary adenomas using positron emission tomography with D-[11C]methionine and L-[11C]methionine. *J Comput.Assist.Tomogr.* 11,384-389
- Bergstrom M, Muhr C, Ericson K, Lundqvist H, Lilja A, Eriksson L, Blomquist G, Langstrom B, Johnstrom P, 1987. The normal pituitary examined with positron emission tomography and (methyl-11C)-L-methionine and (methyl-11C)-D-methionine. *Neuroradiology* 29,221-225
- Bergstrom M, Muhr C, Lundberg PO, Langstrom B, 1991. PET as a tool in the clinical evaluation of pituitary adenomas. *J Nucl Med* 32,610-615
- Bergstrom M, Muhr C, Jossan S, Lilja A, Nyberg G, Langstrom B, 1992. Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L- deprenyl. *Neurosurgery* 30,855-861
- Bergstrom M, Kumlien E, Lilja A, Tyrefors N, Westerberg G, Langstrom B, 1998. Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl--analysis of kinetic data. *Acta Neurol Scand.* 98,224-231
- Berry CR, DeGrado TR, Nutter F, Garg PK, Breitschwerdt EB, Spaulding K, Concannon KD, Zalutsky MR, Coleman RE, 2002. Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. *Vet.Radiol.Ultrasound* 43,183-186
- Berthier ML, Starkstein SE, Leiguarda R, Ruiz A, Mayberg HS, Wagner H, Price TR, Robinson RG, 1991. Transcortical aphasia. Importance of the nonspeech dominant hemisphere in language repetition. *Brain* 114 ( Pt 3),1409-1427

- Betz AL et al., 2003. Blood-brain-cerebrospinal fluid barriers. In: Siegel GJ et al., eds. Basic neurochemistry , Raven Press, New York, NY, pp 681-699
- Beuthien-Baumann B, Zündorf G, Lücke S, Triemer A, Schierz K, Herholz K, Holthoff VA, 2003. Regional cerebral metabolism in unipolar depression: the relationship with clinical characteristics. J.Cereb.Blood Flow Metab 23 (Suppl. 1) ,
- Beuthien-Baumann B, Bredow J, Burchert W, Fuchtnr F, Bergmann R, Alheit HD, Reiss G, Hliscs R, Steinmeier R, Franke WG, Johannsen B, Kotzerke J, 2003. 3-O-Methyl-6-[(18)F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Eur.J Nucl Med Mol.Imaging 30,1004-1008
- Bhatt MH, Snow BJ, Martin WR, Cooper S, Calne DB, 1990. Positron emission tomography in Shy-Drager syndrome. Ann.Neurol 28,101-103
- Bhatt MH, Snow BJ, Martin WR, Peppard R, Calne DB, 1991. Positron emission tomography in progressive supranuclear palsy. Arch.Neurol. 48,389-391
- Bicik I, Radanov BP, Schafer N, Dvorak J, Blum B, Weber B, Burger C, von Schulthess GK, Buck A, 1998. PET with 18fluorodeoxyglucose and hexamethylpropylene amine oxime SPECT in late whiplash syndrome. Neurology 51,345-350
- Binkofski F, Seitz RJ, Arnold S, Classen J, Benecke R, Freund HJ, 1996. Thalamic metabolism and corticospinal tract integrity determine motor recovery in stroke. Annals of Neurology 39,460-470
- Bisaga A, Katz JL, Antonini A, Wright CE, Margouleff C, Gorman JM, Eidelberg D, 1998. Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry 155,1178-1183
- Bittar RG, Andermann F, Olivier A, Dubeau F, Dumoulin SO, Pike GB, Reutens DC, 1999. Interictal spikes increase cerebral glucose metabolism and blood flow: a PET study. Epilepsia 40,170-178
- Biver F, Delvenne V, Goldman S, Luxen A, De M, V, Lotstra F, Mendlewicz J, 1992. [No hypofrontality in schizophrenia demonstrated by positron emission tomography]. Acta Psychiatr.Belg. 92,261-278
- Black KL, Ikezaki K, Santori E, Becker DP, Vinters HV, 1990. Specific high-affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man. Cancer 65,93-97

- Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH, 2000. Occurrence, regulation, and significance of progesterone receptors in human meningioma. *Steroids* 65,795-800
- Blasberg R, 2002. PET imaging of gene expression. *Eur.J Cancer* 38,2137-2146
- Blasberg RG, Fenstermacher JD, Patlak CS, 1983. Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. *J.Cereb.Blood Flow Metab.* 3,8-32
- Blasberg RG, Kobayashi T, Horowitz M, Rice JM, Groothuis D, Molnar P, Fenstermacher JD, 1983. Regional blood flow in ethylnitrosourea-induced brain tumors. *Annals of Neurology* 14,189-201
- Blasberg RG, Roelcke U, Weinreich R, Beattie B, von Ammon K, Yonekawa Y, Landolt H, Guenther I, Crompton NE, Vontobel P, Missimer J, Maguire RP, Kozirowski J, Knust EJ, Finn RD, Leenders KL, 2000. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. *Cancer Res.* 60,624-635
- Blasberg RG, Tjuvavev JG, 2003. Molecular-genetic imaging: current and future perspectives. *J Clin.Invest* 111,1620-1629
- Blennow M, Ingvar M, Lagercrantz H, Stone-Elander S, Eriksson L, Forssberg H, Ericson K, Flodmark O, 1995. Early [18F]FDG positron emission tomography in infants with hypoxic-ischaemic encephalopathy shows hypermetabolism during the postasphyctic period. *Acta Paediatr.* 84,1289-1295
- Blin J, Pappata S, Kiyosawa M, Crouzel C, Baron JC, 1988. [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. *European Journal of Pharmacology* 147,73-82
- Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, Agid Y, 1990. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. *Arch Neurol* 47,747-752
- Blin J, Denis A, Yamaguchi T, Crouzel C, MacKenzie ET, Baron JC, 1991. PET studies of [18F]methyl-MK-801, a potential NMDA receptor complex radioligand. *Neurosci.Lett.* 121,183-186

- Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y, 1992. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. *Movement Disorders* 7,348-354
- Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN, 1994. Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. *Journal of the Neurological Sciences* 123,44-51
- Blin J, Mazetti P, Mazoyer B, Rivaud S, Ben Ayed S, Malapani C, Pillon B, Agid Y, 1995. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? *Brain* 118,1485-1495
- Blin J, Ivanoiu A, De Volder A, Michel C, Bol A, Verellen C, Seron X, Duprez T, Laterre EC, 1998. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease. *Psychopharmacology (Berl.)* 136,256-263
- Blinkenberg M, Jensen CV, Holm S, Paulson OB, Sorensen PS, 1999. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. *Neurology* 53,149-153
- Blomqvist G, 1984. On the construction of functional maps in positron emission tomography. *J.Cereb.Blood Flow Metab.* 4,629-632
- Blomqvist G, Pauli S, Farde L, Eriksson L, Persson A, Halldin C, 1990. Maps of receptor binding parameters in the human brain--a kinetic analysis of PET measurements. *Eur.J Nucl Med* 16,257-265
- Blomqvist G, Stone-Elander S, Halldin C, Roland PE, Widen L, Lindqvist M, Swahn CG, Langstrom B, Wiesel FA, 1990. Positron emission tomographic measurements of cerebral glucose utilization using [1-11C]D-glucose. *J.Cereb.Blood Flow Metab.* 10,467-483
- Blomqvist G, Thorell JO, Ingvar M, Grill V, Widen L, Stone-Elander S, 1995. Use of R-beta-[1-11C]hydroxybutyrate in PET studies of regional cerebral uptake of ketone bodies in humans. *Am.J Physiol* 269,E948-E959
- Blomqvist G, Tavitian B, Pappata S, Crouzel C, Jobert A, Doignon I, Di Giambardino L, 2001. Quantitative Measurement of Cerebral Acetylcholinesterase Using [11C]physostigmine. *J.Cereb.Blood Flow Metab.* 21,114-131

- Blomqvist G, Alvarsson M, Grill V, Von Heijne G, Ingvar M, Thorell JO, Stone-Elander S, Widen L, Ekberg K, 2002. Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. *Am.J Physiol Endocrinol.Metab* 283,E20-E28
- Bloomfield PM, Spinks TJ, Reed J, Schnorr L, Westrip AM, Livieratos L, Fulton R, Jones T, 2003. The design and implementation of a motion correction scheme for neurological PET. *Physics in Medicine and Biology* 48,959-978
- Blum DE, Ehsan T, Dungan D, Karis JP, Fisher RS, 1998. Bilateral temporal hypometabolism in epilepsy. *Epilepsia* 39,651-659
- Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM, 1999. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. *Proc.Natl.Acad.Sci.U.S.A* 96,12079-12084
- Boecker H, Weindl A, Leenders K, Antonini A, Kuwert T, Kruggel F, Graf von Einsiedel H, Conrad B, 1996. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [ $^{18}\text{F}$ ]FDG and [ $^{18}\text{F}$ ]fluorodopa. *Acta Neurol Scand.* 93,387-392
- Boecker H, Wills AJ, Ceballos-Baumann A, Samuel M, Thompson PD, Findley LJ, Brooks DJ, 1996. The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. *Ann.Neurol* 39,650-658
- Boecker H, Wills AJ, Ceballos-Baumann A, Samuel M, Thomas DG, Marsden CD, Brooks DJ, 1997. Stereotactic thalamotomy in tremor-dominant Parkinson's disease: an H<sub>2</sub>( $^{15}\text{O}$ ) PET motor activation study. *Ann.Neurol* 41,108-111
- Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE, 1999. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. *Neurology* 52,541-546
- Bohnen NI, Koeppe RA, Meyer P, Ficaró E, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL, 2000. Decreased striatal monoaminergic terminals in Huntington disease. *Neurology* 54,1753-1759
- Bohnen NI, Kaufer DI, Lopresti B, Koeppe RA, Mathis CA, Dekosky ST, Moore RY, 2002. Cerebral acetylcholinesterase activity in patients with Parkinson's disease with and without dementia and Alzheimer's disease. *J Nucl Med* 43 (Suppl.),63P

- Bolla KI, Eldreth DA, London ED, Kiehl KA, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, Cadet JL, Kimes AS, 2003. Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. *Neuroimage* 19,1085-1094
- Bonhomme V, Fiset P, Meuret P, Backman S, Plourde G, Paus T, Bushnell MC, Evans AC, 2001. Propofol anesthesia and cerebral blood flow changes elicited by vibrotactile stimulation: a positron emission tomography study. *J Neurophysiol.* 85,1299-1308
- Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL, Kurian V, Ernst M, London ED, 2002. Neural systems and cue-induced cocaine craving. *Neuropsychopharmacology* 26,376-386
- Bookheimer SY, Zeffiro TA, Blaxton T, Malow BA, Gaillard WD, Sato S, Kufta C, Fedio P, Theodore WH, 1997. A DIRECT COMPARISON OF PET ACTIVATION AND ELECTROCORTICAL STIMULATION MAPPING FOR LANGUAGE LOCALIZATION. *Neurology* 48,1056-1065
- Bookheimer SY, Zeffiro TA, Blaxton TA, Gaillard PW, Theodore WH, 2000. Activation of language cortex with automatic speech tasks. *Neurology* 55,1151-1157
- Borbath I, Gregoire V, Bergstrom M, Laryea D, Langstrom B, Pauwels S, 2002. Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. *Eur.J Nucl Med Mol.Imaging* 29,19-27
- Borbely K, Fulham MJ, Brooks RA, Di Chiro G, 1992. PET-fluorodeoxyglucose of cranial and spinal neuromas. *J.Nucl.Med.* 33,1931-1934
- Boren EL, Jr., Delbeke D, Patton JA, Sandler MP, 1999. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies. *Eur.J Nucl Med* 26,379-387
- Born AP, Law I, Lund TE, Rostrup E, Hanson LG, Wildschiodtz G, Lou HC, Paulson OB, 2002. Cortical deactivation induced by visual stimulation in human slow-wave sleep. *Neuroimage* 17,1325-1335
- Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA, 2002. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. *Biol.Psychiatry* 52,126-135

- Bottlaender M, Dolle F, Guenther I, Roumenov D, Fuseau C, Bramouille Y, Curet O, Jegham J, Pinquier JL, George P, Valette H, 2003. Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [<sup>11</sup>C]Befloxatone. *J Pharmacol.Exp.Ther.* 305,467-473
- Bottlaender M, Valette H, Roumenov D, Dolle F, Coulon C, Ottaviani M, Hinnen F, Ricard M, 2003. Biodistribution and radiation dosimetry of (18)f-fluoro-a-85380 in healthy volunteers. *J Nucl Med* 44,596-601
- Boudraa AE, Champier J, Cinotti L, Bordet JC, Lavenne F, Mallet JJ, 1996. Delineation and quantitation of brain lesions by fuzzy clustering in positron emission tomography. *Comput.Med Imaging Graph.* 20,31-41
- Bouilleret V, Dupont S, Spelle L, Baulac M, Samson Y, Semah F, 2002. Insular cortex involvement in mesiotemporal lobe epilepsy: A positron emission tomography study. *Ann.Neurol.* 51,202-208
- Braak H, Braak E, 1991. Neuropathological stageing of Alzheimer-related changes. [Review]. *Acta Neuropathologica* 82,239-259
- Brandt J, Folstein SE, Wong DF, Links J, Dannals RF, McDonnell-Sill A, Starkstein S, Anders P, Strauss ME, Tune LE, 1990. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. *J Neuropsychiatry Clin.Neurosci.* 2,20-27
- Brashear A, Mulholland GK, Zheng QH, Farlow MR, Siemers ER, Hutchins GD, 1999. PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). *Mov Disord.* 14,132-137
- Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J, Carson RE, Herscovitch P, Chase TN, 1993. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. *Neuropsychopharmacology* 9,277-291
- Braun AR, Randolph C, Stoetter B, Mohr E, Cox C, Vladar K, Sexton R, Carson RE, Herscovitch P, Chase TN, 1995. The functional neuroanatomy of Tourette's syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. *Neuropsychopharmacology* 13,151-168

- Braun AR, Balkin TJ, Wesenten NJ, Carson RE, Varga M, Baldwin P, Selbie S, Belenky G, Herscovitch P, 1997. Regional cerebral blood flow throughout the sleep-wake cycle. An H<sub>2</sub>(15)O PET study. *Brain* 120,1173-1197
- Braun AR, Balkin TJ, Wesensten NJ, Gwadry F, Carson RE, Varga M, Baldwin P, Belenky G, Herscovitch P, 1998. Dissociated pattern of activity in visual cortices and their projections during human rapid eye movement sleep. *Science* 279,91-95
- Braun V, Dempf S, Tomczak R, Wunderlich A, Weller R, Richter HP, 2001. Multimodal cranial neuronavigation: direct integration of functional magnetic resonance imaging and positron emission tomography data: technical note. *Neurosurgery* 48,1178-1181
- Bravo D, Parsons SM, 2002. Microscopic kinetics and structure-function analysis in the vesicular acetylcholine transporter. *Neurochemistry International* 41,285-289
- Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D, 1997. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. *Am J Psychiatry* 154,805-811
- Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D, 1997. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. *American Journal of Psychiatry* 154,805-811
- Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D, 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. *Proc.Natl.Acad.Sci.U.S.A* 94,2569-2574
- Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D, 1998. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. *Synapse* 29,142-147
- Breier JI, Mullani NA, Thomas AB, Wheless JW, Plenger PM, Gould KL, Papanicolaou A, Willmore LJ, 1997. EFFECTS OF DURATION OF EPILEPSY ON THE UNCOUPLING OF METABOLISM AND BLOOD FLOW IN COMPLEX PARTIAL SEIZURES. *Neurology* 48,1047-1053
- Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS, 1999. Neural correlates of memories of childhood sexual abuse in women



- with and without posttraumatic stress disorder. *Am J Psychiatry* 156,1787-1795
- Bremner JD, Staib LH, Kaloupek D, Southwick SM, Soufer R, Charney DS, 1999. Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study. *Biol.Psychiatry* 45,806-816
- Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA, Berman RM, Charney DS, 2003. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. *JAMA* 289,3125-3134
- Bremner JD, Vythilingam M, Vermetten E, Southwick SM, McGlashan T, Staib LH, Soufer R, Charney DS, 2003. Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. *Biol.Psychiatry* 53,879-889
- Bremner JD, Vythilingam M, Vermetten E, Southwick SM, McGlashan T, Nazeer A, Khan S, Vaccarino LV, Soufer R, Garg PK, Ng CK, Staib LH, Duncan JS, Charney DS, 2003. MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. *Am J Psychiatry* 160,924-932
- Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR, Popovic M, 2003. Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. *J Neurosci.* 23,8029-8033
- Bressan RA, Pilowsky LS, 2000. Imaging the glutamatergic system in vivo--relevance to schizophrenia. *Eur.J Nucl Med* 27,1723-1731
- Brett M, Johnsrude IS, Owen AM, 2002. The problem of functional localization in the human brain. *Nat.Rev.Neurosci.* 3,243-249
- Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ, 1997. Performance evaluation of a whole-body PET scanner using the NEMA protocol. *J.Nucl.Med.* 38,1614-1623
- Brix G, Doll J, Bellemann ME, Trojan H, Haberkorn U, Schmidlin P, Ostertag H, 1997. Use of scanner characteristics in iterative image reconstruction for

- high-resolution positron emission tomography studies of small animals.  
Eur.J Nucl Med 24,779-786
- Brock CS, Young H, O'Reilly SM, Matthews J, Osman S, Evans H, Newlands ES, Price PM, 2000. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br.J.Cancer 82,608-615
- Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR, Jr., 1998. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 84,1-6
- Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, Huang SC, Wu HM, Maidment K, Baxter LR, Jr., 1999. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 91,127-139
- Brody AL, Saxena S, Mandelkern MA, Fairbanks LA, Ho ML, Baxter LR, 2001. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol.Psychiatry 50,171-178
- Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR, Jr., Madsen D, Jarvik ME, 2002. Brain metabolic changes during cigarette craving. Arch.Gen.Psychiatry 59,1162-1172
- Bromfield EB, Ludlow CL, Sedory S, Leiderman DB, Theodore WH, 1991. Cerebral activation during speech discrimination in temporal lobe epilepsy. Epilepsy Research 9,49-58
- Brooks DJ, Leenders KL, Head G, Marshall J, Legg NJ, Jones T, 1984. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosurg Psychiatry 47,1182-1191
- Brooks DJ, Frackowiak RS, Lammertsma AA, Herold S, Leenders KL, Selwyn AP, Turton DR, Brady F, Jones T, 1986. A comparison between regional cerebral blood flow measurements obtained in human subjects using 11C-methylalbumin microspheres, the C15O2 steady-state method, and positron emission tomography. Acta Neurologica Scandinavica 73,415-422
- Brooks DJ, Beaney RP, Lammertsma AA, Herold S, Turton DR, Luthra SK, Frackowiak RS, Thomas DG, Marshall J, Jones T, 1986. Glucose

- transport across the blood-brain barrier in normal human subjects and patients with cerebral tumours studied using [ $^{11}\text{C}$ ]3-O-methyl-D-glucose and positron emission tomography. *J.Cereb.Blood Flow Metab.* 6,230-239
- Brooks DJ, Beaney RP, Thomas DG, Marshall J, Jones T, 1986. Studies on regional cerebral pH in patients with cerebral tumours using continuous inhalation of  $^{11}\text{CO}_2$  and positron emission tomography. *J.Cereb.Blood Flow Metab.* 6,529-535
- Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS, 1990. Differing patterns of striatal  $^{18}\text{F}$ -dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Ann.Neurol* 28,547-555
- Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RS, 1990. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. *Brain* 113,1539-1552
- Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS, 1992. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with  $^{11}\text{C}$ -raclopride and positron emission tomography. *Ann.Neurol* 31,184-192
- Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, Findley LJ, Marsden CD, 1992. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an  $^{18}\text{F}$ -dopa PET study [see comments]. *Neurology* 42,1554-1560
- Brooks DJ, 1993. PET studies on the early and differential diagnosis of Parkinson's disease. *Neurology* 43,S6-16
- Brooks DJ, 2001. Functional imaging studies on dopamine and motor control. *J.Neural Transm.* 108,1283-1298
- Brown WD, Oakes TR, DeJesus OT, Taylor MD, Roberts AD, Nickles RJ, Holden JE, 1998. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. *J Nucl Med* 39,1884-1891
- Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, Malischke LM, DeJesus OT, Nickles RJ, 1999. FluoroDOPA PET shows

- the nondopaminergic as well as dopaminergic destinations of levodopa. *Neurology* 53,1212-1218
- Brown WD, DeJesus OT, Pyzalski RW, Malischke L, Roberts AD, Shelton SE, Uno H, Houser WD, Nickles RJ, Holden JE, 1999. Localization of trapping of 6-[(18)F]fluoro-L-m-tyrosine, an aromatic L-amino acid decarboxylase tracer for PET. *Synapse* 34,111-123
- Brownell AL, Hantraye P, Wullner U, Hamberg L, Shoup T, Elmaleh DR, Frim DM, Madras BK, Brownell GL, Rosen BR, 1994. PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. *Exp.Neurol* 125,41-51
- Brownell AL, Livni E, Galpern W, Isacson O, 1998. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. *Ann.Neurol* 43,387-390
- Bruck A, Portin R, Lindell A, Laihininen A, Bergman J, Haaparanta M, Solin O, Rinne JO, 2001. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. *Neurosci.Lett.* 311,81-84
- Bruehlmeier M, Roelcke U, Blauenstein P, Missimer J, Schubiger PA, Locher JT, Pellikka R, Ametamey SM, 2003. Measurement of the Extracellular Space in Brain Tumors Using (76)Br-Bromide and PET. *J Nucl Med* 44,1210-1218
- Brunberg JA, Frey KA, Horton JA, Kuhl DE, 1992. Crossed cerebellar diaschisis - Occurrence and resolution demonstrated with PET during carotid temporary occlusion. *Ajnr: American Journal of Neuroradiology* 13,58-61
- Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, Bjorklund A, Brooks DJ, Marsden CD, Oertel WH, Quinn NP, Rehncrona S, Lindvall O, 2000. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazarooids in Parkinson's disease. *Brain* 123,1380-1390
- Brunetti A, Blasberg RG, Finn RD, Larson SM, 1988. Gallium-transferrin as a macromolecular tracer of vascular permeability. *International Journal of Radiation Applications & Instrumentation - Part B, Nuclear Medicine & Biology* 15,665-672

- Brust P, Zessin J, Kuwabara H, Pawelke B, Kretschmar M, Hinz R, Bergman J, Eskola O, Solin O, Steinbach J, Johannsen B, 2003. Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. *Synapse* 47,143-151
- Bryan RN, 1998. What's your favorite PET story? *AJNR Am.J Neuroradiol.* 19,590
- Buchsbaum MS, Wu J, Haier R, Hazlett E, Ball R, Katz M, Sokolski K, Lagunas-Solar M, Langer D, 1987. Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. *Life Sci.* 40,2393-2400
- Buchsbaum MS, Kesslak JP, Lynch G, Chui H, Wu J, Sicotte N, Hazlett E, Teng E, Cotman CW, 1991. Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. *Arch Gen Psychiatry* 48,840-847
- Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, Reynolds C, 1997. Effect of sertraline on regional metabolic rate in patients with affective disorder. *Biol.Psychiatry* 41,15-22
- Buchsbaum MS, Hazlett EA, Haznedar MM, Spiegel-Cohen J, Wei TC, 1999. Visualizing fronto-striatal circuitry and neuroleptic effects in schizophrenia. *Acta Psychiatr.Scand.Suppl* 395,129-137
- Buchsbaum MS, Nenadic I, Hazlett EA, Spiegel-Cohen J, Fleischman MB, Akhavan A, Silverman JM, Siever LJ, 2002. Differential metabolic rates in prefrontal and temporal Brodmann areas in schizophrenia and schizotypal personality disorder. *Schizophr.Res* 54,141-150
- Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M, 2003. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. *J Nucl Med* 44,1426-1431
- Buckner RL, Corbetta M, Schatz J, Raichle ME, Petersen SE, 1996. Preserved speech abilities and compensation following prefrontal damage. *Proc.Natl.Acad.Sci.USA* 93,1249-1253
- Budinger TF, Derenzo SE, Gullberg GT, Greenberg WL, Huesman RH, 1977. Emission computer assisted tomography with single-photon and positron annihilation photon emitters. *J Comput.Assist.Tomogr.* 1,131-145

- Budinger TF, 1998. PET instrumentation: What are the limits? *Seminars in Nuclear Medicine* 28,247-267
- Burdette JH, Minoshima S, Vander Borcht T, Tran DD, Kuhl DE, 1996. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. *Radiology* 198,837-843
- Burn DJ, Sawle GV, Brooks DJ, 1994. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. *Journal of Neurology, Neurosurgery & Psychiatry* 57,278-284
- Burn DJ, Rinne JO, Quinn NP, Lees AJ, Marsden CD, Brooks DJ, 1995. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [<sup>11</sup>C]diprenorphine PET study. *Brain* 118,951-958
- Burns A, Tyrrell P, 1992. Association of age with regional cerebral oxygen utilization: a positron emission tomography study. *Age Ageing* 21,316-320
- Burns LH, Pakzaban P, Deacon TW, Brownell AL, Tatter SB, Jenkins BG, Isacson O, 1995. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. *Neuroscience* 64,1007-1017
- Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A, 1986. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C<sup>11</sup>-L-Methionine. *Journal of Neuro-Oncology* 3,397-404
- Buvat I, 2002. A non-parametric bootstrap approach for analysing the statistical properties of SPECT and PET images. *Physics in Medicine and Biology* 47,1761-1775
- Buxton RB, Wechsler LR, Alpert NM, Ackerman RH, Elmaleh DR, Correia JA, 1984. Measurement of brain pH using <sup>11</sup>CO<sub>2</sub> and positron emission tomography. *J.Cereb.Blood Flow Metab.* 4,8-16
- Buxton RB, Alpert NM, Babikian V, Weise S, Correia JA, Ackerman RH, 1987. Evaluation of the <sup>11</sup>CO<sub>2</sub> positron emission tomographic method for measuring brain pH. I. pH changes measured in states of altered PCO<sub>2</sub>. *J.Cereb.Blood Flow Metab.* 7,709-719

- Cabeza R, Kingstone A, 2001. Handbook of Functional Neuroimaging of Cognition, MIT Press,
- Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW, Jones T, Banati RB, 2001. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. *Brain* 124,2014-2027
- Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB, 2001. In-vivo measurement of activated microglia in dementia. *Lancet* 358,461-467
- Calautti C, Leroy F, Guincestre JY, Marie RM, Baron JC, 2001. Sequential activation brain mapping after subcortical stroke: changes in hemispheric balance and recovery. *Neuroreport* 12,3883-3886
- Calautti C, Baron JC, 2003. Functional neuroimaging studies of motor recovery after stroke in adults: a review. *Stroke* 34,1553-1566
- Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M, 1985. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. *Nature* 317,246-248
- Calne DB, Fuente-Fernandez R, Kishore A, 1997. Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. *J Neural Transm.Suppl* 50,47-52
- Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE, 1983. Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's disease. *J Neurol.Sci.* 59,277-289
- Caparros-Lefebvre D, Cabaret M, Godefroy O, Steinling M, Remy P, Samson Y, Petit H, 1998. PET study and neuropsychological assessment of a long-lasting post- encephalitic parkinsonism. *J.Neural Transm.* 105,489-495
- Caplan R, Curtiss S, Chugani HT, Vinters HV, 1996. Pediatric Rasmussen encephalitis: social communication, language, PET and pathology before and after hemispherectomy. *Brain Cogn.* 32,45-66

- Cappa SF, Perani D, Messa C, Miozzo A, Fazio F, 1996. Varieties of progressive non-fluent aphasia. *Annals of the New York Academy of Sciences* 777,243-248
- Cappa SF, Perani D, Grassi F, Bressi S, Alberoni M, Franceschi M, Bettinardi V, Todde S, Fazio F, 1997. A PET follow-up study of recovery after stroke in acute aphasics. *Brain & Language* 56,55-67
- Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechttersheimer section, Lehnert T, 2003. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. *Eur.J Surg.Oncol.* 29,536-541
- Carpenter DA, Grubb RL, Jr., Tempel LW, Powers WJ, 1991. Cerebral oxygen metabolism after aneurysmal subarachnoid hemorrhage. *J Cereb.Blood Flow Metab* 11,837-844
- Carpentier A, Pugh KR, Westerveld M, Studholme C, Skrinjar O, Thompson JL, Spencer DD, Constable RT, 2001. Functional MRI of language processing: dependence on input modality and temporal lobe epilepsy. *Epilepsia* 42,1241-1254
- Carson RE, Huang SC, Green MV, 1986. Weighted integration method for local cerebral blood flow measurements with positron emission tomography. *J.Cereb.Blood Flow Metab.* 6,245-258
- Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P, 1993. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. *J Cereb.Blood Flow Metab* 13,24-42
- Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC, 1997. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. *J Cereb.Blood Flow Metab* 17,437-447
- Carson RE, Kiesewetter DO, Jagoda E, Der MG, Herscovitch P, Eckelman WC, 1998. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. *J.Cereb.Blood Flow Metab.* 18,1130-1142
- Carson RE, Lang L, Watabe H, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC, 2000. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. *Nucl Med Biol.* 27,493-497



- Carson RE, Wu Y, Lang L, Ma Y, Der MG, Herscovitch P, Eckelman WC, 2003. Brain Uptake of the Acid Metabolites of F-18-Labeled WAY 100635 Analogs. *J Cereb.Blood Flow Metab* 23,249-260
- Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD, 1998. Functional hypofrontality and working memory dysfunction in schizophrenia. *Am J Psychiatry* 155,1285-1287
- Casey KL, Minoshima S, Berger KL, Koeppe RA, Morrow TJ, Frey KA, 1994. Positron emission tomographic analysis of cerebral structures activated specifically by repetitive noxious heat stimuli. *J Neurophysiol.* 71,802-807
- Casey KL, Minoshima S, Morrow TJ, Koeppe RA, 1996. Comparison of human cerebral activation pattern during cutaneous warmth, heat pain, and deep cold pain. *J Neurophysiol.* 76,571-581
- Casey ME, Nutt R, 1986. A MULTICRYSTAL 2-DIMENSIONAL BGO DETECTOR SYSTEM FOR POSITRON EMISSION TOMOGRAPHY. *IEEE Transactions on Nuclear Science* 33,460-463
- Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R, 2003. Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene. *Science* 301,386
- Castelnau P, Zilbovicius M, Ribeiro MJ, Hertz-Pannier L, Ogier H, Evrard P, 2001. Striatal and pontocerebellar hypoperfusion in Hallervorden-Spatz syndrome. *Pediatr.Neurol* 25,170-174
- Catalan MJ, Ishii K, Honda M, Samii A, Hallett M, 1999. A PET study of sequential finger movements of varying length in patients with Parkinson's disease. *Brain* 122 ( Pt 3),483-495
- Ceballos-Baumann AO, Passingham RE, Warner T, Playford ED, Marsden CD, Brooks DJ, 1995. Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia. *Ann.Neurol* 37,363-372
- Ceballos-Baumann AO, Brooks DJ, 1998. Activation positron emission tomography scanning in dystonia. *Adv.Neurol* 78,135-152
- Ceballos-Baumann AO, Boecker H, Bartenstein P, von F, I, Riescher H, Conrad B, Moringlane JR, Alesch F, 1999. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced

- movement-related activity of motor-association cortex and decreased motor cortex resting activity. *Arch Neurol* 56,997-1003
- Ceballos-Baumann AO, Boecker H, Fogel W, Alesch F, Bartenstein P, Conrad B, Diederich N, von F, I, Moringlane JR, Schwaiger M, Tronnier VM, 2001. Thalamic stimulation for essential tremor activates motor and deactivates vestibular cortex. *Neurology* 56,1347-1354
- Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ, 2002. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. *Synapse* 43,201-207
- Chabriat H, Pappata S, Levasseur M, Fiorelli M, Tran DS, Baron JC, 1992. Cortical metabolism in posterolateral thalamic stroke: PET study. *Acta Neurol Scand.* 86,285-290
- Chalmers TC, 1988. PET scans and technology assessment. *JAMA* 260,2713-2715
- Chang JY, Duara R, Barker W, Apicella A, Finn R, 1987. Two behavioral states studied in a single PET/FDG procedure: theory, method, and preliminary results. *J Nucl Med* 28,852-860
- Chang MC, Arai T, Freed LM, Wakabayashi S, Channing MA, Dunn BB, Der MG, Bell JM, Sasaki T, Herscovitch P, Eckelman WC, Rapoport SI, 1997. Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. *Brain Res.* 755,74-83
- Chao ST, Suh JH, Raja S, Lee SY, Barnett G, 2001. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. *Int.J.Cancer* 96,191-197
- Charalambous A, Marciniak G, Shiue CY, Dewey SL, Schlyer DJ, Wolf AP, Makriyannis A, 1991. PET studies in the primate brain and biodistribution in mice using (-)-5'-18F-delta 8-THC. *Pharmacology, Biochemistry & Behavior* 40,503-507
- Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Di Chiro G, 1984. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. *Annals of Neurology* 15 Suppl,S170-S174

- Chase TN, Tamminga CA, Burrows H, 1988. Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia. *Adv.Neurol* 50,237-241
- Chatziioannou A, Qi J, Moore A, Annala A, Nguyen K, Leahy R, Cherry SR, 2000. Comparison of 3-D maximum a posteriori and filtered backprojection algorithms for high-resolution animal imaging with microPET. *IEEE Trans.Med Imaging* 19,507-512
- Chatziioannou A, Tai YC, Doshi N, Cherry SR, 2001. Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. *Phys.Med Biol.* 46,2899-2910
- Chatziioannou AF, 2002. Molecular imaging of small animals with dedicated PET tomographs. *Eur.J Nucl Med* 29,98-114
- Chawluk JB, Mesulam MM, Hurtig H, Kushner M, Weintraub S, Saykin A, Rubin N, Alavi A, Reivich M, 1986. Slowly progressive aphasia without generalized dementia: studies with positron emission tomography. *Annals of Neurology* 19,68-74
- Chefer SI, London ED, Koren AO, Pavlova OA, Kurian V, Kimes AS, Horti AG, Mukhin AG, 2003. Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. *Synapse* 48,25-34
- Chen AC, 1993. Human brain measures of clinical pain: a review. II. Tomographic imagings. [Review]. *Pain* 54,133-144
- Chen K, Bandy D, Reiman E, Huang SC, Lawson M, Feng D, Yun LS, Palant A, 1998. Noninvasive quantification of the cerebral metabolic rate for glucose using positron emission tomography, 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function. *J.Cereb.Blood Flow Metab.* 18,716-723
- Cherry SR, Marsden PK, Ott RJ, Flower MA, Webb S, Babich JW, 1989. Image Quantification with A Large Area Multiwire Proportional Chamber Positron Camera (Mup-Pet). *Eur.J.Nucl.Med.* 15,694-700
- Cherry SR, Dahlbom M, Hoffman EJ, 1991. 3D PET using a conventional multislice tomograph without septa. *Journal of Computer Assisted Tomography* 15,655-668

- Cherry SR, Meikle SR, Hoffman EJ, 1993. Correction and characterization of scattered events in three- dimensional PET using scanners with retractable septa. *J.Nucl.Med.* 34,671-678
- Cherry SR, Woods RP, Hoffman EJ, Mazziotta JC, 1993. Improved detection of focal cerebral blood flow changes using three-dimensional positron emission tomography. *J.Cereb.Blood Flow Metab.* 13,630-638
- Cherry SR, Shao Y, Silverman RW, Meadors K, Siegel S, Chatziioannou A, Young JW, Jones WF, Moyers JC, Newport D, Boutefnouchet A, Farquhar TH, Andreaco M, Paulus MJ, Binkley DM, Nutt R, Phelps ME, 1997. MicroPET: A high resolution PET scanner for imaging small animals. *IEEE Transactions on Nuclear Science* 44,1161-1166
- Chesis PL, Hwang DR, Welch MJ, 1990. N-(3-[<sup>18</sup>F]fluoropropyl)-N-nordiprenorphine: synthesis and characterization of a new agent for imaging opioid receptors with positron emission tomography. *J Med Chem.* 33,1482-1490
- Chetelat G, Desgranges B, de IS, V, Viader F, Eustache F, Baron JC, 2003. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? *Neurology* 60,1374-1377
- Chetelat G, Baron JC, 2003. Early diagnosis of alzheimer's disease: contribution of structural neuroimaging. *Neuroimage* 18,525-541
- Chiapparini L, Granata T, Farina L, Ciceri E, Erbetta A, Ragona F, Freri E, Fusco L, Gobbi G, Capovilla G, Tassi L, Giordano L, Viri M, Dalla BB, Spreafico R, Savoiardo M, 2003. Diagnostic imaging in 13 cases of Rasmussen's encephalitis: can early MRI suggest the diagnosis? *Neuroradiology* 45,171-183
- Chih CP, Roberts Jr EL, 2003. Energy substrates for neurons during neural activity: a critical review of the astrocyte-neuron lactate shuttle hypothesis. *J Cereb.Blood Flow Metab* 23,1263-1281
- Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP, 1999. Limbic activation during cue-induced cocaine craving. *Am.J.Psychiatry* 156,11-18
- Choi JY, Kim SJ, Hong SB, Seo DW, Hong SC, Kim BT, Kim SE, 2003. Extratemporal hypometabolism on FDG PET in temporal lobe epilepsy as a predictor of seizure outcome after temporal lobectomy. *Eur.J Nucl Med Mol.Imaging* 30,581-587

- Chollet F, DiPiero V, Wise RJ, Brooks DJ, Dolan RJ, Frackowiak RS, 1991. The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. *Annals of Neurology* 29,63-71
- Chou YH, Karlsson P, Halldin C, Olsson H, Farde L, 1999. A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. *Psychopharmacology (Berl)* 146,220-227
- Chou YH, Halldin C, Farde L, 2003. Occupancy of 5-HT<sub>1A</sub> receptors by clozapine in the primate brain: a PET study. *Psychopharmacology (Berl)* 166,234-240
- Christian BT, Babich JW, Livni E, Alpert NM, Bonab AA, Munconi L, Polinski R, Rubin RH, Fischman AJ, 1998. Positron emission tomographic analysis of central dopamine D<sub>1</sub> receptor binding in normal subjects treated with the atypical neuroleptic, SDZ MAR 327. *Int.J Mol.Med* 1,243-247
- Chua P, Krams M, Toni I, Passingham R, Dolan R, 1999. A Functional Anatomy of Anticipatory Anxiety. *Neuroimage* 9,563-571
- Chugani DC, Ackermann RF, Phelps ME, 1988. In vivo [<sup>3</sup>H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. *J Cereb.Blood Flow Metab* 8,291-303
- Chugani DC, Chugani HT, Muzik O, Shah JR, Shah AK, Canady A, Mangner TJ, Chakraborty PK, 1998. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[<sup>11</sup>C]methyl-L-tryptophan positron emission tomography. *Annals of Neurology* 44,858-866
- Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT, 1998. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-<sup>11</sup>]methyl-L-tryptophan. *Synapse* 28,33-43
- Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT, 1999. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. *Ann.Neurol.* 45,287-295
- Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhoury M, Lee ML, Chugani HT, 1999. Increased brain serotonin synthesis in migraine. *Neurology* 53,1473-1479

- Chugani DC, Muzik O, 2000. Alpha[C-11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. *J.Cereb.Blood Flow Metab.* 20,2-9
- Chugani DC, Muzik O, Juhasz C, Janisse JJ, Ager J, Chugani HT, 2001. Postnatal maturation of human GABAA receptors measured with positron emission tomography. *Ann.Neurol* 49,618-626
- Chugani HT, Phelps ME, Mazziotta JC, 1987. Positron emission tomography study of human brain functional development. *Annals of Neurology* 22,487-497
- Chugani HT, Mazziotta JC, Engel J, Jr., Phelps ME, 1987. The Lennox-Gastaut syndrome: metabolic subtypes determined by 2- deoxy-2[18F]fluoro-D-glucose positron emission tomography. *Annals of Neurology* 21,4-13
- Chugani HT, Jacobs B, 1994. Metabolic recovery in caudate nucleus of children following cerebral hemispherectomy. *Annals of Neurology* 36,794-797
- Chugani HT, Chugani DC, 1999. Basic mechanisms of childhood epilepsies: studies with positron emission tomography. *Adv.Neurol.* 79,883-891
- Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, Chang FL, Skinner K, Tasaki C, Jagust WJ, 2000. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. *Arch.Neurol.* 57,191-196
- Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, Jeong JM, Lee DS, Jung HW, Lee MC, 2002. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. *Eur.J Nucl Med Mol.Imaging* 29,176-182
- Clark C, Carson R, 1993. Analysis of covariance in statistical parametric mapping [letter]. *J.Cereb.Blood Flow Metab.* 13,1038-1040
- Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, Szechtman H, Szechtman B, 1989. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. *Psychiatry Res* 28,119-133
- Cleghorn JM, Franco S, Szechtman B, Kaplan RD, Szechtman H, Brown GM, Nahmias C, Garnett ES, 1992. Toward a brain map of auditory hallucinations. *Am J Psychiatry* 149,1062-1069

- Cleon G, Allemand R, Papillon S, Pinot L, Richard A, Charon Y, Laniece P, Menard L, Valentin L, Mastriippolito R, 2002. Design of a new BaF2PET module concept and preliminary evaluation results. IEEE Transactions on Nuclear Science 49,139-140
- Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, Defer G, Samson Y, Peschanski M, Hantraye P, Cesaro P, Remy P, 2003. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov Disord. 18,928-932
- Coenen HH, Laufer P, St"cklin G, Wienhard K, Pawlik G, Bocher-Schwarz HG, Heiss WD, 1987. 3-N-(2-[18F]-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with pet. Life Sciences 40,81-88
- Coenen HH, Wienhard K, St"cklin G, Laufer P, Hebold I, Pawlik G, Heiss WD, 1988. PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain. Eur.J.Nucl.Med. 14,80-87
- Coenen HH, 1993. Biochemistry and evaluation of fluoroamino acids. In: Mazoyer BM et al., eds. PET studies on amino acid metabolism and protein synthesis , Kluwer Academic Publishers, Dordrecht, pp 109-129
- Coghill RC, Talbot JD, Evans AC, Meyer E, Gjedde A, Bushnell MC, Duncan GH, 1994. Distributed processing of pain and vibration by the human brain. J Neurosci. 14,4095-4108
- Coghill RC, Sang CN, Berman KF, Bennett GJ, Iadarola MJ, 1998. Global cerebral blood flow decreases during pain. J.Cereb.Blood Flow Metab. 18,141-147
- Coghill RC, Sang CN, Maisog JM, Iadarola MJ, 1999. Pain intensity processing within the human brain: a bilateral, distributed mechanism. J Neurophysiol. 82,1934-1943
- Cohen RM, Gross M, Semple WE, Nordahl TE, Sunderland T, 1994. The metabolic brain pattern of young subjects given scopolamine. Exp.Brain Res. 100,133-143
- Cohen RM, Carson RE, Sunderland T, 2000. Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. Synapse 38,226-229
- Cohen RM, Podruchny TA, Bokde AL, Carson RE, Herscovitch P, Kiesewetter DO, Eckelman WC, Sunderland T, 2003. Higher in vivo muscarinic-2

- receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. *Synapse* 49,150-156
- Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL, 2002. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. *Cancer Res.* 62,5912-5919
- Collins DL, Zijdenbos AP, Baare WFC, Evans AC, 1999. ANIMAL+INSECT: Improved cortical structure segmentation. *Information Processing in Medical Imaging, Proceedings* 1613,210-223
- Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM, 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. *Pharm.Res.* 17,266-274
- Comtat C, Kinahan PE, Defrise M, Michel C, Townsend DW, 1998. Fast reconstruction of 3D PET data with accurate statistical modeling. *IEEE Transactions on Nuclear Science* 45,1083-1089
- Conti PS, Alauddin MM, Fissekis JR, Schmall B, Watanabe KA, 1995. Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. *Nucl Med Biol.* 22,783-789
- Cooper GE, Rizzo M, Jones RD, 2000. Adult-onset Hallervorden-Spatz syndrome presenting as cortical dementia. *Alzheimer Dis.Assoc.Disord.* 14,120-126
- Cordato DJ, Fulham MJ, Yiannikas C, 1998. Pretreatment and posttreatment positron emission tomographic scan imaging in a 20-year-old patient with Wilson's disease. *Mov Disord.* 13,162-166
- Cordes M, Snow BJ, Morrison S, Sossi V, Ruth TJ, Calne DB, 1993. Parametric imaging of the rate constant Ki using [18Fluoro]-L- dopa positron emission tomography in progressive supranuclear palsy. *Neuroradiology* 35,404-409
- Cornford EM, Hyman S, Cornford ME, Landaw EM, Delgado-Escueta AV, 1998. Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. *J.Cereb.Blood Flow Metab.* 18,26-42



- Cortelli P, Perani D, Parchi P, Grassi F, Montagna P, Demartin M, Castellani R, Tinuper P, Gambetti P, Lugaresi E, Fazio F, 1997. CEREBRAL METABOLISM IN FATAL FAMILIAL INSOMNIA - RELATION TO DURATION, NEUROPATHOLOGY, AND DISTRIBUTION OF PROTEASE-RESISTENT PRION PROTEIN. *Neurology* 49,126-133
- Costes N, Merlet I, Zimmer L, Lavenne F, Cinotti L, Delforge J, Luxen A, Pujol JF, Le Bars D, 2002. Modeling [18 F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. *J Cereb.Blood Flow Metab* 22,753-765
- Cottraux J, Gerard D, Cinotti L, Froment JC, Deiber MP, Le Bars D, Galy G, Millet P, Labbe C, Lavenne F, Bouvard M, Mauguiere F, 1996. A controlled positron emission tomography study of obsessive and neutral auditory stimulation in obsessive-compulsive disorder with checking rituals. *Psychiatry Res* 60,101-112
- Craig AD, Reiman EM, Evans A, Bushnell MC, 1996. Functional imaging of an illusion of pain. *Nature* 384,258-260
- Cramer SC, Nelles G, Benson RR, Kaplan JD, Parker RA, Kwong KK, Kennedy DN, Finklestein SP, Rosen BR, 1997. A functional MRI study of subjects recovered from hemiparetic stroke. *Stroke* 28,2518-2527
- Crone C, 1963. Permeability of capillaries in various organs as determined by use of the indicator diffusion method. *Acta Physiol.Scand.* 58,292-305
- Cumming P, Leger GC, Kuwabara H, Gjedde A, 1993. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. *J Cereb.Blood Flow Metab* 13,668-675
- Cumming P, Munk OL, Doudet D, 2001. Loss of metabolites from monkey striatum during PET with FDOPA. *Synapse* 41,212-218
- Cumming P, Danielsen EH, Vafaei M, Falborg L, Steffensen E, Sorensen JC, Gillings N, Bender D, Marthi K, Andersen F, Munk O, Smith D, Moller A, Gjedde A, 2001. Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts. *Acta Neurol Scand.* 103,309-315
- Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A, 2002. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. *Ann.N Y.Acad.Sci.* 965,440-450

- Cumming P, Gillings NM, Jensen SB, Bjarkam C, Gjedde A, 2003. Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Gottingen miniature pigs. *Nucl Med Biol.* 30,547-553
- Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Jones AK, 1991. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. *J Cereb.Blood Flow Metab* 11,1-9
- Cunningham VJ, Jones T, 1993. Spectral analysis of dynamic PET studies. *J Cereb.Blood Flow Metab* 13,15-23
- D'Antona R, Baron JC, Samson Y, Serdaru M, Viader F, Agid Y, Cambier J, 1985. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. *Brain* 108,785-799
- Da Silva EA, Chugani DC, Muzik O, Chugani HT, 1997. Identification of frontal lobe epileptic foci in children using positron emission tomography. *Epilepsia* 38,1198-1208
- Da Silva EA, Chugani DC, Muzik O, Chugani HT, 1997. Landau-Kleffner syndrome: metabolic abnormalities in temporal lobe are a common feature. *J.Child Neurol.* 12,489-495
- Daemen BJ, Zwertbroek R, Elsinga PH, Paans AM, Doorenbos H, Vaalburg W, 1991. PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. *Eur.J Nucl Med* 18,453-460
- Daemen BJ, Elsinga PH, Paans AM, Wieringa AR, Konings AW, Vaalburg W, 1992. Radiation-induced inhibition of tumor growth as monitored by PET using L-[1-11C]tyrosine and fluorine-18-fluorodeoxyglucose. *J.Nucl.Med.* 33,373-379
- Dagher A, Bleicher C, Aston JA, Gunn RN, Clarke PB, Cumming P, 2001. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. *Synapse* 42,48-53
- Dahlbom M, 2002. Estimation of image noise in PET using the bootstrap method. *IEEE Transactions on Nuclear Science* 49,2062-2066

- Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G, 1987. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. *Ann.Neurol.* 22,580-586
- Damier P, Hirsch EC, Agid Y, Graybiel AM, 1999. The substantia nigra of the human brain: II. Patterns Of loss of dopamine-containing neurons in Parkinson's disease. *Brain* 122,1437-1448
- Danielsen EH, Smith DF, Gee AD, Venkatachalam TK, Hansen SB, Hermansen F, Gjedde A, Cumming P, 1999. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography [In Process Citation]. *Synapse* 33,247-258
- Danielsen EH, Cumming P, Andersen F, Bender D, Brevig T, Falborg L, Gee A, Gillings NM, Hansen SB, Hermansen F, Johansen J, Johansen TE, Dahl-Jorgensen A, Jorgensen HA, Meyer M, Munk O, Pedersen EB, Poulsen PH, Rodell AB, Sakoh M, Simonsen CZ, Smith DF, Sorensen JC, Ostergard L, Zimmer J, Gjedde A, 2000. The DaNeX study of embryonic mesencephalic, dopaminergic tissue grafted to a minipig model of Parkinson's disease: preliminary findings of effect of MPTP poisoning on striatal dopaminergic markers. *Cell Transplant.* 9,247-259
- Dann R, HOFORD J, KOVACIC S, Reivich M, Bajcsy R, 1989. EVALUATION OF ELASTIC MATCHING SYSTEM FOR ANATOMIC (CT, MR) AND FUNCTIONAL (PET) CEREBRAL IMAGES. *Journal of Computer Assisted Tomography* 13,603-611
- Dannals RF, Ravert HT, Frost JJ, Wilson AA, Burns HD, Wagner HN, Jr., 1985. Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. *Int.J Appl.Radiat.Isot.* 36,303-306
- Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL, 1997. Presynaptic dopaminergic function in the striatum of schizophrenic patients. *Schizophr.Res* 23,167-174
- Dasheiff RM, Rosenbek J, Matthews C, Nickles RJ, Koeppe RA, Hutchins GD, Ramirez L, Dickinson LV, 1987. Epilepsy surgery improves regional glucose metabolism on PET scan. A case report. *J Neurol* 234,283-288
- Daube-Witherspoon ME, Muehllehner G, 1987. Treatment of Axial Data in 3-Dimensional Pet. *J.Nucl.Med.* 28,1717-1724

- Davidson LL, Heinrichs RW, 2003. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. *Psychiatry Res* 122,69-87
- Davis KD, Taub E, Houle S, Lang AE, Dostrovsky JO, Tasker RR, Lozano AM, 1997. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. *Nat.Med* 3,671-674
- Davis KD, Taub E, Duffner F, Lozano AM, Tasker RR, Houle S, Dostrovsky JO, 2000. Activation of the anterior cingulate cortex by thalamic stimulation in patients with chronic pain: a positron emission tomography study. *J Neurosurg* 92,64-69
- de la Fuente JM, Goldman S, Stanus E, Vizuete C, Morlan I, Bobes J, Mendlewicz J, 1997. Brain glucose metabolism in borderline personality disorder. *J Psychiatr.Res* 31,531-541
- de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J, 2001. Prediction of cognitive decline in normal elderly subjects with 2-F-18-fluoro-2-deoxy-D-glucose positron-emission tomography (FDG PET). *Proc.Natl.Acad.Sci.U.S.A* 98,10966-10971
- De Ley G, Weyne J, Demeester G, Stryckmans K, Goethals P, Van d, V, Leusen I, 1988. Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. *J Cereb.Blood Flow Metab* 8,539-545
- De Ley G, Eechaute W, Strijckmans K, Goethals P, Lemahieu I, Van d, V, Weyne J, 1993. Hemodynamic and metabolic effects of flunarizine in experimental subarachnoid hemorrhage in dogs. *Stroke* 24,400-405
- De Oliveira SA, Castro MJ, Bittencourt PR, 1989. Slowly progressive aphasia followed by Alzheimer's dementia: a case report. *Arq Neuropsiquiatr.* 47,72-75
- De Reuck J, Decoo D, Lemahieu I, Strijckmans K, Goethals P, Van Maele G, 1997. Crossed cerebellar diaschisis after middle cerebral artery infarction. *Clin.Neurol Neurosurg* 99,11-16
- De Reuck J, Santens P, Goethals P, Strijckmans K, Lemahieu I, Boon P, Achten E, Lemmerling M, Vandekerckhove T, Caemaert J, 1999. [Methyl-

- <sup>11</sup>C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. *Acta Neurol Belg.* 99,118-125
- De Reuck J, Vonck K, Santens P, Boon P, De Bleecker J, Strijckmans K, Lemahieu I, 2000. Cobalt-55 positron emission tomography in late-onset epileptic seizures after thrombo-embolic middle cerebral artery infarction. *J.Neurol.Sci.* 181,13-18
- De Reuck J, Santens P, Strijckmans K, Lemahieu I, 2001. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. *J.Neurol.Sci.* 193,1-6
- De Souza B, Brunetti A, Fulham MJ, Brooks RA, DeMichele D, Cook P, Nieman L, Doppman JL, Oldfield EH, Di Chiro G, 1990. Pituitary microadenomas: a PET study. *Radiology* 177,39-44
- De Volder A, Bol A, Michel C, Cogneau M, Evrard P, Lyon G, Goffinet AM, 1988. Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET). *Brain Dev.* 10,47-50
- De Volder A, Sindic CJ, Goffinet AM, 1988. Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study. *J Neurol Neurosurg Psychiatry* 51,947-949
- De Volder AG, Francart J, Laterre C, Doms G, Bol A, Michel C, Goffinet AM, 1989. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. *Annals of Neurology* 26,239-247
- De Volder AG, Michel C, Guerit JM, Bol A, Georges B, de Barsy T, Laterre C, 1994. Brain glucose metabolism in postanoxic syndrome due to cardiac arrest. *Acta Neurol Belg.* 94,183-189
- De Volder AG, Gadisseux JF, Michel CJ, Maloteaux JM, Bol AC, Grandin CB, Duprez TP, Evrard P, 1994. Brain glucose utilization in band heterotopia: synaptic activity of "double cortex". *Pediatric Neurology* 11,290-294
- De Vos F, Santens P, Vermeirsch H, Dewolf I, Dumont F, Slegers G, Dierckx RA, De Reuck J, 2000. Pharmacological evaluation of [<sup>11</sup>C]donepezil as a tracer for visualization of acetylcholinesterase by PET. *Nucl Med Biol.* 27,745-747
- De Witte O, Hildebrand J, Luxen A, Goldman S, 1994. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. *Cancer* 74,2836-2842

- De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S, 2001. Positron emission tomography with injection of methionine as a prognostic factor in glioma. *J Neurosurg.* 95,746-750
- De A, Lewis XZ, Gambhir SS, 2003. Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. *Mol.Ther.* 7,681-691
- Debets RM, Sadzot B, van Isselt JW, Brekelmans GJ, Meiners LC, van Huffelen AO, Franck G, van Veelen CW, 1997. Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy? *J.Neurol.Neurosurg.Psychiatry* 62,141-150
- Debruyne D, Abadie P, Barre L, Albessard F, Moulin M, Zarifian E, Baron JC, 1991. Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. *European Journal of Drug Metabolism & Pharmacokinetics* 16,141-152
- Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, Achten E, Slegers G, Dierckx RA, Korf J, De Reuck JL, 2003. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. *Eur.J.Neurol.* 10,257-264
- DeCarli C, Atack JR, Ball MJ, Kay JA, Grady CL, Fewster P, Pettigrew KD, Rapoport SI, Schapiro MB, 1992. Post-mortem neurofibrillary tangle densities but not senile plaque densities are related regional metabolic rates for glucose during life in Alzheimer's disease patients. *Neurodegeneration* 1,113-121
- Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P, 1999. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. *Synapse* 34,313-318
- Defrise M, 1995. A Factorization Method for the 3D X-Ray Transform. *Inverse Problems* 11,983-994
- Defrise M, Kinahan P, 1998. Data acquisition and image reconstruction for 3D PET. In: Bendriem B, Townsend DW, eds. *The theory and practice of 3D PET*, Kluwer Academic Publishers, Dordrecht, pp 11-53
- Defrise M, Liu XA, 1999. A fast rebinning algorithm for 3D positron emission tomography using John's equation. *Inverse Problems* 15,1047-1065

- DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE, 1994. Performance characteristics of a whole-body PET scanner. *J.Nucl.Med.* 35,1398-1406
- DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE, 2001. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. *J Nucl Med* 42,1805-1814
- DeJesus OT, Holden JE, Endres C, Murali D, Oakes TR, Shelton S, Uno H, Houser D, Freund L, Perlman SB, 1992. Visualization of dopamine nerve terminals by positron tomography using [18F]fluoro-beta-fluoromethylene-m-tyrosine. *Brain Research* 597,151-154
- DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE, 2001. Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo. *Synapse* 39,58-63
- DeJesus OT, Shelton SE, Roberts AD, Nickles RJ, Holden JE, 2002. Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys. *Synapse* 44,246-251
- Del Guerra A, Belcari N, 2002. Advances in animal PET scanners. *Q.J Nucl Med* 46,35-47
- DeLaPaz RL, Patronas NJ, Brooks RA, Smith BH, Kornblith PL, Milam H, Di Chiro G, 1983. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. *Ajnr: American Journal of Neuroradiology* 4,826-829
- Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM, 1995. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. *Radiology* 195,47-52
- Delbeke D, Lawrence SK, Abou-Khalil BW, Blumenkopf B, Kessler RM, 1996. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. *Invest Radiol.* 31,261-266
- DeLeon MJ, Ferris SH, George AE, Reisberg B, Christman DR, Kricheff II, Wolf AP, 1983. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. *J.Cereb.Blood Flow Metab.* 3,391-394

- Delforge J, Syrota A, Bottlaender M, Varastet M, Loc'h C, Bendriem B, Crouzel C, Brouillet E, Maziere M, 1993. Modeling analysis of [<sup>11</sup>C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. *J.Cereb.Blood Flow Metab.* 13,454-468
- Delforge J, Pappata S, Millet P, Samson Y, Bendriem B, Jobert A, Crouzel C, Syrota A, 1995. Quantification of benzodiazepine receptors in human brain using PET, [<sup>11</sup>C]flumazenil, and a single-experiment protocol. *J.Cereb.Blood Flow Metab.* 15,284-300
- Delforge J, Spelle L, Bendriem B, Samson Y, Bottlaender M, Papageorgiou S, Syrota A, 1996. QUANTITATION OF BENZODIAZEPINE RECEPTORS IN HUMAN BRAIN USING THE PARTIAL SATURATION METHOD. *J.Nucl.Med.* 37,5-11
- Delforge J, Spelle L, Bendriem B, Samson Y, Syrota A, 1997. PARAMETRIC IMAGES OF BENZODIAZEPINE RECEPTOR CONCENTRATION USING A PARTIAL-SATURATION INJECTION. *J.Cereb.Blood Flow Metab.* 17,343-355
- DellaBadia J, Jr., Bell WL, Keyes JW, Jr., Mathews VP, Glazier SS, 2002. Assessment and cost comparison of sleep-deprived EEG, MRI and PET in the prediction of surgical treatment for epilepsy. *Seizure.* 11,303-309
- Delvenne V, Lotstra F, Goldman S, Biver F, De Maertelaer V, Appelboom-Fondu J, Schoutens A, Bidaut LM, Luxen A, Mendelwicz J, 1995. Brain hypometabolism of glucose in anorexia nervosa: a PET scan study. *Biological Psychiatry* 37,161-169
- Delvenne V, Goldman S, De M, V, Simon Y, Luxen A, Lotstra F, 1996. Brain hypometabolism of glucose in anorexia nervosa: normalization after weight gain. *Biol.Psychiatry* 40,761-768
- Delvenne V, Goldman S, De M, V, Wikler D, Damhaut P, Lotstra F, 1997. Brain glucose metabolism in anorexia nervosa and affective disorders: influence of weight loss or depressive symptomatology. *Psychiatry Res* 74,83-92
- Delvenne V, Goldman S, Simon Y, De M, V, Lotstra F, 1997. Brain hypometabolism of glucose in bulimia nervosa. *Int.J Eat.Disord.* 21,313-320
- Derbyshire SW, Jones AK, Devani P, Friston KJ, Feinmann C, Harris M, Pearce S, Watson JD, Frackowiak RS, 1994. Cerebral responses to pain in



- patients with atypical facial pain measured by positron emission tomography. *J Neurol Neurosurg Psychiatry* 57,1166-1172
- Derbyshire SW, Jones AK, 1998. Cerebral responses to a continual tonic pain stimulus measured using positron emission tomography. *Pain* 76,127-135
- Derbyshire SW, Jones AK, Collins M, Feinmann C, Harris M, 1999. Cerebral responses to pain in patients suffering acute post-dental extraction pain measured by positron emission tomography (PET). *Eur.J Pain* 3,103-113
- Derbyshire SW, Jones AK, Creed F, Starz T, Meltzer CC, Townsend DW, Peterson AM, Firestone L, 2002. Cerebral responses to noxious thermal stimulation in chronic low back pain patients and normal controls. *Neuroimage* 16,158-168
- Derdeyn CP, Videen TO, Yundt KD, Fritsch SM, Carpenter DA, Grubb RL, Powers WJ, 2002. Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. *Brain* 125,595-607
- Derlon JM, Petit-Taboue MC, Chapon F, Beaudouin V, Noel MH, Creveuil C, Courtheoux P, Houtteville JP, 1997. The in vivo metabolic pattern of low-grade brain gliomas: A positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. *Neurosurgery* 40,276-288
- Desgranges B, Baron JC, Lalevee C, Giffard B, Viader F, de IS, V, Eustache F, 2002. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. *Brain* 125,1116-1124
- Dethy S, Goldman S, Blecic S, Luxen A, Levivier M, Hildebrand J, 1994. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma. *J.Nucl.Med.* 35,1162-1166
- Dethy S, Manto M, Kentos A, Konopnicki D, Pirotte B, Goldman S, Hildebrand J, 1995. PET findings in a brain abscess associated with a silent atrial septal defect. *Clinical Neurology & Neurosurgery* 97,349-353
- Dethy S, Van Blercom N, Damhaut P, Wikler D, Hildebrand J, Goldman S, 1998. Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism. *Mov Disord.* 13,275-280

- Dettmers C, Hartmann A, Rommel T, Hartmann S, Pappata S, Baron JC, 1995. Contralateral cerebellar diaschisis 7 hours after MCA-occlusion in primates. *Neurological Research* 17,109-112
- Deutsche Gesellschaft für Psychiatrie PuND, 2000. Behandlungsleitlinie Demenz, Steinkopff, Darmstadt
- Deutsche Gesellschaft, für Neurologie. 2002. Diagnose und Therapie der Alzheimer-Demenz (AD) und der Demenz mit Lewy-Körperchen (DLB).
- Dewey SL, Volkow ND, Logan J, MacGregor RR, Fowler JS, Schlyer DJ, Bendriem B, 1990. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). *J Neurosci.Res* 27,569-575
- Dewey SL, MacGregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, Schlyer DJ, Fowler JS, Wolf AP, Gatley SJ, 1990. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. *Synapse* 5,213-223
- Dewey SL, Logan J, Wolf AP, Brodie JD, Angrist B, Fowler JS, Volkow ND, 1991. Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). *Synapse* 7,324-327
- Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA, King PT, MacGregor RR, Martin TP, Wolf AP, 1992. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. *J.Neurosci.* 12,3773-3780
- Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP, 1993. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. *Synapse* 13,350-356
- Dhawan V, Jarden JO, Strother S, Rottenberg DA, 1988. Effect of blood curve smearing on the accuracy of parameter estimates obtained for 82Rb/PET studies of blood-brain barrier permeability. *Physics in Medicine & Biology* 33,61-74
- Dhawan V, Moeller JR, Strother SC, Evans AC, Rottenberg DA, 1989. Effect of selecting a fixed dephosphorylation rate on the estimation of rate constants and rCMRGlu from dynamic [18F] fluorodeoxyglucose/PET data. *J.Nucl.Med.* 30,1483-1488

- Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhlef A, Margoulef C, Mandel F, Eidelberg D, 1996. Combined FDOPA and 3OMFD PET studies in Parkinson's disease [see comments]. *J.Nucl.Med.* 37,209-216
- Dhawan V, Ma Y, Okulski J, Asanuma K, Chaly T, Carbon M, Eidelberg D, 2003. Reduction of striatal D2 receptor binding in non-manifesting carriers of the DYT1 mutation. *J Cereb.Blood Flow Metab* 23 (Suppl. 1),S643
- Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP, 1982. Glucose utilization of cerebral gliomas measured by [<sup>18</sup>F] fluorodeoxyglucose and positron emission tomography. *Neurology* 32,1323-1329
- Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ, 1987. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. *Radiology* 164,521-526
- Di Chiro G, 1987. Positron emission tomography using [F-18]-fluorodeoxyglucose in brain tumors - a powerful diagnostic and prognostic tool. *Investigative Radiology* 22,360-371
- Di Chiro G, Brooks RA, 1988. PET quantitation: blessing and curse. *J Nucl Med* 29,1603-1604
- Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV, 1988. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. *AJR.Am.J.Roentgenol.* 150,189-197
- Di Piero V, Jones AK, Iannotti F, Powell M, Perani D, Lenzi GL, Frackowiak RS, 1991. Chronic pain: a PET study of the central effects of percutaneous high cervical cordotomy. *Pain* 46,9-12
- Diehl B, LaPresto E, Najm I, Raja S, Rona S, Babb T, Ying Z, Bingaman W, Luders HO, Ruggieri P, 2003. Neocortical Temporal FDG-PET Hypometabolism Correlates with Temporal Lobe Atrophy in Hippocampal Sclerosis Associated with Microscopic Cortical Dysplasia. *Epilepsia* 44,559-564
- Dienel GA, Cruz NF, Nakanishi H, Melzer P, Moulis P, Sokoloff L, 1992. Comparison of rates of local cerebral glucose utilization determined with deoxy[1-<sup>14</sup>C]glucose and deoxy[6-<sup>14</sup>C]glucose. *Journal of Neurochemistry* 59,1430-1436

- Dienel GA, Wang RY, Cruz NF, 2002. Generalized sensory stimulation of conscious rats increases labeling of oxidative pathways of glucose metabolism when the brain glucose-oxygen uptake ratio rises. *J Cereb.Blood Flow Metab* 22,1490-1502
- Diener HC, 1997. Positron emission tomography studies in headache. *Headache* 37,622-625
- Dierks T, Linden DE, Hertel A, Gunther T, Lanfermann H, Niesen A, Frolich L, Zanella FE, Hor G, Goebel R, Maurer K, 1999. Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. *Psychiatry Res.* 90,67-75
- Diksic M, Sako K, Feindel W, Kato A, Yamamoto YL, Farrokhzad S, Thompson C, 1984. Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography. *Cancer Res* 44,3120-3124
- Diksic M, Grdisa M, 1995. Alpha-methyl-L-tryptophan as a tracer to study brain serotonergic system. [Review]. *Neurochemical Research* 20,1353-1360
- Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N, 1997. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. *Psychopharmacology (Berl)* 131,71-78
- Ding YS, Molina PE, Fowler JS, Logan J, Volkow ND, Kuhar MJ, Carroll FI, 1999. Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. *Nucl Med Biol.* 26,139-148
- Ding YS, Volkow ND, Logan J, Garza V, Pappas N, King P, Fowler JS, 2000. Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette [In Process Citation]. *Synapse* 35,234-237
- Dinov ID, Mega MS, Thompson PM, Lee L, Woods RP, Holmes CJ, Sumners DW, Toga AW, 2000. Analyzing functional brain images in a probabilistic atlas: a validation of subvolume thresholding. *J.Comput.Assist.Tomogr.* 24,128-138
- Diringer MN, Videen TO, Yundt K, Zazulia AR, Aiyagari V, Dacey RG, Jr., Grubb RL, Powers WJ, 2002. Regional cerebrovascular and metabolic effects of

- hyperventilation after severe traumatic brain injury. *J Neurosurg* 96,103-108
- Dishino DD, Welch MJ, Kilbourn MR, Raichle ME, 1983. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. *J Nucl Med* 24,1030-1038
- Dlugos DJ, Jaggi J, O'Connor WM, Ding XS, Reivich M, O'Connor MJ, Sperling MR, 1999. Hippocampal cell density and subcortical metabolism in temporal lobe epilepsy. *Epilepsia* 40,408-413
- Dobkin JA, Levine RL, Lagreze HL, Dulli DA, Nickles RJ, Rowe BR, 1989. Evidence for transhemispheric diaschisis in unilateral stroke. *Arch Neurol* 46,1333-1336
- Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ, 2003. Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study. *Neurology* 60,601-605
- Dolan RJ, Bench CJ, Brown RG, Scott LC, Friston KJ, Frackowiak RS, 1992. Regional cerebral blood flow abnormalities in depressed patients with cognitive impairment. *Journal of Neurology, Neurosurgery & Psychiatry* 55,768-773
- Dolan RJ, Bench CJ, Liddle PF, Friston KJ, Frith CD, Grasby PM, Frackowiak RS, 1993. Dorsolateral prefrontal cortex dysfunction in the major psychoses; symptom or disease specificity? *Journal of Neurology, Neurosurgery & Psychiatry* 56,1290-1294
- Dolan RJ, Bench CJ, Brown RG, Scott LC, Frackowiak RS, 1994. Neuropsychological dysfunction in depression: the relationship to regional cerebral blood flow. *Psychological Medicine* 24,849-857
- Dolci L, Dolle F, Valette H, Vaufrey F, Fuseau C, Bottlaender M, Crouzel C, 1999. Synthesis of a fluorine-18 labeled derivative of epibatidine for in vivo nicotinic acetylcholine receptor PET imaging. *Bioorg.Med.Chem.* 7,467-479
- Domino EF, Minoshima S, Guthrie S, Ohl L, Ni L, Koeppe RA, Zubieta JK, 2000. Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. *Synapse* 38,313-321

- Domino EF, Minoshima S, Guthrie SK, Ohl L, Ni L, Koeppe RA, Cross DJ, Zubieta J, 2000. Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers. *Neuroscience* 101,277-282
- Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Gelovani TJ, 2001. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. *Proc.Natl.Acad.Sci.U.S.A* 98,9300-9305
- Doubrovin M, Ponomarev V, Serganova I, Soghomonian S, Myagawa T, Beresten T, Ageyeva L, Sadelain M, Koutcher J, Blasberg RG, Tjuvajev JG, 2003. Development of a new reporter gene system--dsRed/xanthine phosphoribosyltransferase-xanthine for molecular imaging of processes behind the intact blood-brain barrier. *Mol.Imaging* 2,93-112
- Doudet DJ, McLellan CA, Carson R, Adams HR, Miyake H, Aigner TG, Finn RT, Cohen RM, 1991. Distribution and kinetics of 3-O-methyl-6-[18F]fluoro-L-dopa in the rhesus monkey brain. *J.Cereb.Blood Flow Metab.* 11,726-734
- Doudet DJ, Chan GL, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ, 1997. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys. *Neuropharmacology* 36,363-371
- Doudet DJ, Chan GL, Holden JE, McGeer EG, Aigner TA, Wyatt RJ, Ruth TJ, 1998. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. *Synapse* 29,225-232
- Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C, Ruth TJ, Holden JE, 1999. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. *J Cereb.Blood Flow Metab* 19,278-287
- Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH, 1987. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. *Journal of Computer Assisted Tomography* 11,563-570
- Drevets WC, Raichle ME, 1992. Neuroanatomical circuits in depression: implications for treatment mechanisms. [Review] [129 refs]. *Psychopharmacology Bulletin*.28(3):261-74,

- Drevets WC, Videen TQ, MacLeod AK, Haller JW, Raichle ME, 1992. PET images of blood flow changes during anxiety: correction [letter]. *Science* 256,1696
- Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME, 1992. A functional anatomical study of unipolar depression. *Journal of Neuroscience* 12,3628-3641
- Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C, 1999. PET imaging of serotonin 1A receptor binding in depression. *Biol.Psychiatry* 46,1375-1387
- Drevets WC, Frank E, Price JC, Kupfer DJ, Greer PJ, Mathis C, 2000. Serotonin type-1A receptor imaging in depression. *Nucl Med Biol.* 27,499-507
- Drevets WC, 2000. Neuroimaging studies of mood disorders. *Biol.Psychiatry* 48,813-829
- Drevets WC, 2000. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. *Prog.Brain Res* 126,413-431
- Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA, 2001. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. *Biol.Psychiatry* 49,81-96
- Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME, 2002. Glucose metabolism in the amygdala in depression: Relationship to diagnostic subtype and plasma cortisol levels. *Pharmacol.Biochem.Behav.* 71,431-447
- Drexler K, Schweitzer JB, Quinn CK, Gross R, Ely TD, Muhammad F, Kilts CD, 2000. Neural activity related to anger in cocaine-dependent men: a possible link to violence and relapse. *Am J Addict.* 9,331-339
- Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A, 2003. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. *Eur.J Nucl Med Mol.Imaging* 30,1104-1113
- Duara R, Grady C, Haxby J, Ingvar D, Sokoloff L, Margolin RA, Manning RG, Cutler NR, Rapoport SI, 1984. Human brain glucose utilization and cognitive function in relation to age. *Annals of Neurology* 16,703-713

- Duara R, Gross-Glenn K, Barker WW, Chang JY, Apicella A, Loewenstein D, Boothe T, 1987. Behavioral activation and the variability of cerebral glucose metabolic measurements. *J.Cereb.Blood Flow Metab.* 7,266-271
- Duara R, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S, 1992. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. *J.Cereb.Blood Flow Metab.* 12,927-934
- Duncan DB, Herholz K, Kugel H, Roth B, Ruitenbeek W, Heindel W, Wienhard K, Heiss WD, 1995. Positron emission tomography and magnetic resonance spectroscopy of cerebral glycolysis in children with congenital lactic acidosis. *Annals of Neurology* 37,351-358
- Duncan JD, Moss SD, Bandy DJ, Manwaring K, Kaplan AM, Reiman EM, Chen K, Lawson MA, Wodrich DL, 1997. Use of positron emission tomography for presurgical localization of eloquent brain areas in children with seizures. *Pediatr.Neurosurg.* 26,144-156
- Duncan JS, 1999. Positron emission tomography receptor studies in epilepsy. *Rev.Neurol (Paris)* 155,482-488
- Dunn RT, Kimbrell TA, Ketter TA, Frye MA, Willis MW, Luckenbaugh DA, Post RM, 2002. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. *Biological Psychiatry*.51(5):387-99,
- Dupont S, Semah F, Baulac M, Samson Y, 1998. The underlying pathophysiology of ictal dystonia in temporal lobe epilepsy: an FDG-PET study. *Neurology* 51,1289-1292
- Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA, 1999. 2-[C-11]thymidine imaging of malignant brain tumors. *Cancer Res.* 59,615-621
- Eberl S, Kanno I, Fulton RR, Ryan A, Hutton BF, Fulham MJ, 1996. AUTOMATED INTERSTUDY IMAGE REGISTRATION TECHNIQUE FOR SPECT AND PET. *J.Nucl.Med.* 37,137-145
- Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivrotto P, VanBrocklin HF, Bankiewicz KS, 1998. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. *Brain Res.* 805,259-262



- Eckelman WC, 2003. The use of PET and knockout mice in the drug discovery process. *Drug Discov.Today* 8,404-410
- Ehrin E, Stone-Elander S, Nilsson JL, Bergstrom M, Blomqvist G, Brismar T, Eriksson L, Greitz T, Jansson PE, Litton JE, Malmberg P, Ugglas M, Widen L, 1983. C-11-labeled glucose and its utilization in positron-emission tomography. *J.Nucl.Med.* 24,326-331
- Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA, 1990. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. *Movement Disorders* 5,203-213
- Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Powers JM, 1991. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. *Journal of Neurology, Neurosurgery & Psychiatry* 54,856-862
- Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E, 1993. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. *Annals of Neurology* 33,518-527
- Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, 1994. The metabolic topography of parkinsonism. *J Cereb.Blood Flow Metab* 14,783-801
- Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Robeson W, Dahl JR, Margouleff D, 1995. Assessment of disease severity in parkinsonism with fluorine-18- fluorodeoxyglucose and PET. *J.Nucl.Med.* 36,378-383
- Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Belakhlef A, Mandel F, Przedborski S, Fahn S, 1995. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. *Neurology* 45,1995-2004
- Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Przedborski S, Fahn S, 1995. The metabolic topography of idiopathic torsion dystonia. *Brain* 118,1473-1484

- Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Silbersweig D, Stern E, Woods RP, Fazzini E, Dogali M, Beric A, 1996. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. *Annals of Neurology* 39,450-459
- Eidelberg D, Moeller JR, Antonini A, Kazumata K, Dhawan V, Budman C, Feigin A, 1997. THE METABOLIC ANATOMY OF TOURETTES-SYNDROME. *Neurology* 48,927-934
- Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, Spetsieris P, DeLeon D, Bressman SB, Fahn S, 1998. Functional brain networks in DYT1 dystonia. *Ann.Neurol* 44,303-312
- Ellison Z, Foong J, Howard R, Bullmore E, Williams S, Treasure J, 1998. Functional anatomy of calorie fear in anorexia nervosa. *Lancet* 352,1192
- Elsinga PH, 2002. Radiopharmaceutical chemistry for positron emission tomography. *Methods* 27,208-217
- Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE, 1997. Kinetic modeling of [<sup>11</sup>C]raclopride: combined PET-microdialysis studies. *J Cereb.Blood Flow Metab* 17,932-942
- Engel J, Jr., Kuhl DE, Phelps ME, 1982. Patterns of human local cerebral glucose metabolism during epileptic seizures. *Science* 218,64-66
- Engel J, Jr., Brown WJ, Kuhl DE, Phelps ME, Mazziotta JC, Crandall PH, 1982. Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy. *Annals of Neurology* 12,518-528
- Engel J, Jr., Kuhl DE, Phelps ME, Rausch R, Nuwer M, 1983. Local cerebral metabolism during partial seizures. *Neurology* 33,400-413
- Engel J, Jr., Lubens P, Kuhl DE, Phelps ME, 1985. Local cerebral metabolic rate for glucose during petit mal absences. *Annals of Neurology* 17,121-128
- Engel J, Jr., Henry TR, Risinger MW, Sutherling WW, Chugani HT, 1992. PET in relation to intracranial electrode evaluations. [Review]. *Epilepsy Research - Supplement* 5,111-120

- Enghardt W, Debus J, Haberer T, Hasch BG, Hinz R, Jakel O, Kramer M, Lauckner K, Pawelke J, 1999. The application of PET to quality assurance of heavy-ion tumor therapy. *Strahlenther.Onkol.* 175 Suppl 2,33-36
- Engler H, Blomqvist G, Bergstrom M, Estrada S, Sandell J, Antoni G, Langstrom B, Nordberg A, Barletta J, Klunk W, Debnath M, Holt D, Wang YM, Huang GF, Mathis C, 2002. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. *Neurobiology of Aging* 23,1568
- Engler H, Lundberg PO, Ekblom K, Nennesmo I, Nilsson A, Bergstrom M, Tsukada H, Hartvig P, Langstrom B, 2003. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. *Eur.J Nucl Med Mol.Imaging* 30,85-95
- Ericson K, Lilja A, Bergstrom M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langstrom BB, Mosskin M, 1985. Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. *J Comput.Assist.Tomogr.* 9,683-689
- Ericson K, Kihlstrom L, Mogard J, Karlsson B, Lindquist C, Widen L, Collins VP, Stone-Elander S, 1996. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irradiated brain metastases. *Stereotact.Funct.Neurosurg* 66 Suppl 1,214-224
- Eriksson H, Tedroff J, Thuomas KA, Aquilonius SM, Hartvig P, Fasth KJ, Bjurling P, Langstrom B, Hedstrom KG, Heilbronn E, 1992. Manganese induced brain lesions in *Macaca fascicularis* as revealed by positron emission tomography and magnetic resonance imaging. *Archives of Toxicology* 66,403-407
- Eriksson L, Kanno I, 1991. Blood sampling devices and measurements. *Medical Progress through Technology* 17,249-257
- Eriksson L, Ingvar M, Rosenqvist G, 1995. Characteristics of A New Automated Blood-Sampling System for Positron Emission Tomography. *IEEE Transactions on Nuclear Science* 42,1007-1011
- Eriksson L, Wienhard K, Eriksson M, Casey ME, Knoess C, Bruckbauer T, Hamill J, Schmand M, Gremillion T, Lenox M, Conti M, Bendriem B, Heiss WD, Nutt R, 2002. The ECAT HRRT: NEMA NEC evaluation of the HRRT system, the new high-resolution research tomograph. *IEEE Transactions on Nuclear Science* 49,2085-2088

- Eriksson L, Wienhard K, Eriksson M, Casey ME, Knoess C, Bruckbauer T, Hamill J, Mulnix T, Vollmar S, Bendriem B, Heiss WD, Nutt R, 2002. NEMA count-rate evaluation of the first and second generation of the Ecat Exact and Ecat Exact HR family of scanners. *IEEE Transactions on Nuclear Science* 49,640-643
- Eriksson S, Arner E, Spasokoukotskaja T, Wang L, Karlsson A, Brosjo O, Gunven P, Julusson G, Liliemark J, 1994. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. *Adv.Enzyme Regul.* 34,13-25
- Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V, 1997. The effect of different diagnostic criteria on the prevalence of dementia. *N.Engl.J.Med.* 337,1667-1674
- Ernst M, Zametkin AJ, Matochik J, Schmidt M, Jons PH, Liebenauer LL, Hardy KK, Cohen RM, 1997. Intravenous dextroamphetamine and brain glucose metabolism. *Neuropsychopharmacology* 17,391-401
- Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM, 1999. High presynaptic dopaminergic activity in children with Tourette's disorder. *J Am.Acad.Child Adolesc.Psychiatry* 38,86-94
- Ernst M, Matochik JA, Heishman SJ, Van Horn JD, Jons PH, Henningfield JE, London ED, 2001. Effect of nicotine on brain activation during performance of a working memory task. *Proc.Natl.Acad.Sci.U.S.A* 98,4728-4733
- European Federation of Neurological Societies Task Force, 2000. Pre-surgical evaluation for epilepsy surgery - European standards. *European Journal of Neurology* 7,119-122
- Evans AC, Marrett S, Torrescorzo J, Ku S, Collins L, 1991. MRI-PET correlation in three dimensions using a volume-of- interest (VOI) atlas. *J.Cereb.Blood Flow Metab.* 11,A69-A78
- Evans AC, Collins DL, 1993. A 305-MEMBER MRI-BASED STEREOTAXIC ATLAS FOR CBF ACTIVATION STUDIES. *J.Nucl.Med.* 34,70-71
- Fakhoury T, Abou-Khalil B, Kessler RM, 1999. Limbic encephalitis and hyperactive foci on PET scan. *Seizure.* 8,427-431

- Falconer J, Wada JA, Martin W, Li D, 1990. PET, CT, and MRI imaging in neuronal migration anomalies in epileptic patients. *Can.J Neurol Sci.* 17,35-39
- Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G, 1985. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. *Proc.Natl.Acad.Sci.U.S.A* 82,3863-3867
- Farde L, Hall H, Ehrin E, Sedvall G, 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. *Science* 231,258-261
- Farde L, Hall H, Ehrin E, Sedvall G, 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. *Science* 231,258-261
- Farde L, Halldin C, Stone-Elander S, Sedvall G, 1987. PET analysis of human dopamine receptor subtypes using <sup>11</sup>C-SCH 23390 and <sup>11</sup>C-raclopride. *Psychopharmacology (Berl)* 92,278-284
- Farde L, Wiesel FA, Halldin C, Sedvall G, 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. *Arch Gen.Psychiatry* 45,71-76
- Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Hogberg T, Nilsson L, Sjogren I, Stone-Elander S, 1988. Stereoselective binding of <sup>11</sup>C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET. *Psychopharmacology (Berl)* 94,471-478
- Farde L, Eriksson L, Blomquist G, Halldin C, 1989. Kinetic analysis of central [<sup>11</sup>C]raclopride binding to D2- dopamine receptors studied by PET--a comparison to the equilibrium analysis. *J.Cereb.Blood Flow Metab.* 9,696-708
- Farde L, Wiesel FA, Nordstrom AL, Sedvall G, 1989. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. *Psychopharmacology (Berl)* 99 Suppl,S28-S31
- Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G, 1990. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [<sup>11</sup>C]raclopride. *Arch Gen.Psychiatry* 47,213-219

- Farde L, 1992. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [<sup>11</sup>C]SCH 23390 and [<sup>11</sup>C]raclopride. *Psychopharmacology (Berl)* 107,23-29
- Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G, 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. *Arch Gen Psychiatry* 49,538-544
- Farde L, Hall H, Pauli S, Halldin C, 1995. Variability in D2-dopamine receptor density and affinity: a PET study with [<sup>11</sup>C]raclopride in man. *Synapse* 20,200-208
- Farde L, Andree B, Ginovart N, Halldin C, Thorberg S, 2000. PET-Determination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain. *Neuropsychopharmacology* 22,422-429
- Fazio F, Perani D, Gilardi MC, Colombo F, Cappa SF, Vallar G, Bettinardi V, Paulesu E, Alberoni M, Bressi S, 1992. Metabolic impairment in human amnesia: a PET study of memory networks. *J.Cereb.Blood Flow Metab.* 12,353-358
- FDA, 2000. Positron Emission Tomography Drug Products; Safety and Effectiveness of Certain PET Drugs for Specific Indications. *Federal Register* 65,12999-13010
- Feany MB, Mattiace LA, Dickson DW, 1996. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. *Journal of Neuropathology & Experimental Neurology* 55,53-67
- Fedi M, Reutens DC, Andermann F, Okazawa H, Boling W, White C, Dubeau F, Nakai A, Gross DW, Andermann E, Diksic M, 2003. alpha-[<sup>11</sup>C]-Methyl-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. *Epilepsy Research* 52,203-213
- Feeney DM, Baron JC, 1986. Diaschisis. [Review]. *Stroke* 17,817-830
- Ferrie CD, Marsden PK, Maisey MN, Robinson RO, 1997. Cortical and subcortical glucose metabolism in childhood epileptic encephalopathies. *J.Neurol.Neurosurg.Psychiatry* 63,181-187

- Fink GR, Pietrzyk U, Herholz K, Huber M, Heiss WD, 1992. Functional and morphological imaging of small striato-capsular infarction by CT, MRI and multitracer PET. *Neurol Res* 14,139-142
- Fink GR, Herholz K, Pietrzyk U, Huber M, Heiss WD, 1993. Peri-infarct perfusion in human ischemia: its relation to tissue metabolism, morphology, and clinical outcome. *Journal of Stroke and Cerebrovascular Disease* 3,123-131
- Fiorella DJ, Provenzale JM, Coleman RE, Crain BJ, Al Sugair AA, 2001. (18)F-fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis. *AJNR Am J Neuroradiol* 22,1291-1299
- Fiorelli M, Blin J, Bakchine S, Laplane D, Baron JC, 1991. PET studies of cortical diaschisis in patients with motor hemi- neglect. *Journal of the Neurological Sciences* 104,135-142
- Fiorelli M, Duboc D, Mazoyer BM, Blin J, Eymard B, Fardeau M, Samson Y, 1992. Decreased cerebral glucose utilization in myotonic dystrophy. *Neurology* 42,91-94
- Firestone LL, Gyulai F, Mintun M, Adler LJ, Urso K, Winter PM, 1996. Human brain activity response to fentanyl imaged by positron emission tomography. *Anesth. Analg.* 82,1247-1251
- Firnao G, Sood S, Chirakal R, Nahmias C, Garnett ES, 1987. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. *J Neurochem.* 48,1077-1082
- Firnao G, Sood S, Chirakal R, Nahmias C, Garnett ES, 1988. Metabolites of 6-[18F]fluoro-L-dopa in human blood. *J Nucl Med* 29,363-369
- Fischer H, Wik G, Fredrikson M, 1996. Functional neuroanatomy of robbery re-experience: affective memories studied with PET. *Neuroreport* 7,2081-2086
- Fischer H, Andersson JL, Furmark T, Fredrikson M, 1998. Brain correlates of an unexpected panic attack: a human positron emission tomographic study. *Neurosci.Lett.* 251,137-140
- Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, Van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B,

- Dale AM, 2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* 33,341-355
- Fiset P, Paus T, Daloze T, Plourde G, Meuret P, Bonhomme V, Hajj-Ali N, Backman SB, Evans AC, 1999. Brain mechanisms of propofol-induced loss of consciousness in humans: a positron emission tomographic study. *J.Neurosci.* 19,5506-5513
- Foldvary N, Lee N, Hanson MW, Coleman RE, Hulette CM, Friedman AH, Bej MD, Radtke RA, 1999. Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. *Epilepsia* 40,26-29
- Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, Dinapoli RP, Atkinson EJ, 1995. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? *J Neurosurg* 82,436-444
- Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G, 1983. Alzheimer's disease: focal cortical changes shown by positron emission tomography. *Neurology* 33,961-965
- Foster NL, VanDerSpek AF, Aldrich MS, Berent S, Hichwa RH, Sackellares JC, Gilman S, Agranoff BW, 1987. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. *J Cereb.Blood Flow Metab* 7,415-420
- Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA, 1988. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. *Ann.Neurol* 24,399-406
- Foster NL, Gilman S, Berent S, Sima AA, D'Amato C, Koeppe RA, Hicks SP, 1992. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. *J Neurol Neurosurg Psychiatry* 55,707-713
- Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, Christman D, Logan J, Smith M, Sachs H, 1987. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. *Science* 235,481-485
- Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Logan J, Bendriem B, Gatley SJ, 1989. Mapping cocaine binding sites in human and baboon brain in vivo. *Synapse* 4,371-377



- Fowler JS, Volkow ND, MacGregor RR, Logan J, Dewey SL, Gatley SJ, Wolf AP, 1992. Comparative PET studies of the kinetics and distribution of cocaine and cocaethylene in baboon brain. *Synapse* 12,220-227
- Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, Schlyer DJ, Pappas N, Alexoff DL, Patlak C, 1995. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11- deprenyl-D2 for MAO B mapping. *J.Nucl.Med.* 36,1255-1262
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Shlyer D, Wolf AP, Warner D, Zezulkoova I, Cilento R, 1996. Inhibition of monoamine oxidase B in the brains of smokers. *Nature* 379,733-736
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkoova I, Wolf AP, 1996. Brain monoamine oxidase A inhibition in cigarette smokers. *Proc.Natl.Acad.Sci.USA* 93,14065-14069
- Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, MacGregor R, 1997. Age-related increases in brain monoamine oxidase B in living healthy human subjects. *Neurobiol.Aging* 18,431-435
- Fowler JS, Volkow ND, Logan J, Gatley SJ, Pappas N, King P, Ding YS, Wang GJ, 1998. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. *Synapse* 28,111-116
- Fowler JS, Volkow ND, Logan J, Pappas N, King P, MacGregor R, Shea C, Garza V, Gatley SJ, 1998. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. *Life Sci.* 63,L19-L23
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Wolf AP, Warner D, Cilento R, Zezulkoova I, 1998. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. *J Addict.Dis.* 17,23-34
- Fowler JS, Volkow ND, Ding YS, Wang GJ, Dewey S, Fischman MW, Foltin R, Hitzemann R, 1999. Positron emission tomography studies of dopamine-enhancing drugs. *J Clin.Pharmacol. Suppl*,13S-16S
- Fowler JS, Wang GJ, Volkow ND, Franceschi D, Logan J, Pappas N, Shea C, MacGregor RR, Garza V, 1999. Smoking a single cigarette does not

- produce a measurable reduction in brain MAO B in non-smokers.  
Nicotine.Tob.Res 1,325-329
- Fowler JS, Logan J, Ding YS, Franceschi D, Wang GJ, Volkow ND, Pappas N, Schlyer D, Gatley SJ, Alexoff D, Felder C, Biegon A, Zhu W, 2001. Non-MAO A binding of clorgyline in white matter in human brain. J Neurochem. 79,1039-1046
- Fox PT, Mintun MA, Raichle ME, Herscovitch P, 1984. A noninvasive approach to quantitative functional brain mapping with H<sub>2</sub> (15)O and positron emission tomography. J.Cereb.Blood Flow Metab. 4,329-333
- Fox PT, Perlmutter JS, Raichle ME, 1985. A stereotactic method of anatomical localization for positron emission tomography. Journal of Computer Assisted Tomography 9,141-153
- Fox PT, Raichle ME, 1986. Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc.Natl.Acad.Sci.USA 83,1140-1144
- Fox PT, Mintun MA, Reiman EM, Raichle ME, 1988. Enhanced detection of focal brain responses using intersubject averaging and change-distribution analysis of subtracted PET images. J Cereb.Blood Flow Metab 8,642-653
- Frackowiak RS, Lenzi GL, Jones T, Heather JD, 1980. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. Journal of Computer Assisted Tomography 4,727-736
- Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, Jones T, 1981. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104,753-778
- Frackowiak RSJ et al., 1997. Human brain function, Academic Press, San Diego
- Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC, 1989. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24,1-5
- Francavilla TL, Miletich RS, DeMichele D, Patronas NJ, Oldfield EH, Weintraub BD, Di Chiro G, 1991. Positron emission tomography of pituitary

- macroadenomas: hormone production and effects of therapies.  
Neurosurgery 28,826-833
- Franck G, Sadzot B, Salmon E, Depresseux JC, Grisar T, Peters JM, Guillaume M, Quaglia L, Delfiore G, Lamotte D, 1986. Regional cerebral blood flow and metabolic rates in human focal epilepsy and status epilepticus. Adv.Neurol 44,935-948
- Franck G, Maquet P, Sadzot B, Salmon E, Debets R, Dive D, Grisar T, Guillaume D, Van Veelen C, Van Huffelen A, 1992. Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin. Advances in Neurology 57,471-485
- Frank GK, Kaye WH, Greer P, Meltzer CC, Price JC, 2000. Regional cerebral blood flow after recovery from bulimia nervosa. Psychiatry Res. 100,31-39
- Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, Skovira K, 2002. Reduced 5-HT<sub>2A</sub> receptor binding after recovery from anorexia nervosa. Biol.Psychiatry 52,896-906
- Frankle WG, Laruelle M, 2002. Neuroreceptor imaging in psychiatric disorders. Ann.Nucl Med 16,437-446
- Frasson E, Moretto G, Beltramello A, Smania N, Pampanin M, Stegagno C, Tanel R, Rizzuto N, 1998. Neuropsychological and neuroimaging correlates in corticobasal degeneration. Ital.J Neurol Sci. 19,321-328
- Fredrikson M, Wik G, Annas P, Ericson K, Stone-Elander S, 1995. Functional neuroanatomy of visually elicited simple phobic fear: additional data and theoretical analysis. Psychophysiology 32,43-48
- Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S, 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N.Engl.J.Med. 344,710-719
- Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJ, 1995. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann.Neurol 38,379-388

- Frey KA, Hichwa RD, Ehrenkaufer RL, Agranoff BW, 1985. Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding. *Proc.Natl.Acad.Sci.U.S.A* 82,6711-6715
- Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE, 1991. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. *Annals of Neurology* 30,663-672
- Frey KA, Ciliax B, Agranoff BW, 1991. Quantitative in vivo receptor binding. IV: Detection of muscarinic receptor down-regulation by equilibrium and by tracer kinetic methods. *Neurochem.Res.* 16,1017-1023
- Frey KA, Koeppe RA, Mulholland GK, Jewett D, Hichwa R, Ehrenkaufer RL, Carey JE, Wieland DM, Kuhl DE, Agranoff BW, 1992. In vivo muscarinic cholinergic receptor imaging in human brain with [<sup>11</sup>C]scopolamine and positron emission tomography. *J Cereb.Blood Flow Metab* 12,147-154
- Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE, 1996. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. *Ann.Neurol* 40,873-884
- Frey KA, 2000. Neuroimaging in neurotoxicology [In Process Citation]. *Neurol.Clin.* 18,615-630
- Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE, 1983. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [<sup>18</sup>F]fluorodeoxyglucose. *J Comput.Assist.Tomogr.* 7,590-598
- Friedland RP, Jagust WJ, Huesman RH, Koss E, Knittel B, Mathis CA, Ober BA, Mazoyer BM, Budinger TF, 1989. Regional cerebral glucose transport and utilization in Alzheimer's disease. *Neurology* 39,1427-1434
- Friedland RP, Koss E, Lerner A, Hedera P, Ellis W, Dronkers N, Ober BA, Jagust WJ, 1993. Functional imaging, the frontal lobes, and dementia. *Dementia* 4,192-203
- Friston K, Phillips J, Chawla D, Buchel C, 1999. Revealing interactions among brain systems with nonlinear PCA. *Hum.Brain Mapp.* 8,92-97
- Friston KJ, Passingham RE, Nutt JG, Heather JD, Sawle GV, Frackowiak RS, 1989. Localisation in PET images: direct fitting of the intercommissural (AC-PC) line. *J.Cereb.Blood Flow Metab.* 9,690-695

- Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS, 1990. The relationship between global and local changes in PET scans. *J.Cereb.Blood Flow Metab.* 10,458-466
- Friston KJ, Frith CD, Liddle PF, Frackowiak RS, 1991. Comparing functional (PET) images: the assessment of significant change. *J.Cereb.Blood Flow Metab.* 11,690-699
- Friston KJ, Frith CD, Liddle PF, Frackowiak RS, 1991. Plastic transformation of PET images. *Journal of Computer Assisted Tomography* 15,634-639
- Friston KJ, Grasby PM, Bench CJ, Frith CD, Cowen PJ, Liddle PF, Frackowiak RS, Dolan R, 1992. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. *Neuroscience Letters* 141,106-110
- Friston KJ, Frith CD, Liddle PF, Frackowiak RS, 1993. Functional connectivity: the principal-component analysis of large (PET) data sets. *J.Cereb.Blood Flow Metab.* 13,5-14
- Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC, 1994. Assessing the significance of focal activations using their spatial extent. *Human Brain Mapping* 1,210-220
- Friston KJ, Ashburner J, Poline JB, Frith CD, Heather JD, Frackowiak RSJ, 1995. Spatial registration and normalisation of images. *Hum.Brain Mapp.* 2,165-189
- Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ, 1995. Statistical parametric maps in functional imaging: a general linear approach. *Human Brain Mapping* 2,189-210
- Friston KJ, Malizia AL, Wilson S, Cunningham VJ, Jones T, Nutt DJ, 1997. ANALYSIS OF DYNAMIC RADIOLIGAND DISPLACEMENT OR ACTIVATION STUDIES. *J.Cereb.Blood Flow Metab.* 17,80-93
- Friston KJ, Penny W, 2003. Posterior probability maps and SPMs. *Neuroimage* 19,1240-1249
- Frith CD, Friston KJ, Herold S, Silbersweig D, Fletcher P, Cahill C, Dolan RJ, Frackowiak RS, Liddle PF, 1995. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. *Br.J Psychiatry* 167,343-349

- Frost JJ, Wagner HN, Jr., Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, McPherson RW, Rosenbaum AE, ., 1985. Imaging opiate receptors in the human brain by positron tomography. *J Comput.Assist.Tomogr.* 9,231-236
- Frost JJ, Mayberg HS, Fisher RS, Douglass KH, Dannals RF, Links JM, Wilson AA, Ravert HT, Rosenbaum AE, Snyder SH, 1988. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. *Annals of Neurology* 23,231-237
- Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA, Ravert HT, Crozier WC, Wagner HN, Jr., 1989. Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. *J Cereb.Blood Flow Metab* 9,398-409
- Frost JJ, Mayberg HS, Sadzot B, Dannals RF, Lever JR, Ravert HT, Wilson AA, Wagner HN, Jr., Links JM, 1990. Comparison of [11C]diprenorphine and [11C]carfentanil binding to opiate receptors in humans by positron emission tomography. *J Cereb.Blood Flow Metab* 10,484-492
- Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF, 1993. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. *Ann.Neurol* 34,423-431
- Fuente-Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ, 2002. Dopamine release in human ventral striatum and expectation of reward. *Behav.Brain Res.* 136,359-363
- Fuente-Fernandez R, Lim AS, Sossi V, Adam MJ, Ruth TJ, Calne DB, Stoessl AJ, Lee CS, 2003. Age and severity of nigrostriatal damage at onset of Parkinson's disease. *Synapse* 47,152-158
- Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, Ruth TJ, Stoessl AJ, 2003. VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET. *Synapse* 49,20-28
- Fujii K, Sadoshima S, Ishitsuka T, Kusuda K, Kuwabara Y, Ichiya Y, Fujishima M, 1989. Regional cerebral blood flow and metabolism in patients with transient global amnesia: a positron emission tomography study. *J Neurol Neurosurg Psychiatry* 52,622-630

- Fujiki N, Naito Y, Hirano S, Kojima H, Shiomi Y, Nishizawa S, Konishi J, Honjo I, 1999. Correlation between rCBF and speech perception in cochlear implant users. *Auris Nasus Larynx* 26,229-236
- Fujita H, Kuwabara H, Reutens DC, Gjedde A, 1999. Oxygen consumption of cerebral cortex fails to increase during continued vibrotactile stimulation. *J.Cereb.Blood Flow Metab.* 19,266-271
- Fukuda M, Mentis M, Ghilardi MF, Dhawan V, Antonini A, Hammerstad J, Lozano AM, Lang A, Lyons K, Koller W, Ghez C, Eidelberg D, 2001. Functional correlates of pallidal stimulation for Parkinson's disease. *Ann.Neurol* 49,155-164
- Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, Lozano AM, Hammerstad J, Lyons K, Koller WC, Moeller JR, Eidelberg D, 2001. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. *Brain* 124,1601-1609
- Fukuda M, Ghilardi MF, Carbon M, Dhawan V, Ma Y, Feigin A, Mentis MJ, Ghez C, Eidelberg D, 2002. Pallidal stimulation for parkinsonism: improved brain activation during sequence learning. *Ann.Neurol* 52,144-152
- Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, Konishi J, 1994. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. *J.Nucl.Med.* 35,1-6
- Fulham MJ, Brooks RA, Hallett M, Di Chiro G, 1992. Cerebellar diaschisis revisited: pontine hypometabolism and dentate sparing. *Neurology* 42,2267-2273
- Fulham MJ, Melisi JW, Nishimiya J, Dwyer AJ, Di Chiro G, 1993. Neuroimaging of juvenile pilocytic astrocytomas: an enigma [see comments]. *Radiology* 189,221-225
- Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G, 1995. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. *Journal of Neurosurgery* 83,657-664
- Fulton RR, Meikle SR, Eberl S, Pfeiffer J, Constable CJ, Fulham MJ, 2002. Correction for head movements in positron emission tomography using an optical motion-tracking system. *IEEE Transactions on Nuclear Science* 49,116-123

- Funaki Y, Kato M, Iwata R, Sakurai E, Sakurai E, Tashiro M, Ido T, Yanai K, 2003. Evaluation of the Binding Characteristics of [5-(11)C-methoxy]Donepezil in the Rat Brain for In Vivo Visualization of Acetylcholinesterase. *J Pharmacol.Sci.* 91,105-112
- Furlan M, Marchal G, Viader F, Derlon JM, Baron JC, 1996. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. *Annals of Neurology* 40,216-226
- Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M, 2002. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. *Arch Gen Psychiatry* 59,425-433
- Furtado S, Farrer M, Tsuboi Y, Klimek ML, Fuente-Fernandez R, Hussey J, Lockhart P, Calne DB, Suchowersky O, Stoessl AJ, Wszolek ZK, 2002. SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. *Neurology* 59,1625-1627
- Gaillard WD, Zeffiro T, Fazilat S, DeCarli C, Theodore WH, 1996. Effect of valproate on cerebral metabolism and blood flow: an 18F-2-deoxyglucose and 15O water positron emission tomography study. *Epilepsia* 37,515-521
- Gaillard WD, Kopylev L, Weinstein S, Conry J, Pearl PL, Spanaki MV, Fazilat S, Fazilat S, Venzina LG, Dubovsky E, Theodore WH, 2002. Low incidence of abnormal (18)FDG-PET in children with new-onset partial epilepsy: a prospective study. *Neurology* 58,717-722
- Galardi G, Perani D, Grassi F, Bressi S, Amadio S, Antoni M, Comi GC, Canal N, Fazio F, 1996. Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. *Acta Neurol Scand.* 94,172-176
- Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ, 1994. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. *Arch Neurol* 51,888-895
- Galynker I, Schlyer DJ, Dewey SL, Fowler JS, Logan J, Gatley SJ, MacGregor RR, Ferrieri RA, Holland MJ, Brodie J, Simon E, Wolf AP, 1996. Opioid receptor imaging and displacement studies with [6-O-[11C]methyl]buprenorphine in baboon brain. *Nucl.Med.Biol.* 23,325-331
- Gamazo-Garran P, Soutullo CA, Ortuno F, 2002. Obsessive-compulsive disorder secondary to brain dysgerminoma in an adolescent boy: a positron



- emission tomography case report. *J Child Adolesc. Psychopharmacol.* 12,259-263
- Gambhir S, Inao S, Tadokoro M, Nishino M, Ito K, Ishigaki T, Kuchiwaki H, Yoshida J, 1997. Comparison of vasodilatory effect of carbon dioxide inhalation and intravenous acetazolamide on brain vasculature using positron emission tomography. *Neurol Res* 19,139-144
- Gambhir SS, 1999. Decision analysis in nuclear medicine. *J.Nucl.Med.* 40,1570-1581
- Gambhir SS, Schwimmer J, 2000. Economic evaluation studies in nuclear medicine: a methodological review of the literature [In Process Citation]. *Q.J.Nucl.Med.* 44,121-137
- Gamma A, Buck A, Berthold T, Vollenweider FX, 2001. No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [ $H_2(15)O$ ]-positron emission tomography study. *J Clin.Psychopharmacol.* 21,66-71
- Ganguli R, Carter C, Mintun M, Brar J, Becker J, Sarma R, Nichols T, Bennington E, 1997. PET brain mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia. *Biological Psychiatry* 41,33-42
- Garcia-Larrea L, Peyron R, Mertens P, Gregoire MC, Lavenne F, Bonnefoi F, Mauguier F, Laurent B, Sindou M, 1997. Positron emission tomography during motor cortex stimulation for pain control. *Stereotact.Funct.Neurosurg.* 68,141-148
- Gardiner RM, 1999. Genetic basis of the human epilepsies. *Epilepsy Res.* 36,91-95
- Garnett ES, Firnau G, Nahmias C, 1983. Dopamine visualized in the basal ganglia of living man. *Nature* 305,137-138
- Garnett ES, Firnau G, Nahmias C, Carbotte R, Bartolucci G, 1984. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease. *J Neurol Sci.* 65,231-237
- Garnett ES, Lang AE, Chirakal R, Firnau G, Nahmias C, 1987. A rostrocaudal gradient for aromatic acid decarboxylase in the human striatum. *Can.J Neurol Sci.* 14,444-447

- Garraux G, Salmon E, Degueldre C, Lemaire C, Laureys S, Franck G, 1999. Comparison of Impaired Subcortico-Frontal Metabolic Networks in Normal Aging, Subcortico-Frontal Dementia, and Cortical Frontal Dementia. *Neuroimage* 10,149-162
- Garraux G, Salmon E, Peigneux P, Kreisler A, Degueldre C, Lemaire C, Destee A, Franck G, 2000. Voxel-based distribution of metabolic impairment in corticobasal degeneration. *Mov Disord.* 15,894-904
- Gatley SJ, 1993. Estimation of upper limits on human radiation absorbed doses from carbon-11-labeled compounds. *J.Nucl.Med.* 34,2208-2215
- Gatley SJ, Yu DW, Fowler JS, MacGregor RR, Schlyer DJ, Dewey SL, Wolf AP, Martin T, Shea CE, Volkow ND, 1994. Studies with differentially labeled [11C]cocaine, [11C]norcocaine, [11C]benzoylecgonine, and [11C]- and 4'-[18F]fluorococaine to probe the extent to which [11C]cocaine metabolites contribute to PET images of the baboon brain. *J Neurochem.* 62,1154-1162
- Gatley SJ, Volkow ND, Gifford AN, Ding YS, Logan J, Wang GJ, 1997. Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. *Biochem.Pharmacol.* 53,43-52
- Gatley SJ, Ding YS, Brady D, Gifford AN, Dewey SL, Carroll FI, Fowler JS, Volkow ND, 1998. In vitro and ex vivo autoradiographic studies of nicotinic acetylcholine receptors using [18F]fluoronocholepipatidine in rodent and human brain [In Process Citation]. *Nucl.Med.Biol.* 25,449-454
- Gatley SJ, 2003. Labeled glucose analogs in the genomic era. *J Nucl Med* 44,1082-1086
- Gee AD, 2003. Neuropharmacology and drug development. *Br.Med Bull.* 65,169-177
- Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L, 2001. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. *Eur.Neuropsychopharmacol.* 11,105-110
- Gerhard A, Neumaier B, Elitok E, Glatting G, Ries V, Tomczak R, Ludolph AC, Reske SN, 2000. In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke. *Neuroreport* 11,2957-2960

- Ghaemi M, Hilker R, Herholz K, Wörker M, Heiss WD, 1999. Midbrain 18F-DOPA uptake differs in Parkinson's disease and in striatonigral degeneration. *J. Neural Transm.* 106,X
- Ghaemi M, Rudolf J, Schmulling S, Bamborschke S, Heiss WD, 2000. FDG- and Dopa-PET in postencephalitic parkinsonism. *J Neural Transm.* 107,1289-1295
- Ghaemi M, Rudolf J, Hilker R, Herholz K, Heiss WD, 2001. Increased pineal Fdopa uptake is related to severity of Parkinson's disease--a PET study. *J.Pineal Res.* 30,213-219
- Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD, 2002. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. *J Neurol Neurosurg Psychiatry* 73,517-523
- Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD, 2002. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. *Mov Disord.* 17,782-788
- Ghika J, Ghika-Schmid F, Fankhauser H, Assal G, Vingerhoets F, Albanese A, Bogousslavsky J, Favre J, 1999. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. *J Neurosurg* 91,313-321
- Giannopoulou C, 2003. Navigating the paraneoplastic neurological syndromes. *Eur.J Nucl Med Mol.Imaging* 30,333-338
- Gibbs JM, Wise RJS, Leenders KL, Jones T, 1984. Evaluation of cerebral perfusion reserve in patients with carotid artery occlusion. *Lancet* I,310-314
- Gibbs JM, Wise RJ, Thomas DJ, Mansfield AO, Russell RW, 1987. Cerebral haemodynamic changes after extracranial-intracranial bypass surgery. *J Neurol Neurosurg Psychiatry* 50,140-150
- Gifford AN, Gatley SJ, Volkow ND, 1998. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers. *Synapse* 28,167-175

- Gifford AN, Makriyannis A, Volkow ND, Gattley SJ, 2002. In vivo imaging of the brain cannabinoid receptor. *Chem.Phys.Lipids* 121,65-72
- Gilissen C, De Groot TJ, Bronfman F, Van Leuven F, Verbruggen AM, Bormans GM, 2003. Evaluation of (18)F-FA-4 and (11)C-pipzA-4 as Radioligands for the In Vivo Evaluation of the High-Affinity Choline Uptake System. *J Nucl Med* 44,269-275
- Gill SS, Rochon PA, Guttman M, Laupacis A, 2003. The value of positron emission tomography in the clinical evaluation of dementia. *J Am Geriatr.Soc.* 51,258-264
- Gillin JC, Buchsbaum MS, Valladares-Neto DC, Hong CC, Hazlett E, Langer SZ, Wu J, 1996. Effects of zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: a positron emission tomography study. *Neuropsychopharmacology* 15,302-313
- Gilman S, Junck L, Young AB, Hichwa RD, Markel DS, Koeppe RA, Ehrenkaufer RL, 1988. Cerebral metabolic activity in idiopathic dystonia studied with positron emission tomography. *Adv.Neurol* 50,231-236
- Gilman S, Markel DS, Koeppe RA, Junck L, Kluin KJ, Gebarski SS, Hichwa RD, 1988. Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. *Ann.Neurol* 23,223-230
- Gilman S, Adams K, Koeppe RA, Berent S, Kluin KJ, Modell JG, Kroll P, Brunberg JA, 1990. Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. *Ann.Neurol* 28,775-785
- Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ, 1990. Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography. *Annals of Neurology* 28,750-757
- Gilman S, Adams K, Koeppe RA, Berent S, Kluin KJ, Modell JG, Kroll P, Brunberg JA, 1990. Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. *Annals of Neurology* 28,775-785
- Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT, 1994. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. *Ann.Neurol* 36,166-175

- Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT, 1995. Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. *Ann.Neurol* 38,176-185
- Gilman S, Sima AAF, Junck L, Kluin KJ, Koeppe RA, Lohman ME, Little R, 1996. Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. *Annals of Neurology* 39,241-255
- Gilman S, Koeppe RA, Adams K, Johnson-Greene D, Junck L, Kluin KJ, Brunberg J, Martorello S, Lohman M, 1996. Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. *Ann.Neurol* 40,163-171
- Gilman S, Adams KM, Johnson-Greene D, Koeppe RA, Junck L, Kluin KJ, Martorello S, Heumann M, Hill E, 1996. Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. *Alcohol Clin.Exp.Res.* 20,1456-1461
- Gilman S, Koeppe RA, Adams KM, Junck L, Kluin KJ, Johnson-Greene D, Martorello S, Heumann M, Bandekar R, 1998. Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. *Ann.Neurol* 44,326-333
- Gilman S, Low PA, Quinn N, Albanese A, Ben Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK, 1999. Consensus statement on the diagnosis of multiple system atrophy. *J Neurol Sci.* 163,94-98
- Gilman S, Koeppe RA, Junck L, Little R, Kluin KJ, Heumann M, Martorello S, Johannis J, 1999. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. *Ann.Neurol* 45,769-777
- Gilman S et al., 2000. Neurodegenerative disorders of the cerebellum. In: Toga AW et al., eds. *Brain mapping: The disorders* , Academic Press, San Diego, pp 417-455
- Ginovart N, Farde L, Halldin C, Swahn CG, 1997. EFFECT OF RESERPINE-INDUCED DEPLETION OF SYNAPTIC DOPAMINE ON [C-11]RACLOPRIDE BINDING TO D-2-DOPAMINE RECEPTORS IN THE MONKEY BRAIN. *Synapse* 25,321-325

- Ginovart N, Lundin A, Farde L, Halldin C, Björckman L, Swahn CG, Pauli S, Sedvall G, 1997. PET STUDY OF THE PRE- AND POST-SYNAPTIC DOPAMINERGIC MARKERS FOR THE NEURODEGENERATIVE PROCESS IN HUNTINGTONS-DISEASE. *Brain* 120,503-514
- Ginovart N, Farde L, Halldin C, Swahn CG, 1999. Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. *Synapse* 31,154-162
- Ginovart N, Hassoun W, Le Cavorsin M, Veyre L, Le Bars D, Leviel V, 2002. Effects of amphetamine and evoked dopamine release on [<sup>11</sup>C]raclopride binding in anesthetized cats. *Neuropsychopharmacology* 27,72-84
- Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S, 2003. [<sup>11</sup>C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. *Synapse* 47,123-133
- Giordani B, Boivin MJ, Berent S, Betley AT, Koeppe RA, Rothley JM, Modell JG, Hichwa RD, Kuhl DE, 1990. Anxiety and cerebral cortical metabolism in normal persons. *Psychiatry Res.* 35,49-60
- Giovacchini G, Chang MC, Channing MA, Toczek M, Mason A, Bokde AL, Connolly C, Vuong BK, Ma Y, Der MG, Doudet DJ, Herscovitch P, Eckelman WC, Rapoport SI, Carson RE, 2002. Brain incorporation of [<sup>11</sup>C]arachidonic acid in young healthy humans measured with positron emission tomography. *J Cereb.Blood Flow Metab* 22,1453-1462
- Giraud AL, Price CJ, Graham JM, Frackowiak RS, 2001. Functional plasticity of language-related brain areas after cochlear implantation. *Brain* 124,1307-1316
- Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, Desco M, 2003. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. *Neuroimage* 19,601-612
- Gjedde A, Wienhard K, Heiss WD, Kloster G, Diemer NH, Herholz K, Pawlik G, 1985. Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant. *J Cereb.Blood Flow Metab* 5,163-178
- Gjedde A, Marrett S, 2001. Glycolysis in neurons, not astrocytes, delays oxidative metabolism of human visual cortex during sustained

- checkerboard stimulation in vivo. *J Cereb.Blood Flow Metab* 21,1384-1392
- Glaser M, Collingridge DR, Aboagye EO, Bouchier-Hayes L, Hutchinson OC, Martin SJ, Price P, Brady F, Luthra SK, 2003. Iodine-124 labelled Annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. *Appl.Radiat.Isot.* 58,55-62
- Goadsby PJ, 2001. Neuroimaging in headache. *Microsc.Res Tech.* 53,179-187
- Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ, 2003. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. *Brain* 126,312-325
- Goerres GW, Revesz T, Duncan J, Banati RB, 2001. Imaging cerebral vasculitis in refractory epilepsy using [(11)C](R)-PK11195 positron emission tomography. *AJR Am.J.Roentgenol.* 176,1016-1018
- Goertzen AL, Meadors AK, Silverman RW, Cherry SR, 2002. Simultaneous molecular and anatomical imaging of the mouse in vivo. *Phys.Med Biol.* 47,4315-4328
- Goffinet AM, De Volder AG, Gillain C, Rectem D, Bol A, Michel C, Cogneau M, Labar D, Laterre C, 1989. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. *Ann.Neurol* 25,131-139
- Goldman S, Amrom D, Szliwowski HB, Detemmerman D, Goldman S, Bidaut LM, Stanus E, Luxen A, 1993. Reversible striatal hypermetabolism in a case of Sydenham's chorea. *Mov Disord.* 8,355-358
- Goldman S, Laird A, Flament-Durand J, Luxen A, Bidaut LM, Stanus E, Hildebrand J, Przedborski S, 1993. Positron emission tomography and histopathology in Creutzfeldt- Jakob disease. *Neurology* 43,1828-1830
- Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Dethy S, Brotchi J, Hildebrand J, 1997. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. *J.Nucl.Med.* 38,1459-1462
- Goldstein DS, Holmes C, Cannon RO, III, Eisenhofer G, Kopin IJ, 1997. Sympathetic cardioneuropathy in dysautonomias. *N Engl J Med* 336,696-702

- Goldstein RZ, Volkow ND, Chang L, Wang GJ, Fowler JS, Depue RA, Gur RC, 2002. The orbitofrontal cortex in methamphetamine addiction: involvement in fear. *Neuroreport* 13,2253-2257
- Gonzalez RG, Fischman AJ, Guimaraes AR, Carr CA, Stern CE, Halpern EF, Growdon JH, Rosen BR, 1995. Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. *AJNR Am J Neuroradiol* 16,1763-1770
- Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, Votaw J, Ely TD, Lambert P, Owens MJ, 2000. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. *Nuclear Medicine and Biology* 27,1-12
- Gordon CM, Dougherty DD, Fischman AJ, Emans SJ, Grace E, Lamm R, Alpert NM, Majzoub JA, Rauch SL, 2001. Neural substrates of anorexia nervosa: a behavioral challenge study with positron emission tomography. *J Pediatr.* 139,51-57
- Gottschalk LA, Buchsbaum MS, Gillin JC, Wu JC, Reynolds CA, Herrera DB, 1991. Anxiety levels in dreams: relation to localized cerebral glucose metabolic rate. *Brain Res.* 538,107-110
- Gottschalk LA, Buchsbaum MS, Gillin JC, Wu J, Reynolds CA, Herrera DB, 1992. The effect of anxiety and hostility in silent mentation on localized cerebral glucose metabolism. *Compr.Psychiatry* 33,52-59
- Gottschalk LA, Fronczek J, Abel L, Buchsbaum MS, Fallon JH, 2001. The cerebral neurobiology of anxiety, anxiety displacement, and anxiety denial. *Psychother.Psychosom.* 70,17-24
- Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K, 2003. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. *J Clin.Endocrinol.Metab* 88,637-641
- Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H, 1999. Neurometabolic effects of psilocybin, 3,4- methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. *Neuropsychopharmacology.* 20,565-581



- Goyer PF, Andreason PJ, Semple WE, Clayton AH, King AC, Compton-Toth BA, Schulz SC, Cohen RM, 1994. Positron-emission tomography and personality disorders. *Neuropsychopharmacology* 10,21-28
- Grachev ID, Berdichevsky D, Rauch SL, Heckers S, Kennedy DN, Caviness VS, Alpert NM, 1999. A Method for Assessing the Accuracy of Intersubject Registration of the Human Brain Using Anatomic Landmarks. *Neuroimage* 9,250-268
- Grady CL, Haxby JV, Schlageter NL, Berg G, Rapoport SI, 1986. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. *Neurology* 36,1390-1392
- Grady CL, Haxby JV, Horwitz B, Berg G, Rapoport SI, 1987. Neuropsychological and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. *Neuropsychologia* 25,807-816
- Grady CL, Haxby JV, Schapiro MB, Gonzalez-Aviles A, Kumar A, Ball MJ, Heston L, Rapoport SI, 1990. Subgroups in dementia of the Alzheimer type identified using positron emission tomography. *Journal of Neuropsychiatry & Clinical Neurosciences* 2,373-384
- Grady CL, Haxby JV, Horwitz B, Gillette J, Salerno JA, Gonzalez-Aviles A, Carson RE, Herscovitch P, Schapiro MB, Rapoport SI, 1993. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. *Neurobiology of Aging* 14,35-44
- Grady CL, Furey ML, Pietrini P, Horwitz B, Rapoport SI, 2001. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. *Brain* 124,739-756
- Grafton ST, Mazziotta JC, Pahl JJ, George-Hyslop P, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME, 1990. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. *Ann.Neurol* 28,614-621
- Grafton ST, Mazziotta JC, Pahl JJ, George-Hyslop P, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME, 1992. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. *Arch Neurol* 49,1161-1167
- Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W, 1995. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. *Ann.Neurol* 37,776-783

- Graham MM, Lewellen BL, 1993. High-speed automated discrete blood sampling for positron emission tomography. *J.Nucl.Med.* 34,1357-1360
- Graham MM, Peterson LM, Muzi M, Graham BB, Spence AM, Link JM, Krohn KA, 1998. 1-[Carbon-11]-glucose radiation dosimetry and distribution in human imaging studies. *J.Nucl.Med.* 39,1805-1810
- Greer P, Villemagne V, Ruszkiewicz J, Graves A, Meltzer C, Mathis C, Price J, 2002. MR atlas of the baboon brain for functional neuroimaging. *Brain Res.Bull.* 58,429
- Greitz T, Bohm C, Holte S, Eriksson L, 1991. A computerized brain atlas: construction, anatomical content, and some applications. *Journal of Computer Assisted Tomography* 15,26-38
- Grierson JR, Shields AF, 2000. Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. *Nucl.Med.Biol.* 27,143-156
- Grigoletto F, Zappala G, Anderson DW, Lebowitz BD, 1999. Norms for the Mini-Mental State Examination in a healthy population. *Neurology* 53,315-320
- Grond M, Pawlik G, Walter H, Lesch OM, Heiss WD, 1995. Hypnotic catalepsy-induced changes of regional cerebral glucose metabolism. *Psychiatry Res.* 61,173-179
- Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M, 1998. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. *Int.J Radiat.Oncol.Biol.Phys.* 41,989-995
- Grosu AL, Lachner R, Wiedenmann N, Stark S, Thamm R, Kneschaurek P, Schwaiger M, Molls M, Weber WA, 2003. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. *Int.J Radiat.Oncol.Biol.Phys.* 56,1450-1463
- Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, Wong DF, 1997. TIME COURSE OF 5-HT<sub>2A</sub> RECEPTOR OCCUPANCY IN THE HUMAN BRAIN AFTER A SINGLE ORAL DOSE OF THE PUTATIVE ANTIPSYCHOTIC DRUG MDL 100,907 MEASURED BY POSITRON EMISSION TOMOGRAPHY. *Neuropsychopharmacology* 17,175-185

- Grunder G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz HG, Stoeter P, Drzezga A, Luddens H, Rosch F, Bartenstein P, 2001. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. *Eur.J Nucl Med* 28,1463-1470
- Grunder G, Siessmeier T, Piel M, Vernaleken I, Buchholz HG, Zhou Y, Hiemke C, Wong DF, Rosch F, Bartenstein P, 2003. Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. *J Nucl Med* 44,109-116
- Grzeszczuk R, Tan KK, Levin DN, Pelizzari CA, Hu X, Chen GT, Beck RN, Chen CT, Cooper M, Milton J, 1992. Retrospective fusion of radiographic and MR data for localization of subdural electrodes. *Journal of Computer Assisted Tomography* 16,764-773
- Gu XH, Zong R, Kula NS, Baldessarini RJ, Neumeyer JL, 2001. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. *Bioorg.Med Chem.Lett.* 11,3049-3053
- Guhlke S, Wester HJ, Bruns C, Stocklin G, 1994. (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. *Nucl.Med.Biol.* 21,819-825
- Guich SM, Buchsbaum MS, Burgwald L, Wu J, Haier R, Asarnow R, Nuechterlein K, Potkin S, 1989. Effect of attention on frontal distribution of delta activity and cerebral metabolic rate in schizophrenia. *Schizophr.Res.* 2,439-448
- Guillery B, Desgranges B, de IS, V, Landeau B, Eustache F, Baron JC, 2002. Transient global amnesia: concomitant episodic memory and positron emission tomography assessment in two additional patients. *Neurosci.Lett.* 325,62-66
- Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ, 1997. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *Neuroimage.* 6,279-287
- Gur RC, Sussman NM, Alavi A, Gur RE, Rosen AD, O'Connor M, Goldberg HI, Greenberg JH, Reivich M, 1982. Positron emission tomography in two cases of childhood epileptic encephalopathy (Lennox-Gastaut syndrome). *Neurology* 32,1191-1194

- Gur RC, Gur RE, Resnick SM, Skolnick BE, Alavi A, Reivich M, 1987. The effect of anxiety on cortical cerebral blood flow and metabolism. *J.Cereb.Blood Flow Metab.* 7,173-177
- Gur RC, Mozley LH, Mozley PD, Resnick SM, Karp JS, Alavi A, Arnold SE, Gur RE, 1995. Sex differences in regional cerebral glucose metabolism during a resting state. *Science* 267,528-531
- Gur RE, Resnick SM, Alavi A, Gur RC, Caroff S, Dann R, Silver FL, Saykin AJ, Chawluk JB, Kushner M, 1987. Regional brain function in schizophrenia. I. A positron emission tomography study. *Arch Gen.Psychiatry* 44,119-125
- Gusnard DA, Raichle ME, Raichle ME, 2001. Searching for a baseline: functional imaging and the resting human brain. *Nat.Rev.Neurosci.* 2,685-694
- Gutschalk A, Kollmar R, Mohr A, Henze M, Ille N, Schwaninger M, Hartmann M, Hahnel S, Haberkorn U, Rupp A, Meyding-Lamade U, 2002. Multimodal functional imaging of prolonged neurological deficits in a patient suffering from familial hemiplegic migraine. *Neurosci.Lett.* 332,115
- Guttman M, Lang AE, Garnett ES, Nahmias C, Firnau G, Tyndel FJ, Gordon AS, 1987. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. *Mov Disord.* 2,201-210
- Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, Dasilva J, Houle S, 1997. [<sup>11</sup>C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. *Neurology* 48,1578-1583
- H"lzer T, Herholz K, Jeske J, Heiss WD, 1993. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. *Journal of Computer Assisted Tomography* 17,681-687
- Haaparanta M, Bergman J, Laakso A, Hietala J, Solin O, 1996. [<sup>18</sup>F]CFT ([<sup>18</sup>F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. *Synapse* 23,321-327
- Hagberg G, Gefvert O, Bergstrom M, Wieselgren IM, Lindstrom L, Wiesel FA, Langstrom B, 1998. N-[<sup>11</sup>C]methylspiperone PET, in contrast to [<sup>11</sup>C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic [In Process Citation]. *Psychiatry Res.* 82,147-160

- Hagberg GE, Torstenson R, Marteinsdottir I, Fredrikson M, Langstrom B, Blomqvist G, 2002. Kinetic compartment modeling of [<sup>11</sup>C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. *J Cereb.Blood Flow Metab* 22,1352-1366
- Hagelberg N, Kajander JK, Nagren K, Hinkka S, Hietala J, Scheinin H, 2002. Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. *Synapse* 45,25-30
- Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Nagren K, Jaaskelainen S, 2003. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. *Pain* 101,149-154
- Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Bjorklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O, 1999. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. *Brain* 122,1121-1132
- Hageman G, van der HJ, van Hout M, van der LG, Steur EJ, de Bruin W, Herholz K, 1999. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. *J Neurol* 246,198-206
- Hagman JO, Buchsbaum MS, Wu JC, Rao SJ, Reynolds CA, Blinder BJ, 1990. Comparison of regional brain metabolism in bulimia nervosa and affective disorder assessed with positron emission tomography. *J Affect.Disord.* 19,153-162
- Hajek M, Antonini A, Leenders KL, Wieser HG, 1991. Epilepsia partialis continua studied by PET. *Epilepsy Research* 9,44-48
- Hajek M, Wieser HG, Khan N, Antonini A, Schrott PR, Maguire P, Beer HF, Leenders KL, 1994. Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. *Neurology* 44,2125-2132
- Hakim AM, Pokrupa RP, Villanueva J, Diksic M, Evans AC, Thompson CJ, Meyer E, Yamamoto YL, Feindel WH, 1987. The effect of spontaneous reperfusion on metabolic function in early human cerebral infarcts. *Ann.Neurol* 21,279-289
- Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Biel C, Pokrupa R, Diksic M, Meyer E, 1989. The effect of nimodipine on the

- evolution of human cerebral infarction studied by PET. *J Cereb.Blood Flow Metab* 9,523-534
- Halber M, Herholz K, Wienhard K, Pawlik G, Heiss WD, 1997. Performance of a randomization test for single-subject 15O-water PET activation studies. *J.Cereb.Blood Flow Metab.* 17,1033-1039
- Hall H, Farde L, Halldin C, Lundkvist C, Sedvall G, 2000. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. *Synapse* 38,421-431
- Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth KJ, Langstrom B, Sedvall G, 1986. Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. *Int.J Rad.Appl.Instrum.[A]* 37,1039-1043
- Halldin C, Stone-Elander S, Thorell JO, Persson A, Sedvall G, 1988. 11C-labelling of Ro 15-1788 in two different positions, and also 11C- labelling of its main metabolite Ro 15-3890, for PET studies of benzodiazepine receptors. *Int.J.Rad.Appl.Instrum.[A.]* 39,993-997
- Halldin C, Farde L, Litton JE, Hall H, Sedvall G, 1992. [11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography. *Psychopharmacology (Berl)* 108,16-22
- Halldin C, Farde L, Lundkvist C, Ginovart N, Nakashima Y, Karlsson P, Swahn CG, 1996. [11C]beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. *Synapse* 22,386-390
- Halldin C, Gulyas B, Langer O, Farde L, 2001. Brain radioligands - State of the art and new trends. *Quarterly Journal of Nuclear Medicine* 45,139-152
- Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L, 2003. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. *Eur.J.Nucl.Med.Mol.Imaging*
- Hallett M, Dubinsky RM, 1993. Glucose metabolism in the brain of patients with essential tremor. *J Neurol Sci.* 114,45-48

- Halliday G, Ng T, Rodriguez M, Harding A, Blumbergs P, Evans W, Fabian V, Fryer J, Gonzales M, Harper C, Kalnins R, Masters CL, McLean C, Milder DG, Pamphlett R, Scott G, Tannenberg A, Kril J, 2002. Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. *Acta Neuropathol.(Berl)* 104,72-78
- Hammers A, Koepp MJ, Labbe C, Brooks DJ, Thom M, Cunningham VJ, Duncan JS, 2001. Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy. *Neurology* 56,897-906
- Hammers A, Koepp MJ, Richardson MP, Labbe C, Brooks DJ, Cunningham VJ, Duncan JS, 2001. Central benzodiazepine receptors in malformations of cortical development: A quantitative study. *Brain* 124,1555-1565
- Hammers A, Koepp MJ, Hurlemann R, Thom M, Richardson MP, Brooks DJ, Duncan JS, 2002. Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. *Brain* 125,2257-2271
- Hammers A, Koepp MJ, Free SL, Brett M, Richardson MP, Labbe C, Cunningham VJ, Brooks DJ, Duncan J, 2002. Implementation and application of a brain template for multiple volumes of interest. *Hum.Brain Mapp.* 15,165-174
- Hammers A, Koepp MJ, Richardson MP, Hurlemann R, Brooks DJ, Duncan JS, 2003. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. *Brain* 126,1300-1318
- Hand KS, Baird VH, Van Paesschen W, Koepp MJ, Revesz T, Thom M, Harkness WF, Duncan JS, Bowery NG, 1997. Central benzodiazepine receptor autoradiography in hippocampal sclerosis. *Br.J Pharmacol.* 122,358-364
- Handforth A, Cheng JT, Mandelkern MA, Treiman DM, 1994. Markedly increased mesiotemporal lobe metabolism in a case with PLEDs: further evidence that PLEDs are a manifestation of partial status epilepticus. *Epilepsia* 35,876-881
- Hansen LK, Larsen J, Nielsen FA, Strother SC, Rostrup E, Savoy R, Lange N, Sidtis J, Svarer C, Paulson OB, 1999. Generalizable patterns in neuroimaging: how many principal components? *Neuroimage.* 9,534-544

- Hanson MW, Glantz MJ, Hoffman JM, Friedman AH, Burger PC, Schold SC, Coleman RE, 1991. FDG-PET in the selection of brain lesions for biopsy. *J Comput.Assist.Tomogr.* 15,796-801
- Harada N, Nishiyama S, Satoh K, Fukumoto D, Kakiuchi T, Tsukada H, 2002. Age-related changes in the striatal dopaminergic system in the living brain: a multiparametric PET study in conscious monkeys. *Synapse* 45,38-45
- Haradahira T, Okauchi T, Maeda J, Zhang MR, Kida T, Kawabe K, Mishina M, Watanabe Y, Suzuki K, Suhara T, 2002. A positron-emitter labeled glycine(B) site antagonist, [(11)C]L-703,717, preferentially binds to a cerebellar NMDA receptor subtype consisting of GluR epsilon3 subunit in vivo, but not in vitro. *Synapse* 43,131-133
- Hardy J, Cookson MR, Singleton A, 2003. Genes and parkinsonism. *The Lancet Neurology* 2,221-228
- Hargreaves R, 2002. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. *Journal of Clinical Psychiatry* 63 Suppl 11,18-24
- Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, Renshaw PF, 1998. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. *AJNR Am J Neuroradiol* 19,1727-1732
- Harrison PJ, 2002. The neuropathology of primary mood disorder. *Brain* 125,1428-1449
- Hartvig P, Bergstrom K, Lindberg B, Lundberg PO, Lundqvist H, Langstrom B, Svard H, Rane A, 1984. Kinetics of 11C-labeled opiates in the brain of rhesus monkeys. *J Pharmacol.Exp.Ther.* 230,250-255
- Hartvig P, Lindner KJ, Tedroff J, Andersson Y, Bjurling P, Langstrom B, 1992. Brain kinetics of 11 C-labelled L-tryptophan and 5-hydroxy-L- tryptophan in the rhesus monkey. A study using positron emission tomography. *Journal of Neural Transmission - General Section* 88,1-10
- Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P, Langstrom B, 1997. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. *J.Neural Transm.* 104,329-339



- Hartvig P, Torstenson R, Bjurling P, Fasth KJ, Langstrom B, Nordberg A, 1997. REGIONAL BRAIN DISTRIBUTION AND BINDING OF THE MUSCARINIC RECEPTOR AGONIST CI-979 STUDIED BY POSITRON EMISSION TOMOGRAPHY IN THE MONKEY. *Dementia & Geriatric Cognitive Disorders* 8,259-266
- Hartvig P, Nordberg A, Torstenson R, Sjoberg P, Fasth KJ, Langstrom B, 2002. Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography. *Dement.Geriatr.Cogn Disord.* 13,199-204
- Haslinger B, Boecker H, Buchel C, Vesper J, Tronnier VM, Pfister R, Alesch F, Moringlane JR, Krauss JK, Conrad B, Schwaiger M, Ceballos-Baumann AO, 2003. Differential modulation of subcortical target and cortex during deep brain stimulation. *Neuroimage* 18,517-524
- Hasselbalch SG, Knudsen GM, Jakobsen J, Hageman LP, Holm S, Paulson OB, 1994. Brain metabolism during short-term starvation in humans. *J Cereb.Blood Flow Metab* 14,125-131
- Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, Paulson OB, 1996. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. *Am.J Physiol* 270,E746-E751
- Hasselbalch SG, Madsen PL, Knudsen GM, Holm S, Paulson OB, 1998. Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. *J.Cereb.Blood Flow Metab.* 18,154-160
- Hasselbalch SG, Knudsen GM, Capaldo B, Postiglione A, Paulson OB, 2001. Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans. *J.Clin.Endocrinol.Metab* 86,1986-1990
- Hatazawa J, Brooks RA, Dalakas MC, Mansi L, Di Chiro G, 1988. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. *J Comput.Assist.Tomogr.* 12,630-636
- Hawkins RA, Phelps ME, Huang SC, Wapenski JA, Grimm PD, Parker RG, Juillard G, Greenberg P, 1984. A kinetic evaluation of blood-brain barrier permeability in human brain tumors with [68Ga]EDTA and positron computed tomography. *J.Cereb.Blood Flow Metab.* 4,507-515
- Hawkins RA, Phelps ME, Huang SC, 1986. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG

- model with and without a vascular compartment: studies in human brain tumors with PET. *J.Cereb.Blood Flow Metab.* 6,170-183
- Hawkins RA, Mazziotta JC, Phelps ME, 1987. Wilson's disease studied with FDG and positron emission tomography. *Neurology* 37,1707-1711
- Hawkins RA, Huang SC, Barrio JR, Keen RE, Feng D, Mazziotta JC, Phelps ME, 1989. Estimation of local cerebral protein synthesis rates with L-[1-<sup>11</sup>C]leucine and PET: methods, model, and results in animals and humans. *J.Cereb.Blood Flow Metab.* 9,446-460
- Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI, 1985. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. *J.Cereb.Blood Flow Metab.* 5,193-200
- Haxby JV, Grady CL, Duara R, Schlageter N, Test T, Rapoport SI, 1986. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. *Arch.Neurol.* 43,882-885
- Haxby JV, Grady CL, Koss E, Horwitz B, Schapiro M, Friedland RP, Rapoport SI, 1988. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. *Neurology* 38,1853-1863
- Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, Friedland RP, Rapoport SI, 1990. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. *Arch.Neurol.* 47,753-760
- Haxby JV, Grady CL, Friedland RP, Rapoport SI, 1994. Neocortical metabolic abnormalities precede nonmemory cognitive impairments in early dementia of the Alzheimer type: longitudinal confirmation. *Journal of Neural Transmission Supplementum* 1987;24,49-53
- Hayase N, Tomiyoshi K, Watanabe K, Horikoshi S, Shibasaki T, Ohye C, 1995. Positron emission tomography with 4-[<sup>18</sup>F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys. *Ann.Nucl Med* 9,119-123
- Hayashi T, Suzuki A, Hatazawa J, Kanno I, Shirane R, Yoshimoto T, Yasui N, 2000. Cerebral circulation and metabolism in the acute stage of subarachnoid hemorrhage. *J Neurosurg.* 93,1014-1018
- Hayashi T, Watabe H, Kudomi N, Kim KM, Enmi J, Hayashida K, Iida H, 2003. A theoretical model of oxygen delivery and metabolism for physiologic

- interpretation of quantitative cerebral blood flow and metabolic rate of oxygen. *J Cereb. Blood Flow Metab* 23,1314-1323
- Hayashida K, Tanaka Y, Hirose Y, Kume N, Iwama T, Miyake Y, Ishida Y, Matsuura H, Miyake Y, Nishimura T, 1996. Vasoreactive effect of acetazolamide as a function of time with sequential PET 15O-water measurement. *Nucl Med Commun.* 17,1047-1051
- Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, Ammann W, Harrop R, Rogers J, Ruth T, 1986. Positron emission tomography in the early diagnosis of Huntington's disease. *Neurology* 36,888-894
- Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR, 1987. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. *Neurology* 37,1441-1447
- Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KHL, Gitschier J, 2003. Genetic, Clinical, and Radiographic Delineation of Hallervorden-Spatz Syndrome. *N Engl J Med* 348,33-40
- Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C, Kinderlehrer R, Haznedar MM, Shihabuddin L, Siever LJ, 1999. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. *Am J Psychiatry* 156,1190-1199
- Hazlett EA, Buchsbaum MS, 2001. Sensorimotor gating deficits and hypofrontality in schizophrenia. *Front Biosci.* 6,D1069-D1072
- Heesters MA, Go KG, Kamman RL, Mooyaart EL, Meertens H, Paans AM, Pruim J, 1998. 11C-tyrosine position emission tomography and 1H magnetic resonance spectroscopy of the response of brain gliomas to radiotherapy. *Neuroradiology* 40,103-108
- Heiss WD, Podreka I, 1978. Assessment of pharmacological effects on cerebral blood flow. *European Neurology* 17 Suppl 1,135-143
- Heiss WD, Pawlik G, Herholz K, Wagner R, Wienhard K, 1985. Regional cerebral glucose metabolism in man during wakefulness, sleep, and dreaming. *Brain Research* 327,362-366

- Heiss WD, Herholz K, Bocher-Schwarz HG, Pawlik G, Wienhard K, Steinbrich W, Friedmann G, 1986. PET, CT, and MR imaging in cerebrovascular disease. *J Comput.Assist.Tomogr.* 10,903-911
- Heiss WD, Hebold I, Klinkhammer P, Ziffling P, Szekies B, Pawlik G, Herholz K, 1988. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. *J.Cereb.Blood Flow Metab.* 8,613-617
- Heiss WD, 1992. Experimental evidence of ischemic thresholds and functional recovery. [Review]. *Stroke* 23,1668-1672
- Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K, 1992. Progressive derangement of periinfarct viable tissue in ischemic stroke. *J Cereb.Blood Flow Metab* 12,193-203
- Heiss WD, Pawlik G, Holthoff V, Kessler J, Szekies B, 1992. PET correlates of normal and impaired memory functions. [Review]. *Cerebrovascular & Brain Metabolism Reviews* 4,1-27
- Heiss WD, Emunds HG, Herholz K, 1993. Cerebral glucose metabolism as a predictor of rehabilitation after ischemic stroke. *Stroke* 24,1784-1788
- Heiss WD, Kessler J, Karbe H, Fink GR, Pawlik G, 1993. Cerebral glucose metabolism as a predictor of recovery from aphasia in ischemic stroke. *Arch Neurol* 50,958-964
- Heiss WD, Graf R, Wienhard K, Lottgen J, Saito R, Fujita T, Rosner G, Wagner R, 1994. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. *J.Cereb.Blood Flow Metab.* 14,892-902
- Heiss WD, Graf R, 1994. The ischemic penumbra. *Curr.Opin.Neurol* 7,11-19
- Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, Pietrzyk U, 1996. F-Dopa as an amino acid tracer to detect brain tumors. *J.Nucl.Med.* 37,1180-1182
- Heiss WD, Graf R, Lottgen J, Ohta K, Fujita T, Wagner R, Grond M, Weinhard K, 1997. Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. *J Cereb.Blood Flow Metab* 17,388-400

- Heiss WD, Graf R, Fujita T, Ohta K, Bauer B, Lottgen J, Wienhard K, 1997. Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats. *Stroke* 28,2045-2051
- Heiss WD, Grond M, Thiel A, Ghaemi M, Sobesky J, Rudolf J, Bauer B, Wienhard K, 1998. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. *Stroke* 29,454-461
- Heiss WD, Kessler J, Thiel A, Ghaemi M, Karbe H, 1999. Differential capacity of left and right hemispheric areas for compensation of poststroke aphasia. *Ann.Neurol* 45,430-438
- Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G, 2001. Penumbra probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. *Brain* 124,20-29
- Helfenbein J, Loc'h C, Bottlaender M, Emond P, Coulon C, Ottaviani M, Fuseau C, Chalon S, Guenther I, Besnard JC, Frangin Y, Guilloteau D, Maziere B, 1999. A selective radiobrominated cocaine analogue for imaging of dopamine uptake sites: pharmacological evaluation and PET experiments. *Life Sci.* 65,2715-2726
- Hempel A, Henze M, Berghoff C, Garcia N, Ody R, Schroder J, 2001. PET findings and neuropsychological deficits in a case of Fahr's disease. *Psychiatry Res* 108,133-140
- Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W, de Vries EG, 1999. Visualization of multidrug resistance in vivo. *Eur.J Nucl Med* 26,283-293
- Hendrikse NH, Vaalburg W, 2002. Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography. *Methods* 27,228-233
- Henry TR, Sutherling WW, Engel J, Jr., Risinger MW, Levesque MF, Mazziotta JC, Phelps ME, 1991. Interictal cerebral metabolism in partial epilepsies of neocortical origin. *Epilepsy Research* 10,174-182
- Henry TR, Mazziotta JC, Engel J, Jr., 1993. Interictal metabolic anatomy of mesial temporal lobe epilepsy. *Arch.Neurol.* 50,582-589
- Henry TR, 1996. Functional neuroimaging with positron emission tomography. *Epilepsia* 37,1141-1154

- Henry TR, Pennell PB, 1998. Neuropharmacological imaging in epilepsy with PET and SPECT. *Q.J Nucl Med* 42,199-210
- Henselmans JM, de Jong BM, Pruim J, Staal MJ, Rutgers AW, Haaxma R, 2000. Acute effects of thalamotomy and pallidotomy on regional cerebral metabolism, evaluated by PET. *Clin.Neurol Neurosurg* 102,84-90
- Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U, 2001. PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. *J Nucl Med* 42,1053-1056
- Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL, 2002. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. *J Clin.Oncol.* 20,3804-3814
- Herholz K, Pawlik G, Wienhard K, Heiss WD, 1985. Computer assisted mapping in quantitative analysis of cerebral positron emission tomograms. *Journal of Computer Assisted Tomography* 9,154-161
- Herholz K, Krieg JC, Emrich HM, Pawlik G, Beil C, Pirke KM, Pahl JJ, Wagner R, Wienhard K, Ploog D, ., 1987. Regional cerebral glucose metabolism in anorexia nervosa measured by positron emission tomography. *Biol.Psychiatry* 22,43-51
- Herholz K, Patlak CS, 1987. The influence of tissue heterogeneity on results of fitting nonlinear model equations to regional tracer uptake curves: with an application to compartmental models used in positron emission tomography. *J.Cereb.Blood Flow Metab.* 7,214-229
- Herholz K, 1988. Non-stationary spatial filtering and accelerated curve fitting for parametric imaging with dynamic PET. *Eur.J Nucl Med* 14,477-484
- Herholz K, Pietrzyk U, Wienhard K, Hebold I, Pawlik G, Wagner R, Holthoff V, Klinkhammer P, Heiss WD, 1989. Regional cerebral blood flow measurement with intravenous [15O]water bolus and [18F]fluoromethane inhalation. *Stroke* 20,1174-1181
- Herholz K, Wienhard K, Pietrzyk U, Pawlik G, Heiss WD, 1989. Measurement of blood-brain hexose transport with dynamic PET: comparison of [18F]2-

- fluoro-2-deoxyglucose and [11C]O-methylglucose. J.Cereb.Blood Flow Metab. 9,104-110
- Herholz K, Wagner R, Wienhard K, Heiss WD, 1990. Use of 18F-fluoromethane for cerebral blood flow measurement with PET. Nuklearmedizin 29,84
- Herholz K, Heindel W, Luyten PR, denHollander JA, Pietrzyk U, Voges J, Kugel H, Friedmann G, Heiss WD, 1992. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Annals of Neurology 31,319-327
- Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, Comar D, 1993. Comparability of FDG PET studies in probable Alzheimer's disease. J.Nucl.Med. 34,1460-1466
- Herholz K, 1996. Neuroimaging in anorexia nervosa. Psychiatry Res 62,105-110
- Herholz K, Thiel A, Wienhard K, Pietrzyk U, von Stockhausen HM, Karbe H, Kessler J, Bruckbauer T, Halber M, Heiss WD, 1996. Individual functional anatomy of verb generation. Neuroimage 3,185-194
- Herholz K et al., 1996. Integrated quantitative analysis of functional and morphological 3D data by volumes of interest. In: Myers R et al., eds. Quantification of brain function using PET , Academic Press, San Diego, pp 175-180
- Herholz K, Reulen HJ, von Stockhausen HM, Thiel A, Ilmberger J, Kessler J, Eisner W, Yousry TA, Heiss WD, 1997. Preoperative activation and intraoperative stimulation of language-related areas in glioma patients. Neurosurgery 41,1253-1262
- Herholz K, H"lzer T, Bauer B, Schr"der R, Voges J, Ernestus RI, Mendoza G, Heiss WD, 1997. C-11-methionine PET for low-grade gliomas. Journal of Neuro-Oncology 35 (Suppl.1),S20
- Herholz K et al., 1998. Magnetic resonance imaging-guided language activation PET in patients: Technical aspects and clinical results. In: Carson RE et al., eds. Quantitative functional brain imaging with positron emission tomography , Academic Press, San Diego, CA, pp 159-163
- Herholz K, H"lzer T, Bauer B, Schr"der R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, L"ttgen J, Thiel A, Wienhard K, Heiss WD, 1998.

- 11C-Methionine PET for differential diagnosis of low-grade gliomas. *Neurology* 50,1316-1322
- Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, Jelic V, Almkvist O, Collette F, Alberoni M, Kennedy A, Hasselbalch S, Fazio F, Heiss WD, 1998. Metabolic impairment of association cortex predicts progression in Alzheimer's disease: a prospective multicenter positron emission tomography (PET) study. *European Journal of Neurology* 5,S24
- Herholz K, Thiel A, Kracht L, Heiss WD, 1999. Two instances of excessive blood flow increase in brain tumors during functional brain activation. *Neuroimage* 9 (Supplement),S569
- Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz O, Strotmann T, Heiss WD, 2000. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. *J.Neural Transm.* 12,1457-1468
- Herholz K, Heiss WD, 2000. Functional imaging correlates of recovery after stroke in humans. *J.Cereb.Blood Flow Metab.* 20,1619-1631
- Herholz K, Lercher M, Wienhard K, Bauer B, Lenz O, Heiss WD, 2001. PET measurement of cerebral acetylcholine esterase activity without blood sampling. *Eur.J.Nucl.Med.* 28,472-477
- Herholz K, Zündorf G, Lercher M, Wienhard K, Bauer B, Weisenbach S, Heiss WD, 2001. PET functional parametric images of acetylcholine esterase activity without blood sampling. *J.Cereb.Blood Flow Metab.* 21 (Suppl. 1),S528
- Herholz K, 2001. Die Wertigkeit funktionell bildgebender Verfahren (PET und SPECT) in der Begutachtung neurotoxischer zerebraler Schädigungen. *Der medizinische Sachverständige* 97,181-184
- Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Fröhlich L, Ito K, Mielke R, Kalbe E, Zündorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Calautti C, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD, 2002. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET. *Neuroimage* 17,302-316
- Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H, Heiss WD, Ebmeier KP, 2002. Direct comparison of spatially



- normalized PET and SPECT scans in Alzheimer disease. J.Nucl.Med. 43,21-26
- Herholz K, Weisenbach S, Zündorf G, Lenz O, Schröder H, Bauer B, Kalbe E, Heiss WD, 2004. In-vivo Study of Acetylcholine Esterase in Basal Forebrain, Amygdala, and Cortex in Mild to Moderate Alzheimer disease. Neuroimage in press,
- Herscovitch P, Markham J, Raichle ME, 1983. Brain blood flow measured with intravenous H<sub>2</sub>(15)O. I. Theory and error analysis. J Nucl Med 24,782-789
- Herscovitch P, Raichle ME, 1985. What is the correct value for the brain--blood partition coefficient for water? J.Cereb.Blood Flow Metab. 5,65-69
- Herscovitch P, Mintun MA, Raichle ME, 1985. Brain oxygen utilization measured with oxygen-15 radiotracers and positron emission tomography: generation of metabolic images. J.Nucl.Med. 26,416-417
- Herscovitch P, Raichle ME, Kilbourn MR, Welch MJ, 1987. Positron emission tomographic measurement of cerebral blood flow and permeability-surface area product of water using [15O]water and [11C]butanol. J.Cereb.Blood Flow Metab. 7,527-542
- Hershey T, Black KJ, Carl JL, McGee-Minnich L, Snyder AZ, Perlmutter JS, 2003. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 74,844
- Herzog H, Seitz RJ, Tellmann L, Rota Kops E, Julicher F, Schlaug G, Kleinschmidt A, Muller-Gartner HW, 1996. Quantitation of regional cerebral blood flow with 15O-butanol and positron emission tomography in humans. J.Cereb.Blood Flow Metab. 16,645-649
- Hietala J, West C, Syvalahti E, Nagren K, Lehtikainen P, Sonninen P, Ruotsalainen U, 1994. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl) 116,285-290
- Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehtikainen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U, 1994. Striatal D2 dopamine receptor characteristics in neuroleptic- naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51,116-123

- Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U, ., 1995. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. *Lancet* 346,1130-1131
- Hietala J, Syvalahti E, Vilkmann H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK, 1999. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. *Schizophr.Res* 35,41-50
- Higano S, Shishido F, Nagashima M, Tomura N, Murakami M, Inugami A, Fujita H, Tabata K, Yasui N, Uemura K, 1990. PET evaluation of spinal cord tumor using <sup>11</sup>C-methionine. *Journal of Computer Assisted Tomography* 14,297-299
- Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, Itoh M, Shin RW, Trojanowski JQ, Sasaki H, 2000. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. *Exp.Neurol.* 162,247-256
- Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, Sasaki H, 2000. Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. *Neuroscience* 99,721-729
- Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, Lenz O, Vieregge P, Herholz K, Heiss WD, Pramstaller PP, 2001. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. *Annals of Neurology* 49,367-376
- Hilker R, Schweitzer K, Ghaemi M, Weisenbach S, Herholz K, Heiss WD, 2002. The decline of dopaminergic neurons in Parkinson's disease is nonlinear: A serial positron emission tomography study with <sup>18</sup>- Fluorodopa. *Movement Disorders* 17,131
- Hilker R, Voges J, Thiel A, Ghaemi M, Herholz K, Sturm V, Heiss WD, 2002. Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET. *Journal of Neural Transmission* 10,1257-1264
- Hilker R, Schweitzer K, Ghaemi M, Weisenbach S, Herholz K, Heiss WD, 2003. Logarithmic estimation of disease progression and preclinical period

- duration with 18F-DOPA positron emission tomography in Parkinson's disease. *European Journal of Neurology* 10 (Suppl. 1),SC202
- Hilker R, Voges J, Ghaemi M, Lehrke R, Rudolf J, Koulousakis A, Herholz K, Wienhard K, Sturm V, Heiss WD, 2003. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. *Mov Disord.* 18,41-48
- Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, Lehrke R, Koulousakis A, Herholz K, Sturm V, Heiss WD, 2004. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. *J.Cereb.Blood Flow Metab.* 24,7-16
- Hino A, Mizukawa N, Tenjin H, Imahori Y, Taketomo S, Yano I, Nakahashi H, Hirakawa K, 1989. Postoperative hemodynamic and metabolic changes in patients with subarachnoid hemorrhage. *Stroke* 20,1504-1510
- Hirai K, Umesaki N, Sumi T, Ishiko O, Kanaoka Y, Ogita S, Koyama K, Kawabe J, Okamura T, Ochi H, 2001. Combined diagnostic imaging for retroperitoneal schwannoma. *Oncol.Rep.* 8,773-775
- Hirani E, Opacka-Juffry J, Gunn R, Khan I, Sharp T, Hume S, 2000. Pindolol occupancy of 5-HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635. *Synapse* 36,330-341
- Hirano T, Minematsu K, Hasegawa Y, Tanaka Y, Hayashida K, Yamaguchi T, 1994. Acetazolamide reactivity on 123I-IMP single photon emission computed tomography in patients with major cerebral artery occlusive disease: correlation with positron emission tomography parameters. *J Cereb.Blood Flow Metab* 14,763-770
- Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Ikeda M, Yamashita H, Takatsuki Y, Sasaki M, 1998. Regional hypometabolism related to language disturbance in Alzheimer's disease. *Dement.Geriatr.Cogn Disord.* 9,68-73
- Hisanaga K, Suzuki H, Tanji H, Mochizuki H, Iwasaki Y, Sato N, Jin K, 2001. Fluoro-DOPA and FDG positron emission tomography in a case of pathologically verified pure diffuse Lewy body disease. *J Neurol.* 248,905-906

- Hodges JR, Patterson K, Oxbury S, Funnell E, 1992. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. *Brain* 115 ( Pt 6),1783-1806
- Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP, 2002. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. *Radiology* 222,507-512
- Hofbauer RK, Rainville P, Duncan GH, Bushnell MC, 2001. Cortical representation of the sensory dimension of pain. *J Neurophysiol.* 86,402-411
- Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, Coleman RE, 1993. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. *J.Nucl.Med.* 34,567-575
- Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE, 2000. FDG PET imaging in patients with pathologically verified dementia. *J.Nucl.Med.* 41,1920-1928
- Hoh CK, Dahlbom M, Harris G, Choi Y, Hawkins RA, Phelps ME, Maddahi J, 1993. Automated iterative three-dimensional registration of positron emission tomography images. *J Nucl Med* 34,2009-2018
- Holden JE, Gatley SJ, Hichwa RD, Ip WR, Shaughnessy WJ, Nickles RJ, Polcyn RE, 1981. Cerebral blood flow using PET measurements of fluoromethane kinetics. *J Nucl Med* 22,1084-1088
- Holmes AP, Blair RC, Watson JDG, Ford I, 1996. NONPARAMETRIC ANALYSIS OF STATISTIC IMAGES FROM FUNCTIONAL MAPPING EXPERIMENTS. *J.Cereb.Blood Flow Metab.* 16,7-22
- Holschbach MH, Olsson RA, 2002. Applications of adenosine receptor ligands in medical imaging by positron emission tomography. *Curr.Pharm.Des* 8,2345-2352
- Holthoff-Detto VA, Kessler J, Herholz K, B"nner H, Pietrzyk U, W"rker M, Ghaemi M, Wienhard K, Wagner R, Heiss WD, 1997. Functional effects of striatal dysfunction in Parkinson disease. *Arch.Neurol.* 54,145-150

- Holthoff VA, Sandmann J, Pawlik G, Schröder R, Heiss WD, 1990. Positron emission tomography in Creutzfeldt-Jakob disease. *Arch.Neurol.* 47,1035-1038
- Holthoff VA, Koeppe RA, Frey KA, Paradise AH, Kuhl DE, 1991. Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for [<sup>11</sup>C]flumazenil. *J.Cereb.Blood Flow Metab.* 11,745-752
- Holthoff VA, Koeppe RA, Frey KA, Penney JB, Markel DS, Kuhl DE, Young AB, 1993. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. *Ann.Neurol* 34,76-81
- Holthoff VA, Herholz K, Berthold F, Widemann B, Schröder R, Neubauer I, Heiss WD, 1993. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. *Cancer* 72,1394-1403
- Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, Wagner R, Wienhard K, Pawlik G, Heiss WD, 1994. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. *Ann.Neurol* 36,176-182
- Holthoff VA, Herholz K, Lücke S, Spirling S, Kalbe E, Lenz O, Zündorf G, Beuthien-Baumann B, 2003. Behavioral disturbances and regional cerebral metabolism in probable Alzheimer's disease. *J.Cereb.Blood Flow Metab* 23 (Suppl. 1) ,631
- Hommer D, Andreasen P, Rio D, Williams W, Ruttimann U, Momenan R, Zametkin A, Rawlings R, Linnoila M, 1997. Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects. *J Neurosci.* 17,2796-2806
- Honda M, Nagamine T, Fukuyama H, Yonekura Y, Kimura J, Shibasaki H, 1997. Movement-related cortical potentials and regional cerebral blood flow change in patients with stroke after motor recovery. *J.Neurol.Sci.* 146,117-126
- Hong CC, Gillin JC, Dow BM, Wu J, Buchsbaum MS, 1995. Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. *Sleep.* 18,570-580

- Hornykiewicz O, Shannak K, 1994. Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease. [Review] [33 refs]. *Journal of Neural Transmission Supplementum*. 42,219-227
- Horowitz M, Blasberg R, Molnar P, Strong J, Kornblith P, Pleasants R, Fenstermacher J, 1983. Regional [<sup>14</sup>C]misonidazole distribution in experimental RT-9 brain tumors. *Cancer Res* 43,3800-3807
- Horti AG, Scheffel U, Kimes AS, Musachio JL, Ravert HT, Mathews WB, Zhan Y, Finley PA, London ED, Dannals RF, 1998. Synthesis and evaluation of N-[<sup>11</sup>C]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. *J.Med.Chem.* 41,4199-4206
- Horti AG, Chefer SI, Mukhin AG, Koren AO, Gundisch D, Links JM, Kurian V, Dannals RF, London ED, 2000. 6-[<sup>18</sup>F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. *Life Sci.* 67,463-469
- Horwitz B, 1991. Functional interactions in the brain: use of correlations between regional metabolic rates. *J.Cereb.Blood Flow Metab.* 11,A114-A120
- Horwitz B, McIntosh AR, Haxby JV, Grady CL, 1995. Network analysis of brain cognitive function using metabolic and blood flow data. [Review]. *Behavioural Brain Research* 66,187-193
- Horwitz B, Tagamets MA, 1999. Predicting human functional maps with neural net modeling. *Hum.Brain Mapp.* 8,137-142
- Horwitz B, 2003. The elusive concept of brain connectivity. *Neuroimage* 19,466-470
- Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, Mori E, 2002. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. *J Neurol Sci.* 199,67-71
- Hosokawa S, Ichiya Y, Kuwabara Y, Ayabe Z, Mitsuo K, Goto I, Kato M, 1987. Positron emission tomography in cases of chorea with different underlying diseases. *J Neurol Neurosurg Psychiatry* 50,1284-1287

- Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA, 2000. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. *Eur.J Nucl Med* 27,1719-1722
- Hounsfield GN, 1973. Computerized transverse axial scanning (tomography): Part. I. Description of system. *British Journal of Radiology* 46,1016-1022
- Howell LL, Hoffman JM, Votaw JR, Landrum AM, Jordan JF, 2001. An apparatus and behavioral training protocol to conduct positron emission tomography (PET) neuroimaging in conscious rhesus monkeys. *J Neurosci.Methods* 106,161-169
- Howell LL, Hoffman JM, Votaw JR, Landrum AM, Wilcox KM, Lindsey KP, 2002. Cocaine-induced brain activation determined by positron emission tomography neuroimaging in conscious rhesus monkeys. *Psychopharmacology (Berl)* 159,154-160
- Hoyer S, 2002. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. *J Neural Transm.* 109,341-360
- Hoyte RM, Zhang JX, Lerum R, Oluyemi A, Persaud P, O'Connor C, Labaree DC, Hochberg RB, 2002. Synthesis of halogen-substituted pyridyl and pyrimidyl derivatives of [3,2-c]pyrazolo corticosteroids: strategies for the development of glucocorticoid receptor mediated imaging agents. *J Med Chem.* 45,5397-5405
- Hsieh JC, Belfrage M, Stone-Elander S, Hansson P, Ingvar M, 1995. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. *Pain* 63,225-236
- Hsieh JC, Meyerson BA, Ingvar M, 1999. PET study on central processing of pain in trigeminal neuropathy. *Eur.J Pain* 3,51-65
- Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, Koepp MJ, Hammers A, Morris RG, Turjanski N, Brooks DJ, 2000. Cortical dysfunction in non-demented Parkinson's disease patients: A combined (31)P-MRS and (18)FDG-PET study. *Brain* 123,340-352
- Hu MT, Chaudhuri KR, Jarosz J, Yaguez L, Brooks DJ, 2002. An imaging study of parkinsonism among African-Caribbean and Indian London communities. *Mov Disord.* 17,1321-1328

- Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, Shinkawa M, Itoh M, Ido T, Sasaki H, 2000. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with lewy bodies. *Neurology* 55,1575-1577
- Huang C, Wahlund LO, Svensson L, Winblad B, Julin P, 2002. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. *BMC.Neurol* 2,9
- Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE, 1980. Noninvasive determination of local cerebral metabolic rate of glucose in man. *American Journal of Physiology* 238,E69-E82
- Huang SC, Carson RE, Phelps ME, 1982. Measurement of local blood flow and distribution volume with short-lived isotopes: a general input technique. *J.Cereb.Blood Flow Metab.* 2,99-108
- Huang SC, Feng DG, Phelps ME, 1986. Model dependency and estimation reliability in measurement of cerebral oxygen utilization rate with oxygen-15 and dynamic positron emission tomography. *J.Cereb.Blood Flow Metab.* 6,105-119
- Huang SC, Barrio JR, Phelps ME, 1986. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. *J.Cereb.Blood Flow Metab.* 6,515-521
- Huang SC, Bahn MM, Barrio JR, Hoffman JM, Satyamurthy N, Hawkins RA, Mazziotta JC, Phelps ME, 1989. A double-injection technique for in vivo measurement of dopamine D2-receptor density in monkeys with 3-(2'-[18F]fluoroethyl)piperone and dynamic positron emission tomography. *J.Cereb.Blood Flow Metab.* 9,850-858
- Huang SC, Quintana J, Satyamurthy N, Lacan G, Yu DC, Phelps ME, Barrio JR, 1999. [18F]Fluoro-beta-fluoromethylene-m-tyrosine derivatives show stereo, geometrical, and regio specificities as in vivo central dopaminergic probes in monkeys. *Nucl.Med.Biol.* 26,365-370
- Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, Mawlawi O, Kegeles LS, Wilson AA, Kung HF, Laruelle M, 2002. Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. *J Cereb.Blood Flow Metab* 22,1377-1398



- Huber M, Siol T, Herholz K, Lenz O, K"hle K, Heiss WD, 2001. Activation of Thalamo - Cortical Systems in Post-Traumatic Flashbacks: A Positron Emission Tomography Study. *Traumatology* 7,
- Hudson H, Larkin R, 1994. Accelerated image reconstruction using ordered subsets of projection data. *IEEE Trans.Med.Imaging* 13 ,601-609
- Huesman RH, Coxson PG, 1997. Consolidation of common parameters from multiple fits in dynamic PET data analysis. *IEEE Trans.Med Imaging* 16,675-683
- Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ, 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. *Brain* 125,861-870
- Hume S, Hirani E, Opacka-Juffry J, Myers R, Townsend C, Pike V, Grasby P, 2001. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(1A) receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. *Synapse* 41,150-159
- Hume SP, Opacka-Juffry J, Myers R, Ahier RG, Ashworth S, Brooks DJ, Lammertsma AA, 1995. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. *Synapse* 21,45-53
- Hume SP, Lammertsma AA, Myers R, Rajeswaran S, Bloomfield PM, Ashworth S, Fricker RA, Torres EM, Watson I, Jones T, 1996. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. *J Neurosci.Methods* 67,103-112
- Hume SP, Luthra SK, Brown DJ, Opacka-Juffry J, Osman S, Ashworth S, Myers R, Brady F, Carroll FI, Kuhar MJ, Brooks DJ, 1996. Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. *Nucl.Med.Biol.* 23,377-384
- Hume SP, Brown DJ, Ashworth S, Hirani E, Luthra SK, Lammertsma AA, 1997. In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner. *J.Neurosci.Methods* 76,45-51
- Hume SP, Gunn RN, Jones T, 1998. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. *Eur.J Nucl Med* 25,173-176

- Hunter KE, Blaxton TA, Bookheimer SY, Figlozzi C, Gaillard WD, Grandin C, Anyanwu A, Theodore WH, 1999. (15)O water positron emission tomography in language localization: a study comparing positron emission tomography visual and computerized region of interest analysis with the Wada test. *Ann.Neurol.* 45,662-665
- Hurn PD, Traystman RJ, 2002. Changes in arterial gas tension. In: Edvinsson L, Krause DN, eds. *Cerebral blood flow and metabolism*, Lippincott Williams & Wilkins, Philadelphia, Pa., pp 384-394
- Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE, 2000. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. *Neurology* 54,1916-1921
- Hutchins GD, Holden JE, Koeppe RA, Halama JR, Gatley SJ, Nickles RJ, 1984. Alternative approach to single-scan estimation of cerebral glucose metabolic rate using glucose analogs, with particular application to ischemia. *J.Cereb.Blood Flow Metab.* 4,35-40
- Hutton BF, Baccarne V, 1998. Efficient scatter modelling for incorporation in maximum likelihood reconstruction. *Eur.J.Nucl.Med.* 25,1658-1665
- Hutton BF, Kyme AZ, Lau YH, Skerrett DW, Fulton RR, 2002. A hybrid 3-D reconstruction/registration algorithm for correction of head motion in emission tomography. *IEEE Transactions on Nuclear Science* 49,188-194
- Hwang DR, Kegeles LS, Laruelle M, 2000. (-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. *Nucl Med Biol.* 27,533-539
- Hwang JJ, Uchio EM, Patel SV, Linehan WM, Walther MM, Pacak K, 2003. Diagnostic localization of malignant bladder pheochromocytoma using 6-18F fluorodopamine positron emission tomography. *J Urol.* 169,274-275
- Hwang SI, Kim JH, Park SW, Han MH, Yu IK, Lee SH, Lee DS, Lee SK, Chung CK, Chang KH, 2001. Comparative analysis of mr imaging, positron emission tomography, and ictal single-photon emission ct in patients with neocortical epilepsy. *AJNR Am.J.Neuroradiol.* 22,937-946
- Iacono RP, Tang ZS, Mazziotta JC, Grafton S, Hoehn M, 1992. Bilateral fetal grafts for Parkinson's disease: 22 months results. *Stereotactic & Functional Neurosurgery* 58,84-87

- Iannotti F, Fieschi C, Alfano B, Picozzi P, Mansi L, Pozzilli C, Punzo A, Del Vecchio G, Lenzi GL, Salvatore M, 1987. Simplified, noninvasive PET measurement of blood-brain barrier permeability. *J Comput.Assist.Tomogr.* 11,390-397
- Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, Rapoport SI, Schapiro MB, Horwitz B, 1998. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. *Neurology* 50,1585-1593
- Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, Inoue M, Yasuno F, Takano A, Maeda J, Shibuya H, 2002. Serotonin transporter binding in patients with mood disorders: a PET study with [<sup>11</sup>C](+)-McN5652. *Biol.Psychiatry* 51,715-722
- Ichise M, Toyama H, Innis RB, Carson RE, 2002. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. *J Cereb.Blood Flow Metab* 22,1271-1281
- Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE, 2003. Linearized reference tissue parametric imaging methods: application to [<sup>11</sup>C]DASB positron emission tomography studies of the serotonin transporter in human brain. *J Cereb.Blood Flow Metab* 23,1096-1112
- Iglesias S, Marchal G, Rioux P, Beaudouin V, Hauttement JL, Delasayette V, Ledoze F, Derlon JM, Viader F, Baron JC, 1996. Do changes in oxygen metabolism in the unaffected cerebral hemisphere underlie early neurological recovery after stroke? - A positron emission tomography study. *Stroke* 27,1192-1199
- Iglesias S, Marchal G, Viader F, Baron JC, 2000. Delayed intrahemispheric remote hypometabolism. Correlations with early recovery after stroke. *Cerebrovasc.Dis.* 10,391-402
- Iida H, Kanno I, Miura S, Murakami M, Takahashi K, Uemura K, 1986. Error analysis of a quantitative cerebral blood flow measurement using H<sub>2</sub>(<sup>15</sup>O) autoradiography and positron emission tomography, with respect to the dispersion of the input function. *J.Cereb.Blood Flow Metab.* 6,536-545
- Iinuma K, Yokoyama H, Otsuki T, Yanai K, Watanabe T, Ido T, Itoh M, 1993. Histamine H<sub>1</sub> receptors in complex partial seizures. *Lancet* 341,238

- Ikedo M, Hokoishi K, Maki N, Nebu A, Tachibana N, Komori K, Shigenobu K, Fukuhara R, Tanabe H, 2001. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. *Neurology* 57,839-844
- Ikezaki K, Matsushima T, Kuwabara Y, Suzuki SO, Nomura T, Fukui M, 1994. Cerebral circulation and oxygen metabolism in childhood moyamoya disease: a perioperative positron emission tomography study. *J Neurosurg* 81,843-850
- Ilgın N, Zubieta J, Reich SG, Dannals RF, Ravert HT, Frost JJ, 1999. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. *Neurology* 52,1221-1226
- Imahori Y, Fujii R, Ueda S, Ohmori Y, Wakita K, Matsumoto K, 1993. Phosphoinositide turnover imaging linked to muscarinic cholinergic receptor in the central nervous system by positron emission tomography. *J.Nucl.Med.* 34,1543-1551
- Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R, 1998. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. *Clin.Cancer Res.* 4,1833-1841
- Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R, 1998. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. *Clin.Cancer Res.* 4,1825-1832
- Ingvar M, Eriksson L, Greitz T, Stone-Elander S, Dahlbom M, Rosenqvist G, af Trampe P, von Euler C, 1994. Methodological aspects of brain activation studies: cerebral blood flow determined with [<sup>15</sup>O]butanol and positron emission tomography. *J.Cereb.Blood Flow Metab.* 14,628-638
- Ingvar M, Ghatan PH, Wirsén-Meurling A, Risberg J, Von Heijne G, Stone-Elander S, Ingvar DH, 1998. Alcohol activates the cerebral reward system in man. *J.Stud.Alcohol* 59,258-269
- Irie T, Fukushi K, Namba H, Iyo M, Tamagami H, Nagatsuka S, Ikota N, 1996. Brain acetylcholinesterase activity - validation of a PET tracer in a rat model of Alzheimers disease. *J.Nucl.Med.* 37,649-655

- Ishii K, ORIHARA H, Matsuzawa T, Binkley DM, Nutt R, 1990. HIGH-RESOLUTION TIME-OF-FLIGHT POSITRON EMISSION TOMOGRAPH. Review of Scientific Instruments 61,3755-3762
- Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Hashimoto M, Hirono N, Shimomura T, Mori E, 1998. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 51,125-130
- Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, Kuhl DE, Schwaiger M, 2001. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl.Med 42,548-557
- Ishikawa T, Yasui N, Suzuki A, Hadeishi H, Shishido F, Uemura K, 1992. STA-MCA bypass surgery for internal carotid artery occlusion--comparative follow-up study. Neurol Med Chir (Tokyo) 32,5-9
- Ishikawa T, Kawamura S, Hadeishi H, Suzuki A, Yasui N, Shishido F, Uemura K, 1992. Uncoupling between CBF and oxygen metabolism in a patient with chronic subdural haematoma: case report. J Neurol Neurosurg Psychiatry 55,401-403
- Ishikawa T, Kawamura S, Hadeishi H, Suzuki A, Yasui N, Uemura K, 1995. Cerebral blood flow and oxygen metabolism in hemiparetic patients with chronic subdural hematoma. Quantitative evaluation using positron emission tomography. Surg.Neurol. 43,130-136
- Ishiwata K, Kubota K, Murakami M, Kubota R, Senda M, 1993. A comparative study on protein incorporation of L-[methyl- 3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nuclear Medicine & Biology 20,895-899
- Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, Senda M, 1993. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J.Nucl.Med. 34,1936-1943
- Ishiwata K, Senda M, 1999. In vivo binding of [11C]nemonapride to sigma receptors in the cortex and cerebellum. Nucl Med Biol. 26,627-631
- Ishiwata K, Kobayashi T, Kawamura K, Matsuno K, Senda M, 2001. [11C]Raclopride binding was reduced in vivo by sigma(1) receptor ligand

- SA4503 in the mouse brain, while [ $^{11}\text{C}$ ]SA4503 binding was not by raclopride. Nucl Med Biol. 28,787-792
- Ishiwata K, Ogi N, Hayakawa N, Oda K, Nagaoka T, Toyama H, Suzuki F, Endo K, Tanaka A, Senda M, 2002. Adenosine A(2A) receptor imaging with [ $^{11}\text{C}$ ]KF18446 PET in the rat brain after quinolinic acid lesion: Comparison with the dopamine receptor imaging. Annals of Nuclear Medicine 16,467-475
- Ishiwata K, Nariai T, Kimura Y, Oda K, Kawamura K, Ishii K, Senda M, Wakabayashi S, Shimada J, 2002. Preclinical studies on [ $^{11}\text{C}$ ]MPDX for mapping adenosine A(1) receptors by positron emission tomography. Annals of Nuclear Medicine 16,377-382
- Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, Tsuchida T, Okazawa H, Miyatake S, Ishikawa M, 1994. Effects of hyperglycemia on FDG uptake in human brain and glioma [see comments]. J.Nucl.Med. 35,1104-1109
- Ito H, Hatazawa J, Murakami M, Miura S, Iida H, Bloomfield PM, Kanno I, Fukuda H, Uemura K, 1995. Aging effect on neutral amino acid transport at the blood-brain barrier measured with L-[2- $^{18}\text{F}$ ]-fluorophenylalanine and PET. J.Nucl.Med. 36,1232-1237
- Ito H, Hietala J, Blomqvist G, Halldin C, Farde L, 1998. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [ $^{11}\text{C}$ ]raclopride binding [In Process Citation]. J.Cereb.Blood Flow Metab. 18,941-950
- Ito H, Kanno I, Shimosegawa E, Tamura H, Okane K, Hatazawa J, 2002. Hemodynamic changes during neural deactivation in human brain: a positron emission tomography study of crossed cerebellar diaschisis. Ann.Nucl Med 16,249-254
- Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ, 2002. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[( $^{18}\text{F}$ )]fluoro-L-dopa PET study. Brain 125,1358-1365
- Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T, 1997. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimers disease. Lancet 349,1805-1809

- Jaaskelainen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, Bergman J, 2001. Role of the dopaminergic system in chronic pain -- a fluorodopa-PET study. *Pain* 90,257-260
- Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R, 2001. Limitations of stereotactic biopsy in the initial management of gliomas. *Neuro.-oncol.* 3,193-200
- Jacobs A, Herholz K, Pietrzyk U, Wurker M, Wienhard K, Heiss WD, 1996. Diaschisis of specific cerebellar lobules: pontine haematoma studied with high-resolution PET and MRI. *J Neurol* 243,131-136
- Jacobs A, Neveling M, Horst M, Ghaemi M, Kessler J, Eichstaedt H, Rudolf J, Model P, Bonner H, de Vivie ER, Heiss WD, 1998. Alterations of neuropsychological function and cerebral glucose metabolism after cardiac surgery are not related only to intraoperative microembolic events. *Stroke* 29,660-667
- Jacobs A, Braunlich I, Graf R, Lercher M, Sakaki T, Voges J, Hesselmann V, Brandau W, Wienhard K, Heiss WD, 2001. Quantitative kinetics of [124I]FIAU in cat and man. *J.Nucl.Med.* 42,467-475
- Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C, Wagner R, Wienhard K, Heiss WD, 2001. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. *Lancet* 358,727-729
- Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG, 2001. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. *Cancer Res.* 61,2983-2995
- Jacobs AH, Dittmar C, Garlip G, Thomas AV, Kracht LW, Wienhard K, Herholz K, Heiss WD, 2003. Identification of DNA and amino acid metabolism in human gliomas by PET. *J.Cereb.Blood Flow Metab* 23 (Suppl. 1) ,376
- Jacobs B, Chugani HT, Allada V, Chen S, Phelps ME, Pollack DB, Raleigh MJ, 1995. Developmental changes in brain metabolism in sedated rhesus macaques and vervet monkeys revealed by positron emission tomography. *Cerebral Cortex* 5,222-233

- Jacobs RE, Cherry SR, 2001. Complementary emerging techniques: high-resolution PET and MRI. *Curr.Opin.Neurobiol.* 11,621-629
- Jagoda EM, Kiesewetter DO, Shimoji K, Ravasi L, Yamada M, Gomeza J, Wess J, Eckelman WC, 2003. Regional brain uptake of the muscarinic ligand, [(18)F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. *Neuropharmacology* 44,653-661
- Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B, 1988. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. *Neurology* 38,909-912
- Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, Coxson PG, Budinger TF, 1991. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. *J.Cereb.Blood Flow Metab.* 11,323-330
- Jagust WJ, Eberling JL, Richardson BC, Reed BR, Baker MG, Nordahl TE, Budinger TF, 1993. The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. *Brain Research* 629,189-198
- Jahanshahi M, Jenkins IH, Brown RG, Marsden CD, Passingham RE, Brooks DJ, 1995. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. *Brain* 118,913-933
- Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, De Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S, 2003. 86Y-DOTA(0)-d-Phe(1)-Tyr(3)-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. *Eur.J Nucl Med Mol.Imaging*
- Jansen HM, Willemsen AT, Sinnige LG, Paans AM, Hew JM, Franssen EJ, Zorgdrager AM, Pruim J, Minderhoud JM, Korf J, 1995. Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis. *J Neurol Sci.* 132,139-145
- Jansen HM, van der NJ, van Zomeren AH, Paans AM, Veenma-van der Duin L, Hew JM, Pruim J, Minderhoud JM, Korf J, 1996. Cobalt-55 positron emission tomography in traumatic brain injury: a pilot study. *J Neurol Neurosurg Psychiatry* 60,221-224



- Jarden JO, Dhawan V, Poltorak A, Posner JB, Rottenberg DA, 1985. Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of  $^{82}\text{Rb}$ : the effect of dexamethasone and whole-brain radiation therapy. *Annals of Neurology* 18,636-646
- Jarden JO, 1994. Pathophysiological aspects of malignant brain tumors studied with positron emission tomography. *Acta Neurologica Scandinavica Supplementum*. 156,1-35
- Jarman PR, Bhatia KP, Davie C, Heales SJ, Turjanski N, Taylor-Robinson SD, Marsden CD, Wood NW, 2000. Paroxysmal dystonic choreoathetosis: clinical features and investigation of pathophysiology in a large family. *Mov Disord*. 15,648-657
- Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H, 2002. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. *J Natl.Cancer Inst*. 94,1484-1493
- Jeavons AP, Chandler RA, Dettmar CAR, 1999. A 3D HIDAC-PET camera with sub-millimetre resolution for imaging small animals. *IEEE Transactions on Nuclear Science* 46,468-473
- Jeavons AP, 2000. Small-animal PET cameras. *J.Nucl.Med*. 41,1442-1443
- Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR, 2002. The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. *Neuropsychopharmacology* 27,92-104
- Jellinger KA, 2000. Morphological substrates of mental dysfunction in Lewy body disease: an update. *J.Neural Transm.Suppl* 59,185-212
- Jellinger KA, 2002. The pathology of ischemic-vascular dementia: An update. *Journal of the Neurological Sciences* 203-204,153-157
- Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, Brooks DJ, 1992. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. *Ann.Neurol* 32,749-757

- Jenkins IH, Bain PG, Colebatch JG, Thompson PD, Findley LJ, Frackowiak RS, Marsden CD, Brooks DJ, 1993. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. *Ann.Neurol* 34,82-90
- Jenkins IH, Brooks DJ, Nixon PD, Frackowiak RS, Passingham RE, 1994. Motor sequence learning: a study with positron emission tomography. *Journal of Neuroscience* 14,3775-3790
- Johnson-Greene D, Adams KM, Gilman S, Koeppe RA, Junck L, Kluin KJ, Martorello S, Heumann M, 1997. Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. *J.Clin.Exp.Neuropsychol.* 19,378-385
- Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL, 1987. Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. *Arch.Neurol.* 44,165-168
- Jones AK, Qi LY, Fujirawa T, Luthra SK, Ashburner J, Bloomfield P, Cunningham VJ, Itoh M, Fukuda H, Jones T, 1991. In vivo distribution of opioid receptors in man in relation to the cortical projections of the medial and lateral pain systems measured with positron emission tomography. *Neurosci.Lett.* 126,25-28
- Jones AK, Brown WD, Friston KJ, Qi LY, Frackowiak RS, 1991. Cortical and subcortical localization of response to pain in man using positron emission tomography. *Proc.R.Soc.Lond B Biol.Sci.* 244,39-44
- Jones AK, Cunningham VJ, Ha-Kawa SK, Fujiwara T, Liyii Q, Luthra SK, Ashburner J, Osman S, Jones T, 1994. Quantitation of [11C]diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols. *J Neurosci.Methods* 51,123-134
- Jones AK, Derbyshire SW, 1997. Reduced cortical responses to noxious heat in patients with rheumatoid arthritis. *Ann.Rheum.Dis.* 56,601-607
- Jones AK, Kitchen ND, Watabe H, Cunningham VJ, Jones T, Luthra SK, Thomas DG, 1999. Measurement of changes in opioid receptor binding in vivo during trigeminal neuralgic pain using [11C] diprenorphine and positron emission tomography. *J Cereb.Blood Flow Metab* 19,803-808

- Jones SC, Ackerman RH, Hoop B, Jr., Baron JC, Brownell GL, Taveras JM, 1983. Brain uptake and organ distribution of  $^{11}\text{C}$  from  $^{11}\text{C}$ -labeled glucose. *International Journal of Nuclear Medicine & Biology* 10,173-180
- Jones T, Chesler DA, Ter Pogossian MM, 1976. The continuous inhalation of oxygen-15 for assessing regional oxygen extraction in the brain of man. *Br.J Radiol.* 49,339-343
- Jons PH, Ernst M, Hankerson J, Hardy K, Zametkin AJ, 1997. Follow-up of radial arterial catheterization for positron emission tomography studies. *Hum.Brain Mapp.* 5,119-123
- Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC, 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. *Mol.Psychiatry* 4,290-296
- Jordan S, Eberling JL, Bankiewicz KS, Rosenberg D, Coxson PG, VanBrocklin HF, O'Neil JP, Emborg ME, Jagust WJ, 1997. 6-[ $^{18}\text{F}$ ]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. *Brain Res.* 750,264-276
- Jordan S, Bankiewicz KS, Eberling JL, VanBrocklin HF, O'Neil JP, Jagust WJ, 1998. An in vivo microdialysis study of striatal 6-[ $^{18}\text{F}$ ]fluoro-L-m-tyrosine metabolism. *Neurochem.Res.* 23,513-517
- Jorm AF, 2000. Is depression a risk factor for dementia or cognitive decline? A review. *Gerontology* 46,219-227
- Joseph R, 1999. Frontal lobe psychopathology: mania, depression, confabulation, catatonia, perseveration, obsessive compulsions, and schizophrenia. *Psychiatry* 62,138-172
- Jovkar S, Wienhard K, Coenen HH, Pawlik G, Heiss WD, 1991. Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2'-F18)fluoroethylspiperone and positron emission tomography. *Eur.J.Nucl.Med.* 18,158-163
- Joyce EM, Rio DE, Ruttimann UE, Rohrbaugh JW, Martin PR, Rawlings RR, Eckardt MJ, 1994. Decreased cingulate and precuneate glucose utilization in alcoholic Korsakoff's syndrome. *Psychiatry Res* 54,225-239

- Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, Lieb K, 2000. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. *Psychopharmacology* 152,383-389
- Juengling FD, Schmahl C, Hesslinger B, Ebert D, Bremner JD, Gostomzyk J, Bohus M, Lieb K, 2003. Positron emission tomography in female patients with Borderline personality disorder. *J Psychiatr.Res* 37,109-115
- Juengling FD, Kassubek J, Martens-Le Bouar H, Reinhardt MJ, Krause T, Nitzsche EU, Moser E, Korinthenberg R, 2002. Cerebral regional hypometabolism caused by propofol-induced sedation in children with severe myoclonic epilepsy: a study using fluorodeoxyglucose positron emission tomography and statistical parametric mapping. *Neuroscience Letters* 335,79-82
- Juhasz C, Nagy F, Muzik O, Watson C, Shah J, Chugani HT, 1999. [11C]Flumazenil PET in patients with epilepsy with dual pathology. *Epilepsia* 40,566-574
- Juhasz C, Chugani DC, Muzik O, Watson C, Shah J, Shah A, Chugani HT, 2000. Electroclinical correlates of flumazenil and fluorodeoxyglucose PET abnormalities in lesional epilepsy. *Neurology* 55,825-835
- Juhasz C, Chugani HT, Muzik O, Chugani DC, 2001. Neuroradiological assessment of brain structure and function and its implication in the pathogenesis of West syndrome. *Brain Dev.* 23,488-495
- Juhasz C, Chugani DC, Muzik O, Shah A, Shah J, Watson C, Canady A, Chugani HT, 2001. Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. *Neurology* 56,1650-1658
- Junck L, Moen JG, Hutchins GD, Brown MB, Kuhl DE, 1990. Correlation methods for the centering, rotation, and alignment of functional brain images. *J.Nucl.Med.* 31,1220-1226
- Kaasinen V, Ruottinen HM, Nagren K, Lehtikainen P, Oikonen V, Rinne JO, 2000. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. *J.Nucl.Med.* 41,65-70
- Kaasinen V, Nurmi E, Bruck A, Eskola O, Bergman J, Solin O, Rinne JO, 2001. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. *Brain* 124,1125-1130

- Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO, 2003. Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. *J Neural Transm.* 110,591-601
- Kahane P, Merlet I, Gregoire MC, Munari C, Perret J, Maguire F, 1999. An H(2)(15)O-PET study of cerebral blood flow changes during focal epileptic discharges induced by intracerebral electrical stimulation. *Brain* 122,1851-1865
- Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT, 1994. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. *AJR* 163,1459-1465
- Kaisti KK, Metsahonkala L, Teras M, Oikonen V, Aalto S, Jaaskelainen S, Hinkka S, Scheinin H, 2002. Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. *Anesthesiology* 96,1358-1370
- Kakiuchi T, Nishiyama S, Sato K, Ohba H, Nakanishi S, Tsukada H, 2000. Age-related reduction of [11C]MDL100,907 binding to central 5-HT(2A) receptors: PET study in the conscious monkey brain. *Brain Res.* 883,135-142
- Kaminska A, Chiron C, Ville D, Dellatolas G, Hollo A, Cieuta C, Jalin C, Delalande O, Fohlen M, Vera P, Soufflet C, Dulac O, 2003. Ictal SPECT in children with epilepsy: comparison with intracranial EEG and relation to postsurgical outcome. *Brain* 126,248-260
- Kamo H, McGeer PL, Harrop R, McGeer EG, Calne DB, Martin WR, Pate BD, 1987. Positron emission tomography and histopathology in Pick's disease. *Neurology* 37,439-445
- Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H, 1998. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). *J.Biol.Chem.* 273,23629-23632
- Kanerva H, Vilkkumäki H, Nagren K, Kilku O, Kuoppamäki M, Syvälahti E, Hietala J, 1999. Brain 5-HT<sub>2A</sub> receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study. *Psychopharmacology (Berl)* 145,76-81
- Kang DH, Kwon JS, Kim JJ, Youn T, Park HJ, Kim MS, Lee DS, Lee MC, 2003. Brain glucose metabolic changes associated with neuropsychological

- improvements after 4 months of treatment in patients with obsessive-compulsive disorder. *Acta Psychiatr.Scand.* 107,291-297
- Kanno I, Lassen NA, 1979. Two methods for calculating regional cerebral blood flow from emission computed tomography of inert gas concentrations. *J Comput.Assist.Tomogr.* 3,71-76
- Kanno I, Lammertsma AA, Heather JD, Gibbs JM, Rhodes CG, Clark JC, Jones T, 1984. Measurement of cerebral blood flow using bolus inhalation of C15O2 and positron emission tomography: description of the method and its comparison with the C15O2 continuous inhalation method. *J.Cereb.Blood Flow Metab.* 4,224-234
- Kanno I, Iida H, Miura S, Murakami M, Takahashi K, Sasaki H, Inugami A, Shishido F, Uemura K, 1987. A system for cerebral blood flow measurement using an H215O autoradiographic method and positron emission tomography. *J Cereb.Blood Flow Metab* 7,143-153
- Kanno I, Iida H, Miura S, Murakami M, 1991. Optimal scan time of oxygen-15-labeled water injection method for measurement of cerebral blood flow [see comments]. *J.Nucl.Med.* 32,1931-1934
- Kao CH, Ho YJ, Lan JL, Changlai SP, Liao KK, Chieng PU, 1999. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. *Arthritis Rheum.* 42,61-68
- Kaplan AM, Bandy DJ, Manwaring KH, Chen K, Lawson MA, Moss SD, Duncan JD, Wodrich DL, Schnur JA, Reiman EM, 1999. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. *J.Neurosurg.* 91,797-803
- Kapoor R, Spence AM, Muzi M, Graham MM, Abbott GL, Krohn KA, 1989. Determination of the deoxyglucose and glucose phosphorylation ratio and the lumped constant in rat brain and a transplantable rat glioma. *Journal of Neurochemistry* 53,37-44
- Kapur S, Jones C, Dasilva J, Wilson A, Houle S, 1997. Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. *Nucl.Med.Comm.* 18,395-399

- Kapur S, Zipursky RB, Remington G, Jones C, Dasilva J, Wilson AA, Houle S, 1998. 5-HT<sub>2</sub> and D<sub>2</sub> receptor occupancy of olanzapine in schizophrenia: a PET investigation. *Am J Psychiatry* 155,921-928
- Kapur S, Zipursky RB, Remington G, 1999. Clinical and theoretical implications of 5-HT<sub>2</sub> and D<sub>2</sub> receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. *Am J Psychiatry* 156,286-293
- Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P, 2000. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D<sub>2</sub> receptor occupancy. *Arch Gen Psychiatry* 57,553-559
- Karbe H, Herholz K, Szekely B, Pawlik G, Wienhard K, Heiss WD, 1989. Regional metabolic correlates of Token test results in cortical and subcortical left hemispheric infarction. *Neurology* 39,1083-1088
- Karbe H, Grond M, Huber M, Herholz K, Kessler J, Heiss WD, 1992. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. *J Neurol* 239,98-102
- Karbe H, Holthoff VA, Rudolf J, Herholz K, Heiss WD, 1992. Positron emission tomography demonstrates frontal cortex and basal ganglia hypometabolism in dystonia. *Neurology* 42,1540-1544
- Karbe H, Holthoff V, Huber M, Herholz K, Wienhard K, Wagner R, Heiss WD, 1992. Positron emission tomography in degenerative disorders of the dopaminergic system. *J Neural Transm. Park Dis. Dement. Sect.* 4,121-130
- Karbe H, Kessler J, Herholz K, Fink GR, Heiss WD, 1995. Long-term prognosis of poststroke aphasia studied with positron emission tomography. *Arch. Neurol.* 52,186-190
- Karbe H, Herholz K, Weber-Luxemburger G, Ghaemi M, Heiss WD, 1998. Cerebral networks and functional brain asymmetry. Evidence from regional metabolic changes during word repetition. *Brain & Language* 63,108-121
- Karbe H, Thiel A, Weber-Luxemburger G, Herholz K, Kessler J, Heiss WD, 1998. Brain plasticity in poststroke aphasia: what is the contribution of the right hemisphere? *Brain Lang* 64,215-230

- Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B, 1993. PET examination of [<sup>11</sup>C]NNC 687 and [<sup>11</sup>C]NNC 756 as new radioligands for the D1-dopamine receptor. *Psychopharmacology* 113,149-156
- Karlsson P, Sedvall G, Halldin C, Swahn CG, Farde L, 1995. Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man. *Psychopharmacology* 121,300-308
- Karlsson P, Farde L, Halldin C, Sedvall G, Ynddal L, Sloth-Nielsen M, 1995. Oral administration of NNC 756--a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. *Psychopharmacology* 119,1-8
- Karp JS, Daube-Witherspoon ME, Muehllehner G, 1991. Factors Affecting Accuracy and Precision in Pet Volume Imaging. *Journal of Cerebral Blood Flow and Metabolism* 11,A38-A44
- Karp JS, Kinahan PE, Muehllehner G, Countryman P, 1993. Effect of Increased Axial-Field of View on the Performance of A Volume Pet Scanner. *IEEE Transactions on Medical Imaging* 12,299-306
- Karp JS, Freifelder R, Geagan MJ, Muehllehner G, Kinahan PE, Lewitt RM, Shao LX, 1997. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner. *J.Nucl.Med.* 38,636-643
- Karp JS, Surti S, Daube-Witherspoon ME, Freifelder R, Cardi CA, Adam LE, Bilger K, Muehllehner G, 2003. Performance of a brain PET camera based on anger-logic gadolinium oxyorthosilicate detectors. *J.Nucl.Med.* 44,1340-1349
- Kasai K, Iwanami A, Yamasue H, Kuroki N, Nakagome K, Fukuda M, 2002. Neuroanatomy and neurophysiology in schizophrenia. *Neurosci.Res* 43,93-110
- Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del FG, Luxen A, Reznik M, 1998. Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. *J.Nucl.Med.* 39,778-785
- Kassubek J, Juengling FD, Nitzsche EU, Lucking CH, 2001. Limbic encephalitis investigated by 18FDG-PET and 3D MRI. *J Neuroimaging* 11,55-59



- Katayama Y, Tsubokawa T, Tsukiyama T, Hirayama T, 1986. Changes in regional cerebral blood flow and oxygen metabolism following ventrolateral thalamotomy in Parkinson syndrome as revealed by positron emission tomography. *Appl. Neurophysiol.* 49,76-85
- Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG, 2003. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. *J Med Chem.* 46,642-645
- Katzenellenbogen JA, Welch MJ, Dehdashti F, 1997. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. *Anticancer Res.* 17,1573-1576
- Kawachi T, Ishii K, Sakamoto S, Matsui M, Mori T, Sasaki M, 2002. Gender differences in cerebral glucose metabolism: a PET study. *J Neurol Sci.* 199,79-83
- Kawai R, Carson RE, Dunn B, Newman AH, Rice KC, Blasberg RG, 1991. Regional brain measurement of Bmax and KD with the opiate antagonist cyclofoxy: equilibrium studies in the conscious rat. *J Cereb. Blood Flow Metab* 11,529-544
- Kawamura K, Ishiwata K, Shimada Y, Kimura Y, Kobayashi T, Matsuno K, Homma Y, Senda M, 2000. Preclinical evaluation of [<sup>11</sup>C]SA4503: radiation dosimetry, in vivo selectivity and PET imaging of sigma1 receptors in the cat brain. *Ann. Nucl Med* 14,285-292
- Kawamura S, Sayama I, Yasui N, Uemura K, 1994. Haemodynamic and metabolic changes following extra-intracranial bypass surgery. *Acta Neurochir.(Wien.)* 126,135-139
- Kaye WH, Frank GK, Meltzer CC, Price JC, McConaha CW, Crossan PJ, Klump KL, Rhodes L, 2001. Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. *Am.J.Psychiatry* 158,1152-1155
- Kazumata K, Antonini A, Dhawan V, Moeller JR, Alterman RL, Kelly P, Sterio D, Fazzini E, Beric A, Eidelberg D, 1997. PREOPERATIVE INDICATORS OF CLINICAL OUTCOME FOLLOWING STEREOTAXIC PALLIDOTOMY. *Neurology* 49,1083-1090
- Kearfott KJ, Junck L, Rottenberg DA, 1983. C-11 dimethyloxazolidinedione (DMO): biodistribution, radiation absorbed dose, and potential for PET

- measurement of regional brain pH: concise communication. *J.Nucl.Med.* 24,805-811
- Keen RE, Barrio JR, Huang SC, Hawkins RA, Phelps ME, 1989. In vivo cerebral protein synthesis rates with leucyl-transfer RNA used as a precursor pool: determination of biochemical parameters to structure tracer kinetic models for positron emission tomography. *J.Cereb.Blood Flow Metab.* 9,429-445
- Kegeles LS, Malone KM, Slifstein M, Ellis SP, Xanthopoulos E, Keilp JG, Campbell C, Oquendo M, Van Heertum RL, Mann JJ, 2003. Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. *Am.J Psychiatry* 160,76-82
- Kempler D, Metter EJ, Riege WH, Jackson CA, Benson DF, Hanson WR, 1990. Slowly progressive aphasia: three cases with language, memory, CT and PET data. *J.Neurol.Neurosurg.Psychiatry* 53,987-993
- Kemppainen N, Ruottinen H, Nagren K, Rinne JO, 2000. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. *Neurology* 55,205-209
- Kemppainen N, Laine M, Laakso MP, Kaasinen V, Nagren K, Vahlberg T, Kurki T, Rinne JO, 2003. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. *Eur.J Neurosci.* 18,149-154
- Kennedy SH, Javanmard M, Vaccarino FJ, 1997. A review of functional neuroimaging in mood disorders: positron emission tomography and depression. *Can.J.Psychiatry* 42,467-475
- Kent DL, Larson EB, 1992. Disease, level of impact, and quality of research methods. Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. *Invest Radiol.* 27,245-254
- Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O, Van Heertum RL, Slifstein M, Abi-Dargham A, Gorman JM, Laruelle M, 2002. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with <sup>11</sup>C McN 5652. *Psychopharmacology (Berl)* 164,341-348
- Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z, 2003. Positron Emission Tomography of Striatal Serotonin Transporters in Parkinson Disease. *Arch.Neurol.* 60,1223-1229

- Kertesz A, Munoz D, 1998. Pick's disease, frontotemporal dementia, and Pick complex: emerging concepts. *Arch.Neurol* 55,302-304
- Kessler J, Herholz K, Grond M, Heiss WD, 1991. Impaired metabolic activation in Alzheimer's disease: a PET study during continuous visual recognition. *Neuropsychologia* 29,229-243
- Kessler J, Mielke R, Grond M, Herholz K, Heiss WD, 2000. Frontal lobe tasks do not reflect frontal lobe function in patients with probable Alzheimer's disease. *International Journal of Neuroscience* 104,1-15
- Kessler J, Thiel A, Karbe H, Heiss WD, 2000. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. *Stroke* 31,2112-2116
- Kessler RM, Goble JC, Bird JH, Girton ME, Doppman JL, Rapoport SI, Barranger JA, 1984. Measurement of blood-brain barrier permeability with positron emission tomography and [68Ga]EDTA. *J Cereb.Blood Flow Metab* 4,323-328
- Ketter TA, Kimbrell TA, George MS, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM, 1999. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. *Biol.Psychiatry* 46,1364-1374
- Ketter TA, Wang PW, 2002. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. *Journal of Clinical Psychiatry* 63 Suppl. 3,21-25
- Kew JJ, Goldstein LH, Leigh PN, Abrahams S, Cosgrave N, Passingham RE, Frackowiak RS, Brooks DJ, 1993. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. *Brain* 116,1399-1423
- Kew JJ, Brooks DJ, Passingham RE, Rothwell JC, Frackowiak RS, Leigh PN, 1994. Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study. *Neurology* 44,1101-1110
- Khan N, Antonini A, Parkes D, Dahlitz MJ, Meier-Ewert K, Weindl A, Leenders KL, 1994. Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride. *Neurology* 44,2102-2104

- Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P, 2002. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An 18F-dopa PET study. *Ann.Neurol* 52,849-853
- Kiebel SJ, Ashburner J, Poline JB, Friston KJ, 1997. MRI and PET coregistration-a cross validation of statistical parametric mapping and automated image registration. *Neuroimage*. 5,271-279
- Kiebel SJ, Poline JB, Friston KJ, Holmes AP, Worsley KJ, 1999. Robust smoothness estimation in statistical parametric maps using standardized residuals from the general linear model. *Neuroimage*. 10,756-766
- Kilbourn MR, Snyder SE, Sherman PS, Kuhl DE, 1996. In vivo studies of acetylcholinesterase activity using a labeled substrate, n-[C-11]methylpiperidin-4-yl propionate ([C-11]PMP). *Synapse* 22,123-131
- Killian DM, Chikhale PJ, 2001. Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature. *Neurosci.Lett*. 306,1-4
- Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP, 2001. Neural activity related to drug craving in cocaine addiction. *Arch Gen Psychiatry* 58,334-341
- Kim CK, Alavi JB, Alavi A, Reivich M, 1991. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. *Journal of Neuro-Oncology* 10,85-91
- Kim JJ, Kwon JS, Park HJ, Youn T, Kang dH, Kim MS, Lee DS, Lee MC, 2003. Functional disconnection between the prefrontal and parietal cortices during working memory processing in schizophrenia: a[15(O)]H2O PET study. *Am J Psychiatry* 160,919-923
- Kim YK, Lee DS, Lee SK, Kim SK, Chung CK, Chang KH, Choi KY, Chung JK, Lee MC, 2003. Differential Features of Metabolic Abnormalities Between Medial and Lateral Temporal Lobe Epilepsy: Quantitative Analysis of (18)F-FDG PET Using SPM. *J Nucl Med* 44,1006-1012
- Kimbrell TA, George MS, Parekh PI, Ketter TA, Podell DM, Danielson AL, Repella JD, Benson BE, Willis MW, Herscovitch P, Post RM, 1999. Regional brain activity during transient self-induced anxiety and anger in healthy adults. *Biol.Psychiatry* 46,454-465

- Kippenhan JS, Barker WW, Pascal S, Nagel J, Duara R, 1992. Evaluation of a neural-network classifier for PET scans of normal and Alzheimer's disease subjects. *J.Nucl.Med.* 33,1459-1467
- Kishore A, Nygaard TG, de IF, Naini AB, Schulzer M, Mak E, Ruth TJ, Calne DB, Snow BJ, Stoessl AJ, 1998. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [<sup>11</sup>C]-raclopride and positron-emission tomography. *Neurology* 50,1028-1032
- Kjaer TW, Law I, Wiltschiotz G, Paulson OB, Madsen PL, 2002. Regional cerebral blood flow during light sleep - a H<sub>2</sub><sup>15</sup>O-PET study. *J Sleep Res.* 11,201-207
- Klee B, Law I, Hojgaard L, Kosteljanetz M, 2002. Detection of unknown primary tumours in patients with cerebral metastases using whole-body <sup>18</sup>F-fluorodeoxyglucose positron emission tomography. *Eur.J Neurol* 9,657-662
- Kleihues P et al., 1993. Histological typing of tumors of the central nervous system, Springer, Berlin
- Klein GJ, Teng X, Jagust WJ, Eberling JL, Acharya A, Reutter BW, Huesman RH, 1997. A methodology for specifying PET VOI's using multimodality techniques. *IEEE Trans.Med.Imaging* 16,405-415
- Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, Kreek MJ, 2000. Opioid receptor imaging with positron emission tomography and [(<sup>18</sup>F)cyclofoxy in long-term, methadone-treated former heroin addicts. *J.Pharmacol.Exp.Ther.* 295,1070-1076
- Kluin KJ, Gilman S, Markel DS, Koeppe RA, Rosenthal G, Junck L, 1988. Speech disorders in olivopontocerebellar atrophy correlate with positron emission tomography findings. *Ann.Neurol* 23,547-554
- Klunk W, Debnath M, Holt D, Wang YM, Huang GF, Mathis C, 2002. Potential amyloid-imaging agents: Binding ratios to homogenates of post-mortem AD and control brain. *Neurobiology of Aging* 23,1149
- Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomic MD, Dekosky ST, Mathis CA, 2003. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. *J Neurosci.* 23,2086-2092

- Knoess C, Boellaard R, Lenox M, Vollmar S, Casey M, Fluegge G, Lammertsma AA, Wienhard K, Heiss WD, 2003. Evaluation of the Depth of Interaction (DOI) for the High Resolution Research Tomograph (HRRT) - a comparison between scanners with and without DOI. IEEE Transactions on Nuclear Science MIC ,
- Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, Jacobs A, Goble RN, Graf R, Wienhard K, Heiss WD, 2003. Performance evaluation of the microPET R4 PET scanner for rodents. Eur.J Nucl Med Mol.Imaging 30,737-747
- Knopman DS, Dekosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC, 2001. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56,1143-1153
- Knorr U, Weder B, Kleinschmidt A, Wirrwar A, Huang Y, Herzog H, Seitz RJ, 1993. Identification of task-specific rCBF changes in individual subjects: validation and application for PET. Journal of Computer Assisted Tomography 17,517-528
- Knowlton RC, Laxer KD, Klein G, Sawrie S, Ende G, Hawkins RA, Aassar OS, Soohoo K, Wong S, Barbaro N, 2001. In vivo hippocampal glucose metabolism in mesial temporal lobe epilepsy. Neurology 57,1184-1190
- Knowlton RC, Abou-Khalil B, Sawrie SM, Martin RC, Faught RE, Kuzniecky RI, 2002. In vivo hippocampal metabolic dysfunction in human temporal lobe epilepsy. Arch.Neurol 59,1882-1886
- Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM, Gelovani Tjuvaje JG, 2003. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat.Biotechnol.
- Koepp MJ, Richardson MP, Labbe C, Brooks DJ, Cunningham VJ, Ashburner J, Vanpaesschen W, Revesz T, Duncan JS, 1997. C-11-FLUMAZENIL PET, VOLUMETRIC MRI, AND QUANTITATIVE PATHOLOGY IN MESIAL TEMPORAL LOBE EPILEPSY. Neurology 49,764-773

- Koepp MJ, Richardson MP, Brooks DJ, Duncan JS, 1998. Focal cortical release of endogenous opioids during reading-induced seizures. *Lancet* 352,952-955
- Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM, 1998. Evidence for striatal dopamine release during a video game. *Nature* 393,266-268
- Koepp MJ, Hand KS, Labbe C, Richardson MP, Van Paesschen W, Baird VH, Cunningham VJ, Bowery NG, Brooks DJ, Duncan JS, 1998. In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. *Ann.Neurol* 43,618-626
- Koepp MJ, Hammers A, Labbe C, Woermann FG, Brooks DJ, Duncan JS, 2000. 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI. *Neurology* 54,332-339
- Koepp RA, Holden JE, Ip WR, 1985. Performance comparison of parameter estimation techniques for the quantitation of local cerebral blood flow by dynamic positron computed tomography. *J.Cereb.Blood Flow Metab.* 5,224-234
- Koepp RA, Hutchins GD, Rothley JM, Hichwa RD, 1987. Examination of assumptions for local cerebral blood flow studies in PET. *J Nucl Med* 28,1695-1703
- Koepp RA, Mangner T, Betz AL, Shulkin BL, Allen R, Kollros P, Kuhl DE, Agranoff BW, 1990. Use of [11C]aminocyclohexanecarboxylate for the measurement of amino acid uptake and distribution volume in human brain. *J Cereb.Blood Flow Metab* 10,727-739
- Koepp RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE, 1991. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. *J.Cereb.Blood Flow Metab.* 11,735-744
- Koepp RA, Frey KA, Mulholland GK, Kilbourn MR, Buck A, Lee KS, Kuhl DE, 1994. [11C]tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. *J.Cereb.Blood Flow Metab.* 14,85-99
- Koepp RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE, 1997. EQUILIBRIUM VERSUS COMPARTMENTAL ANALYSIS FOR ASSESSMENT OF THE VESICULAR MONOAMINE TRANSPORTER

- USING (+)-ALPHA-[C-11]DIHYDROTETRABENAZINE (DTBZ) AND POSITRON EMISSION TOMOGRAPHY. *J.Cereb.Blood Flow Metab.* 17,919-931
- Koepppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE, 1999. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. *J.Cereb.Blood Flow Metab.* 19,1150-1163
- Kole AC, Pruij J, Nieweg OE, Vanginkel RJ, Hoekstra HJ, Koops HS, Vaalburg W, 1997. PET WITH 1-[1-CARBON-11]-TYROSINE TO VISUALIZE TUMORS AND MEASURE PROTEIN SYNTHESIS RATES. *J.Nucl.Med.* 38,191-195
- Komori T, Martin WH, Graber AL, Delbeke D, 2002. Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature. *Clin.Nucl Med* 27,176-178
- Kopelman MD, Reed LJ, Marsden P, MAYES AR, Jaldow E, Laing H, Isaac C, 2001. Amnesic syndrome and severe ataxia following the recreational use of 3,4-methylene-dioxymethamphetamine (MDMA, 'ecstasy') and other substances. *Neurocase.* 7,423-432
- Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, 1995. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. *N Engl J Med* 332,1118-1124
- Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P, 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. *Science* 290,767-773
- Korotkov A, Ljubisavljevic M, Thunberg J, Kataeva G, Roudas M, Pakhomov S, Radovanovic S, Lyskov E, Medvedev S, Johansson H, 2002. Changes in human regional cerebral blood flow following hypertonic saline induced experimental muscle pain: a positron emission tomography study. *Neurosci.Lett.* 335,119-123
- Kracht LW, Bauer A, Herholz K, Terstegge K, Friese M, Schröder R, Heiss WD, 1999. Positron emission tomography in a case of intracranial



- hemangiopericytoma. *Journal of Computer Assisted Tomography* 23,365-368
- Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD, 2003. Methyl-[(11)C]- L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. *Eur.J Nucl Med Mol.Imaging* 30,868-873
- Kracht LW, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M, Lucht H, Herholz K, Heiss WD, 2003. Exact Local Comparison of [11C]-L-methionine Uptake and Histopathologic Findings in 105 Specimen from Serial Stereotactic Biopsies. *Eur.J.Nucl.Med.* 30 (Supl.2 ) ,190
- Krause KH, Dresel S, Krause J, Kung HF, Tatsch K, Lochmuller H, 2002. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate. *J Neurol* 249,1116-1118
- Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R, 2002. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J Drug Target* 10,317-325
- Krieg JC, Lauer C, Pirke KM, 1989. Structural brain abnormalities in patients with bulimia nervosa. *Psychiatry Research* 27,39-48
- Krieg JC, Holthoff V, Schreiber W, Pirke KM, Herholz K, 1991. Glucose metabolism in the caudate nuclei of patients with eating disorders, measured by PET. *Eur.Arch Psychiatry Clin.Neurosci.* 240,331-333
- Kriegeskorte N, Goebel R, 2001. An efficient algorithm for topologically correct segmentation of the cortical sheet in anatomical mr volumes. *Neuroimage* 14,329-346
- Krings T, Schreckenberger M, Rohde V, Foltys H, Spetzger U, Sabri O, Reinges MH, Kemeny S, Meyer PT, Moller-Hartmann W, Korinth M, Gilsbach JM, Buell U, Thron A, 2001. Metabolic and electrophysiological validation of functional MRI. *J Neurol.Neurosurg.Psychiatry* 71,762-771
- Krzywinski M, Sossi V, Ruth TJ, 1999. Comparison of FORE, OSEM and SAGE algorithms to 3DRP in 3D PET using phantom and human subject data. *IEEE Transactions on Nuclear Science* 46,1114-1120

- Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, Staley JK, Garg PK, Seibyl JP, Innis RB, 2003. Increase in Prefrontal Cortex Serotonin(2A) Receptors Following Estrogen Treatment in Postmenopausal Women. *Am J Psychiatry* 160,1522-1524
- Kuhl DE, Phelps ME, Kowell AP, Metter EJ, Selin C, Winter J, 1980. Effects of stroke on local cerebral metabolism and perfusion: mapping by emission computed tomography of 18FDG and 13NH3. *Ann.Neurol* 8,47-60
- Kuhl DE, Engel J, Jr., Phelps ME, Selin C, 1980. Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computed tomography of 18FDG and 13NH3. *Annals of Neurology* 8,348-360
- Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J, 1982. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. *Ann.Neurol* 12,425-434
- Kuhl DE, Metter EJ, Riege WH, Phelps ME, 1982. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. *J.Cereb.Blood Flow Metab.* 2,163-171
- Kuhl DE, Metter EJ, Riege WH, 1984. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. *Annals of Neurology* 15,419-424
- Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficarò EP, Wieland DM, Koeppe RA, 1996. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. *Annals of Neurology* 40,399-410
- Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficarò EP, Foster NL, Frey KA, Kilbourn MR, 1999. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. *Neurology* 52,691-699
- Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA, 2000. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex [In Process Citation]. *Ann.Neurol.* 48,391-395
- Kuikka JT, Sohlberg A, Husso-Saastamoinen M, 2002. PET imaging using a triple-head gamma camera. *Clin.Physiol Funct.Imaging* 22,328-331

- Kulasingham SL, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, McCrory DC, Schmechel DE, Matchar DB, 2003. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. *Value in Health* 6,542-550
- Kullmann DM, 2002. The neuronal channelopathies. *Brain* 125,1177-1195
- Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP, 1990. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. *J.Psychiatr.Res.* 24,97-109
- Kumar A, Mann S, Sossi V, Ruth TJ, Stoessl AJ, Schulzer M, Lee CS, 2003. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. *Brain* 126,2648-2655
- Kumar R, Masih AK, Pardo J, 1996. Global aphasia due to thalamic hemorrhage: a case report and review of the literature. [Review] [16 refs]. *Archives of Physical Medicine & Rehabilitation* 77,1312-1315
- Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM, 1999. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. *Neurology* 53,871-874
- Kume A, Shiratori M, Takahashi A, Kato T, Ito K, Tadokoro M, Sakuma S, 1992. Hemi-parkinsonism in multiple system atrophy: a PET and MRI study. *J Neurol Sci.* 110,37-45
- Kumlien E, Hartvig P, Valind S, Oye I, Tedroff J, Langstrom B, 1999. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. *Epilepsia* 40,30-37
- Kumlien E, Nilsson A, Hagberg G, Langstrom B, Bergstrom M, 2001. PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy. *Acta Neurol Scand.* 103,360-366
- Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VMY, Kung HF, 2002. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. *Brain Research* 956,202-210
- Kung MP, Skovronsky DM, Hou C, Zhuang ZP, Gur TL, Zhang B, Trojanowski JQ, Lee VMY, Kung KF, 2003. Detection of amyloid plaques by

- radioligands for A beta 40 and A beta 42 - Potential imaging agents in Alzheimer's patients. *Journal of Molecular Neuroscience* 20,15-23
- Kunig G, Leenders KL, Antonini A, Vontobel P, Weindl A, Meinck HM, 1998. D2 receptor binding in dopa-responsive dystonia. *Ann.Neurol* 44,758-762
- Kunig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, Gunther I, 2000. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. *Ann.Neurol* 47,644-648
- Kupers RC, Gybels JM, Gjedde A, 2000. Positron emission tomography study of a chronic pain patient successfully treated with somatosensory thalamic stimulation. *Pain* 87,295-302
- Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P, 2003. Biodistribution, radiation dose estimates, and in vivo pgp modulation studies of (18)f-Paclitaxel in nonhuman primates. *J Nucl Med* 44,1330-1339
- Kushner M, Alavi A, Reivich M, Dann R, Burke A, Robinson G, 1984. Contralateral cerebellar hypometabolism following cerebral insult: a positron emission tomographic study. *Ann.Neurol* 15,425-434
- Kushner M, Reivich M, Fieschi C, Silver F, Chawluk J, Rosen M, Greenberg J, Burke A, Alavi A, 1987. Metabolic and clinical correlates of acute ischemic infarction. *Neurology* 37,1103-1110
- Kuwabara H, Evans AC, Gjedde A, 1990. Michaelis-Menten constraints improved cerebral glucose metabolism and regional lumped constant measurements with [18F]fluorodeoxyglucose. *J.Cereb.Blood Flow Metab.* 10,180-189
- Kuwabara Y, Ichiya Y, Otsuka M, Tahara T, Gunasekera R, Hasuo K, Masuda K, Matsushima T, Fukui M, 1990. Cerebral hemodynamic change in the child and the adult with moyamoya disease. *Stroke* 21,272-277
- Kuwabara Y, Ichiya Y, Sasaki M, Yoshida T, Masuda K, 1995. Time dependency of the acetazolamide effect on cerebral hemodynamics in patients with chronic occlusive cerebral arteries. Early steal phenomenon demonstrated by [15O]H2O positron emission tomography. *Stroke* 26,1825-1829

- Kuwabara Y, Ichiya Y, Sasaki M, Yoshida T, Masuda K, Ikezaki K, Matsushima T, Fukui M, 1997. Cerebral hemodynamics and metabolism in moyamoya disease--a positron emission tomography study. Clin.Neurol.Neurosurg. 99 Suppl 2,S74-S78
- Kuwabara Y, Ichiya Y, Sasaki M, Yoshida T, Fukumura T, Masuda K, Fujii K, Fukui M, 1998. PET evaluation of cerebral hemodynamics in occlusive cerebrovascular disease pre- and postsurgery. J Nucl Med 39,760-765
- Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE, 1990. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113 ( Pt 5),1405-1423
- Kuwert T, Lange HW, Langen KJ, Herzog H, Hefter H, Aulich A, Feinendegen LE, 1990. Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography. J Neurol 237,80-84
- Kuwert T, Hefter H, Scholz D, Milz M, Weiss P, Arendt G, Herzog H, Loken M, Hennerici M, Feinendegen LE, 1992. Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson's disease. Eur.J Nucl Med 19,96-101
- Kuwert T, Noth J, Scholz D, Schwarz M, Lange HW, Topper R, Herzog H, Aulich A, Feinendegen LE, 1993. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Mov Disord. 8,98-106
- Kuwert T, Homberg V, Steinmetz H, Unverhau S, Langen KJ, Herzog H, Feinendegen LE, 1993. Posthypoxic amnesia: regional cerebral glucose consumption measured by positron emission tomography. J Neurol Sci. 118,10-16
- Kuwert T, Bartenstein P, Grönwald F, Herholz K, Larisch R, Sabri O, Biersack HJ, Moser E, Müller-Gärtner HW, Schober O, Schwaiger M, Böll U, Heiss WD, 1998. Klinische Wertigkeit der Positronen-Emissions-Tomographie in der Neuromedizin: Positionspapier zu den Ergebnissen einer interdisziplinären Konsensuskonferenz. Nervenarzt 69,1045-1060
- Kuzniecky RI, Knowlton RC, 2002. Neuroimaging of epilepsy. Semin.Neurol 22,279-288

- Kwon JS, Kim JJ, Lee DW, Lee JS, Lee DS, Kim MS, Lyoo IK, Cho MJ, Lee MC, 2003. Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder. *Psychiatry Res* 122,37-47
- Laakso A, Vilkkumäki H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvälahti E, Hietala J, 2000. Striatal dopamine transporter binding in neuroleptic-naïve patients with schizophrenia studied with positron emission tomography. *Am J Psychiatry* 157,269-271
- Laakso A, Wallius E, Kajander J, Bergman J, Eskola O, Solin O, Ilonen T, Salokangas RK, Syvälahti E, Hietala J, 2003. Personality traits and striatal dopamine synthesis capacity in healthy subjects. *Am J Psychiatry* 160,904-910
- Lagreze HL, Levine RL, Pedula KL, Nickles RJ, Sunderland JS, Rowe BR, 1987. Contralateral flow reduction in unilateral stroke: evidence for transhemispheric diaschisis. *Stroke* 18,882-886
- Laihinne AO, Rinne JO, Ruottinen HM, Nagren KA, Lehtikainen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK, 1994. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. *J.Nucl.Med.* 35,1916-1920
- Lammertsma AA, Jones T, Frackowiak RS, Lenzi GL, 1981. A theoretical study of the steady-state model for measuring regional cerebral blood flow and oxygen utilisation using oxygen-15. *Journal of Computer Assisted Tomography* 5,544-550
- Lammertsma AA, Wise RJ, Heather JD, Gibbs JM, Leenders KL, Frackowiak RS, Rhodes CG, Jones T, 1983. Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 2. Results in normal subjects and brain tumour and stroke patients. *J.Cereb.Blood Flow Metab.* 3,425-431
- Lammertsma AA, Brooks DJ, Frackowiak RS, Heather JD, Jones T, 1984. A method to quantitate the fractional extraction of rubidium-82 across the blood-brain barrier using positron emission tomography. *J.Cereb.Blood Flow Metab.* 4,523-534
- Lammertsma AA, Brooks DJ, Beaney RP, Turton DR, Kensett MJ, Heather JD, Marshall J, Jones T, 1984. In vivo measurement of regional cerebral haematocrit using positron emission tomography. *J.Cereb.Blood Flow Metab.* 4,317-322

- Lammertsma AA, Wise RJ, Cox TC, Thomas DG, Jones T, 1985. Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. *Br.J Radiol.* 58,725-734
- Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS, 1996. Comparison of methods for analysis of clinical [<sup>11</sup>C]raclopride studies. *J.Cereb.Blood Flow Metab.* 16,42-52
- Lamusuo S, Ruottinen HM, Knuuti J, Harkonen R, Ruotsalainen U, Bergman J, Haaparanta M, Solin O, Mervaala E, Nousiainen U, Jaaskelainen S, Ylinen A, Kalviainen R, Rinne JK, Vapalahti M, Rinne JO, 1997. Comparison of [<sup>18</sup>F]FDG-PET, [<sup>99m</sup>Tc]-HMPAO-SPECT, and [<sup>123</sup>I]-iomazenil-SPECT in localising the epileptogenic cortex. *J.Neurol.Neurosurg.Psychiatry* 63,743-748
- Lamusuo S, Pitkanen A, Jutila L, Ylinen A, Partanen K, Kalviainen R, Ruottinen HM, Oikonen V, Nagren K, Lehtikainen P, Vapalahti M, Vainio P, Rinne JO, 2000. [<sup>11</sup>C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. *Neurology* 54,2252-2260
- Lamusuo S, Jutila L, Ylinen A, Kalviainen R, Mervaala E, Haaparanta M, Jaaskelainen S, Partanen K, Vapalahti M, Rinne J, 2001. [<sup>18</sup>F]FDG-PET Reveals Temporal Hypometabolism in Patients With Temporal Lobe Epilepsy Even When Quantitative MRI and Histopathological Analysis Show Only Mild Hippocampal Damage. *Arch.Neurol.* 58,933-939
- Lang AE, Garnett ES, 1988. Positron emission tomography in cases of chorea with different underlying disease. *J Neurol Neurosurg Psychiatry* 51,1010-1011
- Lang AE, 1995. Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. *Mov Disord.* 10,489-495
- Langfitt TW, Obrist WD, Alavi A, Grossman RI, Zimmerman R, Jaggi J, Uzzell B, Reivich M, Patton DR, 1986. Computerized tomography, magnetic resonance imaging, and positron emission tomography in the study of brain trauma. Preliminary observations. *J Neurosurg* 64,760-767
- Langstrom B, Kihlberg T, Bergstrom M, Antoni G, Bjorkman M, Forngren BH, Forngren T, Hartvig P, Markides K, Yngve U, Ogren M, 1999. Compounds

- labelled with short-lived beta(+)-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. *Acta Chem.Scand.* 53,651-669
- Laplane D, Levasseur M, Pillon B, Dubois B, Baulac M, Mazoyer B, Tran DS, Sette G, Danze F, Baron JC, 1989. Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. A neuropsychological, magnetic resonance imaging and positron tomography study. *Brain* 112,699-725
- Lapointe D, Cadorette J, Rodrigue S, Rouleau D, Lecomte R, 1998. A microvolumetric blood counter/sampler for metabolic PET studies in small animals. *IEEE Transactions on Nuclear Science* 45,2195-2199
- Larsen PD, Gupta NC, Lefkowitz DM, Van Gundy JC, Hadford DJ, 1993. PET of infant in persistent vegetative state. *Pediatr.Neurol* 9,323-326
- Larson KB, Markham J, Raichle ME, 1987. Tracer-kinetic models for measuring cerebral blood flow using externally detected radiotracers. *J Cereb.Blood Flow Metab* 7,443-463
- Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R, 1999. Increased dopamine transmission in schizophrenia: relationship to illness phases. *Biol.Psychiatry* 46,56-72
- Laruelle M, 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. *J.Cereb.Blood Flow Metab.* 20,423-451
- Lassen NA, Ingvar DH, 1963. Regional cerebral blood flow measurement in man. *Arch.Neurol.* 9,615-622
- Lassen NA, 1966. The luxury perfusion syndrome and its possible relation to acute metabolic acidosis localised within the brain. *Lancet* II,1113-1115
- Lassen NA, 1985. Normal average value of cerebral blood flow in younger adults is 50 ml/100 g/min. *J Cereb.Blood Flow Metab* 5,347-349
- Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN, 1995. Benzodiazepine receptor quantification in vivo in humans using [<sup>11</sup>C]flumazenil and PET: application of the steady-state principle. *J.Cereb.Blood Flow Metab.* 15,152-165



- Laureys S, Salmon E, Garraux G, Peigneux P, Lemaire C, Degueldre C, Franck G, 1999. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. *J.Neurol.* 246,1151-1158
- Laureys S, Antoine S, Boly M, Elincx S, Faymonville ME, Berre J, Sadzot B, Ferring M, De T, X, Van Bogaert P, Hansen I, Damas P, Mavroudakakis N, Lambermont B, Del Fiore G, Aerts J, Degueldre C, Phillips C, Franck G, Vincent JL, Lamy M, Luxen A, Moonen G, Goldman S, Maquet P, 2002. Brain function in the vegetative state. *Acta Neurol Belg.* 102,177-185
- Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Brihaye C, Hassoun W, Leviel V, Mekhsian P, Weissmann D, Pujol JF, Luxen A, Comar D, 1998. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. *Nucl.Med.Biol.* 25,343-350
- Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B, 2003. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. *Biological Psychiatry* 54,800-805
- Leblanc R, Meyer E, Bub D, Zatorre RJ, Evans AC, 1992. Language localization with activation positron emission tomography scanning. *Neurosurgery* 31,369-373
- Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, Fuente-Fernandez R, Calne DB, Stoessl AJ, 2000. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. *Ann.Neurol* 47,493-503
- Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM, 2002. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. *J Cereb.Blood Flow Metab* 22,223-231
- Lee JS, Pfund Z, Juhasz C, Behen ME, Muzik O, Chugani DC, Nigro MA, Chugani HT, 2002. Altered regional brain glucose metabolism in Duchenne muscular dystrophy: A pet study. *Muscle Nerve* 26,506-512
- Lee KS, Frey KA, Koeppe RA, Buck A, Mulholland GK, Kuhl DE, 1996. In vivo quantification of cerebral muscarinic receptors in normal human aging using positron emission tomography and [11C]tropanyl benzilate. *J.Cereb.Blood Flow Metab.* 16,303-310

- Leenders K, Hartvig P, Forsgren L, Holmgren G, Almay B, Eckernas SA, Lundqvist H, Langstrom B, 1993. Striatal [<sup>11</sup>C]-N-methyl-spiperone binding in patients with focal dystonia (torticollis) using positron emission tomography. *J Neural Transm.Park Dis.Dement.Sect.* 5,79-87
- Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD, 1986. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. *Journal of Neurology, Neurosurgery & Psychiatry* 49,853-860
- Leenders KL, Frackowiak RS, Quinn N, Marsden CD, 1986. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. *Mov Disord.* 1,69-77
- Leenders KL, Frackowiak RS, Lees AJ, 1988. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. *Brain* 111,615-630
- Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS, 1990. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. *Arch Neurol* 47,1290-1298
- Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Healy MJ, Gibbs JM, Wise RJ, Hatazawa J, Herold S, 1990. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. *Brain* 113 ( Pt 1),27-47
- Lehericy S, Cohen L, Bazin B, Samson S, Giacomini E, Rougetet R, Hertz-Pannier L, Le Bihan D, Marsault C, Baulac M, 2000. Functional MR evaluation of temporal and frontal language dominance compared with the Wada test. *Neurology* 54,1625-1633
- Leiderman DB, Balish M, Bromfield EB, Theodore WH, 1991. Effect of valproate on human cerebral glucose metabolism. *Epilepsia* 32,417-422
- Leiderman DB, Balish M, Sato S, Kufta C, Reeves P, Gaillard WD, Theodore WH, 1992. Comparison of PET measurements of cerebral blood flow and glucose metabolism for the localization of human epileptic foci. *Epilepsy Research* 13,153-157

- Leiderman DB, Albert P, Balish M, Bromfield E, Theodore WH, 1994. The dynamics of metabolic change following seizures as measured by positron emission tomography with fludeoxyglucose F 18. *Arch.Neurol.* 51,932-936
- Levasseur M, Baron JC, Sette G, Legault-Demare F, Pappata S, Mauguiere F, Benoit N, Tran Dinh S, Degos JD, Laplane D, 1992. Brain energy metabolism in bilateral paramedian thalamic infarcts. A positron emission tomography study. *Brain* 115,795-807
- Levchenko A, Mehta BM, Lee JB, Humm JL, Augensen F, Squire O, Kothari PJ, Finn RD, Leonard EF, Larson SM, 2000. Evaluation of <sup>11</sup>C-colchicine for PET imaging of multiple drug resistance. *J Nucl Med* 41,493-501
- Leveque P, Sanabria-Bohorquez S, Bol A, De Volder A, Labar D, Van Rijckevorsel K, Gallez B, 2003. Quantification of human brain benzodiazepine receptors using [(18)F]fluoroethylflumazenil: a first report in volunteers and epileptic patients. *Eur.J Nucl Med Mol.Imaging* epub,
- Lever JR, Scheffel U, Kinter CM, Ravert HT, Dannals RF, Wagner HN, Jr., Frost JJ, 1992. In vivo binding of N1'-([<sup>11</sup>C]methyl)naltrexone to delta-opioid receptors in mouse brain. *Eur.J Pharmacol.* 216,459-460
- Levin DN, Pelizzari CA, Chen GT, Chen CT, Cooper MD, 1988. Retrospective geometric correlation of MR, CT, and PET images. *Radiology* 169,817-823
- Levine B, Cabeza R, McIntosh AR, Black SE, Grady CL, Stuss DT, 2002. Functional reorganisation of memory after traumatic brain injury: a study with H2150 positron emission tomography. *J Neurol Neurosurg Psychiatry* 73,173-181
- Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, Hildebrand J, Brotchi J, 1995. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [<sup>18</sup>F]fluorodeoxyglucose. *Journal of Neurosurgery* 82,445-452
- Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S, 1996. Radiation necrosis or recurrence. *Journal of Neurosurgery* 84,148-149
- Levivier M, Wikier D, Goldman S, David P, Metens T, Massager N, Gerosa M, Devriendt D, Desmedt F, Simon S, Van Houtte P, Brotchi J, 2000. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. *J Neurosurg* 93 Suppl 3,233-238

- Levivier M, Wikler D, Jr., Massager N, David P, Devriendt D, Lorenzoni J, Pirotte B, Desmedt F, Simon S Jr, Goldman S, Van Houtte P, Brotchi J, 2002. The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. *J Neurosurg* 97,542-550
- Lewis R, Kapur S, Jones C, Dasilva J, Brown GM, Wilson AA, Houle S, Zipursky RB, 1999. Serotonin 5-HT<sub>2</sub> receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naïve patients and normal subjects. *Am J Psychiatry* 156,72-78
- Leyton M, Okazawa H, Diksic M, Paris J, Rosa P, Mzengeza S, Young SN, Blier P, Benkelfat C, 2001. Brain Regional alpha-[11C]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. *Am J Psychiatry* 158,775-782
- Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A, 2002. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. *Neuropsychopharmacology* 27,1027-1035
- Li JY, Boado RJ, Pardridge WM, 2001. Blood-brain barrier genomics. *J Cereb.Blood Flow Metab* 21,61-68
- Li JY, Boado RJ, Pardridge WM, 2001. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na<sup>+</sup> nucleoside cotransporter CNT2. *J Cereb.Blood Flow Metab* 21,929-936
- Liang Q, Gotts J, Satyamurthy N, Barrio J, Phelps ME, Gambhir SS, Herschman HR, 2002. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. *Mol.Ther.* 6,73-82
- Lindau M, Almkvist O, Kushi J, Boone K, Johansson SE, Wahlund LO, Cummings JL, Miller BL, 2000. First symptoms--frontotemporal dementia versus Alzheimer's disease. *Dement.Geriatr.Cogn Disord.* 11,286-293
- Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B, 1999. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. *Biol.Psychiatry* 46,681-688
- Lingford-Hughes A, Hume SP, Feeney A, Hirani E, Osman S, Cunningham VJ, Pike VW, Brooks DJ, Nutt DJ, 2002. Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15

- 4513 positron emission tomography. *J Cereb.Blood Flow Metab* 22,878-889
- Liotti M, Mayberg HS, 2001. The role of functional neuroimaging in the neuropsychology of depression. *J Clin.Exp.Neuropsychol.* 23,121-136
- Liow JS, Strother SC, Rehm K, Rottenberg DA, 1997. Improved resolution for PET volume imaging through three-dimensional iterative reconstruction. *J.Nucl.Med.* 38,1623-1631
- Lipinski B, Herzog H, Kops ER, Oberschelp W, Muller-Gartner HW, 1997. Expectation maximization reconstruction of positron emission tomography images using anatomical magnetic resonance information. *IEEE Trans.Med.Imaging* 16,129-136
- Litton JE, Neiman J, Pauli S, Farde L, Hindmarsh T, Halldin C, Sedvall G, 1993. PET analysis of [<sup>11</sup>C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls. *Psychiatry Res* 50,1-13
- Litton JE, Hall H, Pauli S, 1994. Saturation analysis in PET--analysis of errors due to imperfect reference regions. *J.Cereb.Blood Flow Metab.* 14,358-361
- Liu X, Comtat C, Michel C, Kinahan P, Defrise M, Townsend D, 2001. Comparison of 3-D reconstruction with 3D-OSEM and with FORE+OSEM for PET. *IEEE Trans.Med Imaging* 20,804-814
- Lockhart A, Davis B, Matthews JC, Rahmoune H, Hong G, Gee A, Earnshaw D, Brown J, 2003. The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. *Nucl Med Biol.* 30,199-206
- Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE, 1995. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. *J Nucl Med* 36,1141-1149
- Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, 1990. Graphical analysis of reversible radioligand binding from time- activity measurements applied to [N-<sup>11</sup>C-methyl]-(-)-cocaine PET studies in human subjects. *J.Cereb.Blood Flow Metab.* 10,740-747

- Logan J, Volkow ND, Fowler JS, Wang GJ, Dewey SL, MacGregor R, Schlyer D, Gatley SJ, Pappas N, King P, ., 1994. Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. *J Cereb.Blood Flow Metab* 14,995-1010
- Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL, 1996. Distribution volume ratios without blood sampling from graphical analysis of PET data. *J Cereb.Blood Flow Metab* 16,834-840
- Logan J, Fowler JS, Volkow ND, Wang GJ, MacGregor RR, Shea C, 2000. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. *Nucl Med Biol.* 27,43-49
- Logan J, Fowler JS, Dewey SL, Volkow ND, Gatley SJ, 2001. A consideration of the dopamine D2 receptor monomer-dimer equilibrium and the anomalous binding properties of the dopamine D2 receptor ligand, N-methyl spiperone. *J Neural Transm.* 108,279-286
- Logan J, Fowler JS, Ding YS, Franceschi D, Wang GJ, Volkow ND, Felder C, Alexoff D, 2002. Strategy for the formation of parametric images under conditions of low injected radioactivity applied to PET studies with the irreversible monoamine oxidase A tracers [11C]clorgyline and deuterium-substituted [11C]clorgyline. *J Cereb.Blood Flow Metab* 22,1367-1376
- London ED, Broussolle EP, Links JM, Wong DF, Cascella NG, Dannals RF, Sano M, Herning R, Snyder FR, Rissettoe LR, 1990. Morphine-induced metabolic changes in human brain. Studies with positron emission tomography and [fluorine 18]fluorodeoxyglucose. *Arch Gen Psychiatry* 47,73-81
- Lopresti BJ, Russo A, Jones WF, Fisher T, Crouch DG, Altenburger DE, Townsend DW, 1999. Implementation and performance of an optical motion tracking system for high resolution brain PET imaging. *IEEE Transactions on Nuclear Science* 46,2059-2067
- Lorenz J, Cross D, Minoshima S, Morrow T, Paulson P, Casey K, 2002. A unique representation of heat allodynia in the human brain. *Neuron* 35,383-393
- Lorenz J, Minoshima S, Casey KL, 2003. Keeping pain out of mind: the role of the dorsolateral prefrontal cortex in pain modulation. *Brain* 126,1079

- Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B, 2002. Rat studies comparing  $^{11}\text{C}$ -FMAU,  $^{18}\text{F}$ -FLT, and  $^{76}\text{Br}$ -BFU as proliferation markers. *J Nucl Med* 43,1688-1698
- Lucignani G, Schmidt KC, Moresco RM, Striano G, Colombo F, Sokoloff L, Fazio F, 1993. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. *J.Nucl.Med.* 34,360-369
- Lucignani G, Losa M, Moresco RM, Del Sole A, Matarrese M, Bettinardi V, Mortini P, Giovanelli M, Fazio F, 1997. Differentiation of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography with [ $^{18}\text{F}$ ]fluoro-ethyl-spiperone. *Eur.J Nucl Med* 24,1149-1155
- Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, Bottger IG, Feinendegen L, 1992. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. *Acta Neurol.Scand.* 85,81-89
- Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D, 2002. Noninvasive imaging of protein-protein interactions in living animals. *Proc.Natl.Acad.Sci.U.S.A* 99,6961-6966
- Lundkvist C, Halldin C, Swahn CG, Hall H, Karlsson P, Nakashima Y, Wang S, Milius RA, Neumeyer JL, Farde L, 1995. [ $^{18}\text{F}$ -methyl- $^{11}\text{C}$ ]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. *Nuclear Medicine & Biology* 22,905-913
- Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L, 1996. [ $^{11}\text{C}$ ]MDL 100907, a radioligand for selective imaging of 5-HT(2A) receptors with positron emission tomography. *Life Sciences* 58,L-92
- Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L, 1997. [ $^{18}\text{F}$ ] beta-CIT-FP is superior to [ $^{11}\text{C}$ ] beta-CIT-FP for quantitation of the dopamine transporter. *Nucl Med Biol.* 24,621-627
- Lyden PD, Grotta JC, Levine SR, Marler JR, Frankel MR, Brott TG, 1997. INTRAVENOUS THROMBOLYSIS FOR ACUTE STROKE [Review]. *Neurology* 49,14-20

- Müller RA, Rothermel RD, Behen ME, Muzik O, Chakraborty PK, Chugani HT, 1997. Plasticity of motor organization in children and adults. *Neuroreport* 8,3103-3108
- Müller RA, Chugani HT, Muzik O, Mangner TJ, 1998. Brain organization of motor and language functions following hemispherectomy: a [(15)O]-water positron emission tomography study. *J.Child Neurol.* 13,16-22
- Müller RA, Rothermel RD, Behen ME, Muzik O, Mangner TJ, Chugani HT, 1998. Developmental changes of cortical and cerebellar motor control: a clinical positron emission tomography study with children and adults [In Process Citation]. *J.Child Neurol.* 13,550-556
- Müller RA, Rothermel RD, Muzik O, Becker C, Fuerst DR, Behen ME, Mangner TJ, Chugani HT, 1998. Determination of language dominance by 15O-water PET in children and adolescents: a comparison with the Wada test. *Journal of Epilepsy* 11,152-161
- Müller RA, Rothermel RD, Behen ME, Muzik O, Chakraborty PK, Chugani HT, 1999. Language organization in patients with early and late left-hemisphere lesion: a PET study [In Process Citation]. *Neuropsychologia.* 37,545-557
- Müller RA, Behen ME, Rothermel RD, Muzik O, Chakraborty PK, Chugani HT, 1999. Brain organization for language in children, adolescents, and adults with left hemisphere lesion: a PET study [In Process Citation]. *Prog.Neuropsychopharmacol.Biol.Psychiatry* 23,657-668
- MacFarlane JG, List SJ, Moldofsky H, Firnau G, Chen JJ, Szechtman H, Garnett S, Nahmias C, 1997. Dopamine D2 receptors quantified in vivo in human narcolepsy. *Biol.Psychiatry* 41,305-310
- MacGregor RR, Halldin C, Fowler JS, Wolf AP, Arnett CD, Langstrom B, Alexoff D, 1985. Selective, irreversible in vivo binding of [11C]clorgyline and [11C]-L-deprenyl in mice: potential for measurement of functional monoamine oxidase activity in brain using positron emission tomography. *Biochem.Pharmacol.* 34,3207-3210
- MacHale SM, Lawrie SM, Cavanagh JT, Glabus MF, Murray CL, Goodwin GM, Ebmeier KP, 2000. Cerebral perfusion in chronic fatigue syndrome and depression. *Br.J Psychiatry* 176,550-556
- MacLaren DC, Gambhir SS, Satyamurthy N, Barrio JR, Sharfstein S, Toyokuni T, Wu L, Berk AJ, Cherry SR, Phelps ME, Herschman HR, 1999. Repetitive,



- non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. *Gene Ther.* 6,785-791
- Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL, Mathews WB, Dannals RF, Frost JJ, 1996. Imaging of delta opioid receptors in human brain by N1'-([11C]methyl)naltrindole and PET. *Synapse* 24,19-28
- Madar I, Lesser RP, Krauss G, Zubieta JK, Lever JR, Kinter CM, Ravert HT, Musachio JL, Mathews WB, Dannals RF, Frost JJ, 1997. Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography. *Ann.Neurol* 41,358-367
- Madsen PL, Holm S, Herning M, Lassen NA, 1993. Average blood flow and oxygen uptake in the human brain during resting wakefulness: a critical appraisal of the Kety-Schmidt technique. *J Cereb.Blood Flow Metab* 13,646-655
- Madsen PL, Sperling BK, Warming T, Schmidt JF, Secher NH, Wildschiodtz G, Holm S, Lassen NA, 1993. Middle cerebral artery blood velocity and cerebral blood flow and O2 uptake during dynamic exercise. *J Appl.Physiol* 74,245-250
- Madsen PL, Cruz NF, Sokoloff L, Dienel GA, 1999. Cerebral oxygen/glucose ratio is low during sensory stimulation and rises above normal during recovery: excess glucose consumption during stimulation is not accounted for by lactate efflux from or accumulation in brain tissue. *J Cereb.Blood Flow Metab* 19,393-400
- Maeda J, Suhara T, Kawabe K, Okauchi T, Obayashi S, Hojo J, Suzuki K, 2003. Visualization of alpha5 subunit of GABAA/benzodiazepine receptor by 11C Ro15-4513 using positron emission tomography. *Synapse* 47,200-208
- Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P, 1997. Multimodality image registration by maximization of mutual information. *IEEE Trans.Med.Imaging* 16,187-198
- Maes F, Vandermeulen D, Suetens P, 1999. Comparative evaluation of multiresolution optimization strategies for multimodality image registration by maximization of mutual information. *Medical Image Analysis* 3,373-368
- Maggos CE, Tsukada H, Kakiuchi T, Nishiyama S, Myers JE, Kreuter J, Schlussman SD, Unterwald EM, Ho A, Kreek MJ, 1998. Sustained withdrawal allows normalization of in vivo [11C]N-methylspiperone

- dopamine D2 receptor binding after chronic binge cocaine: a positron emission tomography study in rats. *Neuropsychopharmacology* 19,146-153
- Magistretti PJ, Pellerin L, 1996. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. *Mol.Psychiatry* 1,445-452
- Magyar-Lehmann S, Antonini A, Roelcke U, Maguire RP, Missimer J, Meyer M, Leenders KL, 1997. Cerebral glucose metabolism in patients with spasmodic torticollis. *Mov.Disord.* 12,704-708
- Majerus S, Laureys S, Collette F, Del Fiore G, Degueldre C, Luxen A, Van der LM, Maquet P, Metz-Lutz MN, 2003. Phonological short-term memory networks following recovery from Landau and Kleffner syndrome. *Hum.Brain Mapp.* 19,133-144
- Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ, 1998. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. *Arch.Gen.Psychiatry* 55,715-720
- Mangner TJ, Klecker RW, Anderson L, Shields AF, 2003. Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. *Nucl Med Biol.* 30,215-224
- Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA, 1998. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. *J.Nucl.Med.* 39,1043-1055
- Mankoff DA, Shields AF, Link JM, Graham MM, Muzi M, Peterson LM, Eary JF, Krohn KA, 1999. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. *J.Nucl.Med.* 40,614-624
- Mann DM, Yates PO, Marcyniuk B, 1986. The nucleus basalis of Meynert in multi-infarct (vascular) dementia. *Acta Neuropathol.(Berl)* 71,332-337
- Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE, Mintun MA, 1996. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. *J Cereb.Blood Flow Metab* 16,418-426
- Mann JJ, 2003. Neurobiology of suicidal behaviour. *Nat.Rev.Neurosci.* 4,819-828

- Manno EM, Sperling MR, Ding X, Jaggi J, Alavi A, O'Connor MJ, Reivich M, 1994. Predictors of outcome after anterior temporal lobectomy: positron emission tomography. *Neurology* 44,2331-2336
- Maquet P, Hirsch E, Dive D, Salmon E, Marescaux C, Franck G, 1990. Cerebral glucose utilization during sleep in Landau-Kleffner syndrome: a PET study. *Epilepsia* 31,778-783
- Maquet P, Hirsch E, Metzlutz MN, Motte J, Dive D, Marescaux C, Franck G, 1995. Regional cerebral glucose metabolism in children with deterioration of one or more cognitive functions and continuous spike-and-wave discharges during sleep. *Brain* 118,1497-1520
- Maquet P, Peters JM, Aerts J, Delfiore G, Degueldre C, Luxen A, Franck G, 1996. Functional neuroanatomy of human rapid-eye-movement sleep and dreaming. *Nature* 382,163-166
- Maquet P, Degueldre C, Delfiore G, Aerts J, Peters JM, Luxen A, Franck G, 1997. FUNCTIONAL NEUROANATOMY OF HUMAN SLOW WAVE SLEEP. *Journal of Neuroscience* 17,2807-2812
- Marchal G, Rioux P, Petit-Taboue MC, Sette G, Traverre JM, Le Poec C, Courtheoux P, Derlon JM, Baron JC, 1992. Regional cerebral oxygen consumption, blood flow, and blood volume in healthy human aging. *Arch.Neurol.* 49,1013-1020
- Marchal G, Serrati C, Rioux P, Petit-Taboue MC, Viader F, de la Sayette V, Le Doze F, Lochon P, Derlon JM, Orgogozo JM, Baron JC, 1993. PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. *Lancet* 341,925-927
- Marchal G, Beaudouin V, Rioux P, de la Sayette V, Le Doze F, Viader F, Derlon JM, Baron JC, 1996. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. *Stroke* 27,599-606
- Marchal G, Young AR, Baron JC, 1999. Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography. *J.Cereb.Blood Flow Metab.* 19,467-482
- Marjamaki P, Zessin J, Eskola O, Gronroos T, Haaparanta M, Bergman J, Lehtikoinen P, Forsback S, Brust P, Steinbach J, Solin O, 2003. S-[18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: Evaluation in rats. *Synapse* 47,45-53

- Markowitsch HJ, Kessler J, Van Der Ven C, Weber-Luxemburger G, Albers M, Heiss WD, 1998. Psychic trauma causing grossly reduced brain metabolism and cognitive deterioration. *Neuropsychologia* 36,77-82
- Markowitsch HJ, Kessler J, Weber-Luxemburger G, Van d, V, Albers M, Heiss WD, 2000. Neuroimaging and behavioral correlates of recovery from amnesic block syndrome and other cognitive deteriorations. *Neuropsychiatry Neuropsychol.Behav.Neurol* 13,60-66
- Marrett S, Gjedde A, 1997. Changes of blood flow and oxygen consumption in visual cortex of living humans. *Adv.Exp.Med.Biol.* 413:205-8,205-208
- Marsden PK, Ott RJ, Bateman JE, Cherry SR, Flower MA, Webb S, 1989. The Performance of A Multiwire Proportional Chamber Positron Camera for Clinical Use. *Physics in Medicine and Biology* 34,1043-1062
- Martin-Soelch C, Chevalley AF, Kunig G, Missimer J, Magyar S, Mino A, Schultz W, Leenders KL, 2001. Changes in reward-induced brain activation in opiate addicts. *Eur.J Neurosci.* 14,1360-1368
- Martin-Solch C, Magyar S, Kunig G, Missimer J, Schultz W, Leenders KL, 2001. Changes in brain activation associated with reward processing in smokers and nonsmokers. A positron emission tomography study. *Exp.Brain Res* 139,278-286
- Martin AJ, Friston KJ, Colebatch JG, Frackowiak RS, 1991. Decreases in regional cerebral blood flow with normal aging. *J.Cereb.Blood Flow Metab.* 11,684-689
- Martin PR, Rio D, Adinoff B, Johnson JL, Bisslerbe JC, Rawlings RR, Rohrbaugh JW, Stapleton JM, Eckardt MJ, 1992. Regional cerebral glucose utilization in chronic organic mental disorders associated with alcoholism. *J Neuropsychiatry Clin.Neurosci.* 4,159-167
- Martin WR, Powers WJ, Raichle ME, 1987. Cerebral blood volume measured with inhaled C15O and positron emission tomography. *J.Cereb.Blood Flow Metab.* 7,421-426
- Martin WR, Palmer MR, Patlak CS, Calne DB, 1989. Nigrostriatal function in humans studied with positron emission tomography. *Annals of Neurology* 26,535-542

- Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR, 1992. Cortical glucose metabolism in Huntington's disease. *Neurology* 42,223-229
- Martinez D, Mawlawi O, Hwang D, Kent J, Simpson N, Parsey RV, Hashimoto T, Slifstein M, Huang Y, Van Heertum R, Abi-Dargham A, Caltabiano S, Malizia A, Cowley H, Mann JJ, Laruelle M, 2000. Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses. *Nucl.Med.Biol.* 27,523-527
- Martinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, Simpson N, Parsey RV, Hashimoto T, Huang Y, Shinn A, Van Heertum R, Abi-Dargham A, Caltabiano S, Malizia A, Cowley H, Mann JJ, Laruelle M, 2001. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. *Neuropsychopharmacology* 24,209-229
- Martinot JL, Allilaire JF, Mazoyer BM, Hantouche E, Huret JD, Legaut-Demare F, Deslauriers AG, Hardy P, Pappata S, Baron JC, ., 1990. Obsessive-compulsive disorder: a clinical, neuropsychological and positron emission tomography study. *Acta Psychiatr.Scand.* 82,233-242
- Martinot JL, Peron-Magnan P, Huret JD, Mazoyer B, Baron JC, Boulenger JP, Loc'h C, Maziere B, Caillard V, Loo H, ., 1990. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. *Am J Psychiatry* 147,44-50
- Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot J, 2001. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. *Am.J Psychiatry* 158,314-316
- Massou JM, Trichard C, Attar-Levy D, Feline A, Corruble E, Beaufiles B, Martinot JL, 1997. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. *Psychopharmacology (Berl.)* 133,99-101
- Mata M, Fink DJ, Gainer H, Smith CB, Davidsen L, Savaki H, Schwartz WJ, Sokoloff L, 1980. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. *Journal of Neurochemistry* 34,213-215

- Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE, 2002. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. *Bioorg.Med Chem.Lett.* 12,295-298
- Mathis CA, Wang YM, Holt DP, Huang GF, Debnath ML, Klunk WE, 2003. Synthesis and evaluation of C-11-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. *Journal of Medicinal Chemistry* 46,2740-2754
- Matochik JA, Molchan SE, Zametkin AJ, Warden DL, Sunderland T, Cohen RM, 1995. Regional cerebral glucose metabolism in autopsy-confirmed Creutzfeldt-Jakob disease. *Acta Neurologica Scandinavica* 91,153-157
- Matsuda K, Yamaji S, Ishii K, Sasaki M, Sakamoto S, Kitagaki H, Imamura T, Mori E, 1997. Regional cerebral blood flow and oxygen metabolism in a patient with Korsakoff syndrome. *Ann.Nucl.Med.* 11,33-35
- Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha SH, Inatomi J, Yorifuji H, Fukuda J, Endou H, Kanai Y, 2000. Expression of a system L neutral amino acid transporter at the blood-brain barrier. *Neuroreport* 11,3507-3511
- Matsushima T, Inoue T, Natori Y, Fujii K, Fukui M, Hasuo K, Kuwabara Y, 1994. Children with unilateral occlusion or stenosis of the ICA associated with surrounding moyamoya vessels--"unilateral" moyamoya disease. *Acta Neurochir.(Wien.)* 131,196-202
- Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, Weinberger DR, 1996. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. *J Neurosci.* 16,4816-4822
- Matthew E, Nordahl T, Schut L, King AC, Cohen R, 1993. Metabolic and cognitive changes in hereditary ataxia. *J Neurol Sci.* 119,134-140
- Matthews PM, Evans AC, Andermann F, Hakim AM, 1989. Regional cerebral glucose metabolism differs in adult and rigid juvenile forms of Huntington disease. *Pediatr.Neurol* 5,353-356
- Mattioli F, Grassi F, Perani D, Cappa SF, Miozzo A, Fazio F, 1996. Persistent post-traumatic retrograde amnesia: a neuropsychological and (18F)FDG PET study. *Cortex* 32,121-129

- May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ, 1998. Hypothalamic activation in cluster headache attacks. *Lancet* 352,275-278
- May A, Kaube H, Buchel C, Eichten C, Rijntjes M, Juptner M, Weiller C, Diener HC, 1998. Experimental cranial pain elicited by capsaicin: a PET study. *Pain* 74,61-66
- Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN, Jr., Robinson RG, 1990. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. *Ann.Neurol* 28,57-64
- Mayberg HS, Sadzot B, Meltzer CC, Fisher RS, Lesser RP, Dannals RF, Lever JR, Wilson AA, Ravert HT, Wagner HN, Jr., 1991. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. *Annals of Neurology* 30,3-11
- Mayberg HS, 1994. Frontal lobe dysfunction in secondary depression. [Review] [188 refs]. *Journal of Neuropsychiatry & Clinical Neurosciences*.6(4):428-42,
- Mayberg HS, 1997. Limbic-cortical dysregulation: a proposed model of depression. *J Neuropsychiatry Clin.Neurosci.* 9,471-481
- Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, Fox PT, 1997. Cingulate function in depression: a potential predictor of treatment response. *Neuroreport* 8,1057-1061
- Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT, 1999. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. *Am J Psychiatry* 156,675-682
- Mayberg HS, 2000. Depression. In: Toga AW et al., eds. *Brain mapping: The disorders* , Academic Press, San Diego, pp 485-507
- Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA, 2000. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. *Biological Psychiatry*.48(8):830-43,

- Mayberg HS, 2003. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. *Br.Med Bull.* 65,193-207
- Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, Balatoni J, Bornmann W, Finn R, Larson S, Fong Y, Gelovani TJ, Blasberg R, Bertino JR, 2002. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. *Proc.Natl.Acad.Sci.U.S.A* 99,3400-3405
- Maziere B, Loc'h C, Baron JC, Sgouropoulos P, Duquesnoy N, D'Antona R, Cambon H, 1985. In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone. *Eur.J Pharmacol.* 114,267-272
- Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, Holmes C, Collins L, Thompson P, Macdonald D, Iacoboni M, Schormann T, Amunts K, Palomero-Gallagher N, Geyer S, Parsons L, Narr K, Kabani N, Le Goualher G, Boomsma D, Cannon T, Kawashima R, Mazoyer B, 2001. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). *Philos.Trans.R.Soc.Lond B Biol.Sci.* 356,1293-1322
- Mazziotta JC, Phelps ME, Plummer D, Kuhl DE, 1981. Quantitation in positron emission computed tomography: 5. Physical--anatomical effects. *Journal of Computer Assisted Tomography* 5,734-743
- Mazziotta JC, Phelps ME, Carson RE, Kuhl DE, 1982. Tomographic mapping of human cerebral metabolism: sensory deprivation. *Annals of Neurology* 12,435-444
- Mazziotta JC, Phelps ME, Carson RE, Kuhl DE, 1982. Tomographic mapping of human cerebral metabolism: auditory stimulation. *Neurology* 32,921-937
- Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, 1987. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. *N Engl J Med* 316,357-362
- Mazziotta JC, 1989. Huntington's disease: studies with structural imaging techniques and positron emission tomography. *Seminars in Neurology* 9,360-369



- Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J, 1995. A PROBABILISTIC ATLAS OF THE HUMAN BRAIN - THEORY AND RATIONALE FOR ITS DEVELOPMENT. *Neuroimage* 2,89-101
- McAllister TW, Saykin AJ, Flashman LA, Sparling MB, Johnson SC, Guerin SJ, Mamourian AC, Weaver JB, Yanofsky N, 1999. Brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study. *Neurology* 53,1300-1308
- McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA, 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. *J Neurosci.* 18,8417-8422
- McConathy J, Martarello L, Malveaux EJ, Camp VM, Simpson NE, Simpson CP, Bowers GD, Olson JJ, Goodman MM, 2002. Radiolabeled amino acids for tumor imaging with PET: radiosynthesis and biological evaluation of 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid. *J Med Chem.* 45,2240-2249
- McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ, 1994. Functional anatomy of obsessive-compulsive phenomena. *Br.J Psychiatry* 164,459-468
- Mckee BTA, Gurvey AT, Harvey PJ, Howse DC, 1992. A Deconvolution Scatter Correction for A 3-D Pet System. *IEEE Transactions on Medical Imaging* 11,560-569
- McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. *N Engl J Med* 333,1099-1105
- McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM, 1984. Clinical diagnosis of Alzheimer's disease. *Neurology* 34,939-944
- McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS, 2003. Cost-Effectiveness of PET in the Diagnosis of Alzheimer Disease. *Radiology* 228,2020915
- McNamara D, Horwitz B, Grady CL, Rapoport SI, 1987. Topographical analysis of glucose metabolism, as measured with positron emission tomography,

- in dementia of the Alzheimer type: use of linear histograms. *Int.J Neurosci.* 36,89-97
- Mega MS, Chen SS, Thompson PM, Woods RP, Karaca TJ, Tiwari A, Vinters HV, Small GW, Toga AW, 1997. MAPPING HISTOLOGY TO METABOLISM - COREGISTRATION OF STAINED WHOLE-BRAIN SECTIONS TO PREMORTEM PET IN ALZHEIMERS DISEASE. *Neuroimage* 5,147-153
- Mega MS, Chu T, Mazziotta JC, Trivedi KH, Thompson PM, Shah A, Cole G, Frautschy SA, Toga AW, 1999. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. *Neuroreport* 10,2911-2917
- Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW, 2001. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. *Neuropsychiatry Neuropsychol.Behav.Neurol.* 14,63-68
- Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, Jones T, Price P, 1998. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. *Cancer Chemother.Pharmacol.* 42,183-193
- Meikle SR, Matthews JC, Cunningham VJ, Bailey DL, Livieratos L, Jones T, Price P, 1998. Parametric image reconstruction using spectral analysis of PET projection data. *Phys.Med Biol.* 43,651-666
- Meissner W, Harnack D, Paul G, Reum T, Sohr R, Morgenstern R, Kupsch A, 2002. Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. *Neuroscience Letters* 328,105-108
- Melega WP, Raleigh MJ, Stout DB, Huang SC, Phelps ME, 1997. Ethological and 6-[18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine. *Behav.Brain Res* 84,259-268
- Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME, 1997. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. *Brain Res* 766,113-120

- Melega WP, Lacan G, Harvey DC, Huang SC, Phelps ME, 1998. Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey. *Neurosci.Lett.* 258,17-20
- Melega WP, Lacan G, DeSalles AA, Phelps ME, 2000. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey. *Synapse* 35,243-249
- Melon PG, Boyd CJ, McVey S, Mangner TJ, Wieland DM, Schwaiger M, 1997. Effects of active chronic cocaine use on cardiac sympathetic neuronal function assessed by carbon-11-hydroxyephedrine. *J Nucl Med* 38,451-456
- Meltzer CC, Zubietta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ, 1996. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. *Neurology* 47,454-461
- Meltzer CC, Smith G, Price JC, Reynolds CF, III, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben Eliezer D, Cantwell MN, Kaye W, Dekosky ST, 1998. Reduced binding of [18F]altanserine to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. *Brain Res.* 813,167-171
- Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben Eliezer D, Lopresti B, Dekosky ST, Reynolds CF, III, 1999. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. *Am.J.Psychiatry* 156,1871-1878
- Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, Lin MP, Price JC, 1999. Comparative evaluation of MR-based partial-volume correction schemes for PET. *J.Nucl.Med.* 40,2053-2065
- Meltzer CC, Cantwell MN, Greer PJ, Ben Eliezer D, Smith G, Frank G, Kaye WH, Houck PR, Price JC, 2000. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. *J.Nucl.Med.* 41,1842-1848
- Meltzer CC, Adelson PD, Brenner RP, Crumrine PK, Van Cott A, Schiff DP, Townsend DW, Scheuer ML, 2000. Planned ictal FDG PET imaging for localization of extratemporal epileptic foci. *Epilepsia* 41,193-200

- Meltzer CC, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ, Villemagne VL, Holt D, Mason NS, Houck PR, Reynolds CF, III, Dekosky ST, 2001. Gender-specific aging effects on the serotonin 1A receptor. *Brain Res.* 895,9-17
- Meltzer PC, Liang AY, Brownell AL, Elmaleh DR, Madras BK, 1993. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. *J Med Chem.* 36,855-862
- Mendez MF, Ottowitz W, Brown CV, Cummings JL, Perryman KM, Mandelkern MA, 1999. Dementia with leukoaraiosis: clinical differentiation by temporoparietal hypometabolism on (18)FDG-PET imaging. *Dement.Geriatr.Cogn Disord.* 10,518-525
- Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, Edwards C, Mattis P, Eidelberg D, 2002. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. *Am.J Psychiatry* 159,746-754
- Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, Nitzsche E, Huang SC, Phelps ME, Hawkins RA, 1992. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. *Journal of Computer Assisted Tomography* 16,684-689
- Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, Grassi F, Del Sole A, Franceschi M, Gilardi MC, 1994. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. *J.Nucl.Med.* 35,210-216
- Mesulam MM, Geula C, 1992. Overlap between acetylcholinesterase-rich and choline acetyltransferase- positive (cholinergic) axons in human cerebral cortex. *Brain Res.* 577,112-120
- Metter EJ, Riege WH, Hanson WR, Jackson CA, Kempler D, van Lancker D, 1988. Subcortical structures in aphasia. An analysis based on (F-18)-fluorodeoxyglucose, positron emission tomography, and computed tomography. *Arch.Neurol.* 45,1229-1234
- Metter EJ, Kuhl DE, Riege WH, 1990. Brain glucose metabolism in Parkinson's disease. *Advances in Neurology* 53,135-139

- Metter EJ, Hanson WR, Jackson CA, Kempler D, van Lancker D, Mazziotta JC, Phelps ME, 1990. Temporoparietal cortex in aphasia. Evidence from positron emission tomography. *Arch.Neurol.* 47,1235-1238
- Meyer E, Tyler JL, Thompson CJ, Redies C, Diksic M, Hakim AM, 1987. Estimation of cerebral oxygen utilization rate by single-bolus  $^{15}\text{O}_2$  inhalation and dynamic positron emission tomography. *J.Cereb.Blood Flow Metab.* 7,403-414
- Meyer E, 1989. Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET. *J Nucl Med* 30,1069-1078
- Meyer JH, Cho R, Kennedy S, Kapur S, 1999. The effects of single dose nefazodone and paroxetine upon 5-HT<sub>2A</sub> binding potential in humans using [ $^{18}\text{F}$ ]-setoperone PET. *Psychopharmacology (Berl)* 144,279-281
- Meyer JH, Gunn RN, Myers R, Grasby PM, 1999. Assessment of spatial normalization of PET ligand images using ligand-specific templates. *Neuroimage* 9,545-553
- Meyer JH, Swinson R, Kennedy SH, Houle S, Brown GM, 2000. Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. *Psychiatry Res* 98,133-143
- Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, Dasilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH, 2001. The effect of paroxetine on 5-HT(2A) receptors in depression: an [ $^{18}\text{F}$ ]setoperone PET imaging study. *American Journal of Psychiatry* 158,78-85
- Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S, 2001. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [ $^{11}\text{C}$ ]DASB PET imaging study. *American Journal of Psychiatry* 158,1843-1849
- Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S, 2002. Bupropion occupancy of the dopamine transporter is low during clinical treatment. *Psychopharmacology (Berl)* 163,102-105
- Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE, 1995. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. *Arch.Neurol.* 52,314-317

- Meyer MA, Hubner KF, Raja S, Hunter K, Paulsen WA, 1994. Sequential positron emission tomographic evaluations of brain metabolism in acute herpes encephalitis. *J Neuroimaging* 4,104-105
- Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL, 1999. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. *Neurology* 53,371-374
- Meyer PT, Cortes-Blanco A, Pourdehnad M, Levy-Reis I, Desiderio L, Jang S, Alavi A, 2001. Inter-modality comparisons of seizure focus lateralization in complex partial seizures. *Eur.J Nucl Med* 28,1529-1540
- Meyer PT, Schreckenberger M, Spetzger U, Meyer GF, Sabri O, Setani KS, Zeggel T, Buell U, 2001. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. *Eur.J Nucl Med* 28,165-174
- Mielke R, Herholz K, Grond M, Kessler J, Heiss WD, 1992. Severity of vascular dementia is related to volume of metabolically impaired tissue. *Arch.Neurol.* 49,909-913
- Mielke R, Herholz K, Grond M, Kessler J, Heiss WD, 1992. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. *Neurobiology of Aging* 13,93-98
- Mielke R, Herholz K, Fink G, Ritter D, Heiss WD, 1993. Positron emission tomography in myotonic dystrophy. *Psychiatry Research* 50,93-99
- Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, Herholz K, Heiss WD, 1994. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. *Eur.J Nucl Med* 21,1052-1060
- Mielke R, Kittner B, Ghaemi M, Kessler J, Szekely B, Herholz K, Heiss WD, 1996. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. *Journal of the Neurological Sciences* 141,59-64
- Mielke R, Schröder R, Fink GR, Kessler J, Herholz K, Heiss WD, 1996. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. *Acta Neuropathologica* 91,174-179

- Mies G, Auer LM, Ebhardt G, Traupe H, Heiss WD, 1983. Flow and neuronal density in tissue surrounding chronic infarction. *Stroke* 14,22-27
- Miller DD, Andreasen NC, O'Leary DS, Rezai K, Watkins L, Ponto LB, Hichwa RD, 1997. EFFECT OF ANTIPSYCHOTICS ON REGIONAL CEREBRAL BLOOD FLOW MEASURED WITH POSITRON EMISSION TOMOGRAPHY. *Neuropsychopharmacology* 17,230-240
- Minami T, Otsuka M, Ichiya Y, Nomura A, Ueda K, 1994. Different patterns of [18F]dopa uptake in siblings with hereditary dentato-rubro-pallido-luysian atrophy. *Brain Dev.* 16,335-338
- Mineura K, Sasajima T, Kowada M, Uesaka Y, Shishido F, 1991. Innovative approach in the diagnosis of gliomatosis cerebri using carbon-11-L-methionine positron emission tomography. *J.Nucl.Med.* 32,726-728
- Mineura K, Ogawa T, Sasajima T, Hatazawa J, Kowada M, Uemura K, 1997. INDICATIONS FOR DIFFERENTIAL DIAGNOSIS OF NONTUMOR CENTRAL NERVOUS SYSTEM DISEASES FROM TUMORS - A POSITRON EMISSION TOMOGRAPHY STUDY. *Journal of Neuroimaging* 7,8-15
- Minoshima S, Koeppe RA, Mintun MA, Berger KL, Taylor SF, Frey KA, Kuhl DE, 1993. Automated detection of the intercommissural line for stereotactic localization of functional brain images. *J.Nucl.Med.* 34,322-329
- Minoshima S, Koeppe RA, Frey KA, Ishihara M, Kuhl DE, 1994. Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. *J.Nucl.Med.* 35,949-954
- Minoshima S, Koeppe RA, Frey KA, Kuhl DE, 1994. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. *J.Nucl.Med.* 35,1528-1537
- Minoshima S, Frey KA, Foster NL, Kuhl DE, 1995. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. *Journal of Computer Assisted Tomography* 19,541-547
- Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE, 1997. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann.Neurol.* 42,85-94

- Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE, 2001.  
Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. *Ann.Neurol.* 50,358-365
- Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ, 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. *Annals of Neurology* 15,217-227
- Mintun MA, Raichle ME, Martin WR, Herscovitch P, 1984. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. *J.Nucl.Med.* 25,177-187
- Mintun MA, Dennis DR, Welch MJ, Mathias CJ, Schuster DP, 1987.  
Measurements of pulmonary vascular permeability with PET and gallium-68 transferrin. *J.Nucl.Med.* 28,1704-1716
- Mishina M, Senda M, Ishii K, Ohyama M, Kitamura S, Katayama Y, 1999.  
Cerebellar activation during ataxic gait in olivopontocerebellar atrophy: a PET study. *Acta Neurol Scand.* 100,369-376
- Mithoefer M, Jerome L, Doblin R, 2003. MDMA ("ecstasy") and neurotoxicity. *Science* 300,1504-1505
- Mitsuki S, Diksic M, Conway T, Yamamoto YL, Villemure JG, Feindel W, 1991.  
Pharmacokinetics of <sup>11</sup>C-labelled BCNU and SarCNU in gliomas studied by PET. *J Neurooncol.* 10,47-55
- Miura H, Nagata K, Hirata Y, Satoh Y, Watahiki Y, Hatazawa J, 1994. Evolution of crossed cerebellar diaschisis in middle cerebral artery infarction. *J Neuroimaging* 4,91-96
- Miura K, Watanabe K, Maeda N, Matsumoto A, Kumagai T, Ito K, Kato T, 1993.  
Magnetic resonance imaging and positron emission tomography of band heterotopia. *Brain & Development* 15,288-290
- Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, Blasberg R, 1998.  
"Facilitated" amino acid transport is upregulated in brain tumors. *J.Cereb.Blood Flow Metab.* 18,500-509
- Miyamoto RT, Wong D, 2001. Positron emission tomography in cochlear implant and auditory brainstem implant recipients. *J Commun.Disord.* 34,473-478



- Miyazawa H, Osmont A, Petit-Taboue MC, Tillet I, Traverso JM, Young AR, Barre L, MacKenzie ET, Baron JC, 1993. Determination of <sup>18</sup>F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. *J Neurosci.Methods* 50,263-272
- Moeller JR, Strother SC, 1991. A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. *J Cereb.Blood Flow Metab* 11,A121-A135
- Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, Grady C, Pietrini P, Eidelberg D, 1996. The metabolic topography of normal aging. *J.Cereb.Blood Flow Metab.* 16,385-398
- Molchan SE, Matochik JA, Zametkin AJ, Szymanski HV, Cantillon M, Cohen RM, Sunderland T, 1994. A double FDG/PET study of the effects of scopolamine in older adults. *Neuropsychopharmacology* 10,191-198
- Moore AH, Hovda DA, Cherry SR, Villablanca JP, Pollack DB, Phelps ME, 2000. Dynamic changes in cerebral glucose metabolism in conscious infant monkeys during the first year of life as measured by positron emission tomography. *Brain Res.Dev.Brain Res.* 120,141-150
- Moore TH, Osteen TL, Chatziioannou TF, Hovda DA, Cherry TR, 2000. Quantitative assessment of longitudinal metabolic changes in vivo after traumatic brain injury in the adult rat using FDG-microPET. *J Cereb.Blood Flow Metab* 20,1492-1501
- Moresco FM, Dieci M, Vita A, Messa C, Gobbo C, Galli L, Rizzo G, Panzacchi A, De Peri L, Invernizzi G, Fazio F, 2002. In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study. *Neuroimage* 17,1470-1478
- Moresco RM, Casati R, Lucignani G, Carpinelli A, Schmidt K, Todde S, Colombo F, Fazio F, 1995. Systemic and cerebral kinetics of 16 alpha [<sup>18</sup>F]fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. *J Cereb.Blood Flow Metab* 15,301-311
- Moresco RM, Scheithauer BW, Lucignani G, Lombardi D, Rocca A, Losa M, Casati R, Giovanelli M, Fazio F, 1997. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. *Nucl Med Commun.* 18,606-615
- Moresco RM, Tettamanti M, Gobbo C, Del Sole A, Ravasi L, Messa C, Paulesu E, Lucignani G, Perani D, Fazio F, 2001. Acute effect of 3-(4-acetamido)-

- butyryl-lorazepam (DDS2700) on brain function assessed by PET at rest and during attentive tasks. *Nucl.Med.Comm.* 22,399-404
- Moresco RM, Volonte MA, Messa C, Gobbo C, Galli L, Carpinelli A, Rizzo G, Panzacchi A, Franceschi M, Fazio F, 2002. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET [ $^{11}\text{C}$ ]raclopride study. *J Neural Transm.* 109,1265-1274
- Morgan D, Grant KA, Gage HD, Mach RH, Kaplan JR, Prioleau O, Nader SH, Buchheimer N, Ehrenkaufer RL, Nader MA, 2002. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. *Nat.Neurosci.* 5,169-174
- Morimoto M, Iwama T, Hashimoto N, Kojima A, Hayashida K, 1999. Efficacy of direct revascularization in adult Moyamoya disease: haemodynamic evaluation by positron emission tomography. *Acta Neurochir.(Wien.)* 141,377-384
- Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ, 1998. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [ $^{18}\text{F}$ ]dopa PET. *J Neurol Neurosurg Psychiatry* 64,314-319
- Mountz JM, Modell JG, Wilson MW, Curtis GC, Lee MA, Schmaltz S, Kuhl DE, 1989. Positron emission tomographic evaluation of cerebral blood flow during state anxiety in simple phobia. *Arch Gen Psychiatry* 46,501-504
- Muhr C, Bergstrom M, Lundberg PO, Bergstrom K, Langstrom B, 1986. In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography. *Acta Radiol.Suppl* 369,406-408
- Muhr C, Bergstrom M, Lundberg PO, Bergstrom K, Hartvig P, Lundqvist H, Antoni G, Langstrom B, 1986. Dopamine receptors in pituitary adenomas: PET visualization with  $^{11}\text{C}$ -N-methylspiperone. *J Comput.Assist.Tomogr.* 10,175-180
- Mukherjee J, Yang ZY, Das MK, Brown T, 1995. Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[ $^{18}\text{F}$ ]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. *Nucl.Med.Biol.* 22,283-296
- Mukherjee J, Yang ZY, Brown T, Roemer J, Cooper M, 1996.  $^{18}\text{F}$ -desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. *Life Sci.* 59,669-678

- Mukherjee J, Yang ZY, Lew R, Brown T, Kronmal S, Cooper MD, Seiden LS, 1997. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. *Synapse* 27,1-13
- Mukherjee J, Yang ZY, 1999. Development of N-[3-(2',4'-dichlorophenoxy)-2-18F-fluoropropyl]-N-methylpropargylamine (18F-fluoroclogyline) as a potential PET radiotracer for monoamine oxidase-A. *Nucl Med Biol.* 26,619-625
- Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J, 2001. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. *Neuropsychopharmacology* 25,476-488
- Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J, 2002. Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. *Synapse* 46,170-188
- Mulholland GK, Otto CA, Jewett DM, Kilbourn MR, Koeppe RA, Sherman PS, Petry NA, Carey JE, Atkinson ER, Archer S, 1992. Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2 alpha-tropanyl benzilate: a central muscarinic receptor imaging agent [published erratum appears in *J Nucl Med* 1992 May;33(5):667]. *J.Nucl.Med.* 33,423-430
- Mulholland GK, Kilbourn MR, Sherman P, Carey JE, Frey KA, Koeppe RA, Kuhl DE, 1995. Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. *Nuclear Medicine & Biology* 22,13-17
- Mulholland GK, Wieland DM, Kilbourn MR, Frey KA, Sherman PS, Carey JE, Kuhl DE, 1998. [18F]fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. *Synapse* 30,263-274
- Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ, 1992. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. *J.Cereb.Blood Flow Metab.* 12,571-583

- Muller L, Halldin C, Lundkvist C, Swahn CG, Foged C, Hall H, Karlsson P, Ginovart N, Nakashima Y, Suhara T, Farde L, 1996. DEVELOPMENT OF RADIOLIGANDS FOR THE DOPAMINE TRANSPORTER. *Journal of Radioanalytical & Nuclear Chemistry* 206,133-144
- Muller RA, Chugani HT, Muzik O, Mangner TJ, 1998. Brain organization of motor and language functions following hemispherectomy: a [(15)O]-water positron emission tomography study. *J Child Neurol* 13,16-22
- Mummery CJ, Patterson K, Wise RJ, Vandenberg R, Price CJ, Hodges JR, 1999. Disrupted temporal lobe connections in semantic dementia. *Brain* 122,61-73
- Murakami M, Kondoh Y, Weimin Y, Mizusawa S, Nakamichi H, Takahashi K, Sasaki H, Iida H, Miura S, Kanno I, 1992. A convenient method for regional monoamine oxidase-A determination by [14C]clorgyline autoradiography. *International Journal of Radiation Applications & Instrumentation - Part B, Nuclear Medicine & Biology* 19,619-626
- Murphy DG, Mentis MJ, Pietrini P, Grady C, Daly E, Haxby JV, De LG, Allen G, Largay K, White BJ, Powell CM, Horwitz B, Rapoport SI, Schapiro MB, 1997. A PET study of Turner's syndrome: effects of sex steroids and the X chromosome on brain. *Biol.Psychiatry* 41,285-298
- Murphy DGM, DeCarli C, McIntosh AR, Daly E, Mentis MJ, Pietrini P, Szczepanik J, Schapiro MB, Grady CL, Horwitz B, Rapoport SI, 1996. SEX DIFFERENCES IN HUMAN BRAIN MORPHOMETRY AND METABOLISM - AN IN VIVO QUANTITATIVE MAGNETIC RESONANCE IMAGING AND POSITRON EMISSION TOMOGRAPHY STUDY ON THE EFFECT OF AGING. *Arch Gen Psychiatry* 53,585-594
- Musachio JL, Flesher JE, Scheffel UA, Rauseo P, Hilton J, Mathews WB, Ravert HT, Dannals RF, Frost JJ, 2002. Radiosynthesis and mouse brain distribution studies of [11C] CP-126,998: a PET ligand for in vivo study of acetylcholinesterase. *Nucl Med Biol.* 29,547-552
- Musso M, Weiller C, Kiebel S, Iler SP, Iau P, Rijntjes M, 1999. Training-induced brain plasticity in aphasia. *Brain* 122,1781-1790
- Muzik O, Da Silva EA, Juhasz C, Chugani DC, Shah J, Nagy F, Canady A, von Stockhausen HM, Herholz K, Gates J, Frost M, Ritter F, Watson C, Chugani HT, 2000. Intracranial EEG vs. flumazenil and glucose PET in children with extratemporal lobe epilepsy. *Neurology* 54,171-179

- Nacmias B, Tedde A, Forleo P, Piacentin S, Guarnieri BM, Bartoli A, Ortenzi L, Petruzzi C, Serio A, Marcon G, Sorbi S, 2001. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. *Biol.Psychiatry* 50,472-475
- Nagahama Y, Fukuyama H, Turjanski N, Kennedy A, Yamauchi H, Ouchi Y, Kimura J, Brooks DJ, Shibasaki H, 1997. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. *Mov Disord.* 12,691-696
- Nagasawa H, Tanji H, Nomura H, Saito H, Itoyama Y, Kimura I, Tuji S, Fujiwara T, Iwata R, Itoh M, Ido T, 1996. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. *Journal of the Neurological Sciences* 139,210-217
- Nagatsuka S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T, 2001. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. *J Cereb.Blood Flow Metab* 21,1354-1366
- Nagy F, Chugani DC, Juhasz C, Da Silva EA, Muzik O, Kupsky W, Canady A, Watson C, Shah J, Chugani HT, 1999. Altered in vitro and in vivo flumazenil binding in human epileptogenic neocortex. *J.Cereb.Blood Flow Metab.* 19,939-947
- Nagy TG, Jelencsik I, Szirmai I, 1999. Primary progressive aphasia: a case report. *Eur.J.Neurol.* 6,515-519
- Nahmias C, Garnett ES, Firnau G, Lang A, 1985. Striatal dopamine distribution in parkinsonian patients during life. *Journal of the Neurological Sciences* 69,223-230
- Nahmias C, Wahl L, Chirakal R, Firnau G, Garnett ES, 1995. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain. *Mov Disord.* 10,298-304
- Nahmias C, Nutt R, Hichwa RD, Czernin J, Melcher C, Schmand M, Andreaco M, Eriksson L, Casey M, Moyers C, Michel C, Bruckbauer T, Conti M, Bendriem B, Hamill J, 2002. PET tomograph designed for five minute routine whole body studies. *J.Nucl.Med.* 43,36

- Nakajima T, Nimura T, Yamaguchi K, Ando T, Itoh M, Yoshimoto T, Shirane R, 2003. The impact of stereotactic pallidal surgery on the dopamine D2 receptor in Parkinson disease: a positron emission tomography study. *J Neurosurg* 98,57-63
- Nakamura H, Hishinuma T, Tomioka Y, Ido T, Iwata R, Funaki Y, Itoh M, ujiwara T, anai K, ato M, umachi Y, oshida S, izugaki M, 1996. Positron emission tomography study of the alterations in brain distribution of [11C]methamphetamine in methamphetamine- sensitized dog. *Annals of the New York Academy of Sciences* 801,401-408
- Nakamura H, Hishinuma T, Tomioka Y, Ishiwata S, Ido T, Iwata R, Funaki Y, Itoh M, Fujiwara T, Yanai K, Sato M, Numachi Y, Yoshida S, Mizugaki M, 1997. Effects of haloperidol and cocaine pretreatments on brain distribution and kinetics of [11C]methamphetamine in methamphetamine sensitized dog: application of PET to drug pharmacokinetic study. *Nucl Med Biol.* 24,165-169
- Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS, 1994. The influence of age on stroke outcome. The Copenhagen Stroke Study. *Stroke* 25,808-813
- Namba H, Irie T, Fukushi K, Iyo M, 1994. In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. *Brain Research* 667,278-282
- Namba H, Iyo M, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T, 1999. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. *Eur.J.Nucl.Med.* 26,135-143
- Nariai T, Suzuki R, Hirakawa K, Maehara T, Ishii K, Senda M, 1995. Vascular reserve in chronic cerebral ischemia measured by the acetazolamide challenge test: comparison with positron emission tomography. *AJNR Am.J Neuroradiol.* 16,563-570
- Nariai T, Senda M, Ishii K, Maehara T, Wakabayashi S, Toyama H, Ishiwata K, Hirakawa K, 1997. Three-dimensional imaging of cortical structure, function and glioma for tumor resection. *J.Nucl.Med.* 38,1563-1568
- Nariai T, Ohno K, Ohta Y, Hirakawa K, Ishii K, Senda M, 2001. Discordance between cerebral oxygen and glucose metabolism, and hemodynamics in a mitochondrial encephalomyopathy, lactic acidosis, and strokelike episode patient. *J Neuroimaging* 11,325-329

- Naumann M, Magyar-Lehmann S, Reiners K, Erbguth F, Leenders KL, 2000. Sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming. *Ann.Neurol.* 47,322-328
- Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF, 1998. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 51,1546-1554
- Nelles G, Spiekermann G, Jueptner M, Leonhardt G, Iler S, Gerhard H, Diener HC, 1999. Reorganization of Sensory and Motor Systems in Hemiplegic Stroke Patients : A Positron Emission Tomography Study. *Stroke* 30,1510-1516
- Nelson AD, Miraldi F, Muzic RF, Jr., Leisure GP, Semple WE, 1993. Noninvasive arterial monitor for quantitative oxygen-15-water blood flow studies [see comments]. *J.Nucl.Med.* 34,1000-1006
- Nelson SJ, Day MR, Buffone PJ, Wald LL, Budinger TF, Hawkins R, Dillon WP, Huhn S, Prados MD, Chang S, Vigneron DB, 1997. Alignment of volume MR images and high resolution [18F]fluorodeoxyglucose PET images for the evaluation of patients with brain tumors. *J.Comput.Assist.Tomogr.* 21,183-191
- Nestor PJ, Fryer TD, Smielewski P, Hodges JR, 2003. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. *Ann.Neurol* 54,343-351
- Neumann DR, Basile KE, Bravo EL, Chen EQ, Go RT, 1996. Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. *J Comput.Assist.Tomogr.* 20,312-316
- Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB, 1994. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. *J Med Chem.* 37,1558-1561
- Neuroimaging Subcommittee of the International League Against Epilepsy, 2000. Commission on Diagnostic Strategies: recommendations for functional neuroimaging of persons with epilepsy [In Process Citation]. *Epilepsia* 41,1350-1356

- Newberg A, Hassan A, Alavi A, 2002. Cerebral metabolic changes associated with Lyme disease. Nucl Med Commun. 23,773-777
- Newberg AB, Alavi A, Berlin J, Mozley PD, O'Connor M, Sperling M, 2000. Ipsilateral and contralateral thalamic hypometabolism as a predictor of outcome after temporal lobectomy for seizures. J Nucl Med 41,1964-1968
- Ngan ET, Yatham LN, Ruth TJ, Liddle PF, 2000. Decreased serotonin 2A receptor densities in neuroleptic-naïve patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry 157,1016-1018
- Niimura K, Chugani DC, Muzik O, Chugani HT, 1999. Cerebellar reorganization following cortical injury in humans: effects of lesion size and age. Neurology 52,792-797
- Niimura K, Muzik O, Chugani DC, Shen C, Chugani HT, 1999. [11C]flumazenil PET: activity images versus parametric images for the detection of neocortical epileptic foci. J.Nucl.Med. 40,1985-1991
- Nirkko AC, Rosler KM, Ozdoba C, Heid O, Schroth G, Hess CW, 1997. Human cortical plasticity - Functional recovery with mirror movements. Neurology 48,1090-1093
- Noble EP, Gottschalk LA, Fallon JH, Ritchie TL, Wu JC, 1997. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet. 74,162-166
- Nofzinger EA, Mintun MA, Wiseman M, Kupfer DJ, Moore RY, 1997. Forebrain activation in REM sleep: an FDG PET study. Brain Res. 770,192-201
- Nordahl TE, Benkelfat C, Semple WE, Gross M, King AC, Cohen RM, 1989. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 2,23-28
- Nordahl TE, Semple WE, Gross M, Mellman TA, Stein MB, Goyer P, King AC, Uhde TW, Cohen RM, 1990. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 3,261-272
- Nordahl TE, Stein MB, Benkelfat C, Semple WE, Andreason P, Zametkin A, Uhde TW, Cohen RM, 1998. Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. Biol.Psychiatry 44,998-1006



- Nordberg A, Hartvig P, Lundqvist H, Antoni G, Ulin J, Langstrom B, 1989. Uptake and regional distribution of (+)-(R)- and (-)-(S)-N-[methyl-11C]-nicotine in the brains of rhesus monkey. An attempt to study nicotinic receptors in vivo. *J Neural Transm.Park Dis.Dement.Sect.* 1,195-205
- Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B, 1995. Kinetic analysis of regional (S)(-)-11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. *Alzheimer Disease & Associated Disorders* 9,21-27
- Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B, 1995. Kinetic analysis of regional (S)(-)-11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. *Alzheimer Dis.Assoc.Disord.* 9,21-27
- Nordstrom AL, Farde L, Halldin C, 1992. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. *Psychopharmacology* 106,433-438
- Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G, 1993. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. *Biological Psychiatry* 33,227-235
- Nordstrom AL, Farde L, Eriksson L, Halldin C, 1995. No elevated D2 dopamine receptors in neuroleptic-naïve schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. *Psychiatry Res* 61,67-83
- Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G, 1995. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. *Am J Psychiatry* 152,1444-1449
- Nordstrom AL, Nyberg S, Olsson H, Farde L, 1998. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. *Arch Gen Psychiatry* 55,283-284
- Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO, 2000. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. *Ann.Neurol.* 47,804-808

- Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO, 2001. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. *Mov Disord.* 16,608-615
- Nutt R, 2002. For: Is LSO the future of PET? *Eur.J Nucl Med Mol.Imaging* 29,1523-1525
- Nuttin BJ, Gabriels LA, Cosyns PR, Meyerson BA, Andreewitch S, Sunaert SG, Maes AF, Dupont PJ, Gybels JM, Gielen F, Demeulemeester HG, 2003. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. *Neurosurgery* 52,1263-1272
- Nuutinen J, Sonninen P, Lehtikainen P, Sutinen E, Valavaara R, Eronen E, Norrgard S, Kulmala J, Teras M, Minn H, 2000. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. *Int.J Radiat.Oncol.Biol.Phys.* 48,43-52
- Nyback H, Halldin C, Ahlin A, Curvall M, Eriksson L, 1994. PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. *Psychopharmacology (Berl)* 115,31-36
- Nyberg G, Bergstrom M, Enblad P, Lilja A, Muhr C, Langstrom B, 1997. PET-methionine of skull base neuromas and meningiomas. *Acta Otolaryngol.* 117,482-489
- Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B, 1993. 5-HT<sub>2</sub> and D<sub>2</sub> dopamine receptor occupancy in the living human brain. A PET study with risperidone. *Psychopharmacology* 110,265-272
- Nyberg S, Farde L, Halldin C, 1996. TEST-RETEST RELIABILITY OF CENTRAL [C-11]RACLOPRIDE BINDING AT HIGH D-2 RECEPTOR OCCUPANCY - A PET STUDY IN HALOPERIDOL-TREATED PATIENTS. *Psychiatry Research: Neuroimaging* 67,163-171
- Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L, 1999. Suggested minimal effective dose of risperidone based on PET-measured D<sub>2</sub> and 5-HT<sub>2A</sub> receptor occupancy in schizophrenic patients. *Am J Psychiatry* 156,869-875
- Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB, 1992. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. *Ann.Neurol* 32,603-608

- O'Brien TJ, Hicks RJ, Ware R, Binns DS, Murphy M, Cook MJ, 2001. The utility of a 3-dimensional, large-field-of-view, sodium iodide crystal--based PET scanner in the presurgical evaluation of partial epilepsy. *J Nucl Med* 42,1158-1165
- O'Tuama LA, Guilarte TR, Douglass KH, Wagner HN, Jr., Wong DF, Dannals RF, Ravert HT, Wilson AA, LaFrance ND, Bice AN, 1988. Assessment of [11C]-L-methionine transport into the human brain. *J.Cereb.Blood Flow Metab.* 8,341-345
- O'Tuama LA, Phillips PC, Smith QR, Uno Y, Dannals RF, Wilson AA, Ravert HT, Loats S, Loats HA, Wagner HN, Jr., 1991. L-methionine uptake by human cerebral cortex: maturation from infancy to old age [see comments]. *J.Nucl.Med.* 32,16-22
- Ogawa A, Kameyama M, Muraishi K, Yoshimoto T, Ito M, Sakurai Y, 1992. Cerebral blood flow and metabolism following superficial temporal artery to superior cerebellar artery bypass for vertebrobasilar occlusive disease. *J Neurosurg* 76,955-960
- Ogawa K, Uema T, Motohashi N, Nishikawa M, Takano H, Hiroki M, Imabayashi E, Ohnishi T, Inoue T, Takayama Y, Takeda M, Matsuda H, Andoh T, Yamada Y, 2003. Neural mechanism of propofol anesthesia in severe depression: a positron emission tomographic study. *Anesthesiology* 98,1101-1111
- Ogawa M, Fukuyama H, Harada K, Kimura J, 1998. Cerebral blood flow and metabolism in multiple system atrophy of the Shy-Drager syndrome type: a PET study. *J Neurol Sci.* 158,173-179
- Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H, Murakami M, Uemura K, Yasui N, Mineura K, Kowada M, 1991. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl- 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. *Acta Radiologica* 32,197-202
- Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T, Uemura K, Yasui N, Mineura K, 1993. Cerebral glioma: evaluation with methionine PET. *Radiology* 186,45-53
- Ogawa T, Kanno I, Hatazawa J, Inugami A, Fujita H, Shimosegawa E, Murakami M, Okudera T, Uemura K, Yasui N, 1994. Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. *Radiographics* 14,101-110

- Ogawa T, Inugami A, Fujita H, Hatazawa J, Shimosegawa E, Kanno I, Okudera T, Uemura K, Nagata K, 1995. Serial positron emission tomography with fludeoxyglucose F 18 in Creutzfeldt-Jakob disease. *Ajnr: American Journal of Neuroradiology* 16,978-981
- Ogawa T, Hatazawa J, Inugami A, Murakami M, Fujita H, Shimosegawa E, Noguchi K, Okudera T, Kanno I, Uemura K, 1995. Carbon-11-methionine PET evaluation of intracerebral hematoma: distinguishing neoplastic from non-neoplastic hematoma. *J.Nucl.Med.* 36,2175-2179
- Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K, 1996. CLINICAL POSITRON EMISSION TOMOGRAPHY FOR BRAIN TUMORS - COMPARISON OF FLUDEOXYGLUCOSE F 18 AND L-METHYL-C-11-METHIONINE. *Ajnr: American Journal of Neuroradiology* 17,345-353
- Ohta S, Meyer E, Thompson CJ, Gjedde A, 1992. Oxygen consumption of the living human brain measured after a single inhalation of positron emitting oxygen. *J.Cereb.Blood Flow Metab.* 12,179-192
- Ohya M, Senda M, Kitamura S, Ishii K, Mishina M, Terashi A, 1996. Role of the nondominant hemisphere and undamaged area during word repetition in poststroke aphasics. A PET activation study. *Stroke* 27,897-903
- Ojemann G, Ojemann J, Lettich E, Berger M, 1989. Cortical language localization in left, dominant hemisphere. *Journal of Neurosurgery* 71,316-326
- Ojemann JG, Miller JW, Silbergeld DL, 1996. Preserved function in brain invaded by tumor. *Neurosurgery* 39,253-258
- Ojemann JG, Neil JM, MacLeod AM, Silbergeld DL, Dacey RG, Jr., Petersen SE, Raichle ME, 1998. Increased functional vascular response in the region of a glioma. *J.Cereb.Blood Flow Metab.* 18,148-153
- Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, Kuyama J, Maruno H, Arimizu N, 1991. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. *J.Nucl.Med.* 32,686-691
- Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H, 2002. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease. *Am.J Psychiatry* 159,474-476

- Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M, 1997. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. *Nature* 385,634-636
- Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M, 2000. Serotonin 5-HT<sub>2</sub> receptors in schizophrenic patients studied by positron emission tomography. *Life Sci.* 66,2455-2464
- Olasz EB, Lang L, Seidel J, Green MV, Eckelman WC, Katz SI, 2002. Fluorine-18 labeled mouse bone marrow-derived dendritic cells can be detected in vivo by high resolution projection imaging. *J Immunol.Methods* 260,137-148
- Olson DM, Chugani HT, Shewmon DA, Phelps ME, Peacock WJ, 1990. Electrocorticographic confirmation of focal positron emission tomographic abnormalities in children with intractable epilepsy. *Epilepsia* 31,731-739
- Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, Kung MP, Kung HF, 2003. <sup>11</sup>C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimer's disease. *Nucl Med Biol.* 30,565-571
- Ooiwa Y, Uematsu Y, Terada T, Nakai K, Itakura T, Komai N, Moriwaki H, 1993. Cerebral blood flow in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. *Stroke* 24,304-309
- Oquendo MA, Placidi GP, Malone KM, Campbell C, Keilp J, Brodsky B, Kegeles LS, Cooper TB, Parsey RV, Van Heertum RL, Mann JJ, 2003. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. *Arch.Gen.Psychiatry* 60,14-22
- Osuch EA, Benson B, Geraci M, Podell D, Herscovitch P, McCann UD, Post RM, 2001. Regional cerebral blood flow correlated with flashback intensity in patients with posttraumatic stress disorder. *Biol.Psychiatry* 50,246-253
- Otsuka M, Ichiya Y, Kuwabara Y, Miyake Y, Tahara T, Masuda K, Hosokawa S, Goto I, Kato M, Ichimiya A, 1989. Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy. *Ann.Nucl Med* 3,111-118

- Otsuka M, Ichiya Y, Shima F, Kuwabara Y, Sasaki M, Fukumura T, Kato M, Masuda K, Goto I, 1992. Increased striatal 18F-dopa uptake and normal glucose metabolism in idiopathic dystonia syndrome. *J Neurol Sci.* 111,195-199
- Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Fukumura T, Masuda K, Goto I, Kato M, 1993. Cerebral glucose metabolism and striatal 18F-dopa uptake by PET in cases of chorea with or without dementia. *J Neurol Sci.* 115,153-157
- Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Kato M, Masuda K, 1996. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study. *J Neurol Sci.* 144,77-83
- Otsuka M, Kuwabara Y, Ichiya Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Kato M, Masuda K, 1997. Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG. *Ann.Nucl Med* 11,251-257
- Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M, 1999. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. *Ann.Neurol.* 46,723-731
- Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M, 1999. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography. *Ann.Neurol* 45,601-610
- Ouchi Y, Yoshikawa E, Futatsubashi M, Okada H, Torizuka T, Sakamoto M, 2002. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study. *J Cereb.Blood Flow Metab* 22,746-752
- Owen AM, Menon DK, Johnsrude IS, Bor D, Scott SK, Manly T, Williams EJ, Mummery C, Pickard JD, 2002. Detecting residual cognitive function in persistent vegetative state. *Neurocase.* 8,394-403
- Paans AM, Pruim J, Smit GP, Visser G, Willemsen AT, Ullrich K, 1996. Neurotransmitter positron emission tomographic-studies in adults with

- phenylketonuria, a pilot study. *European Journal of Pediatrics* 155 Suppl 1,S78-S81
- Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Goldstein DS, 2002. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. *Ann.N Y.Acad.Sci.* 970,170-176
- Padma MV, Jacobs M, Kraus G, Collins M, Dunigan K, Mantil J, 2001. 11C-methionine PET imaging of leptomeningeal metastases from primary breast cancer--a case report. *J Neurooncol.* 55,39-44
- Pal PK, Samii A, Calne DB, 1999. Manganese neurotoxicity: a review of clinical features, imaging and pathology. *Neurotoxicology* 20,227-238
- Pal PK, Lee CS, Samii A, Schulzer M, Stoessl AJ, Mak EK, Wudel J, Dobko T, Tsui JK, 2001. Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET. *Parkinsonism Relat Disord.* 7,305-309
- Paller KA, Acharya A, Richardson BC, Plaisant O, Shimamura AP, Reed BR, Jagust WJ, 1997. FUNCTIONAL NEUROIMAGING OF CORTICAL DYSFUNCTION IN ALCOHOLIC KORSAKOFFS SYNDROME. *Journal of Cognitive Neuroscience* 9,277-293
- Palsson S, Aevvarsson O, Skoog I, 1999. Depression, cerebral atrophy, cognitive performance and incidence of dementia. Population study of 85-year-olds. *Br.J.Psychiatry* 174,249-253
- Pantano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser MG, Comar D, 1984. Regional cerebral blood flow and oxygen consumption in human aging. *Stroke* 15,635-641
- Pantano P, Baron JC, Crouzel C, Collard P, Sirou P, Samson Y, 1985. The 15O continuous-inhalation method: correction for intravascular signal using C15O. *Eur.J.Nucl.Med.* 10,387-391
- Pantano P, Baron JC, Samson Y, Bousser MG, Derouesne C, Comar D, 1986. Crossed cerebellar diaschisis. Further studies. *Brain* 109,677-694
- Pantano P, Formisano R, Ricci M, Barbanti P, Fiorelli M, Sabatini U, Di Piero V, Lenzi GL, 1993. Prolonged muscular flaccidity in stroke patients is associated with crossed cerebellar diaschisis. *Cerebrovascular Diseases* 3,80-85

- Papathanassiou D, Etard O, Mellet E, Zago L, Mazoyer B, Tzourio-Mazoyer N, 2000. A common language network for comprehension and production: A contribution to the definition of language epicenters with PET [In Process Citation]. *Neuroimage*. 11,347-357
- Pappata S, Samson Y, Chavoix C, Prenant C, Maziere M, Baron JC, 1988. Regional specific binding of [<sup>11</sup>C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. *J.Cereb.Blood Flow Metab*. 8,304-313
- Pappata S, Mazoyer B, Tran Dinh S, Cambon H, Levasseur M, Baron JC, 1990. Effects of capsular or thalamic stroke on metabolism in the cortex and cerebellum: a positron tomography study. *Stroke* 21,519-524
- Pappata S, Chabriat H, Levasseur M, Legault-Demare F, Baron JC, 1994. Marchiafava-Bignami disease with dementia: severe cerebral metabolic depression revealed by PET. *J Neural Transm.Park Dis.Dement.Sect*. 8,131-137
- Pardo JV, Pardo PJ, Raichle ME, 1993. Neural correlates of self-induced dysphoria. *Am J Psychiatry* 150,713-719
- Pardo JV, Fox PT, 1993. Preoperative assessment of the cerebral hemisphere dominance for language with CBF PET. *Human Brain Mapping* 1,57-68
- Pardridge WM, 1997. DRUG DELIVERY TO THE BRAIN [Review]. *J.Cereb.Blood Flow Metab*. 17,713-731
- Pardridge WM, 1998. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. *Neurochem.Res* 23,635-644
- Pardridge WM, 2002. The blood brain barrier. In: Edvinsson L, Krause DN, eds. *Cerebral blood flow and metabolism* , Lippincott Williams & Wilkins, Philadelphia, Pa., pp 119-139
- Park YD, Hoffman JM, Radtke RA, DeLong GR, 1994. Focal cerebral metabolic abnormality in a patient with continuous spike waves during slow-wave sleep. *J Child Neurol* 9,139-143
- Parodi K, Enghardt W, Haberer T, 2002. In-beam PET measurements of beta+ radioactivity induced by proton beams. *Phys.Med Biol*. 47,21-36



- Parsey RV, Slifstein M, Hwang DR, Abi-Dargham A, Simpson N, Mawlawi O, Guo NN, Van Heertum R, Mann JJ, Laruelle M, 2000. Validation and reproducibility of measurement of 5-HT<sub>1A</sub> receptor parameters with [carbonyl-<sup>11</sup>C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. *J.Cereb.Blood Flow Metab.* 20,1111-1133
- Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, Slifstein M, Van Heertum RL, Mann JJ, Laruelle M, 2000. In vivo quantification of brain serotonin transporters in humans using [<sup>11</sup>C]McN 5652. *J Nucl Med* 41,1465-1477
- Parsey RV, Oquendo MA, Simpson NR, Ogden RT, Van Heertum R, Arango V, Mann JJ, 2002. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT(1A) receptor binding potential measured by PET using [C-<sup>11</sup>]WAY-100635. *Brain Res.* 954,173-182
- Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC, 2002. Imaging the metabolic footprint of Glut1 deficiency on the brain. *Ann.Neurol* 52,458-464
- Passchier J, van Waarde A, 2001. Visualisation of serotonin-1A (5-HT<sub>1A</sub>) receptors in the central nervous system. *Eur.J Nucl Med* 28,113-129
- Passchier J, Gee A, Willemsen A, Vaalburg W, van Waarde A, 2002. Measuring drug-related receptor occupancy with positron emission tomography. *Methods* 27,278-286
- Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, Ruth TJ, Calne DB, 1993. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. *Annals of Neurology* 34,331-338
- Paterson D, Nordberg A, 2000. Neuronal nicotinic receptors in the human brain [In Process Citation]. *Prog.Neurobiol.* 61,75-111
- Patlak CS, Blasberg RG, Fenstermacher JD, 1983. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. *J.Cereb.Blood Flow Metab.* 3,1-7
- Patlak CS, Blasberg RG, 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. *J.Cereb.Blood Flow Metab.* 5,584-590

- Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, O'Connor CM, 1982. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. *Radiology* 144,885-889
- Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM, 1985. Prediction of survival in glioma patients by means of positron emission tomography. *Journal of Neurosurgery* 62,816-822
- Paul AK, Tatsumi M, Yutani K, Fujino K, Hashikawa K, Nishimura T, 2002. Effects of iterative reconstruction on image contrast and lesion detection in gamma camera coincidence imaging in lung and breast cancers. *Nuclear Medicine Communications* 23,103-110
- Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Muller HW, Coenen HH, Langen KJ, 2003. Whole-body distribution and dosimetry of O-(2-[(18)F]fluoroethyl)-l-tyrosine. *Eur.J Nucl Med Mol.Imaging* 30,519-524
- Pauli S, Liljequist S, Farde L, Swahn CG, Halldin C, Litton JE, Sedvall G, 1992. PET analysis of alcohol interaction with the brain disposition of [11C]flumazenil. *Psychopharmacology* 107,180-185
- Paulson PE, Minoshima S, Morrow TJ, Casey KL, 1998. Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans. *Pain* 76,223-229
- Paulus W, Peiffer J, 1989. Intratumoral histologic heterogeneity of gliomas. A quantitative study. *Cancer* 64,442-447
- Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P, 2003. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. *Brain* 126,1127
- Pawlik G et al., 1985. Remote effects of focal lesions on cerebral blood flow and metabolism. In: Heiss WD, ed. *Functional mapping of the brain in vascular disorders*, Springer, Berlin, pp 59-84
- Pawlik G, Holthoff VA, Kessler J, Rudolf J, Hebold IR, Lottgen J, Heiss WD, 1990. Positron emission tomography findings relevant to neurosurgery for epilepsy. *Acta Neurochirurgica* 50 (Suppl.),84-87

- Pawlik G, 1991. Statistical analysis of functional neuroimaging data: exploratory versus inferential methods. [Review]. *J.Cereb.Blood Flow Metab.* 11,A136-A139
- Pawlik G, Fink GR, Kessler J, Heiss WD, 1994. PET and functional testing in temporal lobe epilepsy. *Acta Neurologica Scandinavica Supplementum* 1994;15,150-156
- Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM, Dannals RF, Wilson AA, Ravert HT, Wagner HN, Jr., 1995. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. *Arch Gen.Psychiatry* 52,471-477
- Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, McGeer PL, Phillips AG, Tsui JK, Calne DB, 1992. Cerebral glucose metabolism in Parkinson's disease with and without dementia. *Arch Neurol* 49,1262-1268
- Perani D, Cortelli P, Lucignani G, Montagna P, Tinuper P, Gallassi R, Gambetti P, Lenzi GL, Lugaresi E, Fazio F, 1993. [18F]FDG PET in fatal familial insomnia: the functional effects of thalamic lesions. *Neurology* 43,2565-2569
- Perani D, Vallar G, Paulesu E, Alberoni M, Fazio F, 1993. Left and right hemisphere contribution to recovery from neglect after right hemisphere damage--an [18F]FDG PET study of two cases. *Neuropsychologia* 31,115-125
- Perani D, Bressi S, Cappa SF, Vallar G, Alberoni M, Grassi F, Caltagirone C, Cipolotti L, Franceschi M, Lenzi GL, 1993. Evidence of multiple memory systems in the human brain. A [18F]FDG PET metabolic study. *Brain* 116,903-919
- Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, Savoirdo M, Caraceni T, Fazio F, 1995. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study. *Arch Neurol* 52,179-185
- Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, Bellodi L, Smeraldi E, Fazio F, 1995. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. *British Journal of Psychiatry* 166,244-250

- Perlmutter JS, Raichle ME, 1984. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. *Ann.Neurol* 15,228-233
- Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ, 1987. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. *Neurology* 37,1575-1579
- Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, Moerlein SM, 1997. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. *J Neurosci.* 17,843-850
- Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. *Neuroreport* 5,747-749
- Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK, 1990. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. *J Neurol.Sci.* 95,119-139
- Persson A, Ehrin E, Eriksson L, Farde L, Hedstrom CG, Litton JE, Mindus P, Sedvall G, 1985. Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. *J.Psychiatr.Res.* 19,609-622
- Pert CB, Danks JA, Channing MA, Eckelman WC, Larson SM, Bennett JM, Burke TR, Jr., Rice KC, 1984. 3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals. *FEBS Lett.* 177,281-286
- Petersen RC, 2000. Mild cognitive impairment or questionable dementia? [editorial; comment]. *Arch.Neurol.* 57,643-644
- Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, Dekosky ST, 2001. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 56,1133-1142
- Petersson KM, Nichols TE, Poline JB, Holmes AP, 1999. Statistical limitations in functional neuroimaging. I. Non-inferential methods and statistical models. *Philos.Trans.R.Soc.Lond B Biol.Sci.* 354,1239-1260

- Petersson KM, Nichols TE, Poline JB, Holmes AP, 1999. Statistical limitations in functional neuroimaging. II. Signal detection and statistical inference. *Philos.Trans.R.Soc.Lond B Biol.Sci.* 354,1261-1281
- Petit-Taboue MC, Baron JC, Barre L, Travers JM, Speckel D, Camsonne R, MacKenzie ET, 1991. Brain kinetics and specific binding of [<sup>11</sup>C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. *European Journal of Pharmacology* 200,347-351
- Petit-Taboue MC, Landeau B, Osmont A, Tillet I, Barre L, Baron JC, 1996. Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. *J.Nucl.Med.* 37,95-104
- Petit-Taboue MC, Landeau B, Desson JF, Desgranges B, Baron JC, 1998. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. *Neuroimage* 7,176-184
- Petit-Taboue MC, Landeau B, Barre L, Onfroy MC, Noel MH, Baron JC, 1999. Parametric PET imaging of 5HT<sub>2A</sub> receptor distribution with 18F-setoperone in the normal human neocortex. *J.Nucl.Med.* 40,25-32
- Petrovic P, Ingvar M, Stone-Elander S, Petersson KM, Hansson P, 1999. A PET activation study of dynamic mechanical allodynia in patients with mononeuropathy. *Pain* 83,459-470
- Petrovic P, Petersson KM, Ghatan PH, Stone-Elander S, Ingvar M, 2000. Pain-related cerebral activation is altered by a distracting cognitive task. *Pain* 85,19-30
- Petrovic P, Kalso E, Petersson KM, Ingvar M, 2002. Placebo and opioid analgesia-- imaging a shared neuronal network. *Science* 295,1737-1740
- Peyron R, Cinotti L, Le Bars D, Garcia-Larrea L, Galy G, Landais P, Millet P, Lavenne F, Froment JC, Krosgaard-Larsen P, 1994. Effects of GABAA receptors activation on brain glucose metabolism in normal subjects and temporal lobe epilepsy (TLE) patients. A positron emission tomography (PET) study. Part II: The focal hypometabolism is reactive to GABAA agonist administration in TLE. *Epilepsy Research* 19,55-62
- Peyron R, Larrea L, Gregoire MC, Costes N, Convers P, Lavenne F, Mauguiere F, Michel D, Laurent B, 1999. Haemodynamic brain responses to acute pain in humans: Sensory and attentional networks. *Brain* 122,1765-1780

- Peyron R, Laurent B, Garcia-Larrea L, 2000. Functional imaging of brain responses to pain. A review and meta-analysis. *Neurophysiol.Clin.* 30,263-288
- Pezzoli G, Antonini A, Barbieri S, Canesi M, Perbellini L, Zecchinelli A, Mariani CB, Bonetti A, Leenders KL, 1995. n-Hexane-induced parkinsonism: pathogenetic hypotheses. *Mov Disord.* 10,279-282
- Pfund Z, Chugani DC, Juhasz C, Muzik O, Chugani HT, Wilds IB, Seraji-Bozorgzad N, Moore GJ, 2000. Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and <sup>1</sup>H magnetic resonance spectroscopy in patients with epilepsy. *J Cereb.Blood Flow Metab* 20,871-878
- Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE, 1979. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. *Annals of Neurology* 6,371-388
- Phelps ME, Kuhl DE, Mazziotta JC, 1981. Metabolic mapping of the brain's response to visual stimulation: studies in humans. *Science* 211,1445-1448
- Phelps ME, Barrio JR, Huang SC, Keen RE, Chugani H, Mazziotta JC, 1984. Criteria for the tracer kinetic measurement of cerebral protein synthesis in humans with positron emission tomography. *Annals of Neurology* 15 Suppl,S192-S202
- Phillips PC, Dhawan V, Strother SC, Sidtis JJ, Evans AC, Allen JC, Rottenberg DA, 1987. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. *Annals of Neurology* 21,59-63
- Phillips PC, Moeller JR, Sidtis JJ, Dhawan V, Steinherz PG, Strother SC, Ginos JZ, Rottenberg DA, 1991. Abnormal cerebral glucose metabolism in long-term survivors of childhood acute lymphocytic leukemia. *Annals of Neurology* 29,263-271
- Phillips RL, London ED, Links JM, Cascella NG, 1990. Program for PET image alignment: effects on calculated differences in cerebral metabolic rates for glucose. *J Nucl Med* 31,2052-2057
- Picard F, Saint-Martin A, Salmon E, Hirsch E, Marescaux C, 1996. Postencephalitic stereotyped involuntary movements responsive to L-Dopa. *Mov Disord.* 11,567-570

- Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA, Mark MH, Maraganore DM, Lees AJ, Brooks DJ, 1997. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. *Ann.Neurol* 41,222-229
- Piccini P, Weeks RA, Brooks DJ, 1997. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. *Ann.Neurol* 42,720-726
- Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehnström S, Widner H, Lindvall O, 1999. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. *Nat.Neurosci.* 2,1137-1140
- Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ, 1999. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. *Ann.Neurol.* 45,577-582
- Piccini P, Lindvall O, Björklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehnström S, Widner H, Brooks DJ, 2000. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. *Ann.Neurol.* 48,689-695
- Piccini P, de Yebenez J, Lees AJ, Ceravolo R, Turjanski N, Pramstaller P, Brooks DJ, 2001. Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. *Arch.Neurol.* 58,1846-1851
- Piccini P, Pavese N, Brooks DJ, 2003. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. *Ann.Neurol* 53,647-653
- Pickar D, Su TP, Weinberger DR, Coppola R, Malhotra AK, Knable MB, Lee KS, Gorey J, Bartko JJ, Breier A, Hsiao J, 1996. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. *American Journal of Psychiatry* 153,1571-1578
- Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE, 1996. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. *J.Nucl.Med.* 37,201-208
- Pietrini P, Dani A, Furey ML, Alexander GE, Freo U, Grady CL, Mentis, MJ, Mangot D, Simon EW, Horwitz B, Haxby JV, Schapiro MB, 1997. LOW GLUCOSE METABOLISM DURING BRAIN STIMULATION IN OLDER

- DOWNS SYNDROME SUBJECTS AT RISK FOR ALZHEIMERS DISEASE PRIOR TO DEMENTIA. *American Journal of Psychiatry* 154,1063-1069
- Pietrini P, Furey ML, Alexander GE, Mentis MJ, Dani A, Guazzelli M, Rapoport SI, Schapiro MB, 1999. Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study. *Am.J.Psychiatry* 156,470-473
- Pietrzyk U, Herholz K, Heiss WD, 1990. Three-dimensional alignment of functional and morphological tomograms. *Journal of Computer Assisted Tomography* 14,51-59
- Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Wörker M, Heiss WD, 1994. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. *J.Nucl.Med.* 35,2011-2018
- Pietrzyk U, Herholz K, Schuster A, von Stockhausen HM, Lucht H, Heiss WD, 1996. Clinical applications of registration and fusion of multimodality brain images from PET, SPECT, CT, and MRI. *European Journal of Radiology* 21,174-182
- Pietrzyk U, Thiel A, Herholz K, Heiss WD, 1998. A hybrid image registration method employing interactive and automated techniques. *Neuroimage* 7 (Suppl.),S789
- Pietrzyk U, 2001. Registration of MRI and PET images for clinical applications. In: Hajnal JV et al., eds. *Medical image registration* , CRC Press, Boca Raton, pp 199-216
- Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, Sargent PA, Bench CJ, Cliffe IA, Fletcher A, Grasby PM, 1996. Exquisite delineation of 5-HT<sub>1A</sub> receptors in human brain with PET and [carbonyl-11 C]WAY-100635. *Eur.J.Pharmacol.* 301,R5-R7
- Pike VW, Halldin C, Wikstrom H, Marchais S, McCarron JA, Sandell J, Nowicki B, Swahn CG, Osman S, Hume SP, Constantinou M, Andree B, Farde L, 2000. Radioligands for the study of brain 5-HT(1A) receptors in vivo--development of some new analogues of way. *Nucl Med Biol.* 27,449-455
- Pirotte B, Goldman S, Salzberg S, Wikler D, David P, Vandesteene A, Van Bogaert P, Salmon I, Brotchi J, Levivier M, 2003. Combined positron emission tomography and magnetic resonance imaging for the planning of



- stereotactic brain biopsies in children: experience in 9 cases.  
*Pediatr. Neurosurg* 38,146-155
- Pisani P, Guzzardi R, Bellina CR, Sorace O, 1991. User-friendly image processing software tools: general purpose features and application to the correlation of PET-CT brain images. *Medical Progress through Technology* 17,205-209
- Pissiota A, Frans O, Fernandez M, von Knorring L, Fischer H, Fredrikson M, 2002. Neurofunctional correlates of posttraumatic stress disorder: a PET symptom provocation study. *Eur. Arch Psychiatry Clin. Neurosci.* 252,68-75
- Pitman AG, Hicks RJ, Binns DS, Ware RE, Kalff V, McKenzie AF, Ball DL, MacManus MP, 2002. Performance of sodium iodide based (18)F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses. *Br.J Radiol.* 75,114-121
- Pizzamiglio L, Perani D, Cappa SF, Vallar G, Paolucci S, Grassi F, Paulesu E, Fazio F, 1998. Recovery of neglect after right hemispheric damage: H2(15)O positron emission tomographic activation study. *Arch. Neurol.* 55,561-568
- Planas AM et al., 1993. Protein synthesis studies in rats with methionine. In: Mazoyer B et al., eds. *PET studies on amino acid metabolism and protein synthesis*, Kluwer Academic Publishers, Dordrecht, pp 53-68
- Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ, 1992. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. *Ann. Neurol.* 32,151-161
- Playford ED, Passingham RE, Marsden CD, Brooks DJ, 1998. Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. *Mov Disord.* 13,309-318
- Plum F, Schiff N, Ribary U, Llinas R, 1998. Coordinated expression in chronically unconscious persons. *Philos. Trans. R. Soc. Lond B Biol. Sci.* 353,1929-1933
- Podruchny TA, Connolly C, Bokde A, Herscovitch P, Eckelman WC, Kiesewetter DO, Sunderland T, Carson RE, Cohen RM, 2003. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. *Synapse* 48,39-44

- Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J, 1998. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. *Am J Psychiatry* 155,768-773
- Pohjalainen T, Rinne JO, Nagren K, Lehtikainen P, Anttila K, Syvalahti EK, Hietala J, 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. *Mol.Psychiatry* 3,256-260
- Poline JB, Worsley KJ, Holmes AP, Frackowiak RS, Friston KJ, 1995. Estimating smoothness in statistical parametric maps: variability of p values. *Journal of Computer Assisted Tomography* 19,788-796
- Poline JB, Worsley KJ, Evans AC, Friston KJ, 1997. Combining spatial extent and peak intensity to test for activations in functional imaging. *Neuroimage* 5,83-96
- Pomper MG, Kochanny MJ, Thieme AM, Carlson KE, VanBrocklin HF, Mathias CJ, Welch MJ, Katzenellenbogen JA, 1992. Fluorine-substituted corticosteroids: synthesis and evaluation as potential receptor-based imaging agents for positron emission tomography of the brain. *Int.J Rad.Appl.Instrum.B* 19,461-480
- Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, Tjuvajev JG, 2001. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. *Neoplasia*. 3,480-488
- Potkin SG, Buchsbaum MS, Jin Y, Tang C, Telford J, Friedman G, Lottenberg S, Najafi A, Gulasekaram B, Costa J, ., 1994. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. *J Clin.Psychiatry* 55 Suppl B,63-66
- Powers WJ, Grubb RL, Jr., Darriet D, Raichle ME, 1985. Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. *J.Cereb.Blood Flow Metab.* 5,600-608
- Powers WJ, Press GA, Grubb RL, Jr., Gado M, Raichle ME, 1987. The effect of hemodynamically significant carotid artery disease on the hemodynamic status of the cerebral circulation. *Ann.Intern.Med* 106,27-34
- Powers WJ, Fox PT, Raichle ME, 1988. The effect of carotid artery disease on the cerebrovascular response to physiologic stimulation. *Neurology* 38,1475-1478

- Powers WJ, Grubb RL, Jr., Raichle ME, 1989. Clinical results of extracranial-intracranial bypass surgery in patients with hemodynamic cerebrovascular disease. *J Neurosurg* 70,61-67
- Powers WJ, Berg L, Perlmutter JS, Raichle ME, 1991. Technology assessment revisited: does positron emission tomography have proven clinical efficacy? [see comments]. *Neurology* 41,1339-1340
- Powers WJ, Perlmutter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, Siegel BA, Morris JC, Berg L, 1992. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. *Neurology* 42,765-770
- Powers WJ, Dagogo-Jack S, Markham J, Larson KB, Dence CS, 1995. Cerebral transport and metabolism of 1-11C-D-glucose during stepped hypoglycemia. *Annals of Neurology* 38,599-609
- Powers WJ, Rosenbaum JL, Dence CS, Markham J, Videen TO, 1998. Cerebral glucose transport and metabolism in preterm human infants. *J Cereb.Blood Flow Metab* 18,632-638
- Powers WJ, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Grubb RL, Jr., 2000. Benign prognosis of never-symptomatic carotid occlusion. *Neurology* 54,878-882
- Poyot T, Conde F, Gregoire MC, Frouin V, Coulon C, Fuseau C, Hinnen F, Dolle F, Hantraye P, Bottlaender M, 2001. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. *J Cereb.Blood Flow Metab* 21,782-792
- Pozzilli C, Itoh M, Matsuzawa T, Fukuda H, Abe Y, Sato T, Takeda S, Ido T, 1987. Positron emission tomography in minor ischemic stroke using oxygen-15 steady-state technique. *J Cereb.Blood Flow Metab* 7,137-142
- Pozzilli C, Bernardi S, Mansi L, Picozzi P, Iannotti F, Alfano B, Bozzao L, Lenzi GL, Salvatore M, Conforti P, 1988. Quantitative assessment of blood-brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography. *J Neurol Neurosurg Psychiatry* 51,1058-1062
- Pozzilli C, Fieschi C, Perani D, Paulesu E, Comi G, Bastianello S, Bernardi S, Bettinardi V, Bozzao L, Canal N, ., 1992. Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. *J Neurol Sci.* 112,51-57

- Prevett MC, Cunningham VJ, Brooks DJ, Fish DR, Duncan JS, 1994. Opiate receptors in idiopathic generalised epilepsy measured with [11C]diprenorphine and positron emission tomography. *Epilepsy Res* 19,71-77
- Price JC, Mayberg HS, Dannals RF, Wilson AA, Ravert HT, Sadzot B, Rattner Z, Kimball A, Feldman MA, Frost JJ, 1993. Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]flumazenil. *J.Cereb.Blood Flow Metab.* 13,656-667
- Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA, 2001. Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans. *Synapse* 41,11-21
- Price JC, Drevets WC, Ruszkiewicz J, Greer PJ, Villemagne VL, Xu L, Mazumdar S, Cantwell MN, Mathis CA, 2002. Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. *J Nucl Med* 43,1090-1100
- Pruim J, Willemsen ATM, Molenaar WM, Vanwaarde A, Paans AMJ, Heesters MAAM, Go KG, Visser GM, Franssen EJF, Vaalburg W, 1995. Brain tumors - L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. *Radiology* 197,221-226
- Przedborski S, Goldman S, Levivier M, Giladi N, Bidaut LM, Hildebrand J, Stanus E, Labar D, Luxen A, 1993. Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome. *Mov Disord.* 8,391-395
- Przedborski S, Dhawan V, Donaldson DM, Murphy PL, McKennayasek D, Mandel FS, Brown RH, Eidelberg D, 1996. NIGROSTRIATAL DOPAMINERGIC FUNCTION IN FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS PATIENTS WITH AND WITHOUT COPPER/ZINC SUPEROXIDE DISMUTASE MUTATIONS. *Neurology* 47,1546-1551
- Quarles RP, Mintun MA, Larson KB, Markham J, MacLeod AM, Raichle ME, 1993. Measurement of regional cerebral blood flow with positron emission tomography: a comparison of [15O]water to [11C]butanol with distributed-parameter and compartmental models. *J.Cereb.Blood Flow Metab.* 13,733-747

- Rabiner EA, Gunn RN, Wilkins MR, Sargent PA, Mocaer E, Sedman E, Cowen PJ, Grasby PM, 2000. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. *Nuclear Medicine & Biology* 27,509-513
- Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, Meyer JH, Bench CJ, Harrison PJ, Pazos A, Sharp T, Grasby PM, 2000. Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. *Neuropsychopharmacology* 23,285-293
- Rabiner EA, Wilkins MR, Turkheimer F, Gunn RN, de Haes JU, de Vries M, Grasby PM, 2002. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxyn-5-yl)-1-piperazinyl]butyl]-1, 2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. *J Pharmacol.Exp.Ther.* 301,1144-1150
- Rabiner EA, Messa C, Sargent PA, Husted-Kjaer K, Montgomery A, Lawrence AD, Bench CJ, Gunn RN, Cowen P, Grasby PM, 2002. A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables. *Neuroimage* 15,620-632
- Radanov BP, Bick I, Dvorak J, Antinnes J, von Schulthess GK, Buck A, 1999. Relation between neuropsychological and neuroimaging findings in patients with late whiplash syndrome. *J.Neurol.Neurosurg.Psychiatry* 66,485-489
- Rademacher J, Caviness VS, Jr., Steinmetz H, Galaburda AM, 1993. Topographical variation of the human primary cortices: implications for neuroimaging, brain mapping, and neurobiology. *Cerebral Cortex* 3,313-329
- Radtke RA, Hanson MW, Hoffman JM, Crain BJ, Walczak TS, Lewis DV, Beam C, Coleman RE, Friedman AH, 1993. Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy [see comments]. *Neurology* 43,1088-1092

- Ragland JD, Gur RC, Glahn DC, Censits DM, Smith RJ, Lazarev MG, Alavi A, Gur RE, 1998. Frontotemporal cerebral blood flow change during executive and declarative memory tasks in schizophrenia: a positron emission tomography study. *Neuropsychology* 12,399-413
- Ragland JD, Gur RC, Raz J, Schroeder L, Kohler CG, Smith RJ, Alavi A, Gur RE, 2001. Effect of schizophrenia on frontotemporal activity during word encoding and recognition: a PET cerebral blood flow study. *Am J Psychiatry* 158,1114-1125
- Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J, 1983. Brain blood flow measured with intravenous H<sub>2</sub>(15)O. II. Implementation and validation. *J.Nucl.Med.* 24,790-798
- Raine A, Buchsbaum MS, Stanley J, Lottenberg S, Abel L, Stoddard J, 1994. Selective reductions in prefrontal glucose metabolism in murderers. *Biol.Psychiatry* 36,365-373
- Raine A, Buchsbaum M, LaCasse L, 1997. Brain abnormalities in murderers indicated by positron emission tomography. *Biol.Psychiatry* 42,495-508
- Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC, 1997. Pain affect encoded in human anterior cingulate but not somatosensory cortex. *Science* 277,968-971
- Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, Dagher A, Jenkins IH, Friston KJ, Brooks DJ, 1999. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. *Brain* 122,1637-1650
- Ranicar AS, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, Jones T, 1991. The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. *Medical Progress through Technology* 17,259-264
- Rascol O, Sabatini U, Fabre N, Brefel C, Loubinoux I, Celsis P, Senard JM, Montastruc JL, Chollet F, 1997. THE IPSILATERAL CEREBELLAR HEMISPHERE IS OVERACTIVE DURING HAND MOVEMENTS IN AKINETIC PARKINSONIAN PATIENTS. *Brain* 120,103-110
- Rasgon NL, Small GW, Siddarth P, Miller K, Ercoli LM, Bookheimer SY, Lavretsky H, Huang SC, Barrio JR, Phelps ME, 2001. Estrogen use and brain metabolic change in older adults. A preliminary report. *Psychiatry Res.* 107,11-18

- Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, Fischman AJ, 1994. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography [see comments]. *Arch Gen Psychiatry* 51,62-70
- Rauch SL, Savage CR, Brown HD, Curran T, Alpert NM, Kendrick A, Fischman AJ, Kosslyn SM, 1995. A PET investigation of implicit and explicit sequence learning. *Human Brain Mapping* 3,271-286
- Rauch SL, Savage CR, Alpert NM, Dougherty D, Kendrick A, Curran T, Brown HD, Manzo P, Fischman AJ, Jenike MA, 1997. Probing striatal function in obsessive-compulsive disorder: a PET study of implicit sequence learning. *J Neuropsychiatry Clin.Neurosci.* 9,568-573
- Rauch SL, Dougherty DD, Cosgrove GR, Cassem EH, Alpert NM, Price BH, Nierenberg AA, Mayberg HS, Baer L, Jenike MA, Fischman AJ, 2001. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. *Biol.Psychiatry* 50,659-667
- Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA, 2002. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. *Neuropsychopharmacology* 27,782-791
- Rausch R, Henry TR, Ary CM, Engel J, Jr., Mazziotta J, 1994. Asymmetric interictal glucose hypometabolism and cognitive performance in epileptic patients. *Arch.Neurol.* 51,139-144
- Ray P, Wu AM, Gambhir SS, 2003. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. *Cancer Res.* 63,1160-1165
- Raylman RR, Hammer BE, Christensen NL, 1996. Combined MRI-PET scanner: A Monte Carlo evaluation of the improvements in PET resolution due to the effects of a static homogeneous magnetic field. *IEEE Transactions on Nuclear Science* 43,2406-2412
- Read SJ, Hirano T, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Chan JG, Egan GF, Scott AM, Bladin CF, McKay WJ, Donnan GA, 1998. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. *Neurology* 51,1617-1621

- Read SJ, Hirano T, Abbott DF, Markus R, Sachinidis JI, Tochon-Danguy HJ, Chan JG, Egan GF, Scott AM, Bladin CF, McKay WJ, Donnan GA, 2000. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. *Ann.Neurol* 48,228-235
- Reader AJ, Ally S, Bakatselos F, Manavaki R, Walledge RJ, Jeavons AP, Julyan PJ, Zhao S, Hastings DL, Zweit J, 2002. One-pass list-mode EM algorithm for high-resolution 3-D PET image reconstruction into large arrays. *IEEE Transactions on Nuclear Science* 49,693-699
- Redies C, Hoffer LJ, Beil C, Marliss EB, Evans AC, Lariviere F, Marrett S, Meyer E, Diksic M, Gjedde A, 1989. Generalized decrease in brain glucose metabolism during fasting in humans studied by PET. *American Journal of Physiology* 256,E805-E810
- Reed BR, Eberling JL, Mungas D, Weiner MW, Jagust WJ, 2000. Memory failure has different mechanisms in subcortical stroke and Alzheimer's disease. *Ann.Neurol.* 48,275-284
- Reed LJ, Marsden P, Lasserson D, Sheldon N, Lewis P, Stanhope N, Guinan E, Kopelman MD, 1999. FDG-PET analysis and findings in amnesia resulting from hypoxia. *Memory* 7,599-612
- Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, Keir G, Rudge P, 2001. The role of [(18)F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. *Brain* 124,2223-2231
- Reid MC, Lachs MS, Feinstein AR, 1995. Use of methodological standards in diagnostic test research. Getting better but still not good. *JAMA* 274,645-651
- Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P, Perlmutter J, 1986. The application of positron emission tomography to the study of panic disorder. *Am J Psychiatry* 143,469-477
- Reiman EM, Fusselman MJ, Fox PT, Raichle ME, 1989. Neuroanatomical correlates of anticipatory anxiety. *Science* 243,1071-1074
- Reiman EM, Raichle ME, Robins E, Mintun MA, Fusselman MJ, Fox PT, Price JL, Hackman KA, 1989. Neuroanatomical correlates of a lactate-induced anxiety attack. *Arch Gen.Psychiatry* 46,493-500



- Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D, 1996. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. *New England Journal of Medicine* 334,752-758
- Reiman EM, 1997. The application of positron emission tomography to the study of normal and pathologic emotions. *J Clin.Psychiatry* 58 Suppl 16,4-12
- Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J, 2001. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. *Proc.Natl.Acad.Sci.U.S.A* 98,3334-3339
- Reinders AA, Paans AM, de Jong BM, den Boer JA, Willemsen AT, 2002. Iterative versus filtered backprojection reconstruction for statistical parametric mapping of PET activation measurements: a comparative case study. *Neuroimage* 15,175-181
- Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H, 1997. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. *J.Nucl.Med.* 38,280-287
- Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, 1994. Elevated dopa decarboxylase activity in living brain of patients with psychosis. *Proc.Natl.Acad.Sci.USA* 91,11651-11654
- Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L, 1979. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. *Circulation Research* 44,127-137
- Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, MacGregor RR, Shiue CY, Atkins H, Anand A, 1985. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. *J.Cereb.Blood Flow Metab.* 5,179-192
- Remington G, Kapur S, Zipursky R, 1998. The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study. *J Clin.Psychopharmacol.* 18,82-83

- Remington G, Kapur S, 1999. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. *J Clin.Psychiatry* 60 Suppl 10,15-19
- Reske SN, Kotzerke J, 2001. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. *Eur.J Nucl Med* 28,1707-1723
- Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, Thomas DG, Jones T, 1983. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. *Annals of Neurology* 14,614-626
- Riachi NJ, Arora PK, Sayre LM, Harik SI, 1988. Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease. *J Neurochem.* 50,1319-1321
- Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, Dolle F, Peschanski M, Hantraye P, Cesaro P, Samson Y, Remy P, 2002. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. *Arch.Neurol.* 59,580-586
- Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, Bolander H, Bergstrom M, Smits A, 2001. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. *Cancer* 92,1541-1549
- Ribom D, Engler H, Blomquist E, Smits A, 2002. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. *Eur.J Nucl Med* 29,632-640
- Ricaurte GA, McCann UD, Szabo Z, Scheffel U, 2000. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). *Toxicol.Lett.* 112-113,143-146
- Ricaurte GA, Yuan J, Hatzidimitriou G, Branden JC, McCann UD, 2003. Retraction. *Science* 301,1479
- Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP, 1998. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? [see comments]. *AJNR.Am.J.Neuroradiol.* 19,407-413

- Richardson MP, Koepp MJ, Brooks DJ, Duncan JS, 1998. 11C-flumazenil PET in neocortical epilepsy. *Neurology* 51,485-492
- Richardson MP, Koepp MJ, Brooks DJ, Coull JT, Grasby P, Fish DR, Duncan JS, 1998. Cerebral activation in malformations of cortical development. *Brain* 121,1295-1304
- Richardson MP, Hammers A, Brooks DJ, Duncan JS, 2001. Benzodiazepine-GABA(A) receptor binding is very low in dysembryoplastic neuroepithelial tumor: a PET study. *Epilepsia* 42,1327-1334
- Richardson MP, 2003. Epilepsy and surgical mapping. *Br.Med Bull.* 65,179-192
- Ricker JH, Zafonte RD, 2000. Functional neuroimaging and quantitative electroencephalography in adult traumatic head injury: clinical applications and interpretive cautions. *J.Head Trauma Rehabil.* 15,859-868
- Ricker JH, Muller RA, Zafonte RD, Black KM, Millis SR, Chugani H, 2001. Verbal recall and recognition following traumatic brain injury: a [0-15]-water positron emission tomography study. *J Clin.Exp.Neuropsychol.* 23,196-206
- Rinne JO, Laihin A, Nagren K, Bergman J, Solin O, Haaparanta M, Ruotsalainen U, Rinne UK, 1990. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. *J Neurosci.Res.* 27,494-499
- Rinne JO, Hietala J, Ruotsalainen U, Sako E, Laihin A, Nagren K, Lehtikoinen P, Oikonen V, Syvalahti E, 1993. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. *J.Cereb.Blood Flow Metab.* 13,310-314
- Rinne JO, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ, 1995. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. *Ann.Neurol* 37,568-573
- Rinne JO, Hublin C, Partinen M, Ruottinen H, Ruotsalainen U, Nagren K, Lehtikoinen P, Laihin A, 1995. Positron emission tomography study of human narcolepsy: no increase in striatal dopamine D2 receptors. *Neurology* 45,1735-1738

- Rinne JO, Hublin C, Partinen M, Ruottinen H, Nagren K, Lehtikainen P, Ruotsalainen U, Laihin A, 1996. Striatal dopamine D1 receptors in narcolepsy: a PET study with [11C]NNC 756. *J Sleep Res* 5,262-264
- Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O, 1999. Usefulness of a dopamine transporter PET ligand [(18F)]beta-CFT in assessing disability in Parkinson's disease. *J.Neurol.Neurosurg.Psychiatry* 67,737-741
- Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O, 2000. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. *Arch Neurol* 57,470-475
- Rintahaka PJ, Chugani HT, Sankar R, 1995. Landau-Kleffner syndrome with continuous spikes and waves during slow-wave sleep. *Journal of Child Neurology* 10,127-133
- Ritchie K, Gilham C, Ledesert B, Touchon J, Kotzki PO, 1999. Depressive illness, depressive symptomatology and regional cerebral blood flow in elderly people with sub-clinical cognitive impairment. *Age Ageing* 28,385-391
- Rizzo G, Gilardi MC, Prinster A, Grassi F, Scotti G, Cerutti S, Fazio F, 1995. An elastic computerized brain atlas for the analysis of clinical PET/SPET data. *Eur.J.Nucl.Med.* 22,1313-1318
- Robert G, Milne R, 1999. Positron emission tomography: establishing priorities for health technology assessment. *Health Technol.Assess.* 3,1-54
- Roberts MA, Manshadi FF, Bushnell DL, Hines ME, 1995. Neurobehavioural dysfunction following mild traumatic brain injury in childhood: a case report with positive findings on positron emission tomography (PET). *Brain Inj.* 9,427-436
- Roelcke U, Radu EW, von Ammon K, Hausmann O, Maguire RP, Leenders KL, 1995. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. *Journal of the Neurological Sciences* 132,20-27
- Roelcke U, Kappos L, Lechner-Schott J, Brunnenschweiler H, Huber S, Ammann W, Plohm A, Dellas S, Maguire RP, Missimer J, Radu EW, Steck A, Leenders KL, 1997. REDUCED GLUCOSE METABOLISM IN THE FRONTAL CORTEX AND BASAL GANGLIA OF MULTIPLE SCLEROSIS

- PATIENTS WITH FATIGUE - A F-18- FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY STUDY. *Neurology* 48,1566-1571
- Roelcke U, Blasberg RG, von AK, Hofer S, Vontobel P, Maguire RP, Radu EW, Herrmann R, Leenders KL, 1998. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. *J.Nucl.Med.* 39,879-884
- Roelcke U, Radu EW, Hausmann O, Vontobel P, Maguire RP, Leenders KL, 1998. Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. *J.Neurooncol.* 36,279-283
- Rogers BE, McLean SF, Kirkman RL, Della MD, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ, 1999. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. *Clin.Cancer Res.* 5,383-393
- Rohren EM, Provenzale JM, Barboriak DP, Coleman RE, 2003. Screening for Cerebral Metastases with FDG PET in Patients Undergoing Whole-Body Staging of Non-Central Nervous System Malignancy. *Radiology* 226,181-187
- Romanowski CA, Leslie DF, Thurffjell L, Ericson K, Stone-Elander S, 1997. Construction of a standard reference for PET studies of methionine accumulation using a computerised brain atlas. *Neuroradiology* 39,389-393
- Rose JE, Behm FM, Westman EC, Mathew RJ, London ED, Hawk TC, Turkington TG, Coleman RE, 2003. PET studies of the influences of nicotine on neural systems in cigarette smokers. *Am J Psychiatry* 160,323-333
- Rosenow F, Herholz K, Lanfermann H, Weuthen G, Ebner R, Kessler J, Ghaemi M, Heiss WD, 1995. Neurological sequelae of cyanide intoxication--the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings. *Ann.Neurol* 38,825-828
- Rosenthal G, Gilman S, Koeppe RA, Kluin KJ, Markel DS, Junck L, Gebarski SS, 1988. Motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studied with positron emission tomography. *Ann.Neurol* 24,414-419

- Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L, 1996. Visualisation of loss of 5-HT<sub>2A</sub> receptors with age in healthy volunteers using [<sup>18</sup>F]altanserin and positron emission tomographic imaging. *Psychiatry Res.* 68,11-22
- Rothman DL, Behar KL, Hyder F, Shulman RG, 2003. In Vivo NMR Studies of the Glutamate Neurotransmitter Flux and Neuroenergetics: Implications for Brain Function. *Annu.Rev.Physiol* eprint,
- Rottenberg DA, Ginos JZ, Kearfott KJ, Junck L, Dhawan V, Jarden JO, 1985. In vivo measurement of brain tumor pH using [<sup>11</sup>C]DMO and positron emission tomography. *Annals of Neurology* 17,70-79
- Rottenberg DA, Strother SC, Moeller JR, 1989. In defense of quantitative PET techniques [letter]. *J.Nucl.Med.* 30,564
- Rougemont D, Baron JC, Collard P, Bustany P, Comar D, Agid Y, 1984. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry* 47,824-830
- Rousset OG, Deep P, Kuwabara H, Evans AC, Gjedde AH, Cumming P, 2000. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(<sup>18</sup>F)]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects. *Synapse* 37,81-89
- Rozental JM, Levine RL, Nickles RJ, Dobkin JA, 1989. Glucose uptake by gliomas after treatment. A positron emission tomographic study. *Arch.Neurol.* 46,1302-1307
- Rudolf J, Grond M, Schindler D, Heiss WD, Desnick RJ, 1999. Cerebral glucose metabolism in type I alpha-N-acetylgalactosaminidase deficiency: an infantile neuroaxonal dystrophy. *J.Child Neurol.* 14,543-547
- Rudolf J, Sobesky J, Grond M, Heiss WD, 2000. Identification by positron emission tomography of neuronal loss in acute vegetative state. *Lancet* 355,115-116
- Rudolf J, Sobesky J, Ghaemi M, Heiss WD, 2002. The correlation between cerebral glucose metabolism and benzodiazepine receptor density in the acute vegetative state. *Eur.J Neurol* 9,671-677

- Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinien AO, Rinne UK, 1995. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. *Journal of Neural Transmission - Parkinsons Disease & Dementia* Section 10,91-106
- Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK, 1997. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. *Synapse* 27,336-346
- Rutschmann OT, Matchar DB, 2002. Usefulness of positron emission tomography in evaluating dementia. *JAMA* 287,985-986
- Rutten GJ, Ramsey NF, van Rijen PC, Noordmans HJ, van Veelen CW, 2002. Development of a functional magnetic resonance imaging protocol for intraoperative localization of critical temporoparietal language areas. *Ann.Neurol.* 51,350-360
- Ryvlin P, Bouvard S, Le Bars D, De Lamerie G, Gregoire MC, Kahane P, Froment JC, Mauguiere F, 1998. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. *Brain* 121,2067-2081
- Sabbah P, Chassoux F, Leveque C, Landre E, Baudoin-Chial S, Devaux B, Mann M, Godon-Hardy S, Nioche C, Ait-Ameur A, 2003. Functional MR imaging in assessment of language dominance in epileptic patients. *Neuroimage* 18,460-467
- Sachdev P, Trollor J, Walker A, Wen W, Fulham M, Smith JS, Matheson J, 2001. Bilateral orbitomedial leucotomy for obsessive-compulsive disorder: a single-case study using positron emission tomography. *Aust.N Z.J Psychiatry* 35,684-690
- Sachs H, Wolf A, Russell JA, Christman DR, 1986. Effect of reserpine on regional cerebral glucose metabolism in control and migraine subjects. *Arch Neurol* 43,1117-1123
- Sachs H, Russell JA, Christman DR, Cook B, 1987. Alteration of regional cerebral glucose metabolic rate in non-Korsakoff chronic alcoholism. *Arch Neurol* 44,1242-1251

- Sackellares JC, Siegel GJ, Abou-Khalil BW, Hood TW, Gilman S, McKeever PE, Hichwa RD, Hutchins GD, 1990. Differences between lateral and mesial temporal metabolism interictally in epilepsy of mesial temporal origin. *Neurology* 40,1420-1426
- Sadzot B, Price JC, Mayberg HS, Douglass KH, Dannals RF, Lever JR, Ravert HT, Wilson AA, Wagner HN, Jr., Feldman MA, ., 1991. Quantification of human opiate receptor concentration and affinity using high and low specific activity [<sup>11</sup>C]diprenorphine and positron emission tomography. *J Cereb.Blood Flow Metab* 11,204-219
- Sadzot B, Maquet P, Franck G, 1995. Is positron emission tomography a useful tool for studying migraine? *Cephalalgia* 15,316-322
- Saji H, Magata Y, Yamada Y, Tajima K, Yonekura Y, Konishi J, Ohmomo Y, Yokoyama A, 1992. Synthesis of (S)-N-[methyl-<sup>11</sup>C]nicotine and its regional distribution in the mouse brain: a potential tracer for visualization of brain nicotinic receptors by positron emission tomography. *Chem.Pharm.Bull.(Tokyo)* 40,734-736
- Saji H, Tsutsumi D, Magata Y, Iida Y, Konishi J, Yokoyama A, 1992. Preparation and biodistribution in mice of [<sup>11</sup>C]carfentanil: a radiopharmaceutical for studying brain mu-opioid receptors by positron emission tomography. *Ann.Nucl Med* 6,63-67
- Sakoh M, Ostergaard L, Rohl L, Smith DF, Simonsen CZ, Sorensen JC, Poulsen PV, Gyldensted C, Sakaki S, Gjedde A, 2000. Relationship between residual cerebral blood flow and oxygen metabolism as predictive of ischemic tissue viability: sequential multitracers positron emission tomography scanning of middle cerebral artery occlusion during the critical first 6 hours after stroke in pigs. *J Neurosurg* 93,647-657
- Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar ASO, Brock CS, Stevens MFG, Newlands E, Jones T, Price P, 2003. Metabolic Activation of Temozolomide Measured in Vivo Using Positron Emission Tomography. *Cancer Res* 63,2409
- Salmon E, Sadzot B, Maquet P, Degueldre C, Lemaire C, Rigo P, Comar D, Franck G, 1994. Differential diagnosis of Alzheimer's disease with PET. *J.Nucl.Med.* 35,391-398
- Salmon E, Vanderlinden M, Franck G, 1997. ANTERIOR CINGULATE AND MOTOR NETWORK METABOLIC IMPAIRMENT IN PROGRESSIVE SUPRANUCLEAR PALSY. *Neuroimage* 5,173-178



- Salmon E, Collette F, Degueldre C, Lemaire C, Franck G, 2000. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease. *Hum.Brain Mapp.* 10,39-48
- Salmon E, Sadzot B, Maquet P, Franck G, 2002. Results on coregistration of mediotemporal 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) hyperactivity and 3D magnetic resonance imaging hyperintense lesions in limbic encephalitis. *J Neuroimaging* 12,282-283
- Salmon E, Garraux G, Delbeuck X, Collette F, Kalbe E, Zuendorf G, Perani D, Fazio F, Herholz K, 2003. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. *Neuroimage* 20,435-440
- Samson Y, Hantraye P, Baron JC, Soussaline F, Comar D, Maziere M, 1985. Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. *European Journal of Pharmacology* 110,247-251
- Samson Y, Baron JC, Bousser MG, Rey A, Derlon JM, David P, Comoy J, 1985. Effects of extra-intracranial arterial bypass on cerebral blood flow and oxygen metabolism in humans. *Stroke* 16,609-616
- Samson Y, Baron JC, Feline A, Bories J, Crouzel C, 1986. Local cerebral glucose utilisation in chronic alcoholics: a positron tomographic study. *J Neurol Neurosurg Psychiatry* 49,1165-1170
- Samuel M, Ceballos-Baumann AO, Turjanski N, Boecker H, Gorospe A, Linazasoro G, Holmes AP, Delong MR, Vitek JL, Thomas DT, Quinn NP, Obeso JA, Brooks DJ, 1997. PALLIDOTOMY IN PARKINSONS-DISEASE INCREASES SUPPLEMENTARY MOTOR AREA AND PREFRONTAL ACTIVATION DURING PERFORMANCE OF VOLITIONAL MOVEMENTS - AN (H2O)-O-15 PET STUDY. *Brain* 120,1301-1313
- Samuel M, Ceballos-Baumann AO, Blin J, Uema T, Boecker H, Passingham RE, Brooks DJ, 1997. EVIDENCE FOR LATERAL PREMOTOR AND PARIETAL OVERACTIVITY IN PARKINSONS-DISEASE DURING SEQUENTIAL AND BIMANUAL MOVEMENTS - A PET STUDY. *Brain* 120,963-976
- Samuel M, Ceballos-Baumann AO, Boecker H, Brooks DJ, 2001. Motor imagery in normal subjects and Parkinson's disease patients: an H215O PET study. *Neuroreport* 12,821-828

- Sanabria-Bohorquez SM, Biver F, Damhaut P, Wikler D, Veraart C, Goldman S, 2002. Quantification of 5-HT(1A) receptors in human brain using p-MPPF kinetic modelling and PET. *European Journal of Nuclear Medicine & Molecular Imaging* 29,76-81
- Sandell J, Halldin C, Pike VW, Chou YH, Varnas K, Hall H, Marchais S, Nowicki B, Wikstrom HV, Swahn CG, Farde L, 2001. New halogenated [<sup>11</sup>C]WAY analogues, [<sup>11</sup>C]6FPWAY and [<sup>11</sup>C]6BPWAY--radiosynthesis and assessment as radioligands for the study of brain 5-HT<sub>1A</sub> receptors in living monkey. *Nucl Med Biol.* 28,177-185
- Sandell J, Halldin C, Chou YH, Swahn CG, Thorberg SO, Farde L, 2002. PET-examination and metabolite evaluation in monkey of [(11)C]NAD-299, a radioligand for visualisation of the 5-HT(1A) receptor. *Nucl Med Biol.* 29,39-45
- Sano M, Ishii K, Momose Y, Uchigata M, Senda M, 1995. Cerebral metabolism of oxygen and glucose in a patient with MELAS syndrome. *Acta Neurol.Scand.* 92,497-502
- Santens P, De Reuck J, Crevits L, Decoo D, Lemahieu I, Strijckmans K, Goethals P, 1997. Cerebral oxygen metabolism in patients with progressive supranuclear palsy: a positron emission tomography study. *Eur.Neurol.* 37,18-22
- Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ, 2000. Brain serotonin<sub>1A</sub> receptor binding measured by positron emission tomography with [<sup>11</sup>C]WAY-100635: effects of depression and antidepressant treatment. *Arch.Gen.Psychiatry* 57,174-180
- Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, Morioka T, Fukui M, Masuda K, 1998. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. *Eur.J Nucl Med* 25,1261-1269
- Sato K, Kameyama M, Ishiwata K, Hatazawa J, Katakura R, Yoshimoto T, 1992. Dynamic study of methionine uptake in glioma using positron emission tomography. *Eur.J.Nucl.Med.* 19,426-430
- Sato N, Inoue T, Tomiyoshi K, Aoki J, Oriuchi N, Takahashi A, Otani T, Kurihara H, Sasaki T, Endo K, 2003. Gliomatosis cerebri evaluated by <sup>18</sup>F-alpha-methyl tyrosine positron-emission tomography. *Neuroradiology epub*,

- Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L, 1988. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. *Lancet* 2,863-866
- Savic I, Ingvar M, Stone-Elander S, 1993. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. *Journal of Neurology, Neurosurgery & Psychiatry* 56,615-621
- Savic I, Pauli S, Thorell JO, Blomqvist G, 1994. In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy. *Journal of Neurology, Neurosurgery & Psychiatry* 57,797-804
- Savic I, Thorell JO, Roland P, 1995. [11C]flumazenil positron emission tomography visualizes frontal epileptogenic regions. *Epilepsia* 36,1225-1232
- Savic I, Svanborg E, Thorell JO, 1996. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: a positron emission tomography study. *Epilepsia* 37,236-244
- Savic I, Thorell JO, 1996. Localized cerebellar reductions in benzodiazepine receptor density in human partial epilepsy. *Arch Neurol* 53,656-662
- Savic I, Blomqvist G, Halldin C, Litton JE, Gulyas B, 1998. Regional increases in [11C]flumazenil binding after epilepsy surgery. *Acta Neurol Scand.* 97,279-286
- Sawada Y, Kawai R, McManaway M, Otsuki H, Rice KC, Patlak CS, Blasberg RG, 1991. Kinetic analysis of transport and opioid receptor binding of [3H](-)-cyclofoxy in rat brain in vivo: implications for human studies. *J Cereb.Blood Flow Metab* 11,183-203
- Sawataishi J, Mineura K, Sasajima T, Kowada M, Sugawara A, Shishido F, 1992. Effects of radiotherapy determined by 11C-methyl-L-methionine positron emission tomography in patients with primary cerebral malignant lymphoma. *Neuroradiology* 34,517-519
- Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS, 1990. Striatal function in normal aging: implications for Parkinson's disease. *Annals of Neurology* 28,799-804
- Sawle GV, Brooks DJ, Marsden CD, Frackowiak RS, 1991. Corticobasal degeneration. A unique pattern of regional cortical oxygen

- hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. *Brain* 114,541-556
- Sawle GV, Leenders KL, Brooks DJ, Harwood G, Lees AJ, Frackowiak RS, Marsden CD, 1991. Dopa-responsive dystonia: [18F]dopa positron emission tomography. *Ann.Neurol* 30,24-30
- Sawle GV, Bloomfield PM, Bjorklund A, Brooks DJ, Brundin P, Leenders KL, Lindvall O, Marsden CD, Rehnrcrona S, Widner H, 1992. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. *Ann.Neurol* 31,166-173
- Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ, 1994. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. *Arch Neurol* 51,237-243
- Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ, 1994. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. *Neurology* 44,1292-1297
- Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter LR, Jr., 2001. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. *Biol.Psychiatry* 50,159-170
- Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter LR, Jr., 2002. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. *Arch Gen Psychiatry* 59,250-261
- Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR, Jr., 2003. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. *Am J Psychiatry* 160,522-532
- Scammell TE, 2003. The neurobiology, diagnosis, and treatment of narcolepsy. *Ann.Neurol* 53,154-166
- Schaafsma A, de Jong BM, Bams JL, Haaxma-Reiche H, Pruijm J, Zijlstra JG, 2003. Cerebral perfusion and metabolism in resuscitated patients with

- severe post-hypoxic encephalopathy. *Journal of the Neurological Sciences* 210,23-30
- Schafers KP, 2003. Imaging small animals with positron emission tomography. *Nuklearmedizin-Nuclear Medicine* 42,86-89
- Schapiro MB, Ball MJ, Grady CL, Haxby JV, Kaye JA, Rapoport SI, 1988. Dementia in Down's syndrome: cerebral glucose utilization, neuropsychological assessment, and neuropathology. *Neurology* 38,938-942
- Schapiro MB, Pietrini P, Grady CL, Ball MJ, DeCarli C, Kumar A, Kaye JA, Haxby JV, 1993. Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 56,859-864
- Schatz IJ, 1996. Farewell to the "Shy-Drager syndrome". *Ann.Intern.Med* 125,74-75
- Scheffel U, Steinert C, Kim SE, Ehlers MD, Boja JW, Kuhar MJ, 1996. Effect of dopaminergic drugs on the in vivo binding of [3H]WIN 35,428 to central dopamine transporters. *Synapse* 23,61-69
- Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA, 1998. In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain. *Synapse* 29,183-192
- Scheffel U, Horti AG, Koren AO, Ravert HT, Banta JP, Finley PA, London ED, Dannals RF, 2000. 6-[18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor [In Process Citation]. *Nucl.Med.Biol.* 27,51-56
- Schiepers C, Van Hecke P, Vandenberghe R, Van Oostende S, Dupont P, Demaerel P, Bormans G, Carton H, 1997. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. *Mult.Scler.* 3,8-17
- Schiff ND, Ribary U, Moreno DR, Beattie B, Kronberg E, Blasberg R, Giacino J, McCagg C, Fins JJ, Llinas R, Plum F, 2002. Residual cerebral activity and behavioural fragments can remain in the persistently vegetative brain. *Brain* 125,1210-1234

- Schiffer D, Giordana MT, Soffietti R, Sciolla R, 1982. Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. *Acta Neuropathol.(Berl)* 58,291-299
- Schiffer WK, Logan J, Dewey SL, 2003. Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine. *Neuropsychopharmacology* epub,
- Schlaepfer TE, Pearlson GD, Wong DF, Marengo S, Dannals RF, 1997. PET study of competition between intravenous cocaine and [<sup>11</sup>C]raclopride at dopamine receptors in human subjects. *Am J Psychiatry* 154,1209-1213
- Schlageter NL, Carson RE, Rapoport SI, 1987. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [<sup>68</sup>Ga]EDTA and positron emission tomography. *J Cereb.Blood Flow Metab* 7,1-8
- Schlaug G, Knorr U, Seitz R, 1994. Inter-subject variability of cerebral activations in acquiring a motor skill: a study with positron emission tomography. *Experimental Brain Research* 98,523-534
- Schlaug G, Hefter H, Nebeling B, Engelbrecht V, Weiss P, Stocklin G, Seitz RJ, 1994. Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease. *J Neurol* 241,577-584
- Schlaug G, Hefter H, Engelbrecht V, Kuwert T, Arnold S, Stocklin G, Seitz RJ, 1996. Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI. *J Neurol Sci.* 136,129-139
- Schlosser R, Brodie JD, Dewey SL, Alexoff D, Wang GJ, Fowler JS, Volkow N, Logan J, Wolf AP, 1998. Long-term stability of neurotransmitter activity investigated with <sup>11</sup>C-raclopride PET. *Synapse* 28,66-70
- Schmahl CG, Elzinga BM, Vermetten E, Sanislow C, McGlashan TH, Bremner JD, 2003. Neural correlates of memories of abandonment in women with and without borderline personality disorder. *Biol.Psychiatry* 54,142-151
- Schmalbruch IK, Linde R, Paulson OB, Madsen PL, 2002. Activation-induced resetting of cerebral metabolism and flow is abolished by beta-adrenergic blockade with propranolol. *Stroke* 33,251-255

- Schmidt ME, Ernst M, Matochik JA, Maisog JM, Pan BS, Zametkin AJ, Potter WZ, 1996. Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. *J Nucl Med* 37,1142-1149
- Schober O, Duden C, Meyer GJ, Muller JA, Hundeshagen H, 1987. Non selective transport of [<sup>11</sup>C-methyl]-L-and D-methionine into a malignant glioma. *Eur.J.Nucl.Med.* 13,103-105
- Schoder H, Erdi YE, Larson SM, Yeung HW, 2003. PET/CT: a new imaging technology in nuclear medicine. *Eur.J Nucl Med Mol.Imaging* epub,
- Schonbachler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, Burger C, Berthold T, Bruhlmeier M, Schubiger PA, Ametamey SM, 2002. PET imaging of dopamine transporters in the human brain using [(11)C]-beta-CPPIT, a cocaine derivative lacking the 2 beta-ester function. *Nucl Med Biol.* 29,19-27
- Schreckenberger M, Spetzger U, Sabri O, Meyer P, Schulz G, Hermanns B, Krombach G, Gilsbach J, Buell U, 1999. Preoperative PET activation for assessment of motor cortex area in precentral chondroma. *Surg.Neurol.* 52,24-29
- Schreckenberger M, Gouzoulis-Mayfrank E, Sabri O, Arning C, Zimny M, Zeggel T, Wagenknecht G, Kaiser HJ, Sass H, Buell U, 1999. "Ecstasy"-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study. *Eur.J Nucl Med* 26,1572-1579
- Schultz SK, O'Leary DS, Boles Ponto LL, Arndt S, Magnotta V, Watkins GL, Hichwa RD, Andreasen NC, 2002. Age and regional cerebral blood flow in schizophrenia: age effects in anterior cingulate, frontal, and parietal cortex. *J Neuropsychiatry Clin.Neurosci.* 14,19-24
- Schwartz JM, Baxter LR, Jr., Mazziotta JC, Gerner RH, Phelps ME, 1987. The differential diagnosis of depression. Relevance of positron emission tomography studies of cerebral glucose metabolism to the bipolar-unipolar dichotomy. *JAMA* 258,1368-1374
- Schwartz JM, Stoessel PW, Baxter LR, Jr., Martin KM, Phelps ME, 1996. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive- compulsive disorder. *Arch Gen Psychiatry* 53,109-113
- Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH, 1994. Treatment with D-penicillamine improves dopamine D2-

- receptor binding and T2-signal intensity in de novo Wilson's disease. *Neurology* 44,1079-1082
- Sedvall G, Farde L, Barnett A, Hall H, Halldin C, 1991. 11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. *Psychopharmacology (Berl)* 103,150-153
- Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, Farde L, 1994. Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease. *Eur.Arch Psychiatry Clin.Neurosci.* 243,249-255
- Seeman P, Guan HC, Civelli O, Van Tol HH, Sunahara RK, Niznik HB, 1992. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. *Eur.J Pharmacol.* 227,139-146
- Seidenwurm D, Pounds TR, Globus A, Valk PE, 1997. Abnormal temporal lobe metabolism in violent subjects: correlation of imaging and neuropsychiatric findings. *AJNR Am J Neuroradiol* 18,625-631
- Seitz RJ, Huang Y, Knorr U, Tellmann L, Herzog H, Freund HJ, 1995. Large-scale plasticity of the human motor cortex. *Neuroreport* 6,742-744
- Seitz RJ, Schlaug G, Knorr U, Steinmetz H, Tellmann L, Herzog H, 1996. Neurophysiology of the human supplementary motor area. Positron emission tomography. [Review]. *Advances in Neurology* 70,167-175
- Seitz RJ, Hoflich P, Binkofski F, Tellmann L, Herzog H, Freund HJ, 1998. Role of the premotor cortex in recovery from middle cerebral artery infarction. *Arch.Neurol.* 55,1081-1088
- Seitz RJ, Azari NP, Knorr U, Binkofski F, Herzog H, Freund HJ, 1999. The role of diaschisis in stroke recovery. *Stroke* 30,1844-1850
- Seki C, Kershaw J, Toussaint PJ, Kashikura K, Matsuura T, Fujita H, Kanno I, 2003. 15O Radioactivity clearance is faster after intracarotid bolus injection of 15O-labeled oxyhemoglobin than after 15O-water injection. *J Cereb.Blood Flow Metab* 23,838-844
- Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N, 2001. Methamphetamine-related



- psychiatric symptoms and reduced brain dopamine transporters studied with PET. *Am J Psychiatry* 158,1206-1214
- Selkoe DJ, 2002. Alzheimer's Disease Is a Synaptic Failure. *Science* 298,789-791
- Sell LA, Morris JS, Bearn J, Frackowiak RS, Friston KJ, Dolan RJ, 2000. Neural responses associated with cue evoked emotional states and heroin in opiate addicts. *Drug Alcohol Depend.* 60,207-216
- Semple WE, Goyer PF, McCormick R, Compton-Toth B, Morris E, Donovan B, Muswick G, Nelson D, Garnett ML, Sharkoff J, Leisure G, Miraldi F, Schulz SC, 1996. Attention and regional cerebral blood flow in posttraumatic stress disorder patients with substance abuse histories. *Psychiatry Res* 67,17-28
- Senda M, Alpert NM, Mackay BC, Buxton RB, Correia JA, Weise SB, Ackerman RH, Dorer D, Buonanno FS, 1989. Evaluation of the  $^{11}\text{CO}_2$  positron emission tomographic method for measuring brain pH. II. Quantitative pH mapping in patients with ischemic cerebrovascular diseases. *J Cereb.Blood Flow Metab* 9,859-873
- Servan-Schreiber D, Carter CS, Bruno RM, Cohen JD, 1998. Dopamine and the mechanisms of cognition: Part II. D-amphetamine effects in human subjects performing a selective attention task [In Process Citation]. *Biol.Psychiatry* 43,723-729
- Servan-Schreiber D, Perlstein WM, Cohen JD, Mintun M, 1998. Selective pharmacological activation of limbic structures in human volunteers: a positron emission tomography study. *J.Neuropsychiatry Clin.Neurosci.* 10,148-159
- Sette G, Baron JC, Young AR, Miyazawa H, Tillet I, Barre L, Travers JM, Derlon JM, MacKenzie ET, 1993. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. *Stroke* 24,2046-2057
- Shah N, Sibtain A, Saunders MI, Townsend E, Wong WL, 2000. High FDG uptake in a schwannoma: a PET study. *J Comput.Assist.Tomogr.* 24,55-56
- Shamoto H, Chugani HT, 1997. Glucose metabolism in the human cerebellum: an analysis of crossed cerebellar diaschisis in children with unilateral cerebral injury. *J.Child Neurol.* 12,407-414

- Shapiro WR, 1992. Low-grade gliomas: when to treat? [editorial; comment].  
Annals of Neurology 31,437-438
- Shaw ME, Strother SC, McFarlane AC, Morris P, Anderson J, Clark CR, Egan GF, 2002. Abnormal Functional Connectivity in Posttraumatic Stress Disorder. Neuroimage 15,661-674
- Sheline YI, Mintun MA, Moerlein SM, Snyder AZ, 2002. Greater loss of 5-HT(2A) receptors in midlife than in late life. American Journal of Psychiatry 159,430-435
- Shen D, Davatzikos C, 2003. Very High-Resolution Morphometry Using Mass-Preserving Deformations and HAMMER Elastic Registration. Neuroimage 18,28-41
- Sherley JL, Kelly TJ, 1988. Regulation of human thymidine kinase during the cell cycle. J Biol.Chem. 263,8350-8358
- Shi N, Boado RJ, Pardridge WM, 2000. Antisense imaging of gene expression in the brain in vivo. Proc.Natl.Acad.Sci.U.S.A 97,14709-14714
- Shields AF, Mankoff D, Graham MM, Zheng M, Kozawa SM, Link JM, Krohn KA, 1996. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J.Nucl.Med. 37,290-296
- Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ, 1998. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat.Med. 4,1334-1336
- Shin LM, Kosslyn SM, McNally RJ, Alpert NM, Thompson WL, Rauch SL, Macklin ML, Pitman RK, 1997. Visual imagery and perception in posttraumatic stress disorder. A positron emission tomographic investigation. Arch Gen Psychiatry 54,233-241
- Shin LM, McNally RJ, Kosslyn SM, Thompson WL, Rauch SL, Alpert NM, Metzger LJ, Lasko NB, Orr SP, Pitman RK, 1999. Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD: A PET investigation. Am J Psychiatry 156,575-584
- Shinohara Y, Ohnuki Y, Yoshii F, Takahashi W, Onoe K, Takagi S, 1998. Detection of primary tumor in paraneoplastic cerebellar degeneration by FDG-PET. Ann.Neurol 43,684

- Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T, Yamazaki T, Tateno Y, 1993. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. *J Neurol Neurosurg Psychiatry* 56,467-472
- Shinotoh H, Asahina M, Inoue O, Suhara T, Hirayama K, Tateno Y, 1994. Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography. *J Neural Transm.Park Dis.Dement.Sect.* 7,35-46
- Shinotoh H, Snow BJ, Chu NS, Huang CC, Lu CS, Lee C, Takahashi H, Calne DB, 1997. PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINERGIC FUNCTION IN PATIENTS WITH MANGANESE INTOXICATION - A POSITRON EMISSION TOMOGRAPHY STUDY. *Neurology* 48,1053-1056
- Shinotoh H, Thiessen B, Snow BJ, Hashimoto S, Macleod P, Silveira I, Rouleau GA, Schulzer M, Calne DB, 1997. FLUORODOPA AND RACLOPRIDE PET ANALYSIS OF PATIENTS WITH MACHADO-JOSEPH-DISEASE. *Neurology* 49,1133-1136
- Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T, 1999. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. *Ann.Neurol.* 46,62-69
- Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T, 2000. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. *Ann.Neurol.* 48,194-200
- Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, Tanada S, Irie T, 2001. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. *Neurology* 56,408-410
- Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, Sato K, Shiraishi A, Namba H, Tanada S, Irie T, 2003. Brain acetylcholinesterase activity in dementia with Lewy bodies, Alzheimer's disease and frontotemporal dementia. *J Cereb.Blood Flow Metab* 23 (Suppl. 1),S598
- Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K, Mitsui I, Kosaka N, Kondo T, Hara T, 1997. Brain tumors: detection with C-11 choline PET. *Radiology* 202,497-503

- Shishido F, Uemura K, Inugami A, Ogawa T, Yamaguchi T, Kanno I, Murakami M, Tagawa K, Yasui N, 1987. Remote effects in MCA territory ischemic infarction: a study of regional cerebral blood flow and oxygen metabolism using positron computed tomography and  $^{15}\text{O}$  labeled gases. *Radiat. Med* 5,36-41
- Shiue CY, Bai LQ, Teng RR, Arnett CD, Dewey SL, Wolf AP, McPherson DW, Fowler JS, Logan J, Holland MJ, 1991. A comparison of the brain uptake of N- (cyclopropyl[ $^{11}\text{C}$ ]methyl)norbuprenorphine ([ $^{11}\text{C}$ ]buprenorphine) and N-(cyclopropyl[ $^{11}\text{C}$ ]methyl)nordiprenorphine ([ $^{11}\text{C}$ ]diprenorphine) in baboon using PET. *International Journal of Radiation Applications & Instrumentation - Part B, Nuclear Medicine & Biology* 18,281-288
- Shiue CY, Shiue GG, Mozley PD, Kung MP, Zhuang ZP, Kim HJ, Kung HF, 1997. P-[ $^{18}\text{F}$ ]-MPPF: a potential radioligand for PET studies of 5-HT $_{1A}$  receptors in humans. *Synapse* 25,147-154
- Shiue CY, Vallabhahosula S, Wolf AP, Dewey SL, Fowler JS, Schlyer DJ, Arnett CD, Zhou YG, 1997. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. *Nucl Med Biol.* 24,145-150
- Shoaf SE, Carson R, Hommer D, Williams W, Higley JD, Schmall B, Herscovitch P, Eckelman W, Linnoila M, 1998. Brain serotonin synthesis rates in rhesus monkeys determined by [ $^{11}\text{C}$ ]alpha-methyl-L-tryptophan and positron emission tomography compared to CSF 5-hydroxyindole-3-acetic acid concentrations [In Process Citation]. *Neuropsychopharmacology.* 19,345-353
- Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR, 2002. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am.J Geriatr.Psychiatry* 10,24-35
- Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE, 1992. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. *J.Nucl.Med.* 33,1125-1131
- Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC, 1999. Pheochromocytomas: imaging with 2-[fluorine- $^{18}$ ]fluoro-2-deoxy-D-glucose PET. *Radiology* 212,35-41

- Shulman RG, Hyder F, Rothman DL, 2001. Cerebral energetics and the glycogen shunt: Neurochemical basis of functional imaging. *Proc.Natl.Acad.Sci.U.S.A* 98,6417-6422
- Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG, 1998. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. *Proc.Natl.Acad.Sci.USA* 95,316-321
- Sidtis JJ, Strother SC, Rottenberg DA, 2003. Predicting performance from functional imaging data: methods matter. *Neuroimage* 20,615-624
- Siessmeier T, Nix WA, Hardt J, Schreckenberger M, Egle UT, Bartenstein P, 2003. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. *J.Neurol.Neurosurg.Psychiatry* 74,922-928
- Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, Grassi F, Bettinardi V, Frackowiak RSJ, Fazio F, 1999. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [ $^{18}\text{F}$ ]FDG PET: A clinical validation of statistical parametric mapping. *Neuroimage* 9,63-80
- Sihver S, Sihver W, Bergstrom M, Hoglund AU, Sjoberg P, Langstrom B, Watanabe Y, 1999. Quantitative autoradiography with short-lived positron emission tomography tracers: a study on muscarinic acetylcholine receptors with N-[( $^{11}\text{C}$ )]methyl-4-piperidylbenzilate. *J.Pharmacol.Exp.Ther.* 290,917-922
- Sihver W, Fasth KJ, Horti AG, Koren AO, Bergstrom M, Lu L, Hagberg G, Lundqvist H, Dannals RF, London ED, Nordberg A, Langstrom B, 1999. Synthesis and characterization of binding of 5-[ $^{76}\text{Br}$ ]bromo-3-[[2(S)-azetidiny]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. *J.Neurochem.* 73,1264-1272
- Sihver W, Fasth KJ, Ogren M, Lundqvist H, Bergstrom M, Watanabe Y, Langstrom B, Nordberg A, 1999. In vivo positron emission tomography studies on the novel nicotinic receptor agonist [ $^{11}\text{C}$ ]MPA compared with [ $^{11}\text{C}$ ]ABT-418 and (S)(-)[ $^{11}\text{C}$ ]nicotine in rhesus monkeys. *Nucl.Med.Biol.* 26,633-640
- Sihver W, Langstrom B, Nordberg A, 2000. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. *Acta Neurol.Scand.Suppl* 176,27-33

- Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootenboer S, Seaward J, McKenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ, 1995. A FUNCTIONAL NEUROANATOMY OF HALLUCINATIONS IN SCHIZOPHRENIA. *Nature* 378,176-179
- Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME, 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. *JAMA* 286,2120-2127
- Silverman DHS, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME, 2002. Added Clinical Benefit of Incorporating 2-Deoxy-2-[18F]Fluoro-D-Glucose with Positron Emission Tomography into the Clinical Evaluation of Patients with Cognitive Impairment. *Molecular Imaging & Biology* 4,283-293
- Simpson IA, Davies P, 1994. Reduced glucose transporter concentrations in brains of patients with Alzheimer's disease [letter; comment]. *Ann.Neurol.* 36,800-801
- Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher F, Koehler-Stec EM, Vannucci SJ, Smith QR, 1999. Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. *J.Neurochem.* 72,238-247
- Simpson JR, Jr., Drevets WC, Snyder AZ, Gusnard DA, Raichle ME, 2001. Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. *Proc.Natl.Acad.Sci.U.S.A* 98,688-693
- Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, Zhou Y, Grace AA, Wong DF, 2002. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. *Am.J Psychiatry* 159,1329-1336
- Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS, 2001. Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. *J.Cereb.Blood Flow Metab.* 21,144-148
- Slansky I, Herholz K, Pietrzyk U, Kessler J, Grond M, Mielke R, Heiss WD, 1995. Cognitive impairment in Alzheimer's disease correlates with ventricular width and atrophy-corrected cortical glucose metabolism. *Neuroradiology* 37,270-277

- Small GW, Kuhl DE, Riege WH, Fujikawa DG, Ashford JW, Metter EJ, Mazziotta JC, 1989. Cerebral glucose metabolic patterns in Alzheimer's disease. Effect of gender and age at dementia onset. *Arch Gen Psychiatry* 46,527-532
- Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L, 1995. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. *JAMA* 273,942-947
- Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME, 2000. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. *Proc.Natl.Acad.Sci.U.S.A* 97,6037-6042
- Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, Macke HR, 1994. Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor- positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. *J.Nucl.Med.* 35,317-325
- Smith CB, Deibler GE, Eng N, Schmidt K, Sokoloff L, 1988. Measurement of local cerebral protein synthesis in vivo: influence of recycling of amino acids derived from protein degradation. *Proc.Natl.Acad.Sci.USA* 85,9341-9345
- Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, Golomb J, Ferris SH, Reisberg B, Ciaravino J, ., 1992. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. *Arch Neurol* 49,1142-1150
- Smith GS, Dewey SL, Brodie JD, Logan J, Vitkun SA, Simkowitz P, Schloesser R, Alexoff DA, Hurley A, Cooper T, Volkow ND, 1997. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. *Am.J.Psychiatry* 154,490-496
- Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R, 1998. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. *Neuropsychopharmacology.* 18,18-25

- Smith GS, Price JC, Lopresti BJ, Huang Y, Simpson N, Holt D, Mason NS, Meltzer CC, Sweet RA, Nichols T, Sashin D, Mathis CA, 1998. Test-retest variability of serotonin 5-HT<sub>2A</sub> receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. *Synapse* 30,380-392
- Smith GS, Reynolds CF, III, Pollock B, Derbyshire S, Nofzinger E, Dew MA, Houck PR, Milko D, Meltzer CC, Kupfer DJ, 1999. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. *Am.J.Psychiatry* 156,683-689
- Smith GS, Reynolds III CF, Houck PR, Dew MA, Ma Y, Mulsant BH, Pollock BG, 2002. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. *Am.J Geriatr.Psychiatry* 10,561-567
- Smith JG, Raper SE, Wheeldon EB, Hackney D, Judy K, Wilson JM, Eck SL, 1997. INTRACRANIAL ADMINISTRATION OF ADENOVIRUS EXPRESSING HSV-TK IN COMBINATION WITH GANCICLOVIR PRODUCES A DOSE-DEPENDENT, SELF- LIMITING INFLAMMATORY RESPONSE. *Human Gene Therapy* 8,943-954
- Smith JS, Zubieta JK, Price JC, Flesher JE, Madar I, Lever JR, Kinter CM, Dannals RF, Frost JJ, 1999. Quantification of delta-opioid receptors in human brain with N1'-([11C]methyl) naltrindole and positron emission tomography. *J Cereb.Blood Flow Metab* 19,956-966
- Smith KA, Morris JS, Friston KJ, Cowen PJ, Dolan RJ, 1999. Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. *Br.J.Psychiatry* 174,525-529
- Smith QR, Momma S, Aoyagi M, Rapoport SI, 1987. Kinetics of neutral amino acid transport across the blood-brain barrier. *J Neurochem.* 49,1651-1658
- Snow BJ, Bhatt M, Martin WR, Li D, Calne DB, 1991. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. *J Neurol Neurosurg Psychiatry* 54,12-17
- Snow BJ, Nygaard TG, Takahashi H, Calne DB, 1993. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. *Ann.Neurol* 34,733-738



- Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H, 1993. Human positron emission tomographic [ $^{18}\text{F}$ ]fluorodopa studies correlate with dopamine cell counts and levels. *Annals of Neurology* 34,324-330
- Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR, 1998. Synthesis of 1- $^{11}\text{C}$ methylnpiperidin-4-yl propionate ( $^{11}\text{C}$ PMP) for in vivo measurements of acetylcholinesterase activity. *Nucl.Med.Biol.* 25,751-754
- Snyder SE, Gunupudi N, Sherman PS, Butch ER, Skaddan MB, Kilbourn MR, Koeppe RA, Kuhl DE, 2001. Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. *J.Cereb.Blood Flow Metab.* 21,132-143
- Soares JC, Mann JJ, 1997. THE ANATOMY OF MOOD DISORDERS - REVIEW OF STRUCTURAL NEUROIMAGING STUDIES [Review]. *Biological Psychiatry* 41,86-106
- Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M, 1977. The  $^{14}\text{C}$ deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. *Journal of Neurochemistry* 28,897-916
- Sokoloff L, 1993. Sites and mechanisms of function-related changes in energy metabolism in the nervous system. [Review]. *Developmental Neuroscience* 15,194-206
- Sollevi A, Ericson K, Eriksson L, Lindqvist C, Lagerkranser M, Stone-Elander S, 1987. Effect of adenosine on human cerebral blood flow as determined by positron emission tomography. *J.Cereb.Blood Flow Metab.* 7,673-678
- Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM, 2000. A fenfluramine-activated FDG-PET study of borderline personality disorder. *Biol.Psychiatry* 47,540-547
- Soloff PH, Meltzer CC, Becker C, Greer PJ, Kelly TM, Constantine D, 2003. Impulsivity and prefrontal hypometabolism in borderline personality disorder. *Psychiatry Research: Neuroimaging* 123,153-163
- Son HK, Yun MJ, Jeon TJ, Kim DO, Jung HJ, Lee JD, Yoo HS, Kim HJ, 2003. ROC analysis of ordered subset expectation maximization and filtered

- back projection technique for FDG-PET in lung cancer. IEEE Transactions on Nuclear Science 50,37-41
- Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T, 1998. Clinical usefulness of <sup>11</sup>C-MET PET and <sup>201</sup>Tl SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol.Med.Chir.(Tokyo.) 38,342-347
- Soong B, Liu R, Wu L, Lu Y, Lee H, 2001. Metabolic characterization of spinocerebellar ataxia type 6. Arch.Neurol 58,300-304
- Soong BW, Liu RS, 1998. Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease. J Neurol Neurosurg Psychiatry 64,499-504
- Sossi V, Barney JS, Harrison R, Ruth TJ, 1995. Effect of Scatter from Radioactivity Outside of the Field-Of- View in 3D Pet. IEEE Transactions on Nuclear Science 42,1157-1161
- Sossi V, Oakes TR, Chan GLY, Schulzer M, Ruth TJ, 1998. Quantitative comparison of three- and two-dimensional PET with human brain studies. J.Nucl.Med. 39,1714-1719
- Sossi V, Fuente-Fernandez R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ, 2002. Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence From a New Modeling Approach to PET 18 F-Fluorodopa Data. J Cereb.Blood Flow Metab 22,232-239
- Sossi V, Holden JE, Fuente-Fernandez R, Ruth TJ, Stoessl AJ, 2003. Effect of Dopamine Loss and the Metabolite 3-O-Methyl-[<sup>18</sup>F]Fluoro-dopa on the Relation Between the 18F-Fluorodopa Tissue Input Uptake Rate Constant K<sub>occ</sub> and the [<sup>18</sup>F]Fluorodopa Plasma Input Uptake Rate Constant K<sub>i</sub>. J Cereb.Blood Flow Metab 23,301-309
- Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben Menachem E, Gaillard WD, Theodore WH, 1999. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology 53,1518-1522
- Spanaki MV, Kopylev L, DeCarli C, Gaillard WD, Liow K, Fazilat S, Fazilat S, Reeves P, Sato S, Kufta C, Theodore WH, 2000. Postoperative changes in cerebral metabolism in temporal lobe epilepsy. Arch.Neurol. 57,1447-1452

- Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, Lewellen TK, Lewellen B, Freeman SD, Berger MS, Ojemann GA, 1998. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. *J.Nucl.Med.* 39,440-448
- Spence SA, Hirsch SR, Brooks DJ, Grasby PM, 1998. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. *Br.J Psychiatry* 172,316-323
- Sperling MR, Gur RC, Alavi A, Gur RE, Resnick S, O'Connor MJ, Reivich M, 1990. Subcortical metabolic alterations in partial epilepsy. *Epilepsia* 31,145-155
- Spinks TJ, Jones T, Bailey DL, Townsend DW, Grootenboer S, Bloomfield PM, Gilardi MC, Casey ME, Sipe B, Reed J, 1992. Physical performance of a positron tomograph for brain imaging with retractable septa. *Physics in Medicine & Biology* 37,1637-1655
- Spinks TJ, Jones T, Bloomfield PM, Bailey DL, Miller M, Hogg D, Jones WF, Vaigneur K, Reed J, Young J, Newport D, Moyers C, Casey ME, Nutt R, 2000. Physical characteristics of the ECAT EXACT3D positron tomograph. *Physics in Medicine and Biology* 45,2601-2618
- Springer JA, Binder JR, Hammeke TA, Swanson SJ, Frost JA, Bellgowan PS, Brewer CC, Perry HM, Morris GL, Mueller WM, 1999. Language dominance in neurologically normal and epilepsy subjects: a functional MRI study [see comments]. *Brain* 122,2033-2046
- St"cklin G, 1992. Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology. [Review]. *Eur.J.Nucl.Med.* 19,527-551
- St"cklin G, Pike VW, 1993. Radiopharmaceuticals for positron emission tomography, Kluwer, Dordrecht
- Staffen W, Karbe H, Rudolf J, Herholz K, Diederich N, Heiss WD, 1994. Untersuchung der funktionellen Bedeutung von Stammganglienverkalkungen mit Positronenemissionstomographie. *Fortschritte der Neurologie-Psychiatrie* 62,119-124
- Stange K, Greitz D, Ingvar M, Hindmarsh T, Sollevi A, 1997. Global cerebral blood flow during infusion of adenosine in humans: assessment by

- magnetic resonance imaging and positron emission tomography. *Acta Physiol Scand.* 160,117-122
- Stapleton JM, Morgan MJ, Liu X, Yung BC, Phillips RL, Wong DF, Shaya EK, Dannals RF, London ED, 1997. Cerebral glucose utilization is reduced in second test session. *J Cereb.Blood Flow Metab* 17,704-712
- Stapleton JM, Gilson SF, Wong DF, Villemagne VL, Dannals RF, Grayson RF, Henningfield JE, London ED, 2003. Intravenous Nicotine Reduces Cerebral Glucose Metabolism: A Preliminary Study. *Neuropsychopharmacology* 28,765-772
- Steel RDG, Torrie JH, 1980. Principles and procedures of statistics. A biometrical approach, McGraw-Hill, New York
- Stefan H, Pawlik G, Bocher-Schwarz HG, Biersack HJ, Burr W, Penin H, Heiss WD, 1987. Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT and PET. *J.Neurol.* 234,377-384
- Stefan H, Schneider S, Abraham-Fuchs K, Pawlik G, Feistel H, Bauer J, Neubauer U, Huk WJ, Holthoff V, 1991. The neocortico to mesio-basal limbic propagation of focal epileptic activity during the spike-wave complex. *Electroencephalography & Clinical Neurophysiology* 79,1-10
- Steiner LA, Coles JP, Johnston AJ, Czosnyka M, Fryer TD, Smielewski P, Chatfield DA, Salvador R, Aigbirhio FI, Clark JC, Menon DK, Pickard JD, 2003. Responses of posttraumatic pericontusional cerebral blood flow and blood volume to an increase in cerebral perfusion pressure. *J Cereb.Blood Flow Metab* 23,1371-1377
- Steiner LA, Coles JP, Czosnyka M, Minhas PS, Fryer TD, Aigbirhio FI, Clark JC, Smielewski P, Chatfield DA, Donovan T, Pickard JD, Menon DK, 2003. Cerebrovascular pressure reactivity is related to global cerebral oxygen metabolism after head injury. *J Neurol Neurosurg Psychiatry* 74,765
- Steinmetz H, Furst G, Freund HJ, 1989. Cerebral cortical localization: application and validation of the proportional grid system in MR imaging. *J Comput.Assist.Tomogr.* 13,10-19
- Steinmetz H, Huang Y, Seitz RJ, Knorr U, Schlaug G, Herzog H, Hacklander T, Freund HJ, 1992. Individual integration of positron emission tomography and high- resolution magnetic resonance imaging. *J.Cereb.Blood Flow Metab.* 12,919-926

- Stern E, Silbersweig DA, Chee KY, Holmes A, Robertson MM, Trimble M, Frith CD, Frackowiak RS, Dolan RJ, 2000. A functional neuroanatomy of tics in Tourette syndrome. *Arch Gen Psychiatry* 57,741-748
- Stevens H, Jansen HM, De Reuck J, Lemmerling M, Strijckmans K, Goethals P, Lemahieu I, de Jong BM, Willemsen AT, Korf J, 1999. <sup>55</sup>Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI. *J.Neurol.Sci.* 171,11-18
- Stoeckel MC, Kleinschmidt A, Ebner A, Witte OW, Seitz RJ, 2002. Reorganization of motor representation in a patient with epilepsy partialis continua as shown by [<sup>15</sup>O]-labeled butanol positron emission tomography and functional magnetic resonance imaging. *J Neuroimaging* 12,276-281
- Stoof JC, Winogrodzka A, van Muiswinkel FL, Wolters EC, Voorn P, Groenewegen HJ, Booij J, Drukarch B, 1999. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. *Eur.J Pharmacol.* 375,75-86
- Stoppe G, Wildhagen K, Seidel JW, Meyer GJ, Schober O, Heintz P, Kunkel H, Deicher H, Hundeshagen H, 1990. Positron emission tomography in neuropsychiatric lupus erythematosus [see comments]. *Neurology* 40,304-308
- Stout D, Petric A, Satyamurthy N, Nguyen Q, Huang SC, Namavari M, Barrio JR, 1999. 2Beta-carbomethoxy-3beta-(4- and 2-[<sup>18</sup>F]fluoromethylphenyl)tropanes: specific probes for in vivo quantification of central dopamine transporter sites. *Nucl Med Biol.* 26,897-903
- Strafella AP, Paus T, Barrett J, Dagher A, 2001. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *J Neurosci.* 21: RC157,1-4
- Strafella AP, Dagher A, Sadikot AF, 2003. Cerebral blood flow changes induced by subthalamic stimulation in Parkinson's disease. *Neurology* 60,1039-1042
- Strafella AP, Sadikot AF, Dagher A, 2003. Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease. *Neuroreport* 14,1287-1289
- Strother SC, Anderson JR, Schaper KA, Sidtis JJ, Liow JS, Woods RP, Rottenberg DA, 1995. Principal component analysis and the scaled

- subprofile model compared to intersubject averaging and statistical parametric mapping: I. "Functional connectivity" of the human motor system studied with [ $^{15}\text{O}$ ]water PET. *J.Cereb.Blood Flow Metab.* 15,738-753
- Strul D, Bendriem B, 1999. Robustness of anatomically guided pixel-by-pixel algorithms for partial volume effect correction in positron emission tomography. *J.Cereb.Blood Flow Metab.* 19,547-559
- Studholme C, Hill DL, Hawkes DJ, 1997. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. *Med.Phys.* 24,25-35
- Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, Liu HM, Moeller JR, Eidelberg D, 2001. Metabolic changes following subthalamotomy for advanced Parkinson's disease. *Ann.Neurol.* 50,514-520
- Subramanian T, Emerich DF, Bakay RA, Hoffman JM, Goodman MM, Shoup TM, Miller GW, Levey AI, Hubert GW, Batchelor S, Winn SR, Saydoff JA, Watts RL, 1997. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and  $^{18}\text{F}$ -Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. *Cell Transplant.* 6,469-477
- Suchowersky O, Hayden MR, Martin WR, Stoessl AJ, Hildebrand AM, Pate BD, 1986. Cerebral metabolism of glucose in benign hereditary chorea. *Mov Disord.* 1,33-44
- Suda S, Shinohara M, Miyaoka M, Lucignani G, Kennedy C, Sokoloff L, 1990. The lumped constant of the deoxyglucose method in hypoglycemia: effects of moderate hypoglycemia on local cerebral glucose utilization in the rat. *J.Cereb.Blood Flow Metab.* 10,499-509
- Sudo Y, Suhara T, Honda Y, Nakajima T, Okubo Y, Suzuki K, Nakashima Y, Yoshikawa K, Okauchi T, Sasaki Y, Matsushita M, 1998. Muscarinic cholinergic receptors in human narcolepsy: a PET study. *Neurology* 51,1297-1302
- Suehiro M, Scheffel U, Ravert HT, Dannals RF, Wagner HN, Jr., 1993. [ $^{11}\text{C}$ ](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. *Life Sci.* 53,883-892

- Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A, Tateno Y, 1992. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. *Psychopharmacology* 106,14-18
- Suhara T, Inoue O, Kobayashi K, Satoh T, Tateno Y, 1994. An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography. *Psychopharmacology (Berl)* 113,311-317
- Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y, 2003. High Levels of Serotonin Transporter Occupancy With Low-Dose Clomipramine in Comparative Occupancy Study With Fluvoxamine Using Positron Emission Tomography. *Arch Gen Psychiatry* 60,386
- Suhonen-Polvi H, Kero P, Korvenranta H, Ruotsalainen U, Haaparanta M, Bergman J, Simell O, Wegelius U, 1993. Repeated fluorodeoxyglucose positron emission tomography of the brain in infants with suspected hypoxic-ischaemic brain injury. *Eur.J Nucl Med* 20,759-765
- Sultzer DL, Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C, 1995. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. *Arch.Neurol.* 52,773-780
- Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, Cummings JL, 2003. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. *Am.J Psychiatry* 160,341-349
- Sun X, Tanaka M, Kondo S, Okamoto K, Hirai S, 1998. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. *Ann.Nucl Med* 12,89-94
- Sun Y, Deibler GE, Sokoloff L, Smith CB, 1992. Determination of regional rates of cerebral protein synthesis adjusted for regional differences in recycling of leucine derived from protein degradation into the precursor pool in conscious adult rats. *Journal of Neurochemistry* 59,863-873
- Sunden-Cullberg J, Tedroff J, Aquilonius SM, 1998. Reversible chorea in primary antiphospholipid syndrome. *Mov Disord.* 13,147-149
- Sung NS, Crowley WF, Jr., Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, Grebb J, Martinez RA, Korn A, Rimoin D, 2003.

- Central challenges facing the national clinical research enterprise. JAMA 289,1278-1287
- Sutinen E, Jyrkkio S, Gronroos T, Haaparanta M, Lehtikainen P, Nagren K, 2001. Biodistribution of [<sup>11</sup>C] methylaminoisobutyric acid, a tracer for PET studies on system A amino acid transport in vivo. Eur.J Nucl Med 28,847-854
- Svensson P, Minoshima S, Beydoun A, Morrow TJ, Casey KL, 1997. Cerebral processing of acute skin and muscle pain in humans. J Neurophysiol. 78,450-460
- Svensson P, Johannsen P, Jensen TS, Arendt-Nielsen L, Nielsen J, Stodkilde-Jorgensen H, Gee AD, Baarsgaard HS, Gjedde A, 1998. Cerebral blood-flow changes evoked by two levels of painful heat stimulation: a positron emission tomography study in humans. Eur.J Pain 2,95-107
- Swart JA, van der Werf JF, Wiegman T, Paans AM, Vaalburg W, Korf J, 1990. In vivo binding of spiperone and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: multiple modeling and implications for PET scanning. J.Cereb.Blood Flow Metab. 10,297-306
- Swartz BE, Halgren E, Delgado-Escueta AV, Mandelkern M, Gee M, Quinones N, Bland WH, Repchan J, 1989. Neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia 30,547-558
- Swartz BW, Khonsari A, Vrown C, Mandelkern M, Simpkins F, Krisdakumtorn T, 1995. Improved sensitivity of <sup>18</sup>FDG-positron emission tomography scans in frontal and "frontal plus" epilepsy. Epilepsia 36,388-395
- Syrota A, Castaing M, Rougemont D, Berridge M, Baron JC, Bousser MG, Pocard JJ, 1983. Tissue acid-base balance and oxygen metabolism in human cerebral infarction studied with positron emission tomography. Ann.Neurol 14,419-428
- Syrota A, Samson Y, Boullais C, Wajsborg P, Loc'h C, Crouzel C, Maziere B, Soussaline F, Baron JC, 1985. Tomographic mapping of brain intracellular pH and extracellular water space in stroke patients. J Cereb.Blood Flow Metab 5,358-368
- Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Musachio JL, Marengo S, Kim SE, Ricaurte GA, 1995. Positron emission tomography imaging of serotonin transporters in the human brain using [<sup>11</sup>C](+)-McN5652. Synapse 20,37-43



- Szabo Z, Scheffel U, Suehiro M, Dannals RF, Kim SE, Ravert HT, Ricaurte GA, Wagner HN, Jr., 1995. Positron emission tomography of 5-HT transporter sites in the baboon brain with [11C]McN5652. *J.Cereb.Blood Flow Metab.* 15,798-805
- Szabo Z, Scheffel U, Mathews WB, Ravert HT, Szabo K, Kraut M, Palmon S, Ricaurte GA, Dannals RF, 1999. Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand. *J.Cereb.Blood Flow Metab.* 19,967-981
- Szelies B, Herholz K, Heiss WD, Rackl A, Pawlik G, Wagner R, Ilse HW, Wienhard K, 1983. Hypometabolic cortical lesions in tuberous sclerosis with epilepsy: demonstration by positron emission tomography. *Journal of Computer Assisted Tomography* 7,946-953
- Szelies B, Herholz K, Pawlik G, Karbe H, Hebold I, Heiss WD, 1991. Widespread functional effects of discrete thalamic infarction. *Arch.Neurol.* 48,178-182
- Szelies B, Weber-Luxemburger G, Mielke R, Pawlik G, Kessler J, Pietrzyk U, Bauer B, Heiss WD, 2000. Interictal hippocampal benzodiazepine receptors in temporal lobe epilepsy: comparison with coregistered hippocampal metabolism and volumetry. *Eur.J.Neurol.* 7,393-400
- Szelies B, Sobesky J, Pawlik G, Mielke R, Bauer B, Herholz K, Heiss WD, 2002. Impaired benzodiazepine receptor binding in peri-lesional cortex of patients with symptomatic epilepsies studied by [11C]-flumazenil PET. *Eur.J Neurol.* 9,137-142
- Tölle TR, Kaufmann T, Siessmeier T, Lautenbacher S, Berthele A, Münz F, Ziegler W, Willech F, Schwaiger M, Conrad B, Bartenstein P, 1999. Region-specific encoding of sensory and affective components of pain in the human brain: a positron emission tomography correlation analysis. *Ann.Neurol.* 45,40-47
- Tack CJ, van Gorp PJ, Holmes C, Goldstein DS, 2002. Local sympathetic denervation in painful diabetic neuropathy. *Diabetes* 51,3545-3553
- Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S, Ido T, Itoh M, Sasaki H, Watanabe T, Yanai K, 2001. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. *Br.J Clin.Pharmacol.* 52,501-509

- Tai C, Chatziioannou A, Siegel S, Young J, Newport D, Goble RN, Nutt RE, Cherry SR, 2001. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. *Phys.Med Biol.* 46,1845-1862
- Takada H, Nagata K, Hirata Y, Satoh Y, Watahiki Y, Sugawara J, Yokoyama E, Kondoh Y, Shishido F, Inugami A, 1992. Age-related decline of cerebral oxygen metabolism in normal population detected with positron emission tomography. *Neurol Res.* 14,128-131
- Takahashi H, Levine RA, Galloway MP, Snow BJ, Calne DB, Nygaard TG, 1994. Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa-responsive dystonia. *Ann.Neurol* 35,354-356
- Takahashi S, Tohgi H, Yonezawa H, Obara S, Nagane Y, 1998. Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). *J.Neurol.Sci.* 158,58-64
- Takahashi T, Shirane R, Sato S, Yoshimoto T, 1999. Developmental changes of cerebral blood flow and oxygen metabolism in children. *AJNR Am J Neuroradiol* 20,917-922
- Takamatsu H, Noda A, Murakami Y, Tatsumi M, Ichise R, Nishimura S, 2003. A PET study after treatment with an anxiety-provoking agent, m-chlorophenyl-piperazine, in conscious rhesus monkeys. *J Nucl Med* 44,1516-1521
- Takeda N, Diksic M, Yamamoto YL, 1996. The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. *Cancer* 77,1167-1179
- Taki W, Yonekawa Y, Kobayashi A, Ishikawa M, Kikuchi H, Nishizawa S, Senda M, Yonekawa Y, Fukuyama H, Harada K, ., 1988. Cerebral circulation and oxygen metabolism in moyamoya disease of ischemic type in children. *Childs Nerv.Syst.* 4,259-262
- Taki W, Yonekawa Y, Kobayashi A, Ishikawa M, Kikuchi H, Nishizawa S, Yonekura Y, Tanada S, Fukuyama H, 1989. Cerebral circulation and metabolism in adults' moyamoya disease--PET study. *Acta Neurochir.(Wien.)* 100,150-154

- Takikawa S, Dhawan V, Spetsieris P, Robeson W, Chaly T, Dahl R, Margouleff D, Eidelberg D, 1993. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. *Radiology* 188,131-136
- Talairach J, Tournoux P, 1988. Co-planar stereotaxic atlas of the human brain, Georg Thieme Verlag, Stuttgart
- Talbot JD, Marrett S, Evans AC, Meyer E, Bushnell MC, Duncan GH, 1991. Multiple representations of pain in human cerebral cortex [see comments]. *Science* 251,1355-1358
- Talvik-Lotfi M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F, Farde L, 2000. High 5HT<sub>2A</sub> receptor occupancy in M100907-treated schizophrenic patients. *Psychopharmacology (Berl)* 148,400-403
- Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L, 2001. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. *Am J Psychiatry* 158,926-930
- Tan PZ, Baldwin RM, van Dyck CH, Al Tikriti M, Roth B, Khan N, Charney DS, Innis RB, 1999. Characterization of radioactive metabolites of 5-HT<sub>2A</sub> receptor PET ligand [18F]altanserin in human and rodent. *Nucl.Med.Biol.* 26,601-608
- Tanaka M, Kondo S, Hirai S, Ishiguro K, Ishihara T, Morimatsu M, 1992. Crossed cerebellar diaschisis accompanied by hemiataxia: a PET study. *J Neurol Neurosurg Psychiatry* 55,121-125
- Tanaka M, Kondo S, Hirai S, Sun X, Yamagishi T, Okamoto K, 1993. Cerebral blood flow and oxygen metabolism in progressive dementia associated with amyotrophic lateral sclerosis. *J Neurol.Sci.* 120,22-28
- Tanaka M, Uesugi M, Igeta Y, Kondo S, Sun X, Hirai S, 1995. Luxury perfusion phenomenon in acute herpes simplex virus encephalitis. *Ann.Nucl Med* 9,43-45
- Tanaka M, Hirai S, Kondo S, Sun X, Nakagawa T, Tanaka S, Hayashi K, Okamoto K, 1998. Cerebral hypoperfusion and hypometabolism with altered striatal signal intensity in chorea-acanthocytosis: a combined PET and MRI study. *Mov Disord.* 13,100-107

- Taniguchi K, Ishizu K, Torizuka T, Hasegawa S, Okawada T, Ozawa T, Iino K, Taniguchi M, Ikematsu Y, Nishiwaki Y, Kida H, Waki S, Uchimura M, 2001. Metastases of predominantly dopamine-secreting pheochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. *Eur.J Surg.* 167,866-870
- Taniwaki T, Sakai T, Kobayashi T, Kuwabara Y, Otsuka M, Ichiya Y, Masuda K, Goto I, 1997. Positron emission tomography (PET) in Machado-Joseph disease. *J Neurol Sci.* 145,63-67
- Tanner CM, 1992. Occupational and environmental causes of parkinsonism. *Occupational Medicine* 7,503-513
- Tashiro M, Juengling FD, Reinhardt MJ, Brink I, Hoegerle S, Mix M, Kubota K, Yamaguchi K, Itoh M, Sasaki H, Moser E, Nitzsche EU, 2000. Reproducibility of PET brain mapping of cancer patients. *Psychooncology.* 9,157-163
- Tashiro M, Itoh M, Kubota K, Kumano H, Masud MM, Moser E, Arai H, Sasaki H, 2001. Relationship between trait anxiety, brain activity and natural killer cell activity in cancer patients: a preliminary PET study. *Psychooncology.* 10,541-546
- Tatlidil R, 2000. Persistent postictal hyperperfusion demonstrated with PET. *Epilepsy Res.* 42,83-88
- Tatlidil R, Xiong J, Luther S, 2000. Presurgical lateralization of seizure focus and language dominant hemisphere with O-15 water PET imaging. *Acta Neurol.Scand.* 102,73-80
- Tatsch K, Koch W, Linke R, Poepperl G, Peters N, Holtmannspoetter M, Dichgans M, 2003. Cortical Hypometabolism and Crossed Cerebellar Diaschisis Suggest Subcortically Induced Disconnection in CADASIL: An (18)F-FDG PET Study. *J Nucl Med* 44,862-869
- Tauscher J, Verhoeff NP, Christensen BK, Hussey D, Meyer JH, Kecojevic A, Javanmard M, Kasper S, Kapur S, 2001. Serotonin 5-HT<sub>1A</sub> receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. *Neuropsychopharmacology* 24,522-530
- Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S, 2001. Inverse relationship between serotonin 5-HT<sub>1A</sub> receptor binding

- and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. *Am.J Psychiatry* 158,1326-1328
- Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB, 2002. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [(11)C]WAY-100635. *Arch Gen Psychiatry* 59,514-520
- Tavitian B, Pappata S, Planas AM, Jobert A, Bonnot-Lours S, Crouzel C, DiGiamberardino L, 1993. In vivo visualization of acetylcholinesterase with positron emission tomography. *Neuroreport* 4,535-538
- Tavitian B, Terrazzino S, Kuhnast B, Marzabal S, Stettler O, Dolle F, Deverre JR, Jobert A, Hinnen F, Bendriem B, Crouzel C, Di Giamberardino L, 1998. In vivo imaging of oligonucleotides with positron emission tomography. *Nat.Med.* 4,467-471
- Tavitian B, Marzabal S, Boutet V, Kuhnast B, Terrazzino S, Moynier M, Dolle F, Deverre JR, Thierry AR, 2002. Characterization of a synthetic anionic vector for oligonucleotide delivery using in vivo whole body dynamic imaging. *Pharm.Res* 19,367-376
- Tecco JM, Wuilmart P, Lasseaux L, Wikler D, Jr., Damhaut P, Goldman S, Gilles C, 1998. Cerebello-thalamo-cerebral diaschisis: a case report. *J Neuroimaging* 8,115-116
- Tedroff J, Aquilonius SM, Hartvig P, Lundqvist H, Gee AG, Uhlin J, Langstrom B, 1988. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. *Acta Neurol Scand.* 77,192-201
- Tedroff J, Aquilonius SM, Hartvig P, Bredberg E, Bjurling P, Langstrom B, 1992. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response. *Acta Neurol Scand.* 85,95-102
- Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B, 1996. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [(11)C]raclopride displacement and PET. *Neurology* 46,1430-1436

- Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR, 1990. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. *N Engl J Med* 322,1781-1787
- Telang FW, Volkow ND, Levy A, Logan J, Fowler JS, Felder C, Wong C, Wang GJ, 1999. Distribution of tracer levels of cocaine in the human brain as assessed with averaged [<sup>11</sup>C]cocaine images. *Synapse* 31,290-296
- Ter Pogossian MM, Mullani NA, Hood J, Higgins CS, Currie CM, 1978. A multislice positron emission computed tomograph (PETT IV) yielding transverse and longitudinal images. *Radiology* 128,477-484
- Terpogossian MM, Ficke DC, Beecher DE, Hoffmann GR, Bergmann SR, 1994. The Super Pet 3000-e - A Pet Scanner Designed for High Count Rate Cardiac Applications. *Journal of Computer Assisted Tomography* 18,661-669
- Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann.Neurol.* 30,572-580
- Tetrud JW, Langston JW, Irwin I, Snow B, 1994. Parkinsonism caused by petroleum waste ingestion. *Neurology* 44,1051-1054
- Thal DR, Rub U, Orantes M, Braak H, 2002. Phases of A beta-deposition in the human brain and its relevance for the development of AD. *Neurology* 58,1791-1800
- Theodore WH, Di Chiro G, Margolin R, Fishbein D, Porter RJ, Brooks RA, 1986. Barbiturates reduce human cerebral glucose metabolism. *Neurology* 36,60-64
- Theodore WH, Bairamian D, Newmark ME, Di Chiro G, Porter RJ, Larson S, Fishbein D, 1986. Effect of phenytoin on human cerebral glucose metabolism. *J.Cereb.Blood Flow Metab.* 6,315-320
- Theodore WH, Rose D, Patronas N, Sato S, Holmes M, Bairamian D, Porter RJ, Di Chiro G, Larson S, Fishbein D, 1987. Cerebral glucose metabolism in the Lennox-Gastaut syndrome. *Annals of Neurology* 21,14-21
- Theodore WH, 1988. Antiepileptic drugs and cerebral glucose metabolism. *Epilepsia* 29,S48-S55

- Theodore WH, Bromfield E, Onorati L, 1989. The effect of carbamazepine on cerebral glucose metabolism. *Ann.Neurol* 25,516-520
- Theodore WH, Carson RE, Andreasen P, Zametkin A, Blasberg R, Leiderman DB, Rice K, Newman A, Channing M, Dunn B, 1992. PET imaging of opiate receptor binding in human epilepsy using [18F]cyclofoxy. *Epilepsy Research* 13,129-139
- Theodore WH, Sato S, Kufta C, Balish MB, Bromfield EB, Leiderman DB, 1992. Temporal lobectomy for uncontrolled seizures: the role of positron emission tomography. *Annals of Neurology* 32,789-794
- Theodore WH, Gaillard WD, Sato S, Kufta C, Leiderman D, 1994. Positron emission tomographic measurement of cerebral blood flow and temporal lobectomy. *Annals of Neurology* 36,241-244
- Theodore WH, Balish M, Leiderman D, Bromfield E, Sato S, Herscovitch P, 1996. Effect of seizures on cerebral blood flow measured with 15O-H2O and positron emission tomography. *Epilepsia* 37,796-802
- Theodore WH, Bhatia S, Hatta J, Fazilat S, DeCarli C, Bookheimer SY, Gaillard WD, 1999. Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures. *Neurology* 52,132-136
- Theodore WH, Gaillard WD, 2000. Positron emission tomography in neocortical epilepsies. *Adv.Neurol.* 84,435-446
- Theodore WH, Gaillard WD, De Carli C, Bhatia S, Hatta J, 2001. Hippocampal volume and glucose metabolism in temporal lobe epileptic foci. *Epilepsia* 42,130-132
- Theodore WH, 2002. Imaging in epilepsy. *Curr Science* 82,1-9
- Theodore WH, Gaillard WD, 2002. Neuroimaging and the progression of epilepsy. *Prog.Brain Res.* 135,305-313
- Theodore WH, 2002. When is positron emission tomography really necessary in epilepsy diagnosis? *Curr.Opin.Neurol.* 15,191-195
- Thibaut F, Vaugeois JM, Bonnet JJ, Costentin J, 1996. In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmission. *Neuropharmacology* 35,267-272

- Thie JA, Smith GT, Hubner KF, 1997. Linear least squares compartmental-model-independent parameter identification in PET. *IEEE Trans.Med Imaging* 16,11-16
- Thiel A, Herholz K, von Stockhausen HM, Leyen-Pilgram K, Pietrzyk U, Kessler J, Wienhard K, Klug N, Heiss WD, 1998. Localization of language-related cortex with O-15-water in patients with gliomas. *Neuroimage* 7,284-295
- Thiel A, Pietrzyk U, Sturm V, Herholz K, Hovels M, Schroder R, 2000. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. *Neurosurgery* 46,232-234
- Thiel A, Herholz K, Koyuncu A, Ghaemi M, Kracht LW, Habedank B, Heiss WD, 2001. Plasticity of language networks in patients with brain tumors. A positron emission tomography activation study. *Annals of Neurology* 50,620-629
- Thiel A, Hilker R, Kessler J, Habedank B, Herholz K, Heiss WD, 2001. Neuroanatomic correlates for deficits in decision making in Parkinson's disease: a PET study. *J.Cereb.Blood Flow Metab.* 21 (Suppl. 1),S301
- Thobois S, Dominey PF, Decety PJ, Pollak PP, Gregoire MC, Le Bars PD, Broussolle E, 2000. Motor imagery in normal subjects and in asymmetrical Parkinson's disease: a PET study [In Process Citation]. *Neurology* 55,996-1002
- Thompson PM, Woods RP, Mega MS, Toga AW, 2000. Mathematical/computational challenges in creating deformable and probabilistic atlases of the human brain. *Hum.Brain Mapp.* 9,81-92
- Thompson SA, Hodges JR, 2002. Mild Cognitive Impairment: a Clinically Useful but Currently Ill-defined Concept? *Neurocase* 8,405-410
- Thompson TP, Lunsford LD, Kondziolka D, 1999. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. *Stereotact.Funct.Neurosurg* 73,9-14
- Thorngren-Jerneck K, Ohlsson T, Sandell A, Erlandsson K, Strand SE, Ryding E, Svenningsen NW, 2001. Cerebral glucose metabolism measured by positron emission tomography in term newborn infants with hypoxic ischemic encephalopathy. *Pediatr.Res* 49,495-501



- Thurfjell L, Pagani M, Andersson JLR, Jonsson C, Lundqvist R, Wagner A, 2000. Registration of neuroimaging data: Implementation and clinical applications. *Journal of Neuroimaging* 10,39-46
- Tien RD, Ashdown BC, Lewis DV, Jr., Atkins MR, Burger PC, 1992. Rasmussen's encephalitis: neuroimaging findings in four patients. *AJR Am J Roentgenol.* 158,1329-1332
- Tierney MC, Varga M, Hosey L, Grafman J, Braun A, 2001. PET evaluation of bilingual language compensation following early childhood brain damage. *Neuropsychologia* 39,114-121
- Tiihonen J, Vilkmann H, Rasanen P, Ryyanen OP, Hakko H, Bergman J, Hamalainen T, Laakso A, Haaparanta-Solin M, Solin O, Kuoppamaki M, Syvalahti E, Hietala J, 1998. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. *Mol.Psychiatry* 3,156-161
- Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M, 2002. Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. *Biol.Psychiatry* 52,1113-1119
- Tjuvajev JG, Stockhammer G, Desai R, Uehara H, Watanabe K, Gansbacher B, Blasberg RG, 1995. Imaging the expression of transfected genes in vivo. *Cancer Res.* 55,6126-6132
- Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J, Beattie B, Koutcher J, Larson S, Blasberg RG, 1996. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. *Cancer Res.* 56,4087-4095
- Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit J, Humm J, Larson SM, Finn R, Blasberg R, 1998. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography [In Process Citation]. *Cancer Res.* 58,4333-4341
- Tjuvajev JG, Chen SH, Joshi A, Joshi R, Guo ZS, Balatoni J, Ballon D, Koutcher J, Finn R, Woo SL, Blasberg RG, 1999. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. *Cancer Res.* 59,5186-5193
- Tjuvajev JG, Joshi A, Callegari J, Lindsley L, Joshi R, Balatoni J, Finn R, Larson SM, Sadelain M, Blasberg RG, 1999. A general approach to the non-

- invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. *Neoplasia*. 1,315-320
- Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, Finn R, Bornmann W, Thaler H, Conti PS, Blasberg RG, 2002. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. *J Nucl Med* 43,1072-1083
- Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, Fazilat S, Kopylev L, Herscovitch P, Eckelman WC, Theodore WH, 2003. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. *Neurology* 60,749-756
- Toga AW, Mazziotta JC, 2002. Brain mapping. The methods, Academic Press, San Diego
- Torres GE, Gainetdinov RR, Caron MG, 2003. Plasma membrane monoamine transporters: structure, regulation and function. *Nat.Rev.Neurosci.* 4,13-25
- Torstenson R, Hartvig P, Langstrom B, Westerberg G, Tedroff J, 1997. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. *Ann.Neurol* 41,334-340
- Torstenson R, Tedroff J, Hartvig P, Fasth KJ, Langstrom B, 1999. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system [In Process Citation]. *J.Cereb.Blood Flow Metab.* 19,1142-1149
- Townsend D, Frey P, DONATH A, Clack R, Schorr B, Jeavons A, 1984. Volume Measurement In vivo Using Positron Tomography. *Nuclear Instruments & Methods in Physics Research Section A-Accelerators Spectrometers Detectors and Associated Equipment* 221,105-112
- Townsend D, Frey P, Jeavons A, Reich G, TOCHONDANGUY HJ, DONATH A, CHRISTIN A, Schaller G, 1987. High-Density Avalanche Chamber (Hidac) Positron Camera. *J.Nucl.Med.* 28,1554-1562
- Townsend DW, Geissbuhler A, Defrise M, Hoffman EJ, Spinks TJ, Bailey DL, Gilardi MC, Jones T, 1991. Fully 3-dimensional reconstruction for a PET camera with retractable septa. *IEEE Transactions on Medical Imaging* 10,505-512

- Townsend DW, WENSVEEN M, Byars LG, Geissbuhler A, TOCHONDANGUY HJ, CHRISTIN A, Defrise M, Bailey DL, Grootenboer S, DONATH A, Nutt R, 1993. A Rotating Pet Scanner Using BGO Block Detectors - Design, Performance and Applications. *J.Nucl.Med.* 34,1367-1376
- Townsend DW, Cherry SR, 2001. Combining anatomy and function: the path to true image fusion. *Eur.Radiol.* 11,1968-1974
- Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomilly R, Hummel S, Scharnhorst J, Krohn KA, Spence AM, 2002. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. *J Nucl Med* 43,1667-1673
- Traykov L, Tavitian B, Jobert A, Boller F, Forette F, Crouzel C, Di Giamberardino L, Pappata S, 1999. In vivo PET study of cerebral [<sup>11</sup>C] methyl-tetrahydroaminoacridine distribution and kinetics in healthy human subjects. *Eur.J Neurol.* 6,273-278
- Treyer V, Jobin M, Burger C, Teneggi V, Buck A, 2003. Quantitative cerebral H<sub>2</sub>(<sup>15</sup>O) perfusion PET without arterial blood sampling, a method based on washout rate. *Eur.J Nucl Med Mol.Imaging* 30,572-580
- Trichard C, Paillere-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL, 1998. No serotonin 5-HT<sub>2A</sub> receptor density abnormality in the cortex of schizophrenic patients studied with PET. *Schizophr.Res.* 31,13-17
- Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL, 1998. Binding of antipsychotic drugs to cortical 5-HT<sub>2A</sub> receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. *Am J Psychiatry* 155,505-508
- Tsuchida T, Sadato N, Nishizawa S, Yonekura Y, Itoh H, 2002. Effect of postprandial hyperglycaemia in non-invasive measurement of cerebral metabolic rate of glucose in non-diabetic subjects. *Eur.J Nucl Med Mol.Imaging* 29,248-250
- Tsukada H, Kreuter J, Maggos CE, Unterwald EM, Kakiuchi T, Nishiyama S, Futatsubashi M, Kreek MJ, 1996. Effects of binge pattern cocaine administration on dopamine D<sub>1</sub> and D<sub>2</sub> receptors in the rat brain: an in vivo study using positron emission tomography. *J Neurosci.* 16,7670-7677
- Tsukada H, Kakiuchi T, Ando I, Shizuno H, Nakanishi S, Ouchi Y, 1997. Regulation of cerebral blood flow response to somatosensory stimulation

- through the cholinergic system: a positron emission tomography study in unanesthetized monkeys. *Brain Res.* 749,10-17
- Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, Nakanishi S, 1999. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. *Brain Res* 849,85-96
- Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T, 2000. Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. *J Neurosci.* 20,7067-7073
- Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D, Kakiuchi T, 2000. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. *Synapse* 37,95-103
- Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T, 2000. Dose-response and duration effects of acute administrations of cocaine and GBR12909 on dopamine synthesis and transporter in the conscious monkey brain: PET studies combined with microdialysis. *Brain Res.* 860,141-148
- Tsukada H, Kakiuchi T, Nishiyama S, Ohba H, Harada N, 2001. Effects of aging on 5-HT(1A) receptors and their functional response to 5-HT(1a) agonist in the living brain: PET study with [carbonyl-(11)C]WAY-100635 in conscious monkeys. *Synapse* 42,242-251
- Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, 2001. Ketamine alters the availability of striatal dopamine transporter as measured by [(11)C]beta-CFT and [(11)C]beta-CIT-FE in the monkey brain. *Synapse* 42,273-280
- Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF, 2002. Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. *Synapse* 45,207-212
- Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, Otsuka Y, Sakamoto S, Ohata K, Goto T, Hara M, 2003. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation

- necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 98,1056-1064
- Tsuyuguchi N, Sunada I, Ohata K, Takami T, Nishio A, Hara M, Kawabe J, Okamura T, Ochi H, 2003. Evaluation or treatment effects in brain abscess with positron emission tomography: comparison of Fluorine-18-Fluorodeoxyglucose and Carbon-11-Methionine. Ann.Nucl Med 17,47-51
- Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J, 1993. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res. 49,219-237
- Tuominen S, Juvonen V, Amberla K, Jolma T, Rinne JO, Tuisku S, Kurki T, Marttila R, Poyhonen M, Savontaus ML, Viitanen M, Kalimo H, 2001. Phenotype of a homozygous CADASIL patient in comparison to 9 age-matched heterozygous patients with the same R133C Notch3 mutation. Stroke 32,1767-1774
- Turjanski N, Bhatia K, Burn DJ, Sawle GV, Marsden CD, Brooks DJ, 1993. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology 43,1563-1568
- Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ, 1995. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 118,689-696
- Turjanski N, Brooks DJ, 1997. PET and the investigation of dementia in the parkinsonian patient. J Neural Transm.Suppl 51,37-48
- Turjanski N, Lees AJ, Brooks DJ, 1999. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52,932-937
- Turkheimer FE, Brett M, Aston JA, Leff AP, Sargent PA, Wise RJ, Grasby PM, Cunningham VJ, 2000. Statistical modeling of positron emission tomography images in wavelet space. J.Cereb.Blood Flow Metab. 20,1610-1618
- Tyler JL, Yamamoto YL, Diksic M, Theron J, Villemure JG, Worthington C, Evans AC, Feindel W, 1986. Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J.Nucl.Med. 27,775-780

- Tyler JL, Diksic M, Villemure JG, Evans AC, Meyer E, Yamamoto YL, Feindel W, 1987. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. *J.Nucl.Med.* 28,1123-1133
- Tyrrell PJ, Warrington EK, Frackowiak RS, Rossor MN, 1990. Progressive degeneration of the right temporal lobe studied with positron emission tomography. *Journal of Neurology, Neurosurgery & Psychiatry* 53,1046-1050
- Tyrrell PJ, Sawle GV, Ibanez V, Bloomfield PM, Leenders KL, Frackowiak RS, Rossor MN, 1990. Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type. *Arch Neurol* 47,1318-1323
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M, 2002. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain. *Neuroimage* 15,273-289
- Tzourio N, Crivello F, Mellet E, Nkanga-Ngila B, Mazoyer B, 1998. Functional anatomy of dominance for speech comprehension in left handers vs right handers. *Neuroimage.* 8,1-16
- Uemura K, Shishido F, Higano S, Inugami A, Kanno I, Takahashi K, Yasui N, Tagawa K, 1986. Positron emission tomography in patients with a primary intracerebral hematoma. *Acta Radiol.Suppl* 369,426-428
- Uitti RJ, Snow BJ, Shinotoh H, Vingerhoets FJ, Hayward M, Hashimoto S, Richmond J, Markey SP, Markey CJ, Calne DB, 1994. Parkinsonism induced by solvent abuse. *Ann.Neurol.* 35,616-619
- Umile EM, Sandel ME, Alavi A, Terry CM, Plotkin RC, 2002. Dynamic imaging in mild traumatic brain injury: support for the theory of medial temporal vulnerability. *Arch.Phys.Med Rehabil.* 83,1506-1513
- Utriainen M, Metsahonkala L, Salmi TT, Utriainen T, Kalimo H, Pihko H, Makiperna A, Harila-Saari A, Jyrkkio S, Laine J, Nagren K, Minn H, 2002. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. *Cancer* 95,1376-1386
- Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Langstrom B, Lemaire C, Meyer GJ, 1992. Amino acids for the measurement of protein synthesis in

- vivo by PET. [Review]. International Journal of Radiation Applications & Instrumentation - Part B, Nuclear Medicine & Biology 19,227-237
- Vaidyanathan G, Affleck DJ, Zalutsky MR, 1994. (4-[<sup>18</sup>F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. Journal of Medicinal Chemistry 37,3655-3662
- Vaidyanathan G, Affleck DJ, Zalutsky MR, 1995. Validation of 4-[fluorine-<sup>18</sup>]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 36,644-650
- Valette H, Bottlaender M, Dolle F, Guenther I, Coulon C, Hinnen F, Fuseau C, Ottaviani M, Crouzel C, 1999. Characterization of the nicotinic ligand 2-[<sup>18</sup>F]fluoro-3-[2(S)-2-azetidylmethoxy]pyridine in vivo. Life Sci. 64,L93-L97
- Valette H, Bottlaender M, Dolle F, Guenther I, Fuseau C, Coulon C, Ottaviani M, Crouzel C, 1999. Imaging central nicotinic acetylcholine receptors in baboons with [<sup>18</sup>F]fluoro-A-85380. J.Nucl.Med. 40,1374-1380
- Valette H, Bottlaender M, Dolle F, Coulon C, Ottaviani M, Syrota A, 2003. Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J Neurochem. 84,105-111
- Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK, 1988. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 69,830-838
- Valk PE, Jagust WJ, Derenzo SE, Huesman RH, Geyer AB, Budinger TF, 1990. Clinical evaluation of a high-resolution (2.6-mm) positron emission tomography. Radiology 176,783-790
- Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF, 1992. Hypoxia in human gliomas: demonstration by PET with fluorine-<sup>18</sup>-fluoromisonidazole. J.Nucl.Med. 33,2133-2137
- Valk PE et al., 2003. Positron Emission Tomography. Basic Science and Clinical Practice, Springer Verlag,
- van der Kallen BF, Morris GL, Yetkin FZ, van Erning LJ, Thijssen HO, Haughton VM, 1998. Hemispheric language dominance studied with functional MR:

- preliminary study in healthy volunteers and patients with epilepsy.  
AJNR.Am.J.Neuroradiol. 19,73-77
- Van Horn JD, Ellmore TM, Esposito G, Berman KF, 1998. Mapping voxel-based statistical power on parametric images. *Neuroimage*. 7,97-107
- van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de K, I, Kamphorst W, Ravid R, Spillantini MG, Niermeijer, Heutink P, 1999. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. *Ann.Neurol*. 46,617-626
- Vandenberghe S, D'Asseler Y, Van de Walle R, Kauppinen T, Koole M, Bouwens L, Van Laere K, Lemahieu I, Dierckx RA, 2001. Iterative reconstruction algorithms in nuclear medicine. *Comput.Med Imaging Graph*. 25,105-111
- Vannucci SJ, Clark RR, Koehler-Stec E, Li K, Smith CB, Davies P, Maher F, Simpson IA, 1998. Glucose transporter expression in brain: relationship to cerebral glucose utilization. *Dev.Neurosci*. 20,369-379
- Varastet M, Brouillet E, Chavoix C, Prenant C, Crouzel C, Stulzaft O, Bottlaender M, Cayla J, Maziere B, Maziere M, 1992. In vivo visualization of central muscarinic receptors using [<sup>11</sup>C]quinuclidinyl benzilate and positron emission tomography in baboons. *European Journal of Pharmacology* 213,275-284
- Verghese J, Crystal HA, Dickson DW, Lipton RB, 1999. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. *Neurology* 53,1974-1982
- Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallieres E, Wood DE, 2002. In Vivo Validation of 3'-deoxy-3'-[(18)F]fluorothymidine ([<sup>18</sup>F]FLT) as a Proliferation Imaging Tracer in Humans: Correlation of [<sup>18</sup>F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors. *Clin.Cancer Res*. 8,3315-3323
- Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA, 2003. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. *J Nucl Med* 44,1482-1488
- Vidailhet M, Dupel C, Lehericy S, Remy P, Dormont D, Serdaru M, Jedynak P, Veber H, Samson Y, Marsault C, Agid Y, 1999. Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography. *Arch.Neurol*. 56,982-989



- Videbaek C, Ott P, Paulson OB, Knudsen GM, 1999. Blood-brain barrier transport and protein binding of flumazenil and iomazenil in the rat: implications for neuroreceptor studies. *J.Cereb.Blood Flow Metab.* 19,948-955
- Vielhaber S, Von Oertzen JH, Kudin AF, Schoenfeld A, Menzel C, Biersack HJ, Kral T, Elger CE, Kunz WS, 2003. Correlation of Hippocampal Glucose Oxidation Capacity and Interictal FDG-PET in Temporal Lobe Epilepsy. *Epilepsia* 44,193-199
- Viergever MA, Maintz JB, Niessen WJ, Noordmans HJ, Pluim JP, Stokking R, Vincken KL, 2001. Registration, segmentation, and visualization of multimodal brain images. *Comput.Med.Imaging Graph.* 25,147-151
- Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA, 1998. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. *J Neurosci.* 18,419-427
- Villemagne VL, Horti A, Scheffel U, Ravert HT, Finley P, Clough DJ, London ED, Wagner HN, Jr., Dannals RF, 1997. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. *J.Nucl.Med.* 38,1737-1741
- Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB, 1999. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. *Synapse* 33,268-273
- Villemagne VL, Rothman RB, Yokoi F, Rice KC, Matecka D, Dannals RF, Wong DF, 1999. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. *Synapse* 32,44-50
- Vinas FC, Zamorano L, Mueller RA, Jiang Z, Chugani H, Fuerst D, Muzik O, Mangner TJ, Diaz FG, 1997. [15O]-water PET and intraoperative brain mapping: a comparison in the localization of eloquent cortex. *Neurol.Res.* 19,601-608
- Vingerhoets FJ, Snow BJ, Tetrad JW, Langston JW, Schulzer M, Calne DB, 1994. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. *Ann.Neurol* 36,765-770

- Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB, 1994. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. *Ann.Neurol* 36,759-764
- Vingerhoets FJ, Schulzer M, Ruth TJ, Holden JE, Snow BJ, 1996. Reproducibility and discriminating ability of fluorine-18-6- fluoro-L-Dopa PET in Parkinson's disease. *J.Nucl.Med.* 37,421-426
- Visser GM, Krugers HJ, Luurtsema G, van Waarde A, Elsinga PH, deKloet ER, Groen MB, Bohus B, Go KG, Paans AM, ., 1995. Synthesis and organ distribution of [18F]fluoro-Org 6141 in the rat: a potential glucocorticoid receptor ligand for positron emission tomography. *Nucl Med Biol.* 22,915-920
- Visser PJ, Verhey FR, Ponds RW, Kester A, Jolles J, 2000. Distinction between preclinical Alzheimer's disease and depression. *J Am Geriatr.Soc.* 48,479-484
- Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, Heiss WD, Jacobs AH, 2003. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. *Ann.Neurol* 54,479-487
- Vogt BA, Watanabe H, Grooten S, Jones AKP, 1995. TOPOGRAPHY OF DIPRENORPHINE BINDING IN HUMAN CINGULATE GYRUS AND ADJACENT CORTEX DERIVED FROM COREGISTERED PET AND MR IMAGES. *Human Brain Mapping* 3,1-12
- Vogt BA, Derbyshire S, Jones AK, 1996. Pain processing in four regions of human cingulate cortex localized with co-registered PET and MR imaging. *Eur.J Neurosci.* 8,1461-1473
- Volkow ND, Brodie JD, Wolf AP, Gomez-Mont F, Cancro R, Van Gelder P, Russell JA, Overall J, 1986. Brain organization in schizophrenia. *J Cereb.Blood Flow Metab* 6,441-446
- Volkow ND, Brodie JD, Wolf AP, Angrist B, Russell J, Cancro R, 1986. Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. *J Neurol Neurosurg Psychiatry* 49,1199-1202
- Volkow ND, Tancredi L, 1987. Neural substrates of violent behaviour. A preliminary study with positron emission tomography. *Br.J Psychiatry* 151,668-673

- Volkow ND, Warner N, McIntyre R, Valentine A, Kulkarni M, Mullani N, Gould L, 1988. Cerebral involvement in systemic lupus erythematosus. *Am J Physiol Imaging* 3,91-98
- Volkow ND, Mullani N, Gould L, Adler SS, Guynn RW, Overall JE, Dewey S, 1988. Effects of acute alcohol intoxication on cerebral blood flow measured with PET. *Psychiatry Res* 24,201-209
- Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K, 1988. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. *Br.J Psychiatry* 152,641-648
- Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D, ., 1990. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. *Am J Psychiatry* 147,719-724
- Volkow ND, Hitzemann R, Wolf AP, Logan J, Fowler JS, Christman D, Dewey SL, Schlyer D, Burr G, Vitkun S, ., 1990. Acute effects of ethanol on regional brain glucose metabolism and transport. *Psychiatry Res* 35,39-48
- Volkow ND, Mullani N, Gould LK, Adler SS, Gatley SJ, 1991. Sensitivity of measurements of regional brain activation with oxygen-15-water and PET to time of stimulation and period of image reconstruction. *J.Nucl.Med.* 32,58-61
- Volkow ND, Fowler JS, Wolf AP, Hitzemann R, Dewey S, Bendriem B, Alpert R, Hoff A, 1991. Changes in brain glucose metabolism in cocaine dependence and withdrawal. *Am J Psychiatry* 148,621-626
- Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Dewey SL, Handlesman L, 1992. Long-term frontal brain metabolic changes in cocaine abusers. *Synapse* 11,184-190
- Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Burr G, Pascani K, Dewey SL, Wolf AP, 1992. Decreased brain metabolism in neurologically intact healthy alcoholics. *Am J Psychiatry* 149,1016-1022
- Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP, 1993. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. *Synapse* 14,169-177

- Volkow ND, Wang GJ, Hitzemann R, Fowler JS, Wolf AP, Pappas N, Biegon A, Dewey SL, 1993. Decreased cerebral response to inhibitory neurotransmission in alcoholics. *Am J Psychiatry* 150,417-422
- Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, 1994. Imaging endogenous dopamine competition with [<sup>11</sup>C]raclopride in the human brain. *Synapse* 16,255-262
- Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, Hitzemann R, Wolf AP, 1994. Decreased dopamine transporters with age in healthy human subjects. *Ann.Neurol* 36,237-239
- Volkow ND, Wang GJ, Begleiter H, Hitzemann R, Pappas N, Burr G, Pascani K, Wong C, Fowler JS, Wolf AP, 1995. Regional brain metabolic response to lorazepam in subjects at risk for alcoholism. *Alcohol Clin.Exp.Res.* 19,510-516
- Volkow ND, Tancredi LR, Grant C, Gillespie H, Valentine A, Mullani N, Wang GJ, Hollister L, 1995. Brain glucose metabolism in violent psychiatric patients: a preliminary study. *Psychiatry Res* 61,243-253
- Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Lieberman J, Hitzemann R, 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. *Arch Gen Psychiatry* 52,456-463
- Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Pascani K, 1996. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. *Alcohol Clin.Exp.Res* 20,1594-1598
- Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Gatley SJ, MacGregor RR, Wolf AP, 1996. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. *Neuropsychopharmacology* 14,159-168
- Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, Lieberman J, 1996. Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. *Proc.Natl.Acad.Sci.U.S.A* 93,10388-10392
- Volkow ND, Ding YS, Fowler JS, Wang GJ, 1996. Cocaine addiction: hypothesis derived from imaging studies with PET. *J Addict.Dis.* 15,55-71

- Volkow ND, Wang GJ, Overall JE, Hitzemann R, Fowler JS, Pappas N, Frecska E, Pascani K, 1997. Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification. *Alcohol Clin.Exp.Res.* 21,1278-1284
- Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Pappas N, Pascani K, Wong C, 1997. Gender differences in cerebellar metabolism: test-retest reproducibility. *American Journal of Psychiatry* 154,119-121
- Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE, 1997. RELATIONSHIP BETWEEN SUBJECTIVE EFFECTS OF COCAINE AND DOPAMINE TRANSPORTER OCCUPANCY. *Nature* 386,827-830
- Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen, Dewey SL, Pappas N, 1997. DECREASED STRIATAL DOPAMINERGIC RESPONSIVENESS IN DETOXIFIED COCAINE-DEPENDENT SUBJECTS. *Nature* 386,830-833
- Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N, 1998. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am.J.Psychiatry* 155,1325-1331
- Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Gatley SJ, Dewey SS, Pappas N, 1998. Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study. *Am.J.Psychiatry* 155,200-206
- Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N, 1999. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. *Life Sci.* 65,L7-12
- Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P, 1999. Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. *Synapse* 31,59-66
- Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N, 1999. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. *Am J Psychiatry* 156,19-26

- Volkow ND, Fowler JS, Wang GJ, 1999. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. *J.Psychopharmacol.* 13,337-345
- Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Dewey SL, Hitzemann R, Gifford AN, Pappas NR, 1999. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". *J Pharmacol.Exp.Ther.* 288,14-20
- Volkow ND, Logan J, Fowler JS, Wang GJ, Gur RC, Wong C, Felder C, Gatley SJ, Ding YS, Hitzemann R, Pappas N, 2000. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. *Am.J Psychiatry* 157,75-80
- Volkow ND, Fowler JS, 2000. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. *Cereb.Cortex* 10,318-325
- Volkow ND, Wang GJ, Fowler JS, Franceschi D, Thanos PK, Wong C, Gatley SJ, Ding YS, Molina P, Schlyer D, Alexoff D, Hitzemann R, Pappas N, 2000. Cocaine abusers show a blunted response to alcohol intoxication in limbic brain regions. *Life Sci.* 66,L161-L167
- Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D, Franceschi M, Logan J, Gatley SJ, Wong C, Ding YS, Hitzemann R, Pappas N, 2000. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. *Life Sci.* 67,1507-1515
- Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Wong C, Logan J, 2001. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. *Am J Psychiatry* 158,383-389
- Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN, 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. *Am J Psychiatry* 158,377-382
- Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, Gifford A, Wong C, Pappas N, 2001. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. *Am J Psychiatry* 158,2015-2021

- Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J, 2001. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. *J Neurosci.* 21,9414-9418
- Volkow ND, Ding YS, Fowler JS, Gatley SJ, 2001. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. *Biol.Psychiatry* 49,211-220
- Volkow ND, Wang GJ, Maynard L, Fowler JS, Jayne B, Telang F, Logan J, Ding YS, Gatley SJ, Hitzemann R, Wong C, Pappas N, 2002. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. *Psychiatry Res.* 116,163-172
- Volkow ND, Fowler JS, Wang GJ, 2003. The addicted human brain: insights from imaging studies. *J Clin.Invest* 111,1444-1451
- Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J, 1998. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). *Psychiatry Res.* 83,149-162
- Vollenweider FX, Vontobel P, Hell D, Leenders KL, 1999. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [<sup>11</sup>C]raclopride. *Neuropsychopharmacology* 20,424-433
- Vollmar S, Michel C, Treffert JT, Newport DF, Casey M, Knoss C, Wienhard K, Liu X, Defrise M, Heiss WD, 2002. HeinzCluster: accelerated reconstruction for FORE and OSEM3D. *Physics in Medicine and Biology* 47,2651-2658
- Volpe JJ, Herscovitch P, Perlman JM, Raichle ME, 1983. Positron emission tomography in the newborn: extensive impairment of regional cerebral blood flow with intraventricular hemorrhage and hemorrhagic intracerebral involvement. *Pediatrics* 72,589-601
- Volpe JJ, Herscovitch P, Perlman JM, Kreusser KL, Raichle ME, 1985. Positron emission tomography in the asphyxiated term newborn: parasagittal impairment of cerebral blood flow. *Ann.Neurol* 17,287-296
- von Giesen HJ, Schlaug G, Steinmetz H, Benecke R, Freund HJ, Seitz RJ, 1994. Cerebral network underlying unilateral motor neglect: evidence from

- positron emission tomography. Journal of the Neurological Sciences 125,29-38
- von Stockhausen, H. M. 1998. 3D-Visualisierung der Funktion und der Morphologie des menschlichen Gehirns aus tomographischen Daten. Universität zu Köln.
- von Stockhausen HM, Pietrzyk U, Herholz K, 1998. "3D-Tool" - A software system for visualization and analysis of coregistered multimodality volume datasets of individual subjects. Neuroimage 7 (Suppl.),S799
- Votaw J, Byas-Smith M, Hua J, Voll R, Martarello L, Levey AI, Bowman FD, Goodman M, 2003. Interaction of isoflurane with the dopamine transporter. Anesthesiology 98,404-411
- Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP, 1997. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J.Neurosci.Res. 50,345-353
- Wörker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, Sturm V, Heiss WD, 1996. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur.J.Nucl.Med. 23,583-586
- Wagner HN, Jr., Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, 1984. Assessment of dopamine receptor densities in the human brain with carbon-11-labeled N-methylspiperone. Annals of Neurology 15 Suppl,S79-S84
- Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, Bommer M, Leithauser F, Wawra E, Munzert G, Reske SN, 2003. 3'-[18F]Fluoro-3'-Deoxythymidine ([18F]-FLT) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease. Cancer Res 63,2681
- Wahl L, Chirakal R, Firnau G, Garnett ES, Nahmias C, 1994. The distribution and kinetics of [18F]6-fluoro-3-O-methyl-L-dopa in the human brain. J Cereb.Blood Flow Metab 14,664-670
- Wahl L, Nahmias C, 1996. Modeling of fluorine-18-6-fluoro-L-Dopa in humans. J.Nucl.Med. 37,432-437



- Wakita K, Imahori Y, Ido T, Fujii R, Horii H, Shimizu M, Nakajima S, Mineura K, Nakamura T, Kanatsuna T, 2000. Simplification for measuring input function of FDG PET: investigation of 1-point blood sampling method. *J.Nucl.Med.* 41,1484-1490
- Walsh SL, Gilson SF, Jasinski DR, Stapleton JM, Phillips RL, Dannals RF, Schmidt J, Preston KL, Grayson R, Bigelow GE, 1994. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers. *Neuropsychopharmacology* 10,157-170
- Walter H, Kristeva R, Knorr U, Schlaug G, Huang Y, Steinmetz H, Nebeling B, Herzog H, Seitz RJ, 1992. Individual somatotopy of primary sensorimotor cortex revealed by intermodal matching of MEG, PET, and MRI. *Brain Topography* 5,183-187
- Wang GJ, Volkow ND, Fowler JS, Ding YS, Logan J, Gatley SJ, MacGregor RR, Wolf AP, 1995. Comparison of two pet radioligands for imaging extrastriatal dopamine transporters in human brain. *Life Sci.* 57,L187-L191
- Wang GJ, Volkow ND, Logan J, Fowler JS, Schlyer D, MacGregor RR, Hitzemann RJ, Gjedde A, Wolf AP, 1995. Serotonin 5-HT<sub>2</sub> receptor availability in chronic cocaine abusers. *Life Sci.* 56,L299-L303
- Wang GJ, Volkow ND, Fowler JS, Pappas NR, Wong CT, Pascani K, Felder CA, Hitzemann RJ, 1998. Regional cerebral metabolism in female alcoholics of moderate severity does not differ from that of controls. *Alcohol Clin.Exp.Res* 22,1850-1854
- Wang GJ, Volkow ND, Fowler JS, Hitzemann RJ, Pappas NR, Netusil N, 1998. Evaluation of gender difference in regional brain metabolic responses to lorazepam. *Psychiatry Res.* 82,37-46
- Wang GJ, Volkow ND, Levy AV, Felder CA, Fowler JS, Pappas NR, Hitzemann RJ, Wong CT, 1999. Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps. *J.Nucl.Med.* 40,715-720
- Wang GJ, Volkow ND, Fowler JS, Logan J, Pappas NR, Wong CT, Hitzemann RJ, Netusil N, 1999. Reproducibility of repeated measures of endogenous dopamine competition with [<sup>11</sup>C]raclopride in the human brain in response to methylphenidate. *J.Nucl.Med.* 40,1285-1291

- Wang GJ, Volkow ND, Fowler JS, Cervany P, Hitzemann RJ, Pappas NR, Wong CT, Felder C, 1999. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. *Life Sci.* 64,775-784
- Wang GJ, Volkow ND, Franceschi D, Fowler JS, Thanos PK, Scherbaum N, Pappas N, Wong CT, Hitzemann RJ, Felder CA, 2000. Regional brain metabolism during alcohol intoxication. *Alcohol Clin.Exp.Res.* 24,822-829
- Wang GJ, Volkow ND, Fowler JS, Franceschi D, Wong CT, Pappas NR, Netusil N, Zhu W, Felder C, Ma Y, 2003. Alcohol intoxication induces greater reductions in brain metabolism in male than in female subjects. *Alcohol Clin.Exp.Res* 27,909-917
- Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M, Huser JM, Snow BJ, Ruth TJ, Calne DB, Stoessl AJ, 1998. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. *Synapse* 30,56-61
- Warburg O, 1956. On the origin of cancer cells. *Science* 123,309-314
- Warburton E, Price CJ, Swinburn K, Wise RJ, 1999. Mechanisms of recovery from aphasia: evidence from positron emission tomography studies [see comments]. *J.Neurol.Neurosurg.Psychiatry* 66,155-161
- Watabe H, Itoh M, Cunningham V, Lammertsma AA, Bloomfield P, Mejia M, Fujiwara T, Jones AKP, Jones T, Nakamura T, 1996. Noninvasive quantification of rCBF using positron emission tomography. *Journal of Cerebral Blood Flow and Metabolism* 16,311-319
- Webb S, Ott RJ, Cherry SR, 1989. Quantitation of blood-brain barrier permeability by positron emission tomography. *Phys.Med Biol.* 34,1767-1771
- Weber S, Bauer A, Herzog H, Kehren F, Muhlensiepen H, Vogelbruch J, Coenen HH, Zilles K, Halling H, 2000. Recent results of the TierPET scanner. *IEEE Transactions on Nuclear Science* 47,1665-1669
- Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M, 2000. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study [In Process Citation]. *Eur.J.Nucl.Med.* 27,542-549
- Weder B, Seitz RJ, 1994. Deficient cerebral activation pattern in stroke recovery. *Neuroreport* 5,457-460

- Weder B, Knorr U, Herzog H, Nebeling B, Kleinschmidt A, Huang Y, Steinmetz H, Freund HJ, Seitz RJ, 1994. Tactile exploration of shape after subcortical ischaemic infarction studied with PET. *Brain* 117,593-605
- Weeks RA, Piccini P, Harding AE, Brooks DJ, 1996. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. *Ann.Neurol* 40,49-54
- Weeks RA, Cunningham VJ, Piccini P, Waters S, Harding AE, Brooks DJ, 1997. <sup>11</sup>C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. *J Cereb.Blood Flow Metab* 17,943-949
- Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ, 1997. Cortical control of movement in Huntington's disease. A PET activation study. *Brain* 120 ( Pt 9),1569-1578
- Weiller C, Chollet F, Friston KJ, Wise RJ, Frackowiak RS, 1992. Functional reorganization of the brain in recovery from striatocapsular infarction in man. *Annals of Neurology* 31,463-472
- Weiller C, Ramsay SC, Wise RJ, Friston KJ, Frackowiak RS, 1993. Individual patterns of functional reorganization in the human cerebral cortex after capsular infarction. *Ann.Neurol* 33,181-189
- Weiller C, Isensee C, Rijntjes M, Huber W, Muller S, Bier D, Dutschka K, Woods RP, Noth J, Diener HC, 1995. Recovery from Wernicke's aphasia: a positron emission tomographic study. *Annals of Neurology* 37,723-732
- Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC, 1995. Brain stem activation in spontaneous human migraine attacks. *Nat.Med* 1,658-660
- Weinberger DR, Berman KF, 1988. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. *Schizophr.Bull.* 14,157-168
- Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, Otto P, Nitzsche EU, Moser E, Peter HH, 2000. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. *Ann.Rheum.Dis.* 59,377-385
- Weisenbach S, Hilker R, Herholz K, Kalbe E, Zündorf G, Bauer B, Heiss WD, 2002. Different pattern of decreased cortical acetylcholine esterase in

- Alzheimer's and Parkinson's disease: A PET study. *Neurology* 58 (Suppl. 3),A144
- Welch LW, Nimmerrichter A, Kessler R, King D, Hoehn R, Margolin R, Martin PR, 1996. Severe global amnesia presenting as Wernicke-Korsakoff syndrome but resulting from atypical lesions. *Psychol.Med* 26,421-425
- Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR, 2003. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. *J Natl.Cancer Inst.* 95,675-682
- Wengenack TM, Curran GL, Poduslo JF, 2000. Targeting alzheimer amyloid plaques in vivo. *Nat.Biotechnol.* 18,868-872
- Werling A, Bublitz O, Doll J, Adam LE, Brix G, 2002. Fast implementation of the single scatter simulation algorithm and its use in iterative image reconstruction of PET data. *Phys.Med Biol.* 47,2947-2960
- Wester HJ, Brockmann J, Rosch F, Wutz W, Herzog H, Smith-Jones P, Stolz B, Bruns C, Stocklin G, 1997. PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. *Nucl.Med.Biol.* 24,275-286
- Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stocklin G, 1999. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. *J.Nucl.Med.* 40,205-212
- Westermarck K, Tedroff J, Thuomas KA, Hartvig P, Langstrom B, Andersson Y, Hornfeldt K, Aquilonius SM, 1995. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers. *Mov Disord.* 10,596-603
- Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. *Ann.Neurol.* 54,93-101
- Whone AL, Moore RY, Piccini PP, Brooks DJ, 2003. Plasticity of the nigropallidal pathway in Parkinson's disease. *Ann.Neurol* 53,206-213
- Widen L, Blomqvist G, Greitz T, Litton JE, Bergstrom M, Ehrin E, Ericson K, Eriksson L, Ingvar DH, Johansson L, Nilsson JL, Stone-Elander S, Sedvall

- G, Wiesel F, Wiik G, 1983. PET studies of glucose metabolism in patients with schizophrenia. *AJNR Am J Neuroradiol* 4,550-552
- Widen L, Eriksson L, Ingvar M, Parsons SM, Rogers GA, Stone-Elander S, 1992. Positron emission tomographic studies of central cholinergic nerve terminals. *Neurosci.Lett.* 136,1-4
- Widner H, Tetud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Bjorklund A, Lindvall O, Langston JW, 1992. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *N Engl J Med* 327,1556-1563
- Wienhard K, Pawlik G, Herholz K, Wagner R, Heiss WD, 1985. Estimation of local cerebral glucose utilization by positron emission tomography of [18F]2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures. *J.Cereb.Blood Flow Metab.* 5,115-125
- Wienhard K, Coenen HH, Pawlik G, Rudolf J, Laufer P, Jovkar S, St"cklin G, Heiss WD, 1990. PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system. *Journal of Neural Transmission - General Section* 81,195-213
- Wienhard K, Pawlik G, Nebeling B, Rudolf J, Fink G, Hamacher K, St"cklin G, Heiss WD, 1991. Estimation of local cerebral glucose utilization by positron emission tomography: comparison of [18F]2-fluoro-2-deoxy-D-glucose and [18F]2-fluoro-2-deoxy-D-mannose in patients with focal brain lesions. *J.Cereb.Blood Flow Metab.* 11,485-491
- Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, St"cklin G, Heiss WD, 1991. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. *J.Nucl.Med.* 32,1338-1346
- Wienhard K, Eriksson L, Grootoonk S, Casey M, Pietrzyk U, Heiss WD, 1992. Performance evaluation of the positron scanner ECAT EXACT. *Journal of Computer Assisted Tomography* 16,804-813
- Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD, 1994. The ECAT EXACT HR: performance of a new high resolution positron scanner. *Journal of Computer Assisted Tomography* 18,110-118
- Wienhard K, Schmand M, Casey ME, Baker K, Bao J, Eriksson L, Jones WF, Knoess C, Lenox M, Lercher M, Luk P, Michel C, Reed JH, Richerzhagen N, Treffert J, Vollmar S, Young JW, Heiss WD, Nutt R, 2002. The ECAT

- HRRT: performance and first clinical application of the new high resolution research tomograph. *IEEE Transactions on Nuclear Science* 49,104-110
- Wiesel FA, Blomqvist G, Halldin C, Sjogren I, Bjerkenstedt L, Venizelos N, Hagenfeldt L, 1991. The transport of tyrosine into the human brain as determined with L-[1-11C]tyrosine and PET. *J.Nucl.Med.* 32,2043-2049
- Wik G, Borg S, Sjogren I, Wiesel FA, Blomqvist G, Borg J, Greitz T, Nyback H, Sedvall G, Stone-Elander S, 1988. PET determination of regional cerebral glucose metabolism in alcohol-dependent men and healthy controls using 11C-glucose. *Acta Psychiatr.Scand.* 78,234-241
- Wik G, Wiesel FA, 1991. Regional brain glucose metabolism: correlations to biochemical measures and anxiety in patients with schizophrenia. *Psychiatry Res* 40,101-114
- Wik G, Fredrikson M, Ericson K, Eriksson L, Stone-Elander S, Greitz T, 1993. A functional cerebral response to frightening visual stimulation. *Psychiatry Res* 50,15-24
- Wik G, Fredrikson M, Fischer H, 1997. Evidence of altered cerebral blood-flow relationships in acute phobia. *Int.J Neurosci.* 91,253-263
- Wik G, Lekander M, Fredrikson M, 1998. Human brain-immune relationships: a PET study. *Brain Behav.Immun.* 12,242-246
- Wilcox KM, Lindsey KP, Votaw JR, Goodman MM, Martarello L, Carroll FI, Howell LL, 2002. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. *Synapse* 43,78-85
- Wilkinson MD, Fulham MJ, Besser M, 2003. Neuroimaging findings in a suprasellar granular cell tumor. *J Comput.Assist.Tomogr.* 27,26-29
- Willemsen AT, van Waarde A, Paans AM, Pruim J, Luurtsema G, Go KG, Vaalburg W, 1995. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET. *J.Nucl.Med.* 36,411-419
- Willoch F, Tolle TR, Wester HJ, Munz F, Petzold A, Schwaiger M, Conrad B, Bartenstein P, 1999. Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. *AJNR Am J Neuroradiol* 20,686-690

- Willoch F, Rosen G, Tolle TR, Oye I, Wester HJ, Berner N, Schwaiger M, Bartenstein P, 2000. Phantom limb pain in the human brain: unraveling neural circuitries of phantom limb sensations using positron emission tomography. *Ann.Neurol.* 48,842-849
- Willoch F, Gamringer U, Medele R, Steude U, Tolle TR, 2003. Analgesia by electrostimulation of the trigeminal ganglion in patients with trigeminopathic pain: a PET activation study. *Pain* 103,119-130
- Wills AJ, Jenkins IH, Thompson PD, Findley LJ, Brooks DJ, 1994. Red nuclear and cerebellar but no olivary activation associated with essential tremor: a positron emission tomographic study. *Ann.Neurol* 36,636-642
- Wills AJ, Thompson PD, Findley LJ, Brooks DJ, 1996. A positron emission tomography study of primary orthostatic tremor. *Neurology* 46,747-752
- Wilson AA, DaSilva JN, Houle S, 1996. In vivo evaluation of [11C]- and [18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. *Nucl Med Biol.* 23,141-146
- Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S, 2002. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. *Nucl Med Biol.* 29,509-515
- Wise RJ, Bernardi S, Frackowiak RS, Legg NJ, Jones T, 1983. Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. *Brain* 106,197-222
- Wise RJ, Rhodes CG, Gibbs JM, Hatazawa J, Palmer T, Frackowiak RS, Jones T, 1983. Disturbance of oxidative metabolism of glucose in recent human cerebral infarcts. *Ann.Neurol* 14,627-637
- Wiser AK, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD, 1998. Dysfunctional cortico-cerebellar circuits cause 'cognitive dysmetria' in schizophrenia. *Neuroreport* 9,1895-1899
- Wolf AP, 1984. Cyclotrons, radionuclides, precursors, and demands for routine versus research compounds. *Annals of Neurology* 15 Suppl,S19-S24

- Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO, 2003. A critical discussion of the role of neuroimaging in mild cognitive impairment. *Acta Neurol Scand.Suppl* 179,52-76
- Wolkin A, Angrist B, Wolf A, Brodie J, Wolkin B, Jaeger J, Cancro R, Rotrosen J, 1987. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. *Psychopharmacology (Berl)* 92,241-246
- Wolkin A, Angrist B, Wolf A, Brodie JD, Wolkin B, Jaeger J, Cancro R, Rotrosen J, 1988. Low frontal glucose utilization in chronic schizophrenia: a replication study. *Am J Psychiatry* 145,251-253
- Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J, 1992. Negative symptoms and hypofrontality in chronic schizophrenia. *Arch Gen Psychiatry* 49,959-965
- Wolkin A, Sanfilipo M, Angrist B, Duncan E, Wieland S, Wolf AP, Brodie JD, Cooper TB, Laska E, Rotrosen JP, 1994. Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology. *Biol.Psychiatry* 36,317-325
- Wolkin A, Sanfilipo M, Duncan E, Angrist B, Wolf AP, Cooper TB, Brodie JD, Laska E, Rotrosen JP, 1996. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. *American Journal of Psychiatry* 153,346-354
- Wollenweber SD, Hichwa RD, Ponto LLB, 1997. A simple on-line arterial time-activity curve detector for [O-15]water PET studies: Part 2. *IEEE Transactions on Nuclear Science* 44,1417-1419
- Wollenweber SD, Hichwa RD, Ponto LLB, 1997. A simple on-line arterial time-activity curve detector for [O-15]water PET studies: Part 1. *IEEE Transactions on Nuclear Science* 44,1613-1617
- Wolters EC, Huang CC, Clark C, Peppard RF, Okada J, Chu NS, Adam MJ, Ruth TJ, Li D, Calne DB, 1989. Positron emission tomography in manganese intoxication. *Ann.Neurol* 26,647-651
- Wong DF, Gjedde A, Wagner HN, Jr., 1986. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. *J.Cereb.Blood Flow Metab.* 6,137-146



- Wong DF, Gjedde A, Wagner HN, Jr., Dannals RF, Douglass KH, Links JM, Kuhar MJ, 1986. Quantification of Neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity. *J.Cereb.Blood Flow Metab.* 6,147-153
- Wong DF, Wagner HN, Jr., Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, 1986. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. *Science* 234,1558-1563
- Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, Chan B, Folio T, Scheffel U, Ricaurte GA, 1993. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [<sup>11</sup>C]WIN 35,428. *Synapse* 15,130-142
- Wong DF, Harris JC, Naidu S, Yokoi F, Marengo S, Dannals RF, Ravert HT, Yaster M, Evans A, Rousset O, Bryan RN, Gjedde A, Kuhar MJ, Breese GR, 1996. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. *Proc.Natl.Acad.Sci.U.S.A* 93,5539-5543
- Wong DF, Singer HS, Brandt J, Shaya E, Chen C, Brown J, Kimball AW, Gjedde A, Dannals RF, Ravert HT, Wilson PD, Wagner HN, Jr., 1997. D2-like dopamine receptor density in Tourette syndrome measured by PET. *J.Nucl.Med.* 38,1243-1247
- Wong KP, Feng D, Meikle SR, Fulham MJ, 2001. Simultaneous estimation of physiological parameters and the input function--in vivo PET data. *IEEE Trans.Inf.Technol.Biomed.* 5,67-76
- Wong MT, Fenwick PB, Lumsden J, Fenton GW, Maisey MN, Lewis P, Badawi R, 1997. Positron emission tomography in male violent offenders with schizophrenia. *Psychiatry Res.* 68,111-123
- Wong WH, Mullani NA, Wardworth G, Hartz RK, Bristow D, 1984. Characteristics of Small Barium Fluoride (BaF<sub>2</sub>) Scintillator for High Intrinsic Resolution Time-Of-Flight Positron Emission Tomography. *IEEE Transactions on Nuclear Science* 31,381-386
- Wong WH, Hicks K, 1994. A clinically practical method to acquire parametric images of unidirectional metabolic rates and blood spaces. *J.Nucl.Med.* 35,1206-1212

- Woods RP, Grafton ST, Watson JD, Sicotte NL, Mazziotta JC, 1998. Automated image registration: II. Intersubject validation of linear and nonlinear models. *J.Comput.Assist.Tomogr.* 22,153-165
- Woods RP, Grafton ST, Holmes CJ, Cherry SR, Mazziotta JC, 1998. Automated image registration: I. General methods and intrasubject, intramodality validation. *J.Comput.Assist.Tomogr.* 22,139-152
- Worley G, Hoffman JM, Paine SS, Kalman SL, Claerhout SJ, Boyko OB, Kandt RS, Santos CC, Hanson MW, Oakes WJ, ., 1995. 18-Fluorodeoxyglucose positron emission tomography in children and adolescents with traumatic brain injury. *Dev.Med Child Neurol* 37,213-220
- Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC, 1996. A UNIFIED STATISTICAL APPROACH FOR DETERMINING SIGNIFICANT SIGNALS IN IMAGES OF CEREBRAL ACTIVATION. *Human Brain Mapping* 4,58-73
- Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M, Snow BJ, Rodnitzky RL, Wolters EC, Arwert F, Calne DB, 1992. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. *Annals of Neurology* 32,312-320
- Wu D, Yang J, Pardridge WM, 1997. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. *J Clin.Invest* 100,1804-1812
- Wu HM, Bergsneider M, Glenn TC, Yeh E, Hovda DA, Phelps ME, Huang SC, 2003. Measurement of the Global Lumped Constant for 2-Deoxy-2-[18F]Fluoro-D-Glucose in Normal Human Brain Using [15O]Water and 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography Imaging: A Method with Validation Based on Multiple Methodologies. *Molecular Imaging & Biology* 5,32-41
- Wu J, Buchsbaum MS, Gillin JC, Tang C, Cadwell S, Wiegand M, Najafi A, Klein E, Hazen K, Bunney WE, Jr., Fallon JH, Keator D, 1999. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. *American Journal of Psychiatry* 156,1149-1158
- Wu JC, Hagman J, Buchsbaum MS, Blinder B, Derrflier M, Tai WY, Hazlett E, Sicotte N, 1990. Greater left cerebral hemispheric metabolism in bulimia assessed by positron emission tomography. *Am J Psychiatry* 147,309-312

- Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson JC, 1991. PET in generalized anxiety disorder. *Biol.Psychiatry* 29,1181-1199
- Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE, Jr., 1992. Effect of sleep deprivation on brain metabolism of depressed patients. *American Journal of Psychiatry* 149,538-543
- Wu JC, Bell K, Najafi A, Widmark C, Keator D, Tang C, Klein E, Bunney BG, Fallon J, Bunney WE, 1997. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. *Neuropsychopharmacology* 17,402-409
- Wu JC, Iacono R, Ayman M, Salmon E, Lin SD, Carlson J, Keator D, Lee A, Najafi A, Fallon J, 2000. Correlation of intellectual impairment in Parkinson's disease with FDG PET scan [In Process Citation]. *Neuroreport* 11,2139-2144
- Wu RM, Shan DE, Sun CM, Liu RS, Hwu WL, Tai CH, Hussey J, West A, Gwinn-Hardy K, Hardy J, Chen J, Farrer M, Lincoln S, 2002. Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. *Mov Disord.* 17,670-675
- Wu TH, Wang JK, Lee JJ, Liu RS, Guo WY, 2003. An imaging co-registration system using novel non-invasive and non-radioactive external markers. *Eur.J Nucl Med Mol.Imaging*
- Wullner U, Pakzaban P, Brownell AL, Hantraye P, Burns L, Shoup T, Elmaleh D, Petto AJ, Speelman RD, Brownell GL, 1994. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT. *Exp.Neurol* 126,305-309
- Wunderlich G, Knorr U, Herzog H, Kiwit JC, Freund HJ, Seitz RJ, 1998. Precentral glioma location determines the displacement of cortical hand representation. *Neurosurgery* 42,18-26
- Xiong J, Rao S, Jerabek P, Zamarripa F, Woldorff M, Lancaster J, Fox PT, 2000. Intersubject variability in cortical activations during a complex language task. *Neuroimage* 12,326-339
- Xu X, Fukuyama H, Yazawa S, Mima T, Hanakawa T, Magata Y, Kanda M, Fujiwara N, Shindo K, Nagamine T, Shibasaki H, 1997. Functional localization of pain perception in the human brain studied by PET. *Neuroreport* 8,555-559

- Yaghoubi S, Barrio JR, Dahlbom M, Iyer M, Namavari M, Satyamurthy N, Goldman R, Herschman HR, Phelps ME, Gambhir SS, 2001. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. *J Nucl Med* 42,1225-1234
- Yamaguchi S, Fukuyama H, Ogawa M, Yamauchi H, Harada K, Nakamura S, Kimura J, 1994. Olivopontocerebellar atrophy studied by positron emission tomography and magnetic resonance imaging. *J Neurol Sci.* 125,56-61
- Yamaguchi S, Meguro K, Itoh M, Hayasaka C, Shimada M, Yamazaki H, Yamadori A, 1997. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. *J.Neurol.Neurosurg.Psychiatry* 62,596-600
- Yamaki T, Imahori Y, Ohmori Y, Yoshino E, Hohri T, Ebisu T, Ueda S, 1996. Cerebral hemodynamics and metabolism of severe diffuse brain injury measured by PET [see comments]. *J.Nucl.Med.* 37,1166-1170
- Yamamoto F, Aoki M, Furusawa Y, Ando K, Kuwabara Y, Masuda K, Sasaki S, Maeda M, 2002. Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent. *Biol.Pharm.Bull.* 25,616-621
- Yamamoto T, Nishizawa S, Maruyama I, Yoshida M, Tsuchida T, Waki A, Fujibayashi Y, Kubota T, Yonekura Y, Itoh H, 2001. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. *Ann.Nucl Med* 15,103-109
- Yamamoto YL, Thompson CJ, Meyer E, Robertson JS, Feindel W, 1977. Dynamic positron emission tomography for study of cerebral hemodynamics in a cross section of the head using positron-emitting 68Ga-EDTA and 77Kr. *J Comput.Assist.Tomogr.* 1,43-56
- Yamauchi H, Fukuyama H, Nagahama Y, Nabatame H, Nakamura K, Yamamoto Y, Yonekura Y, Konishi J, Kimura J, 1996. Evidence of misery perfusion and risk for recurrent stroke in major cerebral arterial occlusive diseases from PET. *Journal of Neurology, Neurosurgery & Psychiatry* 61,18-25
- Yamauchi H, Fukuyama H, Nagahama Y, Katsumi Y, Dong Y, Konishi J, Kimura J, 1997. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy. *Ann.Neurol* 41,606-614

- Yamauchi H, Fukuyama H, Nagahama Y, Katsumi Y, Hayashi T, Okazawa H, Yonekura Y, 1999. Selective cerebral hematocrit decrease in the centrum semiovale after carotid artery occlusion: a PET study. *J.Cereb.Blood Flow Metab.* 19,109-114
- Yamauchi H, Fukuyama H, Nagahama Y, Okazawa H, Konishi J, 1999. A decrease in regional cerebral blood volume and hematocrit in crossed cerebellar diaschisis. *Stroke* 30,1429-1431
- Yasuno F, Nishikawa T, Nakagawa Y, Ikejiri Y, Tokunaga H, Mizuta I, Shinozaki K, Hashikawa K, Sugita Y, Nishimura T, Takeda M, 2000. Functional anatomical study of psychogenic amnesia. *Psychiatry Res* 99,43-57
- Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, Ando T, Inoue M, Maeda J, Suzuki K, 2003. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. *Am.J Psychiatry* 160,334-340
- Yasuno F, Hasnine AH, Suhara T, Ichimiya T, Sudo Y, Inoue M, Takano A, Ou T, Ando T, Toyama H, 2002. Template-Based Method for Multiple Volumes of Interest of Human Brain PET Images. *Neuroimage* 16,577-586
- Yatham LN, Clark CC, Zis AP, 2000. A preliminary study of the effects of electroconvulsive therapy on regional brain glucose metabolism in patients with major depression. *Journal of ECT.*16(2):171-6,
- Yee RE, Huang SC, Stout DB, Irwin I, Shoghi-Jadid K, Togasaki DM, DeLanney LE, Langston JW, Satyamurthy N, Farahani KF, Phelps ME, Barrio JR, 2000. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations [In Process Citation]. *J.Neurochem.* 74,1147-1157
- Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, DeLanney LE, Togasaki DM, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR, 2001. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. *Mov Disord.* 16,838-848
- Yen CK, Yano Y, Budinger TF, Friedland RP, Derenzo SE, Huesman RH, O'Brien HA, 1982. Brain tumor evaluation using Rb-82 and positron emission tomography. *J.Nucl.Med.* 23,532-537
- Yetkin FZ, Swanson S, Fischer M, Akansel G, Morris G, Mueller W, Haughton V, 1998. Functional MR of frontal lobe activation: comparison with Wada language results. *AJNR Am.J.Neuroradiol.* 19,1095-1098

- Yokoi F, Komiyama T, Ito T, Hayashi T, Lio M, Hara T, 1993. Application of carbon-11 labelled nicotine in the measurement of human cerebral blood flow and other physiological parameters. *Eur.J Nucl Med* 20,46-52
- Yokoi T, Kanno I, Iida H, Miura S, Uemura K, 1991. A new approach of weighted integration technique based on accumulated images using dynamic PET and H<sub>2</sub>(15)O. *J.Cereb.Blood Flow Metab.* 11,492-501
- Yoshii F, Kozuma R, Takahashi W, Haida M, Takagi S, Shinohara Y, 1998. Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. *J Neurol Sci.* 160,87-91
- Yoshikawa H, Fueki N, Sasaki M, Sakuragawa N, 1991. Uncoupling of blood flow and oxygen metabolism in the cerebellum in type 3 Gaucher disease. *Brain Dev.* 13,190-192
- Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R, 1986. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. *Ann.Neurol* 20,296-303
- Young AB, Penney JB, Starosta-Rubinstein S, Markel D, Berent S, Rothley J, Betley A, Hichwa R, 1987. Normal caudate glucose metabolism in persons at risk for Huntington's disease. *Arch Neurol* 44,254-257
- Young LT, Wong DF, Goldman S, Minkin E, Chen C, Matsumura K, Scheffel U, Wagner HN, Jr., 1991. Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. *Synapse* 9,188-194
- Yu DW, Gatley SJ, Wolf AP, MacGregor RR, Dewey SL, Fowler JS, Schlyer DJ, 1992. Synthesis of carbon-11 labeled iodinated cocaine derivatives and their distribution in baboon brain measured using positron emission tomography. *J Med Chem.* 35,2178-2183
- Yvert JP, Maziere B, Verhas M, Comar D, 1979. Simple, fast preparation of gallium-68-labelled human serum albumin microspheres. *Eur.J.Nucl.Med.* 4,95-99
- Zandorf G et al., 2002. PET functional parametric images of acetylcholine esterase activity without blood sampling. In: Senda M et al., eds. *Brain imaging using PET*, Academic Press, San Diego, Ca., pp 41-46

- Zündorf, G., Holthoff, V., Kerrouche, N., Beuthien-Baumann, B., and Herholz, K. 2002. Individual classification of Alzheimer's disease and depression by linear subspace analysis of FDG PET . Human Brain Mapping 2002 Meeting , 741.
- Zündorf G, Kerrouche N, Herholz K, Baron JC, 2003. An efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum.Brain Mapp. 18,13-21
- Zaidi H, Hasegawa B, 2003. Determination of the attenuation map in emission tomography. J Nucl Med 44,291-315
- Zazulia AR, Diringner MN, Videen TO, Adams RE, Yundt K, Aiyagari V, Grubb RL, Jr., Powers WJ, 2001. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb.Blood Flow Metab 21,804-810
- Zhang Y, Jeong LH, Boado RJ, Pardridge WM, 2002. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 4,183-194
- Zhou Y, Huang SC, Bergsneider M, Wong DF, 2002. Improved Parametric Image Generation Using Spatial-Temporal Analysis of Dynamic PET Studies. Neuroimage 15,697-707
- Zhuang ZP, Kung MP, Wilson A, Lee CW, Plossl K, Hou C, Holtzman DM, Kung HF, 2003. Structure-activity relationship of imidazo[1,2- $\alpha$ ]pyridines as ligands for detecting beta-amyloid plaques in the brain. Journal of Medicinal Chemistry 46,237-243
- Ziegler SI, Pichler BJ, Boening G, Rafecas M, Pimpl W, Lorenz E, Schmitz N, Schwaiger M, 2001. A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals. Eur.J.Nucl.Med. 28,136-143
- Ziemer S, Evans M, Kachur V, Shuman L, Cardi A, Jenkins T, Karp S, Alavi A, Dolbier R, Jr., Koch J, 2003. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole (18)F-EF5. Eur.J Nucl Med Mol.Imaging 30,259-266
- Zijlstra S, van der WH, Wiegman T, Visser GM, Korf J, Vaalburg W, 1993. Synthesis and in vivo distribution in the rat of a dopamine agonist: N-([11C]methyl)norapomorphine. Nucl Med Biol. 20,7-12

- Zimmer L, Mauger G, Le Bars D, Bonmarchand G, Luxen A, Pujol JF, 2002. Effect of endogenous serotonin on the binding of the 5-HT<sub>1A</sub> PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. *J Neurochem.* 80,278-286
- Zinn KR, Chaudhuri TR, 2002. The type 2 human somatostatin receptor as a platform for reporter gene imaging. *Eur.J Nucl Med Mol.Imaging* 29,388-399
- Zubieta J, Lombardi U, Minoshima S, Guthrie S, Ni L, Ohl LE, Koeppe RA, Domino EF, 2001. Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. *Biol.Psychiatry* 49,906-913
- Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ, 1996. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. *Nat.Med* 2,1225-1229
- Zubieta JK, Koeppe RA, Mulholland GK, Kuhl DE, Frey KA, 1998. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding. *J.Cereb.Blood Flow Metab.* 18,619-631
- Zubieta JK, Dannals RF, Frost JJ, 1999. Gender and age influences on human brain mu-opioid receptor binding measured by PET. *Am J Psychiatry* 156,842-848
- Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS, 2001. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. *Science* 293,311-315
- Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, Kuhl DE, 2001. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. *Synapse* 39,275-287
- Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS, 2002. mu-opioid receptor-mediated antinociceptive responses differ in men and women. *J Neurosci.* 22,5100-5107
- Zunkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH, 1996. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. *Journal of Neurosurgery* 85,1056-1065



Zunkeler B, Carson RE, Olson J, Blasberg RG, Girton M, Bacher J, Herscovitch P, Oldfield EH, 1996. HYPEROSMOLAR BLOOD-BRAIN BARRIER DISRUPTION IN BABOONS - AN IN VIVO STUDY USING POSITRON EMISSION TOMOGRAPHY AND RUBIDIUM-82. Journal of Neurosurgery 84,494-502